
<html lang="en"     class="pb-page"  data-request-id="c4553e27-c9c9-4121-aea9-d5b1c622c1d5"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;article:article:10.1021/acs.jmedchem.0c01498;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2020.63.issue-22"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of Potent and Brain-Penetrant GPR52 Agonist that Suppresses Psychostimulant Behavior" /></meta><meta name="dc.Creator" content="Pingyuan  Wang" /></meta><meta name="dc.Creator" content="Daniel E.  Felsing" /></meta><meta name="dc.Creator" content="Haiying  Chen" /></meta><meta name="dc.Creator" content="Sonja J.  Stutz" /></meta><meta name="dc.Creator" content="Ryan E.  Murphy" /></meta><meta name="dc.Creator" content="Kathryn A.  Cunningham" /></meta><meta name="dc.Creator" content="John A.  Allen" /></meta><meta name="dc.Creator" content="Jia  Zhou" /></meta><meta name="dc.Description" content="The G protein-coupled receptor 52 (GPR52) is an orphan receptor that is selectively expressed in the striatum and regulates various brain functions through activation of cAMP-dependent pathways. GP..." /></meta><meta name="Description" content="The G protein-coupled receptor 52 (GPR52) is an orphan receptor that is selectively expressed in the striatum and regulates various brain functions through activation of cAMP-dependent pathways. GP..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="November 16, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01498" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01498" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01498" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01498" /></link>
        
    
    

<title>Discovery of Potent and Brain-Penetrant GPR52 Agonist that Suppresses Psychostimulant Behavior | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01498" /></meta><meta property="og:title" content="Discovery of Potent and Brain-Penetrant GPR52 Agonist that Suppresses Psychostimulant Behavior" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/large/jm0c01498_0020.jpeg" /></meta><meta property="og:description" content="The G protein-coupled receptor 52 (GPR52) is an orphan receptor that is selectively expressed in the striatum and regulates various brain functions through activation of cAMP-dependent pathways. GPR52 has been identified as a promising therapeutic target for central nervous system disorders including schizophrenia and substance use disorders. Here, a series of novel GPR52 agonists were designed, synthesized, and evaluated based on compound 4. Several potent and efficacious GPR52 agonists (12c, 23a, 23d, 23e, 23f, and 23h) were identified with nanomolar range potency based on a systematic structure–activity relationship exploration. Further studies of 12c indicate enhanced efficacy, excellent target selectivity, and pharmacokinetic properties including good brain permeability. In vivo proof-of-concept investigations revealed that 12c displayed antipsychotic-like activity by significantly inhibiting amphetamine-induced hyperlocomotor behavior in mice. Collectively, our findings have resulted in an efficacious, brain-penetrant GPR52 agonist as a valuable pharmacological tool for investigating the physiological and therapeutic potential of GPR52 activation." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01498"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01498">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01498&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01498&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01498&amp;href=/doi/10.1021/acs.jmedchem.0c01498" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 22</span><span class="cit-fg-pageRange">, 13951-13972</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/22" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01385" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c01544" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of Potent and Brain-Penetrant GPR52 Agonist that Suppresses Psychostimulant Behavior</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Pingyuan Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Pingyuan Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas 77555, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Pingyuan++Wang">Pingyuan Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Daniel E. Felsing</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Daniel E. Felsing</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Center for Addiction Research, University of Texas Medical Branch, Galveston, Texas 77555, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Daniel+E.++Felsing">Daniel E. Felsing</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Haiying Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Haiying Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas 77555, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Haiying++Chen">Haiying Chen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sonja J. Stutz</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sonja J. Stutz</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Center for Addiction Research, University of Texas Medical Branch, Galveston, Texas 77555, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sonja+J.++Stutz">Sonja J. Stutz</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ryan E. Murphy</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ryan E. Murphy</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Center for Addiction Research, University of Texas Medical Branch, Galveston, Texas 77555, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ryan+E.++Murphy">Ryan E. Murphy</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kathryn A. Cunningham</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kathryn A. Cunningham</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas 77555, United States</div><div class="loa-info-affiliations-info">Center for Addiction Research, University of Texas Medical Branch, Galveston, Texas 77555, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kathryn+A.++Cunningham">Kathryn A. Cunningham</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4257-1739" title="Orcid link">http://orcid.org/0000-0002-4257-1739</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">John A. Allen</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">John A. Allen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas 77555, United States</div><div class="loa-info-affiliations-info">Center for Addiction Research, University of Texas Medical Branch, Galveston, Texas 77555, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#d5bfbab4b4b9b9b0bb95a0a1b8b7fbb0b1a0"><span class="__cf_email__" data-cfemail="385257595954545d56784d4c555a165d5c4d">[email protected]</span></a>. Phone: (409) 772-9621. Fax: 409-747-7050.</span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=John+A.++Allen">John A. Allen</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Jia Zhou</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jia Zhou</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas 77555, United States</div><div class="loa-info-affiliations-info">Center for Addiction Research, University of Texas Medical Branch, Galveston, Texas 77555, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#4822213220273d083d3c252a662d2c3d"><span class="__cf_email__" data-cfemail="3852514250574d784d4c555a165d5c4d">[email protected]</span></a>. Phone: (409) 772-9748. Fax: (409) 772-9648.</span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jia++Zhou">Jia Zhou</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2811-1090" title="Orcid link">http://orcid.org/0000-0002-2811-1090</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01498&amp;href=/doi/10.1021%2Facs.jmedchem.0c01498" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 22</span><span class="cit-pageRange">, 13951–13972</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 16, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>27 August 2020</li><li><span class="item_label"><b>Published</b> online</span>16 November 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 25 November 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01498" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01498</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D13951%26pageCount%3D22%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DPingyuan%2BWang%252C%2BDaniel%2BE.%2BFelsing%252C%2BHaiying%2BChen%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D22%26contentID%3Dacs.jmedchem.0c01498%26title%3DDiscovery%2Bof%2BPotent%2Band%2BBrain-Penetrant%2BGPR52%2BAgonist%2Bthat%2BSuppresses%2BPsychostimulant%2BBehavior%26numPages%3D22%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D13972%26publicationDate%3DNovember%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01498"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1055</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01498" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of Potent and Brain-Penetrant GPR52 Agonist that Suppresses Psychostimulant Behavior&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Pingyuan&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Daniel&quot;,&quot;last_name&quot;:&quot;E. Felsing&quot;},{&quot;first_name&quot;:&quot;Haiying&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Sonja&quot;,&quot;last_name&quot;:&quot;J. Stutz&quot;},{&quot;first_name&quot;:&quot;Ryan&quot;,&quot;last_name&quot;:&quot;E. Murphy&quot;},{&quot;first_name&quot;:&quot;Kathryn&quot;,&quot;last_name&quot;:&quot;A. Cunningham&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;A. Allen&quot;},{&quot;first_name&quot;:&quot;Jia&quot;,&quot;last_name&quot;:&quot;Zhou&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;11&quot;,&quot;day&quot;:&quot;16&quot;,&quot;issue&quot;:&quot;22&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;13951-13972&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01498&quot;},&quot;abstract&quot;:&quot;The G protein-coupled receptor 52 (GPR52) is an orphan receptor that is selectively expressed in the striatum and regulates various brain functions through activation of cAMP-dependent pathways. GPR52 has been identified as a promising therapeutic target for central nervous system disorders including schizophrenia and substance use disorders. Here, a series of novel GPR52 agonists were designed, synthesized, and evaluated based on compound 4. Several potent and efficacious GPR52 agonists (12c, 23a, 23d, 23e, 23f, and 23h) were identified with nanomolar range potency based on a systematic structure–activity relationship exploration. Further studies of 12c indicate enhanced efficacy, excellent target selectivity, and pharmacokinetic properties including good brain permeability. In vivo proof-of-concept investigations revealed that 12c displayed antipsychotic-like activity by significantly inhibiting amphetamine-induced hyperlocomotor behavior in mice. Collectively, our findings have resulted in an efficacious, &quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01498&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01498" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01498&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01498" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01498&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01498" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01498&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01498&amp;href=/doi/10.1021/acs.jmedchem.0c01498" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01498" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01498" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01498&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01498%26sid%3Dliteratum%253Aachs%26pmid%3D33198466%26genre%3Darticle%26aulast%3DWang%26date%3D2020%26atitle%3DDiscovery%2Bof%2BPotent%2Band%2BBrain-Penetrant%2BGPR52%2BAgonist%2Bthat%2BSuppresses%2BPsychostimulant%2BBehavior%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D22%26spage%3D13951%26epage%3D13972%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (3)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292589" title="Agonists">Agonists</a>,</li><li><a href="/action/doSearch?ConceptID=292366" title="Ligands">Ligands</a>,</li><li><a href="/action/doSearch?ConceptID=290676" title="Substituents">Substituents</a>,</li><li><a href="/action/doSearch?ConceptID=292529" title="Aromatic compounds">Aromatic compounds</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/22" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/jmcmar.2020.63.issue-22/20201125/jmcmar.2020.63.issue-22.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/medium/jm0c01498_0020.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/large/jm0c01498_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01498&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The G protein-coupled receptor 52 (GPR52) is an orphan receptor that is selectively expressed in the striatum and regulates various brain functions through activation of cAMP-dependent pathways. GPR52 has been identified as a promising therapeutic target for central nervous system disorders including schizophrenia and substance use disorders. Here, a series of novel GPR52 agonists were designed, synthesized, and evaluated based on compound <b>4</b>. Several potent and efficacious GPR52 agonists (<b>12c</b>, <b>23a</b>, <b>23d</b>, <b>23e</b>, <b>23f</b>, and <b>23h</b>) were identified with nanomolar range potency based on a systematic structure–activity relationship exploration. Further studies of <b>12c</b> indicate enhanced efficacy, excellent target selectivity, and pharmacokinetic properties including good brain permeability. <i>In vivo</i> proof-of-concept investigations revealed that <b>12c</b> displayed antipsychotic-like activity by significantly inhibiting amphetamine-induced hyperlocomotor behavior in mice. Collectively, our findings have resulted in an efficacious, brain-penetrant GPR52 agonist as a valuable pharmacological tool for investigating the physiological and therapeutic potential of GPR52 activation.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70484" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70484" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">G-protein-coupled receptors (GPCRs) are a superfamily of seven-transmembrane spanning receptor proteins, with over 800 members. GPCRs play critical roles in cellular communication and regulate a wide range of physiological and pathological processes.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> To date, GPCRs have accounted for approximately 30% of all U.S. Food and Drug Administration (FDA)-approved drugs for the therapies of numerous human diseases including cancer, central nervous system (CNS) disorders, metabolic disorders, inflammation diseases, infection, immune diseases, and others.<a onclick="showRef(event, 'ref2 ref3 ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref2 ref3 ref4 ref5">(2−5)</a> However, only a fraction of GPCRs are successfully targeted in drug development,<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> and roughly one third of the non-sensory GPCRs remain orphan receptors whose endogenous ligands and physiological functions are largely unknown. Despite limited knowledge of these orphan GPCRs, their crucial roles in physiological signaling pathways and putative druggability make them attractive novel therapeutic targets.<a onclick="showRef(event, 'ref2 ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref2 ref7 ref8">(2,7,8)</a></div><div class="NLM_p">GPR52 is an understudied brain orphan receptor selectively expressed in the striatum and cortex with the highest level of expression in the nucleus accumbens (NAc).<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9,10)</a> The selective expression of GPR52 in the NAc and other striatal regions suggests an important function for this receptor in primary striatal neurons and broader corticostriatal circuitry.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Moreover, GPR52 is colocalized exclusively with dopamine D2 receptors in medium spiny neurons (MSNs) in the striatum and has lesser expression in neurons of the medial prefrontal cortex.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Notably in transgenic mice, the overexpression of GPR52 significantly decreased methamphetamine-induced locomotion, while GPR52 knockout mice showed an anxiolytic-like phenotype.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Studies have indicated that GPR52 couples to G<sub>as/olf</sub>- G proteins to activate adenylyl cyclase and modulate 5′-cyclic adenosine monophosphate (cAMP) signaling and displays high levels of constitutive activity.<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12,13)</a> Thus, GPR52 signaling via cAMP could oppose activity of D2 signaling in the striatum while stimulating the D1/<i>N</i>-methyl-<span class="smallcaps smallerCapital">d</span>-aspartate (NMDA) function in the frontal cortex.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Therefore, GPR52 may serve as a promising novel target for psychiatric disorders<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> including schizophrenia<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> and substance use disorders (SUDs).<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a></div><div class="NLM_p">To date, the natural ligand of GPR52 has not been elucidated, but several surrogate ligands have been reported.<a onclick="showRef(event, 'ref14 ref16 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref14 ref16 ref17 ref18">(14,16−18)</a> Most recently, Lin et al. found that the orthosteric ligand binding pocket of GPR52 (PDB codes: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6LI1">6LI1</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6LI2">6LI2</a>) was occupied by its extracellular loop 2 (ECL2).<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> They suggested that GPR52 was an unprecedented self-activating receptor and GPR52 ligands could function as allosteric agonists to control GPR52 self-activation.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Compound <b>1</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) is the first reported potent GPR52 agonist with a half maximal effective concentration (EC<sub>50</sub>) of about 30 nM, on the basis of their high-throughput screening (HTS) hits.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Particularly, compound <b>1</b> had excellent bioavailability (<i>F</i> = 73%) and brain penetration (brain/plasma AUC ratio = 0.94).<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Additionally, compound <b>1</b> significantly inhibited rodent methamphetamine-induced hyperactivity at a dose of 3 mg/kg. However, compound <b>1</b> has some drawbacks including high lipophilicity/poor aqueous solubility, which limit its application for further use.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Further modifications of compound <b>1</b> resulted in optimized compound <b>2</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) with slightly improved GPR52 potency (EC<sub>50</sub> = 21 nM and <i>E</i><sub>max</sub> = 103%) and water solubility (21 μg/mL at pH 6.8) and similar activity to inhibit stimulant-induced hyperactivity.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Interestingly, the cocrystal structure of GPR52 and compound <b>2</b> (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6LI0">6LI0</a>) was recently solved.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Compound <b>2</b> was found located in a small extracellular pocket of GPR52 surrounded by ECL2, transmembrane helix 1 (TM1), TM2, and TM7. The agonist formed multiple interactions with GPR52 including hydrogen bonds with residues Cys40, Glu191, Ile189, and Asp188 in ECL2, π–π stacking with residue Phe300 of TM7, and hydrophobic contacts with residues Phe117, Thr303, Trp304, and Ile307. The elucidation of this GPR52 ligand-binding pocket is anticipated to facilitate further drug discovery of potent and selective GPR52 modulators. Recently, Tokumaru et al. reported another series of novel GPR52 agonists.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Among those GPR52 agonists, compound <b>3</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) was an effective agonist with good potency and efficacy (EC<sub>50</sub> of 75 nM and <i>E</i><sub>max</sub> of 122%).<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Animal model studies indicated that compound <b>3</b> inhibited MK-801-induced hyperactivity and improved memory recognition.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Likewise, Arena Pharmaceuticals patented and disclosed a series of 1-heteroaryl-indoline-4-carboxamines as GPR52 agonists, among which, compound <b>4</b> displayed potent GPR52 agonist activity.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Here, we choose compound <b>4</b> as a starting point for our medicinal chemistry efforts due to its amenability to chemical synthesis, optimal physical–chemical properties, and lack of previously known structure–activity relationship (SAR). Taken together, GPR52 is emerging as a promising neurotherapeutic target of interest for the treatment of schizophrenia and SUDs, and the reported agonists as well as the recently disclosed cocrystal structural analysis serve as new starting points to facilitate further drug discovery of novel GPR52 ligands as pharmacological tools and potential drug candidates for preclinical and clinical development.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/medium/jm0c01498_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/large/jm0c01498_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of representative reported GPR52 agonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/large/jm0c01498_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01498&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">As part of our ongoing research program in understanding the GPR52-associated pharmacology and identifying novel ligands through HTS campaign and structure-based rational drug design, herein, we report our findings in the chemical optimization and pharmacological evaluation of novel GPR52 activators based on compound <b>4</b><a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> as the advanced chemical lead to understand the key interactions of agonists with the receptor and to identify improved ligands. Systematic SAR studies around three pharmacological moieties of compound <b>4</b> have been explored. A series of novel 1-(pyrimidin-4-yl)indoline-4-carboxamide analogues have been identified as potent and selective GPR52 agonists with nanomolar range potency and varied levels of improved efficacy. This work culminated in discovery of compound <b>12c</b> (<b>PW0787</b>) with a new pyrimidine core scaffold that is an orally bioavailable, brain-penetrant, potent, and selective GPR52 agonist. This novel ligand dose-dependently suppresses amphetamine-evoked hyperactivity, suggesting a therapeutic potential for neuropsychiatric diseases.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73355" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73355" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Design</h3><div class="NLM_p">As described in the <a class="ref internalNav" href="#sec1" aria-label="Introduction">Introduction</a>, one of the drawbacks of previously reported GPR52 agonists is the poor aqueous solubility, limiting their use as pharmacological tools or potential drug candidates. The replacement of a CH group with a N atom in aromatic and heteroaromatic rings of the pharmacophore could improve its physicochemical properties for better <i>in vivo</i> pharmacokinetic (PK) properties.<a onclick="showRef(event, 'ref19 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref19 ref20 ref21">(19−21)</a> Additionally, compared to the CH group, the N atom has an extra unshared electron pair, which could form hydrogen bonds to potentially improve binding affinity. On this basis, we hypothesized that an extra N atom in the core heteroaromatic ring B of advanced chemical lead <b>4</b> could improve its potency as well as physicochemical properties. Therefore, we first altered moiety B (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>, highlight in magenta) by insertion of a nitrogen atom in the pyridine ring of compound <b>4</b> as the starting point to systematically pursue SAR studies. Next, we substituted various moieties onto the aromatic ring of moiety C (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>, highlight in cyan). Then, the methylene linker between moieties B and C was also investigated. Finally, we investigated substituents on moiety A (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>, highlight in green) of compound <b>4</b> by replacement of aminoethanol with various side chains to understand the critical ligand–receptor interactions.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/medium/jm0c01498_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/large/jm0c01498_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Proposed structural modifications of three substructures (A, B, and C) based on advanced chemical lead <b>4</b> for SAR exploration to understand the key interactions of agonists with the receptor GPR52 and to identify newer ligands.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/large/jm0c01498_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01498&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Chemistry</h3><div class="NLM_p">The synthetic procedures of these newly synthesized GPR52 agonists are depicted in <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a>–<named-content content-type="anchor" rid="sch2" type="simple"></named-content><named-content content-type="anchor" rid="sch3" type="simple"></named-content><named-content content-type="anchor" rid="sch4" type="simple"></named-content><named-content content-type="anchor" rid="sch5" type="simple"></named-content><named-content content-type="anchor" rid="sch6" type="simple"></named-content><a class="ref internalNav" href="#sch7" aria-label="7">7</a>. As outlined in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, intermediate <b>6</b> was prepared by reduction of starting material <b>5</b> with triethylsilane and trifluoroacetic acid.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Intermediates <b>8a</b>–<b>c</b> were generated by reaction of compound <b>6</b> with commercially available compounds <b>7a</b>–<b>c</b> in the presence of Et<sub>3</sub>N in yields of 63–67%.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Intermediates <b>10a</b>–<b>c</b> were produced via nucleophilic substitution of compounds <b>8a</b>–<b>c</b> with commercially available 2-(3-fluoro-5-(trifluoromethyl)phenyl)acetonitrile (<b>9a</b>).<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Refluxing of intermediates <b>10a</b>–<b>c</b> in the HCl/AcOH/H<sub>2</sub>O mixed solvent system led to key intermediates <b>11a</b>–<b>c</b> in excellent yields.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Coupling of intermediates <b>11a</b>–<b>c</b> with aminoethanol produced compounds <b>12a</b>–<b>c</b> and resulted in good yields (73–83%).</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/medium/jm0c01498_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/large/jm0c01498_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthetic Routes of Compounds <b>12a</b>–<b>c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/large/jm0c01498_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01498&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) CF<sub>3</sub>COOH, Et<sub>3</sub>SiH, CH<sub>2</sub>Cl<sub>2</sub>, overnight, and 89%. (b) Et<sub>3</sub>N, EtOH, rt., overnight, and 63–67%. (c) 2-(3-Fluoro-5-(trifluoromethyl)phenyl)acetonitrile (<b>9a</b>), NaH, DMF, 0 °C to rt., 2 h, and 53–66%. (d) Con. HCl/AcOH/H<sub>2</sub>O, reflux, overnight, and 91–93%. (e) NH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>OH, EDCI, DMAP, DMF, rt., overnight, and 73–83%.</p></p></figure><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/medium/jm0c01498_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/large/jm0c01498_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthetic Routes of Compound <b>12d</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/large/jm0c01498_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01498&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaH, DMF, 0 °C to rt., 2 h, and 73%. (b) (1) Con. HCl/AcOH/H<sub>2</sub>O, reflux, and overnight; (2) POCl<sub>3</sub>, reflux, 3 h, and 51% for two steps. (c) <b>6</b>, Pd(OAc)<sub>2</sub>, XantPhos, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, 100 °C, overnight, and 56%. (d) (1) 2 N NaOH, MeOH, reflux, and 1 h; (2) 2 N HCl, rt., and 95%. (e) NH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>OH, EDCI, DMAP, DMF, rt., overnight, and 83%.</p></p></figure><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/medium/jm0c01498_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/large/jm0c01498_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthetic Routes of Compounds <b>12e</b> and <b>12f</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/large/jm0c01498_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01498&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaH, DMF, 0 °C to rt., 2 h, 36% for <b>17a</b>, and 63% for <b>17b</b>. (b) HCl, AcOH, H<sub>2</sub>O, 120 °C, overnight, 78% for <b>18a</b>, and 83% for <b>18b</b>. (c) POCl<sub>3</sub>, 120 °C, 12 h, 83% for <b>19a</b>, and 80% for <b>19b</b>. (d) <b>6</b>, Pd(OAc)<sub>2</sub>, XantPhos, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxnae, 100 °C, overnight, 64% for <b>20a</b>, and 60% for <b>20b</b>. (e) (i) 2 N NaOH, MeOH, reflux, and 1 h; (ii) 2 N HCl, rt., 92% for <b>21a</b>, and 90% for <b>21b</b>. (f) NH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>OH, EDCI, DMAP, DMF, rt., overnight, 79% for <b>12e</b>, and 59% for <b>12f</b>.</p></p></figure><figure id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/medium/jm0c01498_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/large/jm0c01498_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthetic Routes of Compounds <b>23a</b>–<b>k</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/large/jm0c01498_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01498&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (1) NaH, DMF, 0 °C to rt., and 2 h; (2) Con. HCl/AcOH/H<sub>2</sub>O, reflux, overnight, and 54–90% for two steps. (b) NH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>OH, EDCI, DMAP, DMF, rt., overnight, and 29–83%.</p></p></figure><figure id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/medium/jm0c01498_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/large/jm0c01498_0011.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthetic Routes of Compounds <b>25a</b>–<b>i</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/large/jm0c01498_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01498&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) For <b>24a</b>, (i) <b>7a</b>, NaH, DMF, 0 °C to rt., and 2 h; (ii) <i>m</i>CPBA, 0 °C to rt., 10 min, and 47% for two steps; (iii) <b>6</b>, XantPhos, Cs<sub>2</sub>CO<sub>3</sub>, Pd(OAc)<sub>2</sub>, 1,4-dioxane, 100 °C, overnight, and 82%; for <b>24b</b> and <b>24c</b>, (i) <b>8c</b>, NaH, DMF, 0 °C to rt., and 2 h; (ii) <i>m</i>CPBA, 0 °C to rt., 10 min, 49% over two steps for <b>24b</b>, and 79% over two steps for <b>24c</b>. (b) (i) Con. HCl/AcOH/H<sub>2</sub>O, reflux, and overnight; (ii) NH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>OH, EDCI, DMAP, DMF, rt., overnight, and 63–77% for two steps. (c) NaBH<sub>4</sub>, DMF/MeOH, 0 °C to rt., 30 min, and 68–90%. (d) (i) NaBH<sub>4</sub>, DMF/MeOH, 0 °C to rt., and 30 min; (ii) con. HCl/AcOH/H<sub>2</sub>O, reflux, overnight, and 78–90%. (e) (i) DAST, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt., and 10 min; (ii) THF/H<sub>2</sub>O, reflux, overnight, and 60–76% for two steps. (f) NH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>OH, EDCI, DMAP, DMF, rt., overnight, and 68–86%.</p></p></figure><figure id="sch6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/medium/jm0c01498_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/large/jm0c01498_0012.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthetic Routes of Compounds <b>25j</b>–<b>l</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/large/jm0c01498_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01498&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) For <b>29a</b>, Pd(OAc)<sub>2</sub>, XantPhos, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxnae, 100 °C, overnight, and 69%; for <b>29b</b> and <b>29c</b>, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 120 °C, overnight, 63% for <b>29b</b>, and 71% for <b>29c</b>. (b) (i) Con. HCl/AcOH/H<sub>2</sub>O, reflux, and overnight; (ii) NH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>OH, EDCI, DMAP, DMF, rt., overnight, and 43–73% for two steps.</p></p></figure><figure id="sch7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/medium/jm0c01498_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/large/jm0c01498_0013.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthetic Routes of Compounds <b>30a</b>–<b>g</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/large/jm0c01498_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01498&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) EDCI, DMAP, DMF, rt., overnight, and 37–78%.</p></p></figure><div class="NLM_p">As outlined in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>, intermediate <b>13</b> was obtained by reaction of compound <b>9a</b> with <b>7a</b> in the presence of NaH. Refluxing of intermediate <b>13</b> in the HCl/AcOH/H<sub>2</sub>O solvent system followed by chlorination with phosphorus oxychloride produced compound <b>14</b>. Compound <b>15</b> was prepared <i>via</i> palladium-catalyzed C–N coupling reaction of <b>14</b> with <b>6</b> in a yield of 56%. Hydrolysis of intermediate <b>15</b> generated key intermediate acid <b>16</b>. Further, condensation of compound <b>16</b> with aminoethanol afforded compound <b>12d</b> following the same procedure as that of preparing compound <b>12a</b>.</div><div class="NLM_p">As outlined in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>, with starting material <b>9a</b> and compounds <b>7d</b><a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> and <b>7e</b>,<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> intermediates <b>17a</b> and <b>17b</b> were obtained following the similar synthetic procedure to that of preparing compound <b>13</b>, respectively. Removing the cyano and the tetrahydro-2<i>H</i>-pyran protection groups of <b>17a</b> and <b>17b</b> at the same time led to compounds <b>18a</b> and <b>18b</b> in the HCl/AcOH/H<sub>2</sub>O solvent system. Compounds <b>18a</b> and <b>18b</b> were converted into compounds <b>19a</b> and <b>19b</b> by a standard chlorination reaction. Key intermediates <b>20a</b> and <b>20b</b> were synthesized by C–N coupling reaction of intermediates <b>19a</b> and <b>19b</b> with compound <b>6</b>, respectively, under the palladium-catalyzed conditions. Acids <b>21a</b> and <b>21b</b> were prepared by hydrolysis of intermediates <b>20a</b> and <b>20b</b>. Compounds <b>12e</b> and <b>12f</b> were synthesized following the similar procedure to that of preparing <b>12a</b> by coupling <b>21a</b> and <b>21b</b> with aminoethanol, respectively.</div><div class="NLM_p">Compounds <b>23a</b>–<b>k</b> were synthesized following the same procedures for preparing <b>12a</b> from various commercially available substituted 2-phenylacetonitriles (<b>9b</b>–<b>l</b>) (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>). As outlined in <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>, intermediate <b>24a</b> was obtained by reaction of compound <b>9a</b> with compound <b>7a</b> in the presence of NaH followed by oxidation of the intermediate and then coupling with compound <b>6</b>. Compounds <b>24b</b> and <b>24c</b> were synthesized <i>via</i> reaction of compounds <b>9a</b> and <b>9b</b> with compound <b>8c</b>, respectively, following similar processes to the synthesis of compound <b>24a</b>. Hydrolysis of esters <b>24a</b>–<b>c</b> followed by condensation with aminoethanol provided compounds <b>25a</b>–<b>c</b> in yields of 63–77% over two steps. Treatment of <b>25a</b>–<b>c</b> with NaBH<sub>4</sub> as the reducing agent afforded compounds <b>25d</b>–<b>f</b> accordingly. Ester intermediates <b>24a</b>–<b>c</b> were converted into intermediates <b>26a</b>–<b>c</b> by a reduction reaction and then a hydrolysis reaction. Fluoridation of acid intermediates <b>26a</b>–<b>c</b> by using diethylaminosulfur trifluoride followed by hydrolysis reactions led to acid compounds <b>27a</b>–<b>c</b>. Compounds <b>25g</b>–<b>i</b> were produced following the same procedure as that of preparing <b>12a</b> from compounds <b>27a</b>–<b>c</b>.</div><div class="NLM_p last">As depicted in <a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>, compounds <b>29a</b>–<b>c</b> were produced <i>via</i> coupling reaction of <b>8c</b> with corresponding commercially available compounds <b>28a</b>–<b>c</b> in yields of 63–71%. Subsequently, intermediates <b>29a</b>–<b>c</b> were converted to corresponding final compounds <b>25j</b>–<b>l</b> by acidolysis and coupling with aminoethanol, following the similar procedures to that of preparing <b>25a</b>. Compounds <b>30a</b>–<b>g</b> were prepared by coupling <b>11c</b> with corresponding aminoethanol derivatives following the similar procedure to that of preparing <b>12a</b>, as outlined in <a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> <i>In Vitro</i> Evaluation of GPR52 Activation</h3><div class="NLM_p">Newly synthesized compounds were evaluated in a twelve-point concentration response for GPR52 agonist activity using the Glosensor cAMP assay in HEK293 cells transiently expressing human GPR52. Transient expression of GPR52 resulted in a dramatic increase in basal cAMP levels (>100-fold over an empty vector, Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01498/suppl_file/jm0c01498_si_001.pdf" class="ext-link">Figure S1</a>), indicating that GPR52 displays high constitutive activity for the cAMP pathway. As summarized in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>–<named-content content-type="anchor" rid="tbl2" type="simple"></named-content><named-content content-type="anchor" rid="tbl3" type="simple"></named-content><a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>, the EC<sub>50</sub> (nM) indicates the potency of these novel GPR52 agonists, while the efficacy (<i>E</i><sub>max</sub>) indicates the maximal activity to increase cAMP. Previously reported GPR52 agonist compound <b>4</b> was used as the reference compound to highlight SAR comparisons.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a><i>E</i><sub>max</sub> (%) was evaluated with compound <b>4</b> as 100% and 0.5% DMSO (vehicle control) as 0%. Compound <b>4</b> exhibited very good potency and robust efficacy in the cAMP assay (EC<sub>50</sub> of 119 nM and <i>E</i><sub>max</sub> of ∼3-fold over basal values, Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01498/suppl_file/jm0c01498_si_001.pdf" class="ext-link">Figure S1</a>). All synthesized ligands were screened in the assay in a full concentration response (0.1 nM to 30 μM). Some data points, at higher concentrations, were excluded from pharmacological analysis due to limited aqueous solubility (as shown in Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01498/suppl_file/jm0c01498_si_001.pdf" class="ext-link">Figure S1</a>).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. EC<sub>50</sub> and <i>E</i><sub>max</sub> of Compounds <b>12a</b>–<b>f</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/medium/jm0c01498_0014.gif" alt="" id="gr13" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/medium/jm0c01498_0015.gif" alt="" id="gr14" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">cLogP: <a href="http://biosig.unimelb.edu.au/pkcsm/prediction" class="extLink">http://biosig.unimelb.edu.au/pkcsm/prediction</a>.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">The values are the mean ± SEM of at least three independent experiments. <i>E</i><sub>max</sub> (%) is the efficacy maximum of the compounds in the cAMP assay relative to compound <b>4</b> as 100% and 0.5% DMSO as 0%.</p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. EC<sub>50</sub> and <i>E</i><sub>max</sub> of Compounds <b>23a</b>–<b>k</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/medium/jm0c01498_0016.gif" alt="" id="gr15" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">R<sup>2</sup></th><th class="colsep0 rowsep0" align="center" char=".">ClogP<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char="±">EC<sub>50</sub> (nM)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char="±"><i>E</i><sub>max</sub> (%)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">4.11</td><td class="colsep0 rowsep0" align="char" char="±">119 ± 18</td><td class="colsep0 rowsep0" align="char" char="±">100 ± 5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23a</b></td><td class="colsep0 rowsep0" align="left">3-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">3.50</td><td class="colsep0 rowsep0" align="char" char="±">101 ± 31</td><td class="colsep0 rowsep0" align="char" char="±">127 ± 10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23b</b></td><td class="colsep0 rowsep0" align="left">2-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">3.50</td><td class="colsep0 rowsep0" align="char" char="±">711 ± 160</td><td class="colsep0 rowsep0" align="char" char="±">115 ± 6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23c</b></td><td class="colsep0 rowsep0" align="left">4-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">3.50</td><td class="colsep0 rowsep0" align="char" char="±">109 ± 19</td><td class="colsep0 rowsep0" align="char" char="±">136 ± 7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23d</b></td><td class="colsep0 rowsep0" align="left">3-Me</td><td class="colsep0 rowsep0" align="char" char=".">2.79</td><td class="colsep0 rowsep0" align="char" char="±">90 ± 19</td><td class="colsep0 rowsep0" align="char" char="±">144 ± 9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23e</b></td><td class="colsep0 rowsep0" align="left">3-F</td><td class="colsep0 rowsep0" align="char" char=".">2.62</td><td class="colsep0 rowsep0" align="char" char="±">106 ± 35</td><td class="colsep0 rowsep0" align="char" char="±">148 ± 14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23f</b></td><td class="colsep0 rowsep0" align="left">3,5-di-Me</td><td class="colsep0 rowsep0" align="char" char=".">3.10</td><td class="colsep0 rowsep0" align="char" char="±">97 ± 20</td><td class="colsep0 rowsep0" align="char" char="±">140 ± 11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23g</b></td><td class="colsep0 rowsep0" align="left">3,5-di-F</td><td class="colsep0 rowsep0" align="char" char=".">2.76</td><td class="colsep0 rowsep0" align="char" char="±">115 ± 19</td><td class="colsep0 rowsep0" align="char" char="±">142 ± 10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23h</b></td><td class="colsep0 rowsep0" align="left">3-OCF<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">3.38</td><td class="colsep0 rowsep0" align="char" char="±">131 ± 24</td><td class="colsep0 rowsep0" align="char" char="±">113 ± 11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23i</b></td><td class="colsep0 rowsep0" align="left">3-OMe</td><td class="colsep0 rowsep0" align="char" char=".">2.49</td><td class="colsep0 rowsep0" align="char" char="±">351 ± 6</td><td class="colsep0 rowsep0" align="char" char="±">122 ± 8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23j</b></td><td class="colsep0 rowsep0" align="left">3,5-di-OMe</td><td class="colsep0 rowsep0" align="char" char=".">2.50</td><td class="colsep0 rowsep0" align="char" char="±">850 ± 35</td><td class="colsep0 rowsep0" align="char" char="±">113 ± 2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23k</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">2.48</td><td class="colsep0 rowsep0" align="char" char="±">292 ± 17</td><td class="colsep0 rowsep0" align="char" char="±">134 ± 4</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">cLogP: <a href="http://biosig.unimelb.edu.au/pkcsm/prediction" class="extLink">http://biosig.unimelb.edu.au/pkcsm/prediction</a>.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">The values are the mean ± SEM of at least three independent experiments. <i>E</i><sub>max</sub> (%) is the efficacy maximum of the compounds in the cAMP assay relative to compound <b>4</b> as 100% and 0.5% DMSO as 0%.</p></div></div></div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. EC<sub>50</sub> and <i>E</i><sub>max</sub> of Compounds <b>25a</b>–<b>l</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/medium/jm0c01498_0017.gif" alt="" id="gr16" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">R<sup>2</sup></th><th class="colsep0 rowsep0" align="center">Y</th><th class="colsep0 rowsep0" align="center">W</th><th class="colsep0 rowsep0" align="center">Z</th><th class="colsep0 rowsep0" align="center" char=".">ClogP<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char="±">EC<sub>50</sub> (nM)<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char="±"><i>E</i><sub>max</sub> (%)<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" colspan="4" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">4.11</td><td class="colsep0 rowsep0" align="char" char="±">119 ± 18</td><td class="colsep0 rowsep0" align="char" char="±">100 ± 5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25a</b></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">CO</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="char" char=".">3.28</td><td class="colsep0 rowsep0" align="char" char="±">1589 ± 166</td><td class="colsep0 rowsep0" align="char" char="±">96 ± 7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25b</b></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">CO</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="char" char=".">3.28</td><td class="colsep0 rowsep0" align="char" char="±">1693 ± 437</td><td class="colsep0 rowsep0" align="char" char="±">22 ± 3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25c</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CO</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="char" char=".">3.14</td><td class="colsep0 rowsep0" align="char" char="±">1008 ± 237</td><td class="colsep0 rowsep0" align="char" char="±">22 ± 4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25d</b></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">CHOH</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="char" char=".">3.13</td><td class="colsep0 rowsep0" align="char" char="±">399 ± 68</td><td class="colsep0 rowsep0" align="char" char="±">130 ± 9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25e</b></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">CHOH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="char" char=".">3.13</td><td class="colsep0 rowsep0" align="char" char="±">338 ± 26</td><td class="colsep0 rowsep0" align="char" char="±">134 ± 28</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25f</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CHOH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="char" char=".">2.99</td><td class="colsep0 rowsep0" align="char" char="±">560 ± 19</td><td class="colsep0 rowsep0" align="char" char="±">89 ± 4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25g</b></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">CHF</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="char" char=".">4.10</td><td class="colsep0 rowsep0" align="char" char="±">329 ± 113</td><td class="colsep0 rowsep0" align="char" char="±">144 ± 9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25h</b></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">CHF</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="char" char=".">4.10</td><td class="colsep0 rowsep0" align="char" char="±">330 ± 38</td><td class="colsep0 rowsep0" align="char" char="±">85 ± 5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25i</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CHF</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="char" char=".">3.97</td><td class="colsep0 rowsep0" align="char" char="±">557 ± 273</td><td class="colsep0 rowsep0" align="char" char="±">83 ± 5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25j</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">NH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="char" char=".">3.66</td><td class="colsep0 rowsep0" align="char" char="±">1105 ± 24</td><td class="colsep0 rowsep0" align="char" char="±">81 ± 2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25k</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="char" char=".">3.70</td><td class="colsep0 rowsep0" align="char" char="±">2404 ± 292</td><td class="colsep0 rowsep0" align="char" char="±">99 ± 4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25l</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="char" char=".">4.06</td><td class="colsep0 rowsep0" align="char" char="±">371 ± 47</td><td class="colsep0 rowsep0" align="char" char="±">123 ± 6</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">cLogP: <a href="http://biosig.unimelb.edu.au/pkcsm/prediction" class="extLink">http://biosig.unimelb.edu.au/pkcsm/prediction</a>.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">The values are the mean ± SEM of at least three independent experiments. <i>E</i><sub>max</sub> (%) is the efficacy maximum of the compounds in the cAMP assay relative to compound <b>4</b> as 100% and 0.5% DMSO as 0%.</p></div></div></div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. EC<sub>50</sub> and <i>E</i><sub>max</sub> of Compounds <b>30a</b>–<b>g</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/medium/jm0c01498_0018.gif" alt="" id="gr17" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/medium/jm0c01498_0019.gif" alt="" id="gr18" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">cLogP: <a href="http://biosig.unimelb.edu.au/pkcsm/prediction" class="extLink">http://biosig.unimelb.edu.au/pkcsm/prediction</a>.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">The values are the mean ± SEM of at least three independent experiments. <i>E</i><sub>max</sub> (%) is the efficacy maximum of the compounds in the cAMP assay relative to compound <b>4</b> as 100% and 0.5% DMSO as 0%.</p></div></div><div></div></div><div class="NLM_p">As summarized in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, to begin a systematic SAR study of the scaffold of compound <b>4</b>,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> we first investigated the core ring B (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>, highlight in magenta) by insertion of an additional N atom in the pyridine ring of compound <b>4</b>. Replacement of the pyridine ring by a pyrimidine ring with two N atoms at positions 2 and 4, leading to compound <b>12a</b>, resulted in ∼3-fold loss of potency with an EC<sub>50</sub> value of 373 nM relative to compound <b>4</b>. However, compared to compound <b>4</b>, the efficacy of compound <b>12a</b> increased with an <i>E</i><sub>max</sub> of 144%. In addition, <b>12a</b> has a more favorable ClogP relative to that of <b>4</b> (3.64 <i>vs</i> 4.11), suggesting that <b>12a</b> may have a better PK profile. In the further SAR studies, the pyridine ring of compound <b>4</b> was replaced with a pyridazine ring to obtain compound <b>12b</b> (EC<sub>50</sub> = 158 nM and <i>E</i><sub>max</sub> = 158%), which exhibited comparable potency to that of <b>4</b>, with improved efficacy. Next, modification of the pyridine ring of compound <b>4</b> to a pyrimidine ring with the two N atoms fixed at positions 4 and 6 led to compound <b>12c</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A). Compound <b>12c</b> showed equal potency as that of lead <b>4</b> (135 nM <i>vs</i> 119 nM) but interestingly resulted in a superior efficacy (<i>E</i><sub>max</sub> of 136%), which was the best compound among this series. However, when the two N atoms were moved to positions 2 and 6 to obtain <b>12d</b>, the potency decreased slightly (EC<sub>50</sub> = 186 nM) compared to <b>12c</b>. To explore the effect of adding a substituent on potency, we introduced a methyl or a chlorine at the 2-position on compound <b>12b,</b> leading to compounds <b>12e</b> and <b>12f</b>, respectively. However, both compounds showed substantial loss of potency (>4-fold decreased EC<sub>50</sub>), indicating that adding a substituent on core moiety B was not favorable.</div><figure id="fig3" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/medium/jm0c01498_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/large/jm0c01498_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Concentration responses of select GPR52 agonists on cAMP signaling in HEK293 cells. HEK293 cells expressing human GPR52 and the cAMP Glosensor reporter were subjected to twelve-point concentration response (0.3 nM–30 μM) testing. (A) Modifications around ring B (magenta): comparison with compounds <b>4</b>, <b>12a</b>, <b>12b</b>, <b>12c</b>, and <b>12e</b>. (B) Modifications around ring C (cyan): comparison with compounds <b>4</b>, <b>23a</b>, <b>23d</b>, <b>23f</b>, <b>23i</b>, <b>23j</b>. (C) Modifications around carbon linker (cyan): comparison with compounds <b>4</b>, <b>25c</b>, <b>25e</b>, <b>25g</b>, <b>25i</b>, and <b>25l</b>. (D) Modifications around head group A (green): comparison with compounds <b>4</b>, <b>30a</b>, <b>30c</b>, <b>30d</b>, and <b>30g</b>. All results are presented as the mean ± SEM from triplicate testing in a representative experiment, with similar results observed in 3–17 experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/large/jm0c01498_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01498&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Having identified an optimal heterocycle in moiety B that maintains potency while increasing efficacy, we next focused on probing the role of the substituents on the benzene ring of moiety C (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>, highlight in cyan), with results summarized in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>. To evaluate the importance of the F substituent, we removed the F from compound <b>12c</b>, leading to compound <b>23a</b>, resulting in a slight increase in potency (EC<sub>50</sub> of 101 nM) and minor decrease in efficacy relative to compound <b>12c</b> (127% <i>vs</i> 136%) (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Compounds <b>23b</b> and <b>23c</b> were then designed and synthesized to explore whether the CF<sub>3</sub> position had an influence on agonist potency. CF<sub>3</sub> at the <i>ortho</i>-position (<b>23b</b>) resulted in a dramatic loss of potency (>7-fold loss) compared with CF<sub>3</sub> at the <i>meta</i>-position (<b>23a</b>). Remarkably, when the CF<sub>3</sub> moiety was moved to the <i>para</i>-position (<b>23c</b>), a similar potency and efficacy was observed to that of <b>23a</b> (109 nM <i>vs</i> 101 nM for EC<sub>50</sub> and 136% <i>vs</i> 127% for <i>E</i><sub>max</sub> (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> and <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B)). From these results, we can conclude that the substituent position on the benzene ring of moiety C has an important role in compound potency and their preferred order is the <i>meta</i> > <i>para</i> > <i>ortho</i> position. Further, we probed the electronic properties of substituents on the benzene ring of moiety C. Replacement of <i>meta-</i>CF<sub>3</sub> of <b>23a</b> with a methyl group led to compound <b>23d</b>, which displayed the best potency among this series with an EC<sub>50</sub> of 90 nM while maintaining excellent efficacy with an <i>E</i><sub>max</sub> of 144% (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> and <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B). Similarly, compound <b>23e</b> was obtained by substitution of <i>meta</i>-CF<sub>3</sub> of <b>23a</b> with a F atom, which displayed no change in potency, an EC<sub>50</sub> of 106 nM, and maintained excellent efficacy, an <i>E</i><sub>max</sub> of 148%, (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Next, we probed whether a second additional electron-withdrawing moiety in the 5<i>-</i>position would further improve potency and efficacy. Disubstituted variants of <b>23d</b> and <b>23e</b>, leading to compounds <b>23f</b> and <b>23g</b>, respectively, displayed identical pharmacologic profiles as their monosubstituted counter parts (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> and <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B). These data suggest that the addition of an extra electron-withdrawing substituent at the 5-position of the benzene ring C has limited influence on the potency and efficacy. However, substitution of <i>meta</i>-CF<sub>3</sub> of <b>23a</b> with an electron-donating group such as OCF<sub>3</sub> (<b>23h</b>), OMe (<b>23i</b>), and 3,5-di-OMe (<b>23j</b>) dramatically decreased the potency as well as the efficacy (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> and <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B). Moreover, compound <b>23k</b> was synthesized without any substituent on the benzene ring C, resulting in ∼3-fold loss of potency relative to <b>23a</b>, suggesting that an electron-withdrawing substituent (e.g., <b>23a</b>, <b>23c</b>, and <b>23e</b>) on the benzene ring of moiety C is favorable for the potency. Taken together, these findings suggest that electron-withdrawing or small alkyl substituents at the 3-position are favorable for improved potency, with an additional small substituent at the 5-position also well-tolerated, while compounds without any substituent on the benzene ring or with electron-donating groups are not tolerated.</div><div class="NLM_p">To probe the impact of the flexibility and steric availability around the linker between moieties B and C, compounds <b>25a</b>–<b>l</b> were designed, synthesized, and evaluated, with the results summarized in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>. We first replaced the methylene linker with a carbonyl moiety to yield compounds <b>25a</b>–<b>c</b>, which were found to dramatically decrease the potency and efficacy, likely due to limited flexibility. Reduction of the carbonyl moiety of compounds <b>25a</b>–<b>c</b> produced compounds <b>25d</b>–<b>f</b>, and this restored a certain degree of the potency and efficacy but still at least 3-fold less potency than compound <b>23a</b>. Fluorination of compounds <b>25d</b>–<b>f</b> yielded compounds <b>25g</b>–<b>i</b>, which failed to improve the potency or efficacy (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a> and <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>C). Replacement of the methylene linker of compound <b>23a</b> with either an NH, O, or S led to corresponding compounds <b>25j</b>–<b>l</b>; however, none of these three compounds showed favorable potency and efficacy (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a> and <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>C). Taken together, these results suggest that GPR52 ligands of this scaffold need to have a flexible and sterically limited linker to achieve good potency. These SAR results are consistent with the recently disclosed cocrystal structure of compound <b>2</b> and GPR52, suggesting that the GPR52 binding region for these molecules is a narrow sterically limited pocket.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a></div><div class="NLM_p last">Finally, to detect the impact of an amino alcohol side chain in moiety A, compounds with various lengths and flexibilities were designed through different strategies, including introducing extra hydroxyl groups (<b>30a</b> and <b>30g</b>), modification of the terminal hydroxyl group (<b>30b</b> and <b>30f</b>), and changing the length of the alkyl linker between amino and hydroxyl groups (<b>30c</b>–<b>e</b>) (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>D). Unfortunately, these seven compounds substantially lost GPR52 potency compared to compound <b>12c</b> (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>), indicating that moiety A is critical and unlikely amenable for further optimization.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Molecular Docking Study of Compound <b>12c</b> with GPR52</h3><div class="NLM_p">To understand the potential binding mode and the receptor–ligand interactions that are important for agonist activity at GPR52, molecular docking using Schrödinger Drug Discovery Suite was employed. Interestingly, the cocrystal structure of GPR52 bound to compound <b>2</b> was recently solved (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6LI0">6LI0</a>), affording an unprecedented opportunity to pursue computational docking studies with an orphan GPCR.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Compound <b>12c</b> was selected as the example of our optimized compounds to further explore the binding interactions with GPR52. As shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>, the docking results indicated that compound <b>12c</b> has energetically favorable interactions with the narrow pocket surrounded by ECL2, TM1, TM2, and TM7 and forms a similar binding pose to compound <b>2</b> with GPR52 in the solved cocrystal structure.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Notably, there are three critical hydrogen bonding interactions between compound <b>12c</b> and the residues of the ECL2 and TM1 of the receptor: the <b>12c</b> terminal hydroxyl group forms hydrogen bonds with residues Glu191 and Ile189 of ECL2, and the <b>12c</b> carbonyl group of the amide forms a hydrogen bond with residue Cys40 from TM1. This binding model may explain the significant activity loss when replacing the amino alcohol side chain into other side chains. The pyrimidine ring (core ring B) forms a π–π stacking interaction with the residue Phe300 of TM7. Moreover, the benzene ring (moiety C) of compound <b>12c</b> pointed into a narrow hydrophobic pocket and formed hydrophobic interactions with residues Phe117, Cys94, Tyr185, Ile47, Ile121, Ile307, and Trp304. This may explain why modifications with only small substitutions on moiety C are tolerated, and why the hydrophobic groups (e.g., F and CF<sub>3</sub>) are more favorable for the binding to drive potency. This docking also indicates that the binding pocket near ECL2 is a hot spot of interaction for both previously identified GPR52 agonists as well as <b>12c</b> and likely other indoline-carboxamide-based ligands.</div><figure id="fig4" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/medium/jm0c01498_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/large/jm0c01498_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Putative binding mode and molecular docking of compound <b>12c</b> with GPR52 (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6LI0">6LI0</a>). (A) Docking of compound <b>12c</b> (magenta) into the binding pocket of GPR52. Important residues are drawn as sticks. Hydrogen bonds are shown as dashed red lines. (B) Docking of compound <b>12c</b> into the binding pocket of GPR52 in 2D view. Hydrogen bonds are shown as magenta lines, and π–π interaction is shown as a green line.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/large/jm0c01498_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01498&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> <i>In Vitro</i> Assessment of Off-Target Effects of Compound <b>12c</b></h3><div class="NLM_p">Considering the potential drug-like properties of chemical scaffolds and overall <i>in vitro</i> activities of GPR52 activation, compound <b>12c</b> was selected as a representative chemical probe among the identified active analogs to pursue further pharmacological evaluations in a proof-of-concept study. To evaluate if the cAMP signaling activity of optimized compound <b>12c</b> is indeed due to GPR52 agonist activation, <b>12c</b> was further tested in control studies using HEK293 cells lacking GPR52. Results determined that <b>12c</b> did not increase cAMP in the cells lacking GPR52 (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01498/suppl_file/jm0c01498_si_001.pdf" class="ext-link">Figure S2</a>). Therefore, compound <b>12c</b> regulates cAMP increases through a direct interaction with GPR52 in this cellular system. To determine the selectivity of <b>12c</b> against other GPCRs, a broad-panel counter screening was tested by the National Institute of Mental Health Psychoactive Drug Screening Program (NIMH-PDSP).<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> This testing determined that compound <b>12c</b> at a concentration of 10 μM displayed no significant binding affinity (<i>K</i><sub>i</sub>) at over 30 brain receptors or channels, including important GPCRs that are current targets of antipsychotic medications (e.g., 5-HT<sub>2A</sub> and D<sub>2</sub> receptors), as shown in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>. In addition, compound <b>12c</b> at 10 μM did not show any human ether-a-go-go-related gene (hERG) potassium channel binding activity (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>), indicating that compound <b>12c</b> should not have undesirable hERG inhibition known to cause cardiotoxicity.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Broad-Panel Counter Screening of <b>12c</b> against Other GPCRs and Transporters<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">GPCRs</th><th class="colsep0 rowsep0" align="center" char=".">% inhibition (10 μM)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center"><i>K</i><sub>i</sub> (μM)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">GPCRs, transporters, ion channels</th><th class="colsep0 rowsep0" align="center" char=".">% inhibition (10 μM)</th><th class="colsep0 rowsep0" align="center"><i>K</i><sub>i</sub> (μM)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-HT1A</td><td class="colsep0 rowsep0" align="char" char=".">8.68</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">D1</td><td class="colsep0 rowsep0" align="char" char=".">12.29</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-HT1B</td><td class="colsep0 rowsep0" align="char" char=".">6.3</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">D2</td><td class="colsep0 rowsep0" align="char" char=".">2.51</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-HT1D</td><td class="colsep0 rowsep0" align="char" char=".">29.64</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">D3</td><td class="colsep0 rowsep0" align="char" char=".">10.64</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-HT1E</td><td class="colsep0 rowsep0" align="char" char=".">7.71</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">D4</td><td class="colsep0 rowsep0" align="char" char=".">29.91</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-HT2A</td><td class="colsep0 rowsep0" align="char" char=".">10.62</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">D5</td><td class="colsep0 rowsep0" align="char" char=".">–7.17</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-HT2B</td><td class="colsep0 rowsep0" align="char" char=".">28.69</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">DAT</td><td class="colsep0 rowsep0" align="char" char=".">24.83</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-HT2C</td><td class="colsep0 rowsep0" align="char" char=".">52.62</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">GABAA</td><td class="colsep0 rowsep0" align="char" char=".">5.98</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-HT3</td><td class="colsep0 rowsep0" align="char" char=".">26.82</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">H1</td><td class="colsep0 rowsep0" align="char" char=".">6.43</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-HT5A</td><td class="colsep0 rowsep0" align="char" char=".">13.95</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">H2</td><td class="colsep0 rowsep0" align="char" char=".">22.36</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-HT6</td><td class="colsep0 rowsep0" align="char" char=".">7.98</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">KOR</td><td class="colsep0 rowsep0" align="char" char=".">1.48</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-HT7A</td><td class="colsep0 rowsep0" align="char" char=".">5.16</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">M1</td><td class="colsep0 rowsep0" align="char" char=".">2.86</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Alpha1A</td><td class="colsep0 rowsep0" align="char" char=".">13.56</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">M2</td><td class="colsep0 rowsep0" align="char" char=".">–1.87</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Alpha1B</td><td class="colsep0 rowsep0" align="char" char=".">–5.42</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">M3</td><td class="colsep0 rowsep0" align="char" char=".">45.38</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Alpha2A</td><td class="colsep0 rowsep0" align="char" char=".">4.45</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">M4</td><td class="colsep0 rowsep0" align="char" char=".">29.26</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Beta1</td><td class="colsep0 rowsep0" align="char" char=".">17.2</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">M5</td><td class="colsep0 rowsep0" align="char" char=".">0.82</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Beta2</td><td class="colsep0 rowsep0" align="char" char=".">–14.07</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">MOR</td><td class="colsep0 rowsep0" align="char" char=".">16.24</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">hERG</td><td class="colsep0 rowsep0" align="char" char=".">11.04</td><td class="colsep0 rowsep0" align="left">ND</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">The broad-panel counter screening of <b>12c</b> against a panel of GPCRs and transporters was generously provided by the NIMH Psychoactive Drug Screening Program.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">The values are the mean percent inhibition of binding from at least three independent experiments, SEM < 20%. “ND” means that a <i>K</i><sub>i</sub> binding affinity was not detected.</p></div></div></div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> <i>In Vivo</i> PK Profile of Compound <b>12c</b></h3><div class="NLM_p">Based on its potency and efficacy as well as potential drug-like properties, compound <b>12c</b> was selected as the representative compound for further PK evaluations. Compound <b>12c</b> was evaluated in rats after a single dose of 20 mg/kg by oral (PO) or 10 mg/kg by intravenous (IV) administration, and the results are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>. Compound <b>12c</b> has excellent plasma exposure after PO (AUC<sub>0-inf</sub> = 13,749 ng·h/mL) and IV dosing (AUC<sub>0-inf</sub> = 9030 ng·h/mL), as well as high maximum serum concentration following PO (<i>C</i><sub>max</sub> = 3407 ng/mL) and IV administration (<i>C</i><sub>max</sub> = 6726 ng/mL). Additionally, compound <b>12c</b> displayed good volume of plasma distribution (<i>V</i><sub>ss</sub> = 1.5 L/kg) and acceptable plasma clearance (CL = 1.1 L/h/kg) after 10 mg/kg IV. Excellent oral bioavailability (<i>F</i>) with the value of 76% was observed. Compound <b>12c</b> was evaluated in rats for brain permeability and concentration after a single dose of 10 mg/kg by IV administration, and the concentrations of <b>12c</b> in the brain and plasma were measured at 0.25 and 1 h after administration. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>, compound <b>12c</b> exhibits a good concentration in the brain at 0.25 h with the value of 1807 ng/g and also exhibits an acceptable brain permeability with a brain/plasma ratio of 0.28. The high brain concentration and brain permeability of <b>12c</b> persisted for at least 1 h, with a brain concentration over 1000 ng/g and a brain/plasma ratio of 0.39 after 1 h injection. Based upon these collective findings, compound <b>12c</b> was selected for further <i>in vivo</i> evaluation.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. <i>In Vivo</i> Pharmacokinetic Parameters of Compound <b>12c</b> in Rats<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">route</th><th class="colsep0 rowsep0" align="center" char="±">AUC<sub>0-∞</sub> (ng·h/mL)</th><th class="colsep0 rowsep0" align="center" char="±"><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="±"><i>C</i><sub>max</sub> (ng/mL)</th><th class="colsep0 rowsep0" align="center" char="±">CL (L/h/kg)</th><th class="colsep0 rowsep0" align="center" char="±"><i>V</i><sub>ss</sub> (L/kg)</th><th class="colsep0 rowsep0" align="center" char="±"><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PO</td><td class="colsep0 rowsep0" align="char" char="±">13,749 ± 2710</td><td class="colsep0 rowsep0" align="char" char="±">2.5 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">3407 ± 179</td><td class="colsep0 rowsep0" align="char" char="±">1.5 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">5.5 ± 1.16</td><td class="colsep0 rowsep0" align="char" char="±">76 ± 15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IV</td><td class="colsep0 rowsep0" align="char" char="±">9030 ± 1018</td><td class="colsep0 rowsep0" align="char" char="±">1.0 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="±">6726 ± 727</td><td class="colsep0 rowsep0" align="char" char="±">1.1 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="±">1.5 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±"> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">AUC<sub>0-∞</sub>, area under the curve (<i>t</i> = 0 to 24 h); <i>t</i><sub>1/2</sub>, terminal half-life; <i>C</i><sub>max</sub>, maximum concentration of the drug in plasma; CL, plasma clearance; <i>V</i><sub>ss</sub>, volume of distribution at steady state; <i>F</i>, absolute oral bioavailability. Experiments were studied in biological triplicates, and data values are shown as the mean ± SEM.</p></div></div></div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Brain Permeability of Compound <b>12c</b> in Rats<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">route</th><th class="colsep0 rowsep0" align="center" char=".">time (h)</th><th class="colsep0 rowsep0" align="center" char="±">brain conc. (ng/g)</th><th class="colsep0 rowsep0" align="center" char="±">plasma conc. (ng/g)</th><th class="colsep0 rowsep0" align="center" char="±">brain/plasma ratio</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">IV</td><td class="colsep0 rowsep0" align="char" char=".">0.25</td><td class="colsep0 rowsep0" align="char" char="±">1807 ± 198</td><td class="colsep0 rowsep0" align="char" char="±">6324 ± 271</td><td class="colsep0 rowsep0" align="char" char="±">0.28 ± 0.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char="±">1006 ± 43</td><td class="colsep0 rowsep0" align="char" char="±">2589 ± 241</td><td class="colsep0 rowsep0" align="char" char="±">0.39 ± 0.02</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">Concentrations of compound <b>12c</b> in the brain and plasma were determined at 0.25 and 1 h after a single dose of 10 mg/kg by IV. Experiments were studied in biological triplicates, and data values are shown as the mean ± SEM.</p></div></div></div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Efficacy Evaluation of Compound <b>12c</b><i>In Vivo</i></h3><div class="NLM_p">Compound <b>12c</b> exhibited potent GPR52 activity <i>in vitro</i> and a good PK profile to support further <i>in vivo</i> assessment. Amphetamine-induced hyperlocomotion in rodents is a well-characterized task with high translational validity for predicting preclinical antipsychotic-like activity.<a onclick="showRef(event, 'ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref28 ref29">(28,29)</a> Given that GPR52 agonists inhibit hyperactivity induced by psychostimulants,<a onclick="showRef(event, 'ref10 ref30'); return false;" href="javascript:void(0);" class="ref ref10 ref30">(10,30)</a> we employed this assay to investigate the efficacy of compound <b>12c</b><i>in vivo</i>. Mice were injected intraperitoneally (IP) with a vehicle or compound <b>12c</b> (0.3, 1, 3, or 10 mg/kg in vehicle; <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A); automated activity monitoring began immediately and continued for 30 min. Mice were then injected with amphetamine (AMPH; 3 mg/kg IP), and activity was monitored for the next 90 min (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A). A one-way ANOVA indicated that compound <b>12c</b> suppressed horizontal activity (F4,54 = 3.287, <i>P</i> < 0.05); Dunnett’s <i>a priori</i> comparisons indicated that 3 mg/kg (<i>P</i> < 0.05) and 10 mg/kg (<i>P</i> < 0.05) suppressed horizontal activity (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B). Additionally, compound <b>12c</b> suppressed AMPH-induced horizontal activity (F4,54 = 4.736, <i>P</i> < 0.05; <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>C) at both 3 mg/kg (<i>P</i> < 0.05) and 10 mg/kg doses (<i>P</i> < 0.05). Taken together, compound <b>12c</b> is an orally bioavailable and brain-penetrant GPR52 agonist, which dose-dependently inhibits amphetamine-evoked hyperactivity, suggesting therapeutic potential for neuropsychiatric diseases.</div><figure id="fig5" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/medium/jm0c01498_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/large/jm0c01498_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Compound <b>12c</b> shows antipsychotic-like activity in mice. (A) Time course of horizontal activity (counts/5 min; mean ± SEM) following injection of the vehicle (black circles) or compound <b>12c</b> (0.3 (blue squares), 1 (burgundy triangles), 3 (green inverted triangles), or 10 mg/kg IP (red diamonds) is shown during automated activity monitoring for 30 min (blue dotted box)). Mice were then injected with amphetamine (AMPH; 3 mg/kg IP), and activity was monitored for the next 90 min. Horizontal activity (counts/5 min; mean ± SEM) during the first 30 min following AMPH injection is illustrated (purple dotted box). (B) Bar graph showing horizontal activity/30 min (mean ± SEM) following injection of the vehicle (Veh) or compound <b>12c</b>. (C) Bar graph showing horizontal activity (mean ± SEM) in the first 30 min period after AMPH injection. Filled circles indicate horizontal activity for individual animals. <i>n</i> = 12 mice/dose except for the 1 mg/kg AMPH (<i>n</i> = 11 mice/dose). *<i>P</i> < 0.05 <i>vs</i> Veh.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/large/jm0c01498_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01498&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i25">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55770" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55770" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">To understand the key ligand–receptor interactions and identify potent and efficacious GPR52 agonists, we have conducted a comprehensive structural optimization campaign based on previously reported advanced chemical lead <b>4</b> through a systematic SAR study by introduction of various amino alcohol side chains and modifications of numerous substituents on the core B ring and C ring. Among them, several compounds <b>12c (PW0787)</b>, <b>23a (PW0860)</b>, <b>23d (PW0878)</b>, <b>23e (PW0885)</b>, <b>23f (PW0888)</b>, and <b>23h (PW0890)</b> were identified as novel GPR52 agonists that elevated cAMP signaling and were more potent than reference compound <b>4</b>. Compound <b>12c</b> has a favorable ClogP and a good <i>in vivo</i> PK profile. Therefore, compound <b>12c</b> was selected for further <i>in vivo</i> efficacy determination. Molecular docking studies of compound <b>12c</b> and GPR52 suggest a binding mode with three critical hydrogen bond pairs, π–π stacking with ring B, and hydrophobic interactions with ring C. This binding model offers theoretical studies for further SAR studies of compound <b>12c</b>. Compound <b>12c</b> was also counter screened and displayed no off-target affinities at other important brain GPCRs and ion channels. In addition, compound <b>12c</b> has excellent oral plasma exposure, maximum serum concentration, bioavailability, and brain concentration. <i>In vivo</i> studies showed that compound <b>12c</b> significantly inhibited amphetamine-induced hyperactivity in mice. Therefore, newly discovered GPR52 agonist <b>12c</b> provides a useful pharmacological tool for studying GPR52 functions and for evaluating GPR52 agonist therapeutic potential for the treatment of brain diseases such as neuropsychiatric disorders.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i26">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83810" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83810" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> General</h3><div class="NLM_p last">All commercially available starting materials and solvents were reagent grade and used without further purification. Reactions were performed under a nitrogen atmosphere in dry glassware with magnetic stirring. Preparative column chromatography was performed using silica gel 60, particle size 0.063–0.200 mm (70–230 mesh, flash). Analytical TLC was carried out by employing silica gel 60 F254 plates (Merck, Darmstadt). Visualization of the developed chromatograms was performed with detection by UV (254 nm). NMR spectra were recorded on a Bruker-600 (<sup>1</sup>H, 300 MHz; <sup>13</sup>C, 75 MHz) spectrometer. <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded with TMS as an internal reference. Chemical shifts downfield from TMS were expressed in ppm, and <i>J</i> values were given in Hz. High-resolution mass spectra (HRMS) were obtained from a Thermo Fisher LTQ Orbitrap Elite mass spectrometer. Parameters include the following: nano ESI spray voltage was 1.8 kV, capillary temperature was 275 °C, and the resolution was 60,000; ionization was achieved by positive mode. Purity of final compounds was determined by analytical HPLC, which was carried out on a Shimadzu HPLC system (model: CBM-20A LC-20AD SPD-20A UV/vis). HPLC analysis conditions were a Waters μBondapak C18 (300 mm × 3.9 mm), a flow rate 0.5 mL/min, UV detection at 270 and 254 nm, and linear gradient from 10% acetonitrile in water (0.1% TFA) to 100% acetonitrile (0.1% TFA) in 20 min followed by 30 min of the last-named solvent. Compounds <b>4</b> and <b>6</b> were resynthesized in-house following reported synthetic procedures.<a onclick="showRef(event, 'ref16 ref22'); return false;" href="javascript:void(0);" class="ref ref16 ref22">(16,22)</a> All biologically evaluated compounds are >95% pure.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Methyl 1-(2-Chloropyrimidin-4-yl)indoline-4-carboxylate (<b>8a</b>)</h3><div class="NLM_p last">To a solution of <b>6</b> (354 mg, 2 mmol) and 2,4-dichloropyrimidine (<b>7a</b>) (300 mg, 2 mmol) in EtOH (5 mL) was added DIPEA (387 mg, 3 mmol) at rt., and the mixture solution was stirred at rt. overnight. After the reaction was completed (detected by TLC), the white solid was filtered and washed with water and cold EtOH. The cake was collected and dried to afford the product as white solid <b>8a</b> (387 mg, 67%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.53 (d, <i>J</i> = 8.1 Hz, 1H), 8.34 (d, <i>J</i> = 6.0 Hz, 1H), 7.57 (d, <i>J</i> = 7.8 Hz, 1H), 7.40 (t, <i>J</i> = 8.0 Hz, 1H), 6.87 (d, <i>J</i> = 6.1 Hz, 1H), 4.08 (t, <i>J</i> = 8.6 Hz, 2H), 3.85 (s, 3H), 3.50 (s, 2H).</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Methyl 1-(5-Chloropyridazin-3-yl)indoline-4-carboxylate (<b>8b</b>)</h3><div class="NLM_p last">Compound <b>8b</b> (364 mg, 63%) was synthesized by a procedure similar to that used to prepare compound <b>8a</b> as a light yellow solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.89 (s, 1H), 8.68 (d, <i>J</i> = 8.2 Hz, 1H), 7.55–7.47 (m, 2H), 7.37 (s, 1H), 4.11 (t, <i>J</i> = 8.7 Hz, 2H), 3.86 (s, 3H), 3.53 (t, <i>J</i> = 8.7 Hz, 2H).</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Methyl 1-(6-Chloropyrimidin-4-yl)indoline-4-carboxylate (<b>8c</b>)</h3><div class="NLM_p last">Compound <b>8c</b> (370 mg, 64%) was synthesized by a procedure similar to that used to prepare compound <b>8a</b> as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.69 (dd, <i>J</i> = 8.2, 1.1 Hz, 1H), 8.61 (d, <i>J</i> = 0.8 Hz, 1H), 7.56 (dd, <i>J</i> = 7.9, 1.0 Hz, 1H), 7.37 (t, <i>J</i> = 8.0 Hz, 1H), 6.97 (d, <i>J</i> = 0.9 Hz, 1H), 4.07 (t, <i>J</i> = 8.5 Hz, 2H), 3.85 (s, 3H), 3.50 (t, <i>J</i> = 8.5 Hz, 2H).</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> Methyl 1-(2-(Cyano(3-fluoro-5-(trifluoromethyl)phenyl)methyl)pyrimidin-4-yl)indoline-4-carboxylate (<b>10a</b>)</h3><div class="NLM_p last">2-(3-Fluoro-5-(trifluoromethyl)phenyl)acetonitrile (<b>9a</b>) (336 mg, 1.6 mmol) was dissolved in 5 mL of DMF, and the mixture solution was cooled to 0 °C with an ice bath. NaH (141 mg, 3.5 mmol) was added to the solution at 0 °C, and the mixture solution was stirred at 0 °C for 30 min. Then, <b>8a</b> (480 mg, 1.6 mmol) was added to the solution at 0 °C, and the mixture solution was stirred at rt. for 2 h. After the reaction was completed (detected by TLC), the reaction was quenched with NH<sub>4</sub>Cl<sub>(sat. aq.)</sub>. The solution was worked up by the addition of water and then extracted with EtOAc (20 mL × 3). The combined EtOAc extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and condensed by rotary evaporation to yield a yellow oil. The residue was purified by silica gel chromatography (gradient: 1 to 5% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) and provided product <b>10a</b> (300 mg, 66%) as a yellow solid. <sup>1</sup>H NMR (300 MHz, chloroform-<i>d</i>) δ 8.67 (d, <i>J</i> = 8.3 Hz, 1H), 8.40 (d, <i>J</i> = 6.1 Hz, 1H), 7.71 (dd, <i>J</i> = 8.0, 1.0 Hz, 2H), 7.54 (dt, <i>J</i> = 8.8, 2.0 Hz, 1H), 7.36 (t, <i>J</i> = 8.0 Hz, 2H), 6.53 (d, <i>J</i> = 6.1 Hz, 1H), 5.40 (s, 1H), 4.06 (dd, <i>J</i> = 9.3, 7.8 Hz, 2H), 3.94 (s, 3H), 3.66 (t, <i>J</i> = 8.5 Hz, 2H).</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> Methyl 1-(5-(Cyano(3-fluoro-5-(trifluoromethyl)phenyl)methyl)pyridazin-3-yl)indoline-4-carboxylate (<b>10b</b>)</h3><div class="NLM_p last">Compound <b>10b</b> (120 mg, 53%) was synthesized by a procedure similar to that used to prepare compound <b>10a</b> as a yellow solid. <sup>1</sup>H NMR (300 MHz, chloroform-<i>d</i>) δ 8.74–8.62 (m, 2H), 7.66 (dd, <i>J</i> = 7.9, 1.0 Hz, 1H), 7.48 (s, 1H), 7.43 (d, <i>J</i> = 7.8 Hz, 1H), 7.33 (ddd, <i>J</i> = 8.1, 4.9, 3.0 Hz, 2H), 7.01 (dd, <i>J</i> = 1.9, 0.8 Hz, 1H), 5.25 (s, 1H), 4.14 (t, <i>J</i> = 8.6 Hz, 2H), 3.94 (s, 3H), 3.69 (t, <i>J</i> = 8.5 Hz, 2H).</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> Methyl 1-(6-(Cyano(3-fluoro-5-(trifluoromethyl)phenyl)methyl)pyrimidin-4-yl)indoline-4-carboxylate (<b>10c</b>)</h3><div class="NLM_p last">Compound <b>10c</b> (130 mg, 57%) was synthesized by a procedure similar to that used to prepare compound <b>10a</b> as a yellow solid. <sup>1</sup>H NMR (300 MHz, chloroform-<i>d</i>) δ 8.83–8.70 (m, 2H), 7.71 (dd, <i>J</i> = 7.9, 1.0 Hz, 1H), 7.60 (s, 1H), 7.48 (d, <i>J</i> = 8.7 Hz, 1H), 7.36 (t, <i>J</i> = 8.1 Hz, 2H), 6.80 (s, 1H), 5.22 (s, 1H), 4.19–4.07 (m, 2H), 3.95 (s, 3H), 3.69 (t, <i>J</i> = 8.5 Hz, 2H).</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> 1-(2-(3-Fluoro-5-(trifluoromethyl)benzyl)pyrimidin-4-yl)indoline-4-carboxylic acid (<b>11a</b>)</h3><div class="NLM_p last">To a solution of <b>10a</b> (300 mg, 0.7 mmol) in con. HCl (4 mL), H<sub>2</sub>O (1 mL) and AcOH (1 mL) were added, and the mixture solution was stirred at reflux overnight. The reaction was cooled to room temperature, and a yellow solid precipitated from the solution. The yellow solid was filtered and washed with water, and the cake was collected and dried to afford the product as light yellow solid <b>11a</b> (256 mg, 93%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.12 (s, 1H), 8.62–8.51 (m, 1H), 7.89 (d, <i>J</i> = 8.3 Hz, 1H), 7.83–7.55 (m, 4H), 7.10–6.93 (m, 2H), 4.51 (s, 2H), 4.16 (t, <i>J</i> = 8.4 Hz, 2H), 3.52 (t, <i>J</i> = 8.3 Hz, 4H).</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> 1-(5-(3-Fluoro-5-(trifluoromethyl)benzyl)pyridazin-3-yl)indoline-4-carboxylic acid (<b>11b</b>)</h3><div class="NLM_p last">Compound <b>11b</b> (101 mg, 92%) was synthesized by a procedure similar to that used to prepare compound <b>11a</b> as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.99 (d, <i>J</i> = 1.4 Hz, 1H), 8.48 (d, <i>J</i> = 8.1 Hz, 1H), 7.74–7.69 (m, 2H), 7.69–7.63 (m, 1H), 7.57 (dd, <i>J</i> = 10.7, 7.6 Hz, 2H), 7.35 (d, <i>J</i> = 8.0 Hz, 1H), 4.23 (s, 2H), 4.17 (t, <i>J</i> = 8.5 Hz, 2H), 3.54 (s, 2H).</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> 1-(6-(3-Fluoro-5-(trifluoromethyl)benzyl)pyrimidin-4-yl)indoline-4-carboxylic Acid (<b>11c</b>)</h3><div class="NLM_p last">Compound <b>11c</b> (100 mg, 91%) was synthesized by a procedure similar to that used to prepare compound <b>11a</b> as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.92 (s, 1H), 8.71 (d, <i>J</i> = 8.2 Hz, 1H), 7.73 (s, 1H), 7.71–7.65 (m, 2H), 7.62 (dd, <i>J</i> = 8.8, 1.9 Hz, 1H), 7.43 (t, <i>J</i> = 8.0 Hz, 1H), 7.21 (s, 1H), 4.28 (s, 2H), 4.21 (t, <i>J</i> = 8.3 Hz, 2H), 3.59 (t, <i>J</i> = 8.3 Hz, 2H).</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> 1-(2-(3-Fuoro-5-(trifluoromethyl)benzyl)pyrimidin-4-yl)-<i>N</i>-(2-hydroxyethyl)indoline-4-carboxamide (<b>12a</b>)</h3><div class="NLM_p last">Compound <b>11a</b> (42 mg, 0.1 mmol) and 2-aminoethan-1-ol (13 mg, 0.2 mmol) were dissolved in 2 mL of DMF, and the mixture solution was cooled to 0 °C with an ice bath. HOBt (14 mg, 0.1 mmol), EDCI (39 mg, 0.2 mmol), and DMAP (24 mg, 0.2 mmol) were added to the solution at 0 °C. Then, the ice bath was removed, and the mixture solution was stirred at room temperature overnight. After the reaction was completed (detected by TLC), the reaction was worked up by the addition of water and then extracted with EtOAc (20 mL × 3). The combined EtOAc extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and condensed by rotary evaporation to yield a yellow oil. This material was further purified by preparative TLC plates using CH<sub>2</sub>Cl<sub>2</sub>/MeOH = 50:1 as the eluent to yield <b>12a</b> as a white solid (33 mg, 73%). <sup>1</sup>H NMR (300 MHz, chloroform-<i>d</i> and MeOD) δ 8.26 (dd, <i>J</i> = 6.3, 2.6 Hz, 1H), 8.14 (dd, <i>J</i> = 7.9, 2.4 Hz, 1H), 7.45 (s, 1H), 7.29–7.04 (m, 5H), 6.39 (dd, <i>J</i> = 6.5, 2.5 Hz, 1H), 4.20 (s, 2H), 3.93 (t, <i>J</i> = 8.6 Hz, 2H), 3.71 (t, <i>J</i> = 5.0 Hz, 2H), 3.48 (qd, <i>J</i> = 8.7, 7.3, 2.6 Hz, 4H). <sup>13</sup>C NMR (75 MHz, chloroform-<i>d</i> and MeOD) δ 168.9, 167.3, 159.0, 155.9, 144.1, 142.0, 132.4, 130.9, 127.5, 122.4–122.1 (m), 120.3, 120.0, 110.8 (d, <i>J</i> = 24.5 Hz), 103.1, 61.2, 49.2, 45.0, 42.3, 27.5. HRMS (ESI): (M + H)<sup>+</sup> calcd for C<sub>23</sub>H<sub>21</sub>F<sub>4</sub>N<sub>4</sub>O<sub>2</sub>, 461.1595; found, 461.1591.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> 1-(5-(3-Fluoro-5-(trifluoromethyl)benzyl)pyridazin-3-yl)-<i>N</i>-(2-hydroxyethyl)indoline-4-carboxamide (<b>12b</b>)</h3><div class="NLM_p last">Compound <b>12b</b> (35 mg, 76%) was synthesized by a procedure similar to that used to prepare compound <b>12a</b> as a white solid. <sup>1</sup>H NMR (300 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.58 (s, 1H), 8.45 (dd, <i>J</i> = 7.5, 1.7 Hz, 1H), 7.53 (s, 1H), 7.39 (tt, <i>J</i> = 6.3, 2.0 Hz, 2H), 7.29–7.17 (m, 2H), 7.11 (d, <i>J</i> = 1.6 Hz, 1H), 4.14 (s, 2H), 4.03 (t, <i>J</i> = 8.6 Hz, 2H), 3.74 (t, <i>J</i> = 5.8 Hz, 2H), 3.51 (t, <i>J</i> = 5.8 Hz, 2H), 3.45 (t, <i>J</i> = 8.6 Hz, 2H). <sup>13</sup>C NMR (75 MHz, MeOD) δ 169.6, 164.4, 161.1, 144.6, 142.7 (d, <i>J</i> = 7.7 Hz), 131.7, 131.6, 127.1, 121.6–121.4 (m), 119.7, 119.4, 116.7, 114.1, 111.1 (d, <i>J</i> = 4.1 Hz), 111.0, 110.7 (d, <i>J</i> = 4.0 Hz), 60.23, 48.81, 41.92, 37.30, 27.06. HRMS (ESI): (M + H)<sup>+</sup> calcd for C<sub>23</sub>H<sub>21</sub>F<sub>4</sub>N<sub>4</sub>O<sub>2</sub>, 461.1595; found, 461.1591.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> 1-(6-(3-Fluoro-5-(trifluoromethyl)benzyl)pyrimidin-4-yl)-<i>N</i>-(2-hydroxyethyl)indoline-4-carboxamide (<b>12c</b>)</h3><div class="NLM_p last">Compound <b>12c</b> (38 mg, 83%) was synthesized by a procedure similar to that used to prepare compound <b>12a</b> as a white solid. <sup>1</sup>H NMR (300 MHz, chloroform-<i>d</i>) δ 8.70 (s, 1H), 8.57 (d, <i>J</i> = 8.1 Hz, 1H), 7.37 (s, 1H), 7.30–7.16 (m, 3H), 7.10 (d, <i>J</i> = 7.7 Hz, 1H), 6.71 (t, <i>J</i> = 5.6 Hz, 1H), 6.33 (s, 1H), 4.04 (s, 2H), 3.91 (t, <i>J</i> = 8.6 Hz, 2H), 3.83 (t, <i>J</i> = 4.9 Hz, 2H), 3.60 (d, <i>J</i> = 5.1 Hz, 2H), 3.49 (d, <i>J</i> = 8.4 Hz, 3H). <sup>13</sup>C NMR (75 MHz, DMSO) δ 167.5, 166.7, 163.9, 160.7, 159.5, 157.9, 144.3, 143.8, 143.7, 132.6, 132.5, 131.2 (qd, <i>J</i> = 32.1, 8.3 Hz), 127.6, 122.5 (p, <i>J</i> = 3.6 Hz), 123.8 (qd, <i>J</i> = 270.8, 3.0 Hz), 121.1, 120.9, 120.6, 117.9, 111.4 (q, <i>J</i> = 4.0 Hz), 111.1 (q, <i>J</i> = 3.7 Hz), 105.0, 60.2, 48.9, 42.7, 42.4, 27.7. HRMS (ESI): (M + H)<sup>+</sup> calcd for C<sub>23</sub>H<sub>21</sub>F<sub>4</sub>N<sub>4</sub>O<sub>2</sub>, 461.1595; found, 461.1591.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> 2-(2-Chloropyrimidin-4-yl)-2-(3-fluoro-5-(trifluoromethyl)phenyl)acetonitrile (<b>13</b>)</h3><div class="NLM_p last">2-(3-Fluoro-5-(trifluoromethyl)phenyl)acetonitrile (<b>9a</b>) (406 mg, 2 mmol) was dissolved in 5 mL of DMF, and the mixture solution was cooled to 0 °C with an ice bath. NaH (190 mg, 4.4 mmol) was added to the solution at 0 °C, and the mixture solution was stirred at 0 °C for 30 min. Then, 2,4-dichloropyrimidine (<b>7a</b>) (450 mg, 3 mmol) was added to the solution at 0 °C, and the mixture solution was stirred at rt. for 2 h. After the reaction was completed (detected by TLC), the reaction mixture was worked up by the addition of water and then extracted with EtOAc (20 mL × 3). The combined EtOAc extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and condensed by rotary evaporation to yield a yellow oil. The residue was purified by silica gel chromatography (gradient: 10 to 20% EtOAc in hexane) to provide product <b>13</b> (460 mg, 73%) as a yellow oil. <sup>1</sup>H NMR (300 MHz, chloroform-<i>d</i>) δ 8.76 (d, <i>J</i> = 5.0 Hz, 1H), 7.57 (s, 1H), 7.52 (d, <i>J</i> = 5.0 Hz, 1H), 7.43 (ddd, <i>J</i> = 14.3, 7.2, 1.8 Hz, 2H), 5.30 (s, 1H).</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> 2-Chloro-4-(3-fluoro-5-(trifluoromethyl)benzyl)pyrimidine (<b>14</b>)</h3><div class="NLM_p last">To a solution of <b>13</b> (460 mg, 1.5 mmol) in con. HCl (4 mL), H<sub>2</sub>O (1 mL) and AcOH (1 mL) were added, and the mixture solution was stirred at reflux overnight. The reaction was cooled to room temperature, and a yellow solid precipitated from the solution. The yellow solid was filtered and washed with water, and the cake was collected and dried to afford the product as a light yellow solid. The yellow solid was dissolved in 2 mL of POCl<sub>3</sub>, and the mixture solution was stirred at reflux overnight. The reaction was cooled to room temperature. After the reaction was completed (detected by TLC), the reaction was poured into ice water, and the pH of the mixture solution was adjusted to pH = 8 with Na<sub>2</sub>CO<sub>3(sat. aq.)</sub> solution. The solution was extracted with EtOAc (20 mL × 3). The organic phase was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and then concentrated under reduced pressure. The residue was purified by silica gel chromatography (gradient: 10 to 20% EtOAc in hexane) to provide product <b>14</b> as a brown colorless oil (222 mg, 51% for two steps). <sup>1</sup>H NMR (300 MHz, chloroform-<i>d</i>) δ 8.57 (d, <i>J</i> = 5.0 Hz, 1H), 7.36 (s, 1H), 7.30–7.26 (m, 1H), 7.22 (dd, <i>J</i> = 8.8, 1.9 Hz, 1H), 7.09 (d, <i>J</i> = 5.0 Hz, 1H), 4.17 (s, 2H).</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> Methyl 1-(4-(3-Fluoro-5-(trifluoromethyl)benzyl)pyrimidin-2-yl)indoline-4-carboxylate (<b>15</b>)</h3><div class="NLM_p last">A mixture of <b>14</b> (145 mg, 0.5 mmol), Pd(OAc)<sub>2</sub> (6 mg, 0.025 mmol), XantPhos (29 mg, 0.05 mmol), Cs<sub>2</sub>CO<sub>3</sub> (325 mg, 1 mmol), and <b>6</b> (89 mg, 0.5 mmol) in 1,4-dioxane (3 mL) was subjected to three rounds of vacuum evacuation followed by introduction of nitrogen. The reaction mixture was then stirred at 100 °C overnight. The reaction was cooled to room temperature and poured in water and then extracted with EtOAc (10 mL × 3). The organic phase was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and then concentrated under reduced pressure. The residue was purified by silica gel chromatography (gradient: 10 to 20% EtOAc in hexane) to provide product <b>15</b> (120 mg, 56%) as a yellow solid. <sup>1</sup>H NMR (300 MHz, chloroform-<i>d</i>) δ 8.52–8.42 (m, 2H), 7.60 (dd, <i>J</i> = 7.8, 1.1 Hz, 1H), 7.45 (s, 1H), 7.26 (dd, <i>J</i> = 8.4, 3.5 Hz, 3H), 6.62 (d, <i>J</i> = 5.0 Hz, 1H), 4.28 (dd, <i>J</i> = 9.3, 8.2 Hz, 2H), 4.10 (s, 2H), 3.93 (s, 3H), 3.60–3.53 (m, 2H).</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> 1-(4-(3-Fluoro-5-(trifluoromethyl)benzyl)pyrimidin-2-yl)indoline-4-carboxylic Acid (<b>16</b>)</h3><div class="NLM_p last">To a solution of <b>14</b> (120 mg, 0.28 mmol) in MeOH (4 mL) was added a 2 N solution of NaOH (1 mL), and the mixture solution was stirred at reflux for 1 h. The pH of the mixture solution was adjusted to pH = 1 with 2 N HCl solution, and then, a yellow solid precipitated from the solution. The yellow solid was filtered and washed with water, and the cake was collected and dried to afford the product as light yellow solid <b>16</b> (110 mg, 95%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.51 (d, <i>J</i> = 5.0 Hz, 1H), 8.23 (d, <i>J</i> = 8.1 Hz, 1H), 7.67 (s, 1H), 7.59 (dt, <i>J</i> = 9.5, 2.0 Hz, 2H), 7.44 (dd, <i>J</i> = 7.8, 1.1 Hz, 1H), 7.13 (t, <i>J</i> = 8.0 Hz, 1H), 6.91 (d, <i>J</i> = 5.0 Hz, 1H), 4.23 (s, 2H), 4.14 (t, <i>J</i> = 8.7 Hz, 2H), 3.43 (t, <i>J</i> = 8.6 Hz, 2H).</div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> 1-(4-(3-Fluoro-5-(trifluoromethyl)benzyl)pyrimidin-2-yl)-<i>N</i>-(2-hydroxyethyl)indoline-4-carboxamide (<b>12d</b>)</h3><div class="NLM_p last">Compound <b>12d</b> (92 mg, 83%) was synthesized by a procedure similar to that used to prepare compound <b>12a</b> as a white solid. <sup>1</sup>H NMR (300 MHz, chloroform-<i>d</i>) δ 8.37 (d, <i>J</i> = 5.0 Hz, 1H), 8.30 (dd, <i>J</i> = 7.4, 1.5 Hz, 1H), 7.43 (s, 1H), 7.24 (dd, <i>J</i> = 8.9, 1.4 Hz, 2H), 7.16–7.05 (m, 2H), 6.77 (t, <i>J</i> = 5.6 Hz, 1H), 6.57 (d, <i>J</i> = 5.0 Hz, 1H), 4.17 (t, <i>J</i> = 8.7 Hz, 2H), 4.05 (s, 2H), 3.81 (t, <i>J</i> = 4.9 Hz, 2H), 3.58 (d, <i>J</i> = 5.1 Hz, 2H), 3.40 (q, <i>J</i> = 9.6, 8.7 Hz, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 169.2, 167.6, 164.1, 160.8, 159.0, 157.9, 144.6, 141.7 (d, <i>J</i> = 7.7 Hz), 132.6, 130.8, 127.5, 122.1 (dd, <i>J</i> = 7.1, 3.5 Hz), 120.1, 119.8, 119.2, 117.6, 111.3 (q, <i>J</i> = 3.9 Hz), 111.0 (q, <i>J</i> = 3.8 Hz), 110.6, 62.1, 49.0, 43.5, 42.6, 27.3. HRMS (ESI): (M + H)<sup>+</sup> calcd for C<sub>23</sub>H<sub>21</sub>F<sub>4</sub>N<sub>4</sub>O<sub>2</sub>, 461.1595; found, 461.1591.</div></div><div id="sec4_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> 2-(3-Fluoro-5-(trifluoromethyl)phenyl)-2-(5-methyl-6-oxo-1-(tetrahydro-2<i>H</i>-pyran-2-yl)-1,6-dihydropyridazin-4-yl)acetonitrile (<b>17a</b>)</h3><div class="NLM_p last">Compound <b>17a</b> (150 mg, 36%) was synthesized by a procedure similar to that used to prepare compound <b>10a</b> as a yellow oil. <sup>1</sup>H NMR (300 MHz, chloroform-<i>d</i>) δ 7.75 (d, <i>J</i> = 8.8 Hz, 1H), 7.46–7.37 (m, 2H), 7.27 (dt, <i>J</i> = 8.5, 2.3 Hz, 1H), 6.06 (dt, <i>J</i> = 10.6, 1.9 Hz, 1H), 5.30 (d, <i>J</i> = 6.2 Hz, 1H), 4.17–4.09 (m, 1H), 3.75 (ddd, <i>J</i> = 11.7, 9.0, 2.7 Hz, 1H), 2.18 (dd, <i>J</i> = 10.7, 4.2 Hz, 1H), 1.85–1.58 (m, 4H).</div></div><div id="sec4_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> 2-(5-Chloro-6-oxo-1-(tetrahydro-2<i>H</i>-pyran-2-yl)-1,6-dihydropyridazin-4-yl)-2-(3-fluoro-5-(trifluoromethyl)phenyl)acetonitrile (<b>17b</b>)</h3><div class="NLM_p last">Compound <b>17b</b> (520 mg, 63%) was synthesized by a procedure similar to that used to prepare compound <b>10a</b> as a yellow oil. <sup>1</sup>H NMR (300 MHz, chloroform-<i>d</i>) δ 7.90 (d, <i>J</i> = 6.1 Hz, 1H), 7.51 (s, 1H), 7.43 (d, <i>J</i> = 8.0 Hz, 1H), 7.39–7.33 (m, 1H), 6.07 (dt, <i>J</i> = 10.6, 2.7 Hz, 1H), 5.59 (d, <i>J</i> = 6.9 Hz, 1H), 4.13 (td, <i>J</i> = 6.9, 3.2 Hz, 1H), 3.77 (ddd, <i>J</i> = 11.5, 8.7, 3.0 Hz, 1H), 2.24–2.06 (m, 2H), 1.87–1.62 (m, 4H).</div></div><div id="sec4_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> 5-(3-Fluoro-5-(trifluoromethyl)benzyl)-4-methylpyridazin-3(2<i>H</i>)-one (<b>18a</b>)</h3><div class="NLM_p last">To a solution of <b>17a</b> (830 mg, 2 mmol) in con. HCl (8 mL), H<sub>2</sub>O (2 mL) and AcOH (2 mL) were added, and the mixture solution was stirred at reflux overnight. After the reaction was completed (detected by TLC), the reaction was poured into ice water. The pH of the mixture solution was adjusted to pH = 8 with Na<sub>2</sub>CO<sub>3(sat. aq.)</sub> solution. Then, the solution was extracted with EtOAc (20 mL × 3). The organic phase was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and then concentrated under reduced pressure. The residue purification by silica gel chromatography (gradient: 30 to 50% EtOAc in hexane) provided product <b>18a</b> (480 mg, 78%) as a white solid. <sup>1</sup>H NMR (300 MHz, chloroform-<i>d</i>) δ 11.67 (s, 1H), 7.58 (s, 1H), 7.25 (d, <i>J</i> = 7.0 Hz, 2H), 7.07–6.99 (m, 1H), 3.97 (s, 2H), 2.23 (s, 3H).</div></div><div id="sec4_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> 4-Chloro-5-(3-fluoro-5-(trifluoromethyl)benzyl)pyridazin-3(2<i>H</i>)-one (<b>18b</b>)</h3><div class="NLM_p last">Compound <b>18b</b> (410 mg, 83%) was synthesized by a procedure similar to that used to prepare compound <b>18a</b> as a yellow oil. <sup>1</sup>H NMR (300 MHz, chloroform-<i>d</i>) δ 7.65 (s, 1H), 7.38–7.23 (m, 3H), 7.17–7.10 (m, 1H), 4.12 (s, 2H).</div></div><div id="sec4_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> 3-Chloro-5-(3-fluoro-5-(trifluoromethyl)benzyl)-4-methylpyridazine (<b>19a</b>)</h3><div class="NLM_p last">A solution of <b>18a</b> (400 mg, 1.3 mmol) in POCl<sub>3</sub> (3 mL) was heated to reflux for 3 h. After the reaction was completed (detected by TLC), the reaction was cooled to room temperature and poured in ice water. The pH of the mixture solution was adjusted to pH = 8 with 2 N NaOH solution and then extracted with EtOAc (30 mL × 3). The organic phase was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and then concentrated under reduced pressure. The residue purification by silica gel chromatography (gradient: 10 to 20% EtOAc in hexane) provided product <b>19a</b> (350 mg, 83%) as a brown solid. <sup>1</sup>H NMR (300 MHz, chloroform-<i>d</i>) δ 8.83 (s, 1H), 7.29 (d, <i>J</i> = 9.7 Hz, 2H), 7.22 (s, 1H), 6.99 (d, <i>J</i> = 8.8 Hz, 1H), 4.12 (s, 2H), 2.39 (s, 3H).</div></div><div id="sec4_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> 3,4-Dichloro-5-(3-fluoro-5-(trifluoromethyl)benzyl)pyridazine (<b>19b</b>)</h3><div class="NLM_p last">Compound <b>19b</b> (350 mg, 80%) was synthesized by a procedure similar to that used to prepare compound <b>19a</b> as a brown solid. <sup>1</sup>H NMR (300 MHz, chloroform-<i>d</i>) δ 8.87 (s, 1H), 7.35–7.29 (m, 2H), 7.16–7.06 (m, 1H), 4.23 (s, 2H).</div></div><div id="sec4_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> Methyl 1-(5-(3-Fluoro-5-(trifluoromethyl)benzyl)-4-methylpyridazin-3-yl)indoline-4-carboxylate (<b>20a</b>)</h3><div class="NLM_p last">Compound <b>20a</b> (142 mg, 64%) was synthesized by a procedure similar to that used to prepare compound <b>15</b> as a brown solid. <sup>1</sup>H NMR (300 MHz, chloroform-<i>d</i>) δ 8.76 (s, 1H), 7.50 (dd, <i>J</i> = 7.9, 0.9 Hz, 1H), 7.27 (d, <i>J</i> = 7.9 Hz, 4H), 7.10 (q, <i>J</i> = 9.6, 8.7 Hz, 2H), 6.46 (d, <i>J</i> = 7.8 Hz, 1H), 4.27 (t, <i>J</i> = 8.2 Hz, 2H), 4.13 (s, 2H), 3.94 (s, 3H), 3.57 (t, <i>J</i> = 8.2 Hz, 2H), 2.18 (s, 3H).</div></div><div id="sec4_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> Methyl 1-(4-Chloro-5-(3-fluoro-5-(trifluoromethyl)benzyl)pyridazin-3-yl)indoline-4-carboxylate (<b>20b</b>)</h3><div class="NLM_p last">Compound <b>20b</b> (280 mg, 60%) was synthesized by a procedure similar to that used to prepare compound <b>15</b> as a white solid. <sup>1</sup>H NMR (300 MHz, chloroform-<i>d</i>) δ 8.71 (s, 1H), 7.59 (dd, <i>J</i> = 7.9, 1.0 Hz, 1H), 7.37–7.29 (m, 2H), 7.25–7.12 (m, 2H), 7.00 (dd, <i>J</i> = 8.0, 0.9 Hz, 1H), 4.34 (t, <i>J</i> = 8.3 Hz, 2H), 4.23 (s, 2H), 3.94 (s, 3H), 3.60 (t, <i>J</i> = 8.3 Hz, 2H).</div></div><div id="sec4_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> 1-(5-(3-Fluoro-5-(trifluoromethyl)benzyl)-4-methylpyridazin-3-yl)indoline-4-carboxylic Acid (<b>21a</b>)</h3><div class="NLM_p last">Compound <b>21a</b> (126 mg, 92%) was synthesized by a procedure similar to that used to prepare compound <b>16</b> as a yellow solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.91 (d, <i>J</i> = 1.8 Hz, 1H), 7.66–7.47 (m, 3H), 7.38 (d, <i>J</i> = 7.9 Hz, 1H), 7.14 (t, <i>J</i> = 7.9 Hz, 1H), 6.64 (d, <i>J</i> = 7.9 Hz, 1H), 4.29 (s, 2H), 4.12 (t, <i>J</i> = 8.3 Hz, 2H), 3.45 (t, <i>J</i> = 8.0 Hz, 2H), 2.20 (d, <i>J</i> = 1.9 Hz, 3H).</div></div><div id="sec4_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> 1-(4-Chloro-5-(3-fluoro-5-(trifluoromethyl)benzyl)pyridazin-3-yl)indoline-4-carboxylic Acid (<b>21b</b>)</h3><div class="NLM_p last">Compound <b>21a</b> (243 mg, 90%) was synthesized by a procedure similar to that used to prepare compound <b>16</b> as a yellow solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.00 (s, 1H), 7.65–7.51 (m, 3H), 7.44 (dd, <i>J</i> = 7.8, 1.0 Hz, 1H), 7.18 (t, <i>J</i> = 7.9 Hz, 1H), 6.95 (dd, <i>J</i> = 8.0, 1.0 Hz, 1H), 4.34 (s, 2H), 4.21 (t, <i>J</i> = 8.3 Hz, 4H), 3.46 (t, <i>J</i> = 8.2 Hz, 2H).</div></div><div id="sec4_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> 1-(5-(3-Fluoro-5-(trifluoromethyl)benzyl)-4-methylpyridazin-3-yl)-<i>N</i>-(2-hydroxyethyl)indoline-4-carboxamide (<b>12e</b>)</h3><div class="NLM_p last">Compound <b>12e</b> (107 mg, 79%) was synthesized by a procedure similar to that used to prepare compound <b>12a</b> as a white solid. <sup>1</sup>H NMR (300 MHz, chloroform-<i>d</i>) δ 8.71 (s, 1H), 7.29 (d, <i>J</i> = 9.7 Hz, 1H), 7.24 (s, 1H), 7.07 (d, <i>J</i> = 9.0 Hz, 1H), 7.02–6.84 (m, 3H), 6.29 (dd, <i>J</i> = 5.4, 3.4 Hz, 1H), 4.25–4.08 (m, 4H), 3.86 (t, <i>J</i> = 4.8 Hz, 2H), 3.63 (q, <i>J</i> = 5.1 Hz, 2H), 3.43 (t, <i>J</i> = 8.1 Hz, 3H), 2.15 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 168.9, 158.9, 149.1, 147.8, 140.9 (d, <i>J</i> = 7.3 Hz), 138.7, 132.0, 131.8, 131.2, 126.8, 121.0 (t, <i>J</i> = 3.3 Hz), 119.3, 119. 0, 118.4, 111.9, 62.1, 53.6, 42.8, 36.0, 28.8, 14.5. HRMS (ESI): (M + H)<sup>+</sup> calcd for C<sub>24</sub>H<sub>23</sub>F<sub>4</sub>N<sub>4</sub>O<sub>2</sub>, 475.1752; found, 475.1748.</div></div><div id="sec4_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> 1-(4-Chloro-5-(3-fluoro-5-(trifluoromethyl)benzyl)pyridazin-3-yl)-<i>N</i>-(2-hydroxyethyl)indoline-4-carboxamide (<b>12f</b>)</h3><div class="NLM_p last">Compound <b>12f</b> (29 mg, 59%) was synthesized by a procedure similar to that used to prepare compound <b>12a</b> as a white solid. <sup>1</sup>H NMR (300 MHz, chloroform-<i>d</i>) δ 8.66 (s, 1H), 7.36–7.24 (m, 2H), 7.14 (d, <i>J</i> = 9.0 Hz, 1H), 7.11–7.02 (m, 2H), 6.89 (dd, <i>J</i> = 6.4, 3.6 Hz, 2H), 4.34–4.15 (m, 4H), 3.81 (t, <i>J</i> = 4.9 Hz, 2H), 3.60 (t, <i>J</i> = 5.1 Hz, 2H), 3.47 (t, <i>J</i> = 8.2 Hz, 2H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 168.8, 164.4, 161.0, 156.8, 148.2, 146.2, 139.9 (d, <i>J</i> = 7.4 Hz), 138.7, 132.1, 131.6, 130.2, 126.8, 121.5–121.4 (m), 119.6, 119.4, 119.3, 115.3, 112.2 (d, <i>J</i> = 3.6 Hz), 111.9 (d, <i>J</i> = 3.9 Hz), 62.1, 53.6, 42.7, 36.1, 29.1. HRMS (ESI): (M + H)<sup>+</sup> calcd for C<sub>23</sub>H<sub>20</sub>ClF<sub>4</sub>N<sub>4</sub>O<sub>2</sub>, 495.1205; found, 495.1201.</div></div><div id="sec4_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> 1-(6-(3-(Trifluoromethyl)benzyl)pyrimidin-4-yl)indoline-4-carboxylic Acid (<b>22a</b>)</h3><div class="NLM_p">2-(3-(Trifluoromethyl)phenyl)acetonitrile (<b>9b</b>) (370 mg, 2 mmol) was dissolved in 5 mL of DMF, and the mixture solution was cooled to 0 °C with an ice bath. NaH (176 mg, 4.4 mmol) was added to the solution at 0 °C, and the mixture solution was stirred at 0 °C for 30 min. Then, <b>8c</b> (580 mg, 2 mmol) was added to the solution at 0 °C, and the mixture solution was stirred at rt. for 2 h. After the reaction was completed (detected by TLC), the reaction mixture was worked up by the addition of water and then extracted with EtOAc (20 mL × 3). The combined EtOAc extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and condensed by rotary evaporation to yield a yellow solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.75 (s, 1H), 8.67 (d, <i>J</i> = 8.0 Hz, 1H), 7.93–7.85 (m, 2H), 7.77 (d, <i>J</i> = 7.9 Hz, 1H), 7.71 (d, <i>J</i> = 7.7 Hz, 1H), 7.54 (dd, <i>J</i> = 7.9, 1.0 Hz, 1H), 7.35 (t, <i>J</i> = 7.9 Hz, 1H), 7.07 (s, 1H), 6.00 (s, 1H), 4.08 (dd, <i>J</i> = 8.8, 2.0 Hz, 2H), 3.85 (s, 3H), 3.51 (t, <i>J</i> = 8.6 Hz, 2H).</div><div class="NLM_p last">To a solution of the yellow solid (100 mg, 0.23 mmol) in con. HCl (2 mL), H<sub>2</sub>O (0.5 mL) and AcOH (0.5 mL) were added, and the mixture solution was stirred at reflux overnight. The reaction was cooled to room temperature, and a yellow solid precipitated from the solution. The yellow solid was filtered and washed with water, and the cake was collected and dried to afford the product as light yellow solid <b>22a</b> (82 mg, 90% for two steps). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.86 (s, 1H), 8.70 (d, <i>J</i> = 8.1 Hz, 1H), 7.81 (s, 1H), 7.73 (d, <i>J</i> = 7.5 Hz, 1H), 7.68–7.53 (m, 3H), 7.40 (t, <i>J</i> = 8.0 Hz, 1H), 7.13 (s, 1H), 4.26–4.11 (m, 4H), 3.57 (t, <i>J</i> = 8.4 Hz, 2H).</div></div><div id="sec4_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> 1-(6-(2-(Trifluoromethyl)benzyl)pyrimidin-4-yl)indoline-4-carboxylic Acid (<b>22b</b>)</h3><div class="NLM_p last">Compound <b>22b</b> (65 mg, 54% for two steps) was synthesized by a procedure similar to that used to prepare compound <b>22a</b> as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.86 (s, 1H), 8.70 (d, <i>J</i> = 8.1 Hz, 1H), 7.79 (d, <i>J</i> = 7.7 Hz, 1H), 7.64 (dd, <i>J</i> = 10.4, 7.6 Hz, 2H), 7.55 (d, <i>J</i> = 7.4 Hz, 1H), 7.46 (d, <i>J</i> = 7.8 Hz, 1H), 7.40 (d, <i>J</i> = 8.1 Hz, 1H), 6.77 (s, 1H), 4.32 (s, 2H), 4.07 (t, <i>J</i> = 8.4 Hz, 2H), 3.53 (t, <i>J</i> = 8.4 Hz, 2H).</div></div><div id="sec4_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> 1-(6-(4-(Trifluoromethyl)benzyl)pyrimidin-4-yl)indoline-4-carboxylic Acid (<b>22c</b>)</h3><div class="NLM_p last">Compound <b>22c</b> (68 mg, 57% for two steps) was synthesized by a procedure similar to that used to prepare compound <b>22a</b> as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.82 (s, 1H), 8.69–8.66 (m, 1H), 7.71 (d, <i>J</i> = 8.1 Hz, 2H), 7.64–7.59 (m, 3H), 7.40 (d, <i>J</i> = 8.2 Hz, 1H), 7.08 (s, 1H), 4.19–4.12 (m, 4H), 3.54 (d, <i>J</i> = 8.7 Hz, 2H).</div></div><div id="sec4_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> 1-(6-(3-Methylbenzyl)pyrimidin-4-yl)indoline-4-carboxylic Acid (<b>22d</b>)</h3><div class="NLM_p last">Compound <b>22d</b> (86 mg, 83% for two steps) was synthesized by a procedure similar to that used to prepare compound <b>22a</b> as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.86 (s, 1H), 8.70 (d, <i>J</i> = 8.1 Hz, 1H), 7.81 (s, 1H), 7.73 (d, <i>J</i> = 7.5 Hz, 1H), 7.68–7.53 (m, 3H), 7.40 (t, <i>J</i> = 8.0 Hz, 1H), 7.13 (s, 1H), 4.26–4.11 (m, 4H), 3.57 (t, <i>J</i> = 8.4 Hz, 2H), 2.49 (s, 3H).</div></div><div id="sec4_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> 1-(6-(3-Fluorobenzyl)pyrimidin-4-yl)indoline-4-carboxylic Acid (<b>22e</b>)</h3><div class="NLM_p last">Compound <b>22e</b> (71 mg, 68% for two steps) was synthesized by a procedure similar to that used to prepare compound <b>22a</b> as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.91 (s, 1H), 8.71 (d, <i>J</i> = 8.5 Hz, 1H), 7.67 (d, <i>J</i> = 7.8 Hz, 1H), 7.47–7.38 (m, 2H), 7.31–7.23 (m, 2H), 7.16–7.06 (m, 2H), 4.24–4.13 (m, 4H), 3.58 (t, <i>J</i> = 8.4 Hz, 2H).</div></div><div id="sec4_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> 1-(6-(3,5-Dimethylbenzyl)pyrimidin-4-yl)indoline-4-carboxylic Acid (<b>22f</b>)</h3><div class="NLM_p last">Compound <b>22f</b> (88 mg, 81% for two steps) was synthesized by a procedure similar to that used to prepare compound <b>22a</b> as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.95 (s, 1H), 8.74 (d, <i>J</i> = 5.7 Hz, 1H), 7.71 (d, <i>J</i> = 7.7 Hz, 1H), 7.58 (s, 1H), 7.43 (d, <i>J</i> = 8.3 Hz, 1H), 7.17 (s, 1H), 7.02 (s, 2H), 4.24 (d, <i>J</i> = 8.1 Hz, 2H), 4.08 (s, 2H), 3.60 (d, <i>J</i> = 8.4 Hz, 2H), 2.25 (s, 6H).</div></div><div id="sec4_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> 1-(6-(3,5-Difluorobenzyl)pyrimidin-4-yl)indoline-4-carboxylic Acid (<b>22g</b>)</h3><div class="NLM_p last">Compound <b>22g</b> (79 mg, 72% for two steps) was synthesized by a procedure similar to that used to prepare compound <b>22a</b> as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.93 (s, 1H), 8.72 (d, <i>J</i> = 8.2 Hz, 1H), 7.69 (d, <i>J</i> = 7.6 Hz, 1H), 7.43 (t, <i>J</i> = 8.0 Hz, 1H), 7.29–7.11 (m, 4H), 4.20 (d, <i>J</i> = 8.3 Hz, 4H), 3.58 (t, <i>J</i> = 8.3 Hz, 2H).</div></div><div id="sec4_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> 1-(6-(3-(Trifluoromethoxy)benzyl)pyrimidin-4-yl)indoline-4-carboxylic Acid (<b>22h</b>)</h3><div class="NLM_p last">Compound <b>22h</b> (87 mg, 70% for two steps) was synthesized by a procedure similar to that used to prepare compound <b>22a</b> as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.95 (s, 1H), 8.71 (d, <i>J</i> = 8.1 Hz, 1H), 7.69 (d, <i>J</i> = 7.7 Hz, 1H), 7.50 (d, <i>J</i> = 4.7 Hz, 3H), 7.43 (t, <i>J</i> = 8.0 Hz, 1H), 7.33–7.27 (m, 1H), 7.20 (s, 1H), 4.25–4.16 (m, 4H), 3.58 (t, <i>J</i> = 8.1 Hz, 2H).</div></div><div id="sec4_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> 1-(6-(3-Methoxybenzyl)pyrimidin-4-yl)indoline-4-arboxylic Acid (<b>22i</b>)</h3><div class="NLM_p last">Compound <b>22i</b> (90 mg, 83% for two steps) was synthesized by a procedure similar to that used to prepare compound <b>22a</b> as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.89 (s, 1H), 8.70 (d, <i>J</i> = 8.0 Hz, 1H), 7.66 (dt, <i>J</i> = 7.8, 1.2 Hz, 2H), 7.45–7.38 (m, 2H), 7.13 (t, <i>J</i> = 7.8 Hz, 1H), 7.08 (d, <i>J</i> = 7.1 Hz, 1H), 6.79 (d, <i>J</i> = 2.0 Hz, 1H), 4.13–4.04 (m, 4H), 3.75 (s, 3H), 3.58 (d, <i>J</i> = 8.2 Hz, 2H).</div></div><div id="sec4_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> 1-(6-(3,5-Dimethoxybenzyl)pyrimidin-4-yl)indoline-4-carboxylic Acid (<b>22j</b>)</h3><div class="NLM_p last">Compound <b>22j</b> (94 mg, 80% for two steps) was synthesized by a procedure similar to that used to prepare compound <b>22a</b> as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.12 (s, 1H), 8.94 (s, 1H), 8.71 (d, <i>J</i> = 8.3 Hz, 1H), 7.69 (d, <i>J</i> = 7.7 Hz, 1H), 7.43 (t, <i>J</i> = 8.1 Hz, 1H), 7.15 (d, <i>J</i> = 9.7 Hz, 1H), 6.44 (d, <i>J</i> = 19.6 Hz, 2H), 6.24 (d, <i>J</i> = 11.6 Hz, 1H), 4.20 (t, <i>J</i> = 8.4 Hz, 2H), 4.02 (s, 2H), 3.71 (d, <i>J</i> = 14.4 Hz, 6H), 3.58 (t, <i>J</i> = 8.2 Hz, 2H).</div></div><div id="sec4_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> 1-(6-Benzylpyrimidin-4-yl)indoline-4-carboxylic Acid (<b>22k</b>)</h3><div class="NLM_p last">Compound <b>22k</b> (76 mg, 77% for two steps) was synthesized by a procedure similar to that used to prepare compound <b>22a</b> as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.19 (s, 1H), 8.96 (s, 1H), 8.71 (d, <i>J</i> = 8.2 Hz, 1H), 7.70 (dd, <i>J</i> = 7.9, 1.0 Hz, 1H), 7.48–7.42 (m, 2H), 7.41–7.27 (m, 3H), 7.17 (s, 1H), 4.25–4.16 (m, 4H), 3.57 (t, <i>J</i> = 8.2 Hz, 2H).</div></div><div id="sec4_42" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> <i>N</i>-(2-Hydroxyethyl)-1-(6-(3-(trifluoromethyl)benzyl)pyrimidin-4-yl)indoline-4-carboxamide (<b>23a</b>)</h3><div class="NLM_p last">Compound <b>23a</b> (52 mg, 59%) was synthesized by a procedure similar to that used to prepare compound <b>12a</b> as a white solid. <sup>1</sup>H NMR (300 MHz, chloroform-<i>d</i> and MeOD) δ 8.62 (s, 1H), 8.48 (d, <i>J</i> = 7.6 Hz, 1H), 7.52–7.37 (m, 4H), 7.21–7.09 (m, 2H), 6.32 (s, 1H), 4.01 (s, 2H), 3.87 (t, <i>J</i> = 8.6 Hz, 2H), 3.70 (t, <i>J</i> = 5.2 Hz, 2H), 3.53–3.37 (m, 4H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub> and MeOD) δ 168.8, 166.7, 159.4, 157.5, 144.2, 138.6, 132.5, 132.4, 131.1 (d, <i>J</i> = 5.2 Hz), 131.0, 129.2, 127.7, 125.9–125.6 (m), 123.7 (d, <i>J</i> = 3.9 Hz), 120.3, 118.6, 103.9, 61.1, 48.7, 43.5, 42.2, 27.4. HRMS (ESI): (M + H)<sup>+</sup> calcd for C<sub>23</sub>H<sub>22</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>, 443.1689; found, 443.1685.</div></div><div id="sec4_43" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> <i>N</i>-(2-Hydroxyethyl)-1-(6-(2-(trifluoromethyl)benzyl)pyrimidin-4-yl)indoline-4-carboxamide (<b>23b</b>)</h3><div class="NLM_p last">Compound <b>23b</b> (36 mg, 61%) was synthesized by a procedure similar to that used to prepare compound <b>12a</b> as a white solid. <sup>1</sup>H NMR (300 MHz, chloroform-<i>d</i> and MeOD) δ 8.65 (s, 1H), 8.48 (d, <i>J</i> = 7.8 Hz, 1H), 7.66 (d, <i>J</i> = 7.8 Hz, 1H), 7.49 (t, <i>J</i> = 7.6 Hz, 1H), 7.34 (d, <i>J</i> = 8.1 Hz, 2H), 7.21 (ddd, <i>J</i> = 28.3, 13.0, 6.9 Hz, 3H), 6.19 (s, 1H), 4.18 (s, 2H), 3.83 (t, <i>J</i> = 8.5 Hz, 2H), 3.70 (t, <i>J</i> = 5.3 Hz, 2H), 3.53–3.39 (m, 4H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub> and MeOD) δ 168.9, 166.9, 159.4, 157.3, 144.3, 135.7, 132.4, 132.1, 131.0, 127.7, 127.1, 126.2 (d, <i>J</i> = 5.6 Hz), 120.2, 118.5, 104.0, 61.1, 48.6, 42.3, 40.1, 27.4. HRMS (ESI): (M + H)<sup>+</sup> calcd for C<sub>23</sub>H<sub>22</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>, 443.1689; found, 443.1685.</div></div><div id="sec4_44" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> <i>N</i>-(2-Hydroxyethyl)-1-(6-(4-(trifluoromethyl)benzyl)pyrimidin-4-yl)indoline-4-carboxamide (<b>23c</b>)</h3><div class="NLM_p last">Compound <b>23c</b> (31 mg, 53%) was synthesized by a procedure similar to that used to prepare compound <b>12a</b> as a white solid. <sup>1</sup>H NMR (300 MHz, chloroform-<i>d</i> and MeOD) δ 8.65 (s, 1H), 8.52 (d, <i>J</i> = 7.8 Hz, 1H), 7.55 (d, <i>J</i> = 7.9 Hz, 2H), 7.38 (d, <i>J</i> = 7.9 Hz, 2H), 7.27–7.12 (m, 3H), 6.35 (s, 1H), 4.03 (s, 2H), 3.91 (t, <i>J</i> = 8.6 Hz, 2H), 3.72 (t, <i>J</i> = 5.2 Hz, 2H), 3.56–3.41 (m, 4H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub> and MeOD) δ 168.9, 166.8, 159.4, 157.5, 144.3, 141.8, 132.4, 131.0, 129.4, 127.7, 125.6 (q, <i>J</i> = 3.7 Hz), 120.3, 118.6, 104.0, 61.2, 48.7, 43.6, 42.3, 27.5. HRMS (ESI): (M + H)<sup>+</sup> calcd for C<sub>23</sub>H<sub>22</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>, 443.1689; found, 443.1685.</div></div><div id="sec4_45" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> <i>N</i>-(2-Hydroxyethyl)-1-(6-(3-methylbenzyl)pyrimidin-4-yl)indoline-4-carboxamide (<b>23d</b>)</h3><div class="NLM_p last">Compound <b>23d</b> (43 mg, 83%) was synthesized by a procedure similar to that used to prepare compound <b>12a</b> as a white solid. <sup>1</sup>H NMR (300 MHz, chloroform-<i>d</i> and MeOD) δ 8.63 (s, 1H), 8.49 (d, <i>J</i> = 7.9 Hz, 1H), 7.34–7.09 (m, 4H), 7.03 (d, <i>J</i> = 7.7 Hz, 3H), 6.33 (s, 1H), 3.99–3.82 (m, 4H), 3.71 (t, <i>J</i> = 5.1 Hz, 2H), 3.56–3.34 (m, 5H), 2.30 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub> and MeOD) δ 168.9, 168.1, 159.4, 157.3, 144.4, 138.3, 137.5, 132.4, 131.0, 129.8, 128.6, 127.7, 127.5, 126.1, 120.2, 118.5, 103.9, 61.2, 49.1, 43.8, 42.2, 27.4, 21.2. HRMS (ESI): (M + H)<sup>+</sup> calcd for C<sub>23</sub>H<sub>25</sub>N<sub>4</sub>O<sub>2</sub>, 389.1972; found, 389.1968.</div></div><div id="sec4_46" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> 1-(6-(3-Fluorobenzyl)pyrimidin-4-yl)-<i>N</i>-(2-hydroxyethyl)indoline-4-carboxamide (<b>23e</b>)</h3><div class="NLM_p last">Compound <b>23e</b> (38 mg, 72%) was synthesized by a procedure similar to that used to prepare compound <b>12a</b> as a white solid. <sup>1</sup>H NMR (300 MHz, chloroform-<i>d</i> and MeOD) δ 8.68–8.57 (m, 1H), 8.51 (d, <i>J</i> = 7.8 Hz, 1H), 7.32–7.11 (m, 4H), 7.02 (d, <i>J</i> = 7.7 Hz, 1H), 6.98–6.86 (m, 2H), 6.34 (s, 1H), 4.02–3.86 (m, 4H), 3.71 (t, <i>J</i> = 5.2 Hz, 2H), 3.55–3.40 (m, 4H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub> and MeOD) δ 168.9, 168.9, 167.1, 164.5, 161.2, 159.5, 157.4, 144.3, 140.0 (d, <i>J</i> = 7.4 Hz), 132.4, 131.0 (2C), 130.2 (d, <i>J</i> = 8.3 Hz), 127.7, 124.8 (d, <i>J</i> = 2.9 Hz), 120.3, 118.6, 115.9 (d, <i>J</i> = 21.4 Hz), 113.73 (d, <i>J</i> = 21.0 Hz), 103.9, 61.1, 48.7, 43.5, 43.4, 42.2, 27.5. HRMS (ESI): (M + H)<sup>+</sup> calcd for C<sub>22</sub>H<sub>22</sub>FN<sub>4</sub>O<sub>2</sub>, 393.1721; found, 393.1716.</div></div><div id="sec4_47" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> 1-(6-(3,5-Dimethylbenzyl)pyrimidin-4-yl)-<i>N</i>-(2-hydroxyethyl)indoline-4-carboxamide (<b>23f</b>)</h3><div class="NLM_p last">Compound <b>23f</b> (42 mg, 78%) was synthesized by a procedure similar to that used to prepare compound <b>12a</b> as a white solid. <sup>1</sup>H NMR (300 MHz, chloroform-<i>d</i> and MeOD) δ 8.59 (s, 1H), 8.46 (d, <i>J</i> = 7.9 Hz, 1H), 7.40–7.05 (m, 3H), 6.82 (s, 3H), 6.32 (s, 1H), 3.87 (d, <i>J</i> = 5.0 Hz, 4H), 3.73–3.56 (m, 4H), 3.46 (d, <i>J</i> = 6.6 Hz, 2H), 2.23 (s, 6H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub> and MeOD) δ 169.0, 168.1, 159.4, 157.2, 144.3, 138.2, 137.4, 132.3, 131.0, 128.4, 127.6, 126.8, 120.2, 118.4, 103.9, 61.0, 48.7, 43.7, 42.3, 27.4, 21.1 (2C). HRMS (ESI): (M + H)<sup>+</sup> calcd for C<sub>24</sub>H<sub>27</sub>N<sub>4</sub>O<sub>2</sub>, 403.2129; found, 403.2125.</div></div><div id="sec4_48" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> 1-(6-(3,5-Difluorobenzyl)pyrimidin-4-yl)-<i>N</i>-(2-hydroxyethyl)indoline-4-carboxamide (<b>23g</b>)</h3><div class="NLM_p last">Compound <b>23g</b> (37 mg, 67%) was synthesized by a procedure similar to that used to prepare compound <b>12a</b> as a white solid. <sup>1</sup>H NMR (300 MHz, chloroform-<i>d</i>) δ 8.81–8.40 (m, 2H), 7.63–7.05 (m, 3H), 6.96–6.55 (m, 3H), 6.43 (s, 1H), 3.97 (d, <i>J</i> = 9.2 Hz, 4H), 3.89–3.66 (m, 4H), 3.54 (s, 2H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 173.0, 172.9, 170.1, 168.6 (d, <i>J</i> = 13.3 Hz), 165.4, 163.4, 161.4, 148.1, 145.4, 136.3, 135.1, 131.7, 124.4, 122.6, 116.0, 115.7, 108.0, 106.6, 106.2, 105.9, 65.0, 52.7, 47.2, 46.2, 46.1, 31.4. HRMS (ESI): calcd for C<sub>22</sub>H<sub>21</sub>F<sub>2</sub>N<sub>4</sub>O<sub>2</sub>, 411.1627; found, 411.1623.</div></div><div id="sec4_49" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> <i>N</i>-(2-Hydroxyethyl)-1-(6-(3-(trifluoromethoxy)benzyl)pyrimidin-4-yl)indoline-4-carboxamide (<b>23h</b>)</h3><div class="NLM_p last">Compound <b>23h</b> (41 mg, 67%) was synthesized by a procedure similar to that used to prepare compound <b>12a</b> as a white solid. <sup>1</sup>H NMR (300 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.57 (d, <i>J</i> = 3.4 Hz, 2H), 7.43 (t, <i>J</i> = 7.9 Hz, 1H), 7.33 (d, <i>J</i> = 7.8 Hz, 1H), 7.29–7.22 (m, 3H), 7.20–7.13 (m, 1H), 6.65 (s, 1H), 4.05 (s, 2H), 3.94 (t, <i>J</i> = 8.6 Hz, 2H), 3.74 (t, <i>J</i> = 5.8 Hz, 2H), 3.51 (t, <i>J</i> = 5.8 Hz, 2H), 3.41 (t, <i>J</i> = 8.5 Hz, 2H). <sup>13</sup>C NMR (75 MHz, MeOD) δ 169.4, 166.6, 159.6, 156.9, 149.3, 144.0, 140.7, 132.1, 131.6, 129.9, 127.6, 127.1, 121.4, 120.6, 118.8, 118.4, 104.0, 60.2, 48.4, 42.5, 41.9, 26.9. HRMS (ESI): (M + H)<sup>+</sup> calcd for C<sub>23</sub>H<sub>22</sub>F<sub>3</sub>N<sub>4</sub>O<sub>3</sub>, 459.1639; found, 459.1636.</div></div><div id="sec4_50" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> <i>N</i>-(2-Hydroxyethyl)-1-(6-(3-methoxybenzyl)pyrimidin-4-yl)indoline-4-carboxamide (<b>23i</b>)</h3><div class="NLM_p last">Compound <b>23i</b> (26 mg, 48%) was synthesized by a procedure similar to that used to prepare compound <b>12a</b> as a white solid. <sup>1</sup>H NMR (300 MHz, chloroform-<i>d</i>) δ 8.72 (s, 1H), 8.59 (d, <i>J</i> = 8.2 Hz, 1H), 7.28–7.19 (m, 2H), 7.05 (d, <i>J</i> = 7.7 Hz, 1H), 6.95–6.79 (m, 3H), 6.51 (t, <i>J</i> = 5.4 Hz, 1H), 6.36 (s, 1H), 4.01 (s, 2H), 3.94 (t, <i>J</i> = 8.6 Hz, 2H), 3.87 (t, <i>J</i> = 4.9 Hz, 2H), 3.82 (s, 3H), 3.63 (q, <i>J</i> = 5.3 Hz, 2H), 3.54 (t, <i>J</i> = 8.5 Hz, 2H), 2.91 (s, 1H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 168.6, 168.0, 159.9, 159.4, 157.5, 144.7, 139.4, 132.6, 130.7, 129.7, 127.8, 121.6, 119.6, 118.6, 115.1, 112.1, 103.8, 62.4, 55.2, 48.7, 44.3, 42.7, 27.7. HRMS (ESI): (M + H)<sup>+</sup> calcd for C<sub>23</sub>H<sub>25</sub>N<sub>4</sub>O<sub>3</sub>, 405.1921; found, 405.1917.</div></div><div id="sec4_51" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> 1-(6-(3,5-Dimethoxybenzyl)pyrimidin-4-yl)-<i>N</i>-(2-hydroxyethyl)indoline-4-carboxamide (<b>23j</b>)</h3><div class="NLM_p last">Compound <b>23j</b> (17 mg, 29%) was synthesized by a procedure similar to that used to prepare compound <b>12a</b> as a white solid. <sup>1</sup>H NMR (300 MHz, chloroform-<i>d</i>) δ 8.67 (d, <i>J</i> = 1.0 Hz, 1H), 8.55 (d, <i>J</i> = 8.1 Hz, 1H), 7.18 (t, <i>J</i> = 7.9 Hz, 1H), 6.98 (dd, <i>J</i> = 7.8, 1.0 Hz, 1H), 6.56 (t, <i>J</i> = 5.6 Hz, 1H), 6.48 (d, <i>J</i> = 2.3 Hz, 2H), 6.39 (t, <i>J</i> = 2.3 Hz, 1H), 6.32 (d, <i>J</i> = 1.1 Hz, 1H), 3.94 (s, 2H), 3.91 (d, <i>J</i> = 8.5 Hz, 2H), 3.87–3.83 (m, 2H), 3.80 (s, 6H), 3.62 (t, <i>J</i> = 5.1 Hz, 2H), 3.50 (t, <i>J</i> = 8.6 Hz, 2H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 168.5, 167.6, 161.0, 159.3, 157.4, 144.6, 140.0, 132.5, 130.7, 127.7, 119.7, 118.5, 107.4, 103.8, 98.6, 62.2, 55.4 (2C), 48.7, 44.5, 42.7, 27.6. HRMS (ESI): (M + H)<sup>+</sup> calcd for C<sub>24</sub>H<sub>27</sub>N<sub>4</sub>O<sub>4</sub>, 435.2027; found, 435.2024.</div></div><div id="sec4_52" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> 1-(6-Benzylpyrimidin-4-yl)-<i>N</i>-(2-hydroxyethyl)indoline-4-carboxamide (<b>23k</b>)</h3><div class="NLM_p last">Compound <b>23k</b> (39 mg, 78%) was synthesized by a procedure similar to that used to prepare compound <b>12a</b> as a white solid. <sup>1</sup>H NMR (300 MHz, chloroform-<i>d</i> and MeOD) δ 8.60 (s, 1H), 8.47 (d, <i>J</i> = 7.9 Hz, 1H), 7.33–7.07 (m, 8H), 6.27 (s, 1H), 3.96 (s, 2H), 3.82 (t, <i>J</i> = 8.5 Hz, 2H), 3.71 (t, <i>J</i> = 5.1 Hz, 2H), 3.49 (q, <i>J</i> = 5.3 Hz, 2H), 3.44–3.30 (m, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 168.9, 167.9, 166.6, 159.3, 157.2, 144.3, 137.6, 132.3, 131.0, 129.1, 128.7, 127.6, 126.8, 120.2, 118.5, 103.9, 61.2, 48.6, 43.8, 42.3, 27.4. HRMS (ESI): (M + H)<sup>+</sup> calcd for C<sub>22</sub>H<sub>23</sub>N<sub>4</sub>O<sub>2</sub>, 375.1816; found, 375.1812.</div></div><div id="sec4_53" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> Methyl 1-(4-(3-Fluoro-5-(trifluoromethyl)benzoyl)pyrimidin-2-yl)indoline-4-carboxylate (<b>24a</b>)</h3><div class="NLM_p">Compound <b>9a</b> (406 mg, 2 mmol) was dissolved in 5 mL of DMF, and the mixture solution was cooled to 0 °C with an ice bath. NaH (190 mg, 4.4 mmol) was added to the solution at 0 °C, and the mixture solution was stirred at 0 °C for 30 min. Then, 2,4-dichloropyrimidine (450 mg, 3 mmol) was added to the solution at 0 °C. After the mixture solution was stirred at rt. for 2 h, the mixture was cooled to 0 °C with an ice bath. Followed by adding <i>m</i>CPBA (516 mg, 3 mmol), the mixture solution was stirred at 0 °C for 30 min. After the reaction was completed (detected by TLC), the reaction was worked up by the addition of water and EtOAc extraction. The combined EtOAc extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and condensed by rotary evaporation to yield a yellow oil. The residue purification by silica gel chromatography (gradient: 10 to 20% EtOAc in hexane) provided product (2-chloropyrimidin-4-yl)(3-fluoro-5-(trifluoromethyl)phenyl)methanone (280 mg, 47%) as a yellow solid. <sup>1</sup>H NMR (300 MHz, chloroform-<i>d</i>) δ 8.98 (d, <i>J</i> = 4.9 Hz, 1H), 8.30 (s, 1H), 8.14 (dt, <i>J</i> = 8.9, 1.9 Hz, 1H), 7.96 (d, <i>J</i> = 4.9 Hz, 1H), 7.63 (dt, <i>J</i> = 8.1, 2.0 Hz, 1H).</div><div class="NLM_p last">A mixture of (2-chloropyrimidin-4-yl)(3-fluoro-5-(trifluoromethyl)phenyl)methanone (91 mg, 0.3 mmol), Pd(OAc)<sub>2</sub> (3 mg, 0.015 mmol), XantPhos (17 mg, 0.03 mmol), Cs<sub>2</sub>CO<sub>3</sub> (196 mg, 0.6 mmol), and <b>6</b> (53 mg, 0.3 mmol) in 1,4-dioxane (3 mL) was subjected to three rounds of vacuum evacuation followed by introduction of nitrogen. The reaction mixture was then stirred at 100 °C overnight. The reaction mixture was cooled to room temperature and poured into water and then extracted with EtOAc (10 mL × 3). The organic phase was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and then concentrated under reduced pressure. The residue purification by silica gel chromatography (gradient: 10 to 20% EtOAc in hexane) provided product <b>24a</b> (110 mg, 82%) as a yellow solid. <sup>1</sup>H NMR (300 MHz, chloroform-<i>d</i>) δ 8.84 (d, <i>J</i> = 4.8 Hz, 1H), 8.43 (s, 2H), 8.15 (d, <i>J</i> = 8.8 Hz, 1H), 7.64 (dd, <i>J</i> = 7.9, 1.2 Hz, 2H), 7.39 (d, <i>J</i> = 4.8 Hz, 1H), 7.23 (t, <i>J</i> = 8.0 Hz, 1H), 4.32 (t, <i>J</i> = 8.7 Hz, 2H), 3.94 (s, 3H), 3.62 (t, <i>J</i> = 8.7 Hz, 2H).</div></div><div id="sec4_54" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> Methyl 1-(6-(3-Fluoro-5-(trifluoromethyl)benzoyl)pyrimidin-4-yl)indoline-4-carboxylate (<b>24b</b>)</h3><div class="NLM_p last">2-(3-Fluoro-5-(trifluoromethyl)phenyl)acetonitrile (<b>9a</b>) (406 mg, 2 mmol) was dissolved in 5 mL of DMF, and the mixture solution was cooled to 0 °C with an ice bath. NaH (190 mg, 4.4 mmol) was added to the solution at 0 °C, and the mixture solution was stirred at 0 °C for 30 min. Then, compound <b>8c</b> (580 mg, 2 mmol) was added to the solution at 0 °C. After the mixture solution was stirred at rt. for 2 h, the mixture was cooled to 0 °C with an ice bath. Followed by adding <i>m</i>CPBA (516 mg, 3 mmol), the mixture solution was stirred at 0 °C for 10 min. After the reaction was completed (detected by TLC), the reaction was worked up by the addition of water and then extracted with EtOAc (20 mL × 3). The combined EtOAc extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and condensed by rotary evaporation to yield a yellow oil. The residue purification by silica gel chromatography (gradient: 20 to 50% EtOAc in hexane) provided product <b>24b</b> (440 mg, 49%) as a yellow solid. <sup>1</sup>H NMR (300 MHz, chloroform-<i>d</i>) δ 8.97 (d, <i>J</i> = 1.1 Hz, 1H), 8.82 (d, <i>J</i> = 8.1 Hz, 1H), 8.31 (s, 1H), 8.17 (d, <i>J</i> = 9.0 Hz, 1H), 7.73 (dd, <i>J</i> = 7.9, 1.0 Hz, 1H), 7.60 (d, <i>J</i> = 8.0 Hz, 1H), 7.39 (t, <i>J</i> = 8.0 Hz, 1H), 7.31 (s, 1H), 4.21 (t, <i>J</i> = 8.6 Hz, 2H), 3.96 (s, 3H), 3.72 (t, <i>J</i> = 8.6 Hz, 2H).</div></div><div id="sec4_55" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> Methyl 1-(6-(3-(Trifluoromethyl)benzoyl)pyrimidin-4-yl)indoline-4-carboxylate (<b>24c</b>)</h3><div class="NLM_p last">Compound <b>24c</b> (162 mg, 79%) was synthesized by a procedure similar to that used to prepare compound <b>24b</b> as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.75 (d, <i>J</i> = 0.9 Hz, 1H), 8.67 (d, <i>J</i> = 8.1 Hz, 1H), 7.94–7.84 (m, 2H), 7.77 (d, <i>J</i> = 7.9 Hz, 1H), 7.71 (d, <i>J</i> = 7.7 Hz, 1H), 7.54 (dd, <i>J</i> = 7.9, 1.0 Hz, 1H), 7.35 (t, <i>J</i> = 8.0 Hz, 1H), 7.08 (s, 1H), 6.01 (s, 1H), 4.10 (t, <i>J</i> = 9.8 Hz, 2H), 3.85 (s, 3H), 3.51 (t, <i>J</i> = 8.5 Hz, 2H).</div></div><div id="sec4_56" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> 1-(4-(3-Fluoro-5-(trifluoromethyl)benzoyl)pyrimidin-2-yl)-<i>N</i>-(2-hydroxyethyl)indoline-4-carboxamide (<b>25a</b>)</h3><div class="NLM_p last">To a solution of <b>24a</b> (45 mg, 0.1 mmol) in con. HCl (4 mL), H<sub>2</sub>O (1 mL) and AcOH (1 mL) were added, and the mixture solution was stirred at reflux overnight. The reaction mixture was cooled to room temperature, and a yellow solid precipitated from the solution. The yellow solid was filtered and washed with water, and the cake was collected and dried to afford the product as a light yellow solid. The yellow solid and 2-aminoethan-1-ol (13 mg, 0.2 mmol) were dissolved in 2 mL of DMF, and the mixture solution was cooled to 0 °C with an ice bath. HOBt (14 mg, 0.1 mmol), EDCI (39 mg, 0.2 mmol), and DMAP (24 mg, 0.2 mmol) were added to the solution at 0 °C. Then, the ice bath was removed, and the mixture solution was stirred at room temperature overnight. After the reaction was completed (detected by TLC), the reaction was worked up by the addition of water and then extracted with EtOAc (20 mL × 3). The combined EtOAc extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and condensed by rotary evaporation to yield a yellow oil. This material was further purified by preparative TLC plates using CH<sub>2</sub>Cl<sub>2</sub>/MeOH = 50:1 as the eluent to yield <b>25a</b> as a yellow solid (36 mg, 77% for two steps). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.94 (d, <i>J</i> = 4.9 Hz, 1H), 8.33 (s, 1H), 8.17 (dd, <i>J</i> = 26.9, 8.6 Hz, 3H), 7.44 (d, <i>J</i> = 4.9 Hz, 1H), 7.21 (d, <i>J</i> = 7.6 Hz, 1H), 7.10 (s, 1H), 4.71 (t, <i>J</i> = 5.6 Hz, 1H), 4.19 (t, <i>J</i> = 8.6 Hz, 2H), 3.51 (q, <i>J</i> = 6.1 Hz, 2H), 3.39 (t, <i>J</i> = 8.7 Hz, 2H), 3.30 (s, 2H). <sup>13</sup>C NMR (75 MHz, DMSO) δ 159.9, 143.8, 132.7, 127.4, 122.0, 120.9, 116.7, 110.5, 60.2, 49.4, 42.4, 42.3, 40.8, 27.3. HRMS (ESI): (M + H)<sup>+</sup> calcd for C<sub>23</sub>H<sub>19</sub>F<sub>4</sub>N<sub>4</sub>O<sub>3</sub>, 475.1388; found, 475.1385.</div></div><div id="sec4_57" class="NLM_sec NLM_sec_level_2"><div id="ac_i83" class="anchor-spacer"></div><h3 class="article-section__title" id="_i83"> 1-(6-(3-Fluoro-5-(trifluoromethyl)benzoyl)pyrimidin-4-yl)-<i>N</i>-(2-hydroxyethyl)indoline-4-carboxamide (<b>25b</b>)</h3><div class="NLM_p last">Compound <b>25b</b> (35 mg, 75%) was synthesized by a procedure similar to that used to prepare compound <b>25a</b> as a yellow solid. <sup>1</sup>H NMR (300 MHz, chloroform-<i>d</i> and MeOD) δ 8.86 (d, <i>J</i> = 1.1 Hz, 1H), 8.63 (d, <i>J</i> = 7.7 Hz, 1H), 8.21 (s, 1H), 8.07 (dt, <i>J</i> = 8.8, 2.0 Hz, 1H), 7.55 (dt, <i>J</i> = 8.0, 2.0 Hz, 1H), 7.28–7.23 (m, 2H), 7.22–7.20 (m, 1H), 4.10 (t, <i>J</i> = 8.5 Hz, 2H), 3.74 (t, <i>J</i> = 5.1 Hz, 2H), 3.54 (dd, <i>J</i> = 9.3, 7.1 Hz, 4H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub> and MeOD) δ 190.3, 168.8, 166.6, 163.7, 160.4, 159.5 (d, <i>J</i> = 59.6 Hz), 157.3, 143.9, 138.0, 132.7, 131.2, 127.8, 123.9–123.3 (m), 121.3 (d, <i>J</i> = 23.2 Hz), 120.9, 119.0, 117.34 (dd, <i>J</i> = 24.4, 3.2 Hz), 105.1, 61.2, 49.0, 42.3, 27.5. HRMS (ESI): (M + H)<sup>+</sup> calcd for C<sub>23</sub>H<sub>19</sub>F<sub>4</sub>N<sub>4</sub>O<sub>3</sub>, 475.1388; found, 475.1386.</div></div><div id="sec4_58" class="NLM_sec NLM_sec_level_2"><div id="ac_i84" class="anchor-spacer"></div><h3 class="article-section__title" id="_i84"> <i>N</i>-(2-Hydroxyethyl)-1-(6-(3-(trifluoromethyl)benzoyl)pyrimidin-4-yl)indoline-4-carboxamide (<b>25c</b>)</h3><div class="NLM_p last">Compound <b>25c</b> (360 mg, 63%) was synthesized by a procedure similar to that used to prepare compound <b>25a</b> as a yellow solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.92 (d, <i>J</i> = 1.1 Hz, 1H), 8.63 (dd, <i>J</i> = 6.6, 2.6 Hz, 1H), 8.38–8.25 (m, 3H), 8.13–8.05 (m, 1H), 7.88–7.77 (m, 1H), 7.39–7.26 (m, 3H), 4.73 (t, <i>J</i> = 5.6 Hz, 1H), 4.17 (t, <i>J</i> = 8.5 Hz, 2H), 3.59–3.41 (m, 4H), 3.34 (m, 2H). <sup>13</sup>C NMR (75 MHz, DMSO) δ 192.0, 167.4, 160.0, 159.9 (d, <i>J</i> = 8.6 Hz), 157.5, 143.9, 136.4, 135.0, 132.9 (d, <i>J</i> = 14.2 Hz), 132.7, 130.2, 129.4, 127.7, 127.3 (d, <i>J</i> = 3.6 Hz), 127.2, 121.8, 118.3, 105.5, 60.2, 49.0, 42.4, 27.7. HRMS (ESI): (M + H)<sup>+</sup> calcd for C<sub>23</sub>H<sub>20</sub>F<sub>3</sub>N<sub>4</sub>O<sub>3</sub>, 457.1482; found, 457.1480.</div></div><div id="sec4_59" class="NLM_sec NLM_sec_level_2"><div id="ac_i85" class="anchor-spacer"></div><h3 class="article-section__title" id="_i85"> 1-(4-((3-Fluoro-5-(trifluoromethyl)phenyl)(hydroxy)methyl)pyrimidin-2-yl)-<i>N</i>-(2-hydroxyethyl)indoline-4-carboxamide (<b>25d</b>)</h3><div class="NLM_p last">To a solution of <b>25a</b> (10 mg, 0.02 mmol) in MeOH (1 mL) was added NaBH<sub>4</sub> (1 mg, 0.02 mmol) at 0 °C, and the mixture solution was stirred at rt. for 1 h. After the reaction was completed (detected by TLC), the reaction mixture was worked up by the addition of water and EtOAc extraction. The combined EtOAc extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and condensed by rotary evaporation to yield a colorless oil. This material was further purified by preparative TLC plates using CH<sub>2</sub>Cl<sub>2</sub>/MeOH = 50:1 as the eluent to yield <b>25d</b> as a white solid (9 mg, 93%). <sup>1</sup>H NMR (300 MHz, chloroform-<i>d</i>) δ 8.50–8.35 (m, 2H), 7.57 (s, 1H), 7.37 (d, <i>J</i> = 9.1 Hz, 1H), 7.24 (dd, <i>J</i> = 15.9, 7.8 Hz, 2H), 7.12 (d, <i>J</i> = 7.7 Hz, 1H), 6.66 (t, <i>J</i> = 4.5 Hz, 2H), 5.67 (s, 1H), 4.94 (s, 1H), 4.24 (t, <i>J</i> = 8.8 Hz, 2H), 3.85 (t, <i>J</i> = 4.9 Hz, 2H), 3.63 (q, <i>J</i> = 5.2 Hz, 2H), 3.44 (t, <i>J</i> = 8.6 Hz, 2H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 169.1, 168.7, 164.2, 160.9, 158.4, 158.1, 145.8 (d, <i>J</i> = 6.9 Hz), 144.4, 132.9 (d, <i>J</i> = 8.1 Hz), 132.5 (d, <i>J</i> = 8.0 Hz), 130.9, 127.7, 125.0 (d, <i>J</i> = 3.0 Hz), 121.3 (d, <i>J</i> = 3.0 Hz), 119.5–119.24 (m), 117.7, 117.3 (d, <i>J</i> = 22.2 Hz), 112.5 (ddd, <i>J</i> = 24.2, 7.1, 3.4 Hz), 108.0, 73.8, 62.3, 49.2, 42.6, 27.2. HRMS (ESI): (M + H)<sup>+</sup> calcd for C<sub>23</sub>H<sub>21</sub>F<sub>4</sub>N<sub>4</sub>O<sub>3</sub>, 477.1544; found, 477.1540.</div></div><div id="sec4_60" class="NLM_sec NLM_sec_level_2"><div id="ac_i86" class="anchor-spacer"></div><h3 class="article-section__title" id="_i86"> 1-(6-((3-Fluoro-5-(trifluoromethyl)phenyl)(hydroxy)methyl)pyrimidin-4-yl)-<i>N</i>-(2-hydroxyethyl)indoline-4-carboxamide (<b>25e</b>)</h3><div class="NLM_p last">Compound <b>25e</b> (32 mg, 78%) was synthesized by a procedure similar to that used to prepare compound <b>25d</b> as a white solid. <sup>1</sup>H NMR (300 MHz, chloroform-<i>d</i> and MeOD) δ 8.66–8.27 (m, 2H), 7.51 (s, 1H), 7.34 (d, <i>J</i> = 8.5 Hz, 2H), 7.26–7.01 (m, 3H), 6.68 (s, 1H), 5.60 (s, 1H), 3.90 (t, <i>J</i> = 8.6 Hz, 2H), 3.70 (s, 2H), 3.46–3.27 (m, 4H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub> and MeOD) δ 168.7 (d, <i>J</i> = 36.5 Hz), 164.0, 159.4, 156.8, 146.2, 144.1, 132.4, 131.0, 127.6, 120.5, 119.2, 118.7, 117.2 (d, <i>J</i> = 22.5 Hz), 112.4–111.7 (m), 101.0, 73.9, 61.1, 42.3, 42.2, 27.3. HRMS (ESI): (M + H)<sup>+</sup> calcd for C<sub>23</sub>H<sub>21</sub>F<sub>4</sub>N<sub>4</sub>O<sub>3</sub>, 477.1544; found, 477.1540.</div></div><div id="sec4_61" class="NLM_sec NLM_sec_level_2"><div id="ac_i87" class="anchor-spacer"></div><h3 class="article-section__title" id="_i87"> 1-(6-(Hydroxy(3-(trifluoromethyl)phenyl)methyl)pyrimidin-4-yl)-<i>N</i>-(2-hydroxyethyl)indoline-4-carboxamide (<b>25f</b>)</h3><div class="NLM_p last">Compound <b>25f</b> (41 mg, 90%) was synthesized by a procedure similar to that used to prepare compound <b>25d</b> as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.64 (s, 1H), 8.54 (d, <i>J</i> = 7.0 Hz, 1H), 8.25 (t, <i>J</i> = 5.8 Hz, 1H), 7.89–7.72 (m, 2H), 7.69–7.52 (m, 2H), 7.28 (d, <i>J</i> = 6.6 Hz, 2H), 7.09 (s, 1H), 6.45 (d, <i>J</i> = 4.5 Hz, 1H), 5.72 (d, <i>J</i> = 4.5 Hz, 1H), 4.71 (t, <i>J</i> = 5.6 Hz, 1H), 4.11 (q, <i>J</i> = 7.9 Hz, 2H), 3.60–3.33 (m, 6H). <sup>13</sup>C NMR (75 MHz, DMSO) δ 170.9, 167.5, 159.7, 157.4, 145.2, 144.4, 132.6, 131.5, 129.6, 129.2 (d, <i>J</i> = 31.4 Hz), 127.6, 126.5, 124.5 (t, <i>J</i> = 3.9 Hz), 123.7 (t, <i>J</i> = 3.9 Hz), 121.1, 117.9, 101.3, 74.5, 60.3, 49.0, 42.4, 27.7. HRMS (ESI): (M + H)<sup>+</sup> calcd for C<sub>23</sub>H<sub>22</sub>F<sub>3</sub>N<sub>4</sub>O<sub>3</sub>, 459.1639; found, 459.1635.</div></div><div id="sec4_62" class="NLM_sec NLM_sec_level_2"><div id="ac_i88" class="anchor-spacer"></div><h3 class="article-section__title" id="_i88"> 1-(4-((3-Fluoro-5-(trifluoromethyl)phenyl)(hydroxy)methyl)pyrimidin-2-yl)indoline-4-carboxylic Acid (<b>26a</b>)</h3><div class="NLM_p last">To a solution of <b>24a</b> (427 mg, 1 mmol) in DMF (5 mL) and MeOH (5 mL) was added NaBH<sub>4</sub> (38 mg, 1 mmol) at 0 °C, and the mixture solution was stirred at rt. for 30 min. After the reaction was completed (detected by TLC), the reaction mixture was worked up by the addition of water and then extracted with EtOAc (20 mL × 3). The combined EtOAc extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and condensed by rotary evaporation to yield a colorless oil. The colorless oil was dissolved in con. HCl (4 mL), H<sub>2</sub>O (1 mL), and AcOH (1 mL), and the mixture solution was stirred at reflux overnight. The reaction was cooled to room temperature, and a yellow solid precipitated from the solution. The yellow solid was filtered and washed with water, and the cake was collected and dried to afford the product as a light yellow solid (210 mg, 78%). <sup>1</sup>H NMR (300 MHz, chloroform-<i>d</i>) δ 8.63 (s, 1H), 8.51 (d, <i>J</i> = 4.8 Hz, 1H), 7.74 (dd, <i>J</i> = 7.9, 1.0 Hz, 1H), 7.57 (s, 1H), 7.36 (t, <i>J</i> = 10.4 Hz, 3H), 6.67 (d, <i>J</i> = 5.1 Hz, 1H), 5.73 (s, 1H), 4.39 (t, <i>J</i> = 8.3 Hz, 2H), 3.66 (t, <i>J</i> = 8.6 Hz, 2H).</div></div><div id="sec4_63" class="NLM_sec NLM_sec_level_2"><div id="ac_i89" class="anchor-spacer"></div><h3 class="article-section__title" id="_i89"> 1-(6-((3-Fluoro-5-(trifluoromethyl)phenyl)(hydroxy)methyl)pyrimidin-4-yl)indoline-4-carboxylic Acid (<b>26b</b>)</h3><div class="NLM_p last">Compound <b>26b</b> (390 mg, 90%) was synthesized by a procedure similar to that used to prepare compound <b>26a</b> as a yellow solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.86 (s, 1H), 8.71 (d, <i>J</i> = 7.8 Hz, 1H), 7.84 (s, 1H), 7.77 (d, <i>J</i> = 9.5 Hz, 1H), 7.64 (d, <i>J</i> = 7.8 Hz, 2H), 7.45–7.40 (m, 1H), 7.32 (d, <i>J</i> = 2.9 Hz, 1H), 6.00 (s, 1H), 4.24 (dt, <i>J</i> = 9.0, 3.9 Hz, 2H), 3.61–3.50 (m, 3H).</div></div><div id="sec4_64" class="NLM_sec NLM_sec_level_2"><div id="ac_i90" class="anchor-spacer"></div><h3 class="article-section__title" id="_i90"> 1-(6-(Hydroxy(3-(trifluoromethyl)phenyl)methyl)pyrimidin-4-yl)indoline-4-carboxylic Acid (<b>26c</b>)</h3><div class="NLM_p last">Compound <b>26c</b> (117 mg, 68%) was synthesized by a procedure similar to that used to prepare compound <b>26a</b> as a yellow solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.86 (d, <i>J</i> = 3.4 Hz, 1H), 8.71 (d, <i>J</i> = 7.8 Hz, 1H), 7.96 (s, 1H), 7.87 (d, <i>J</i> = 7.6 Hz, 1H), 7.73–7.58 (m, 3H), 7.42 (t, <i>J</i> = 8.0 Hz, 1H), 7.31 (d, <i>J</i> = 2.3 Hz, 1H), 5.99 (s, 1H), 4.32–4.14 (m, 2H), 3.58 (t, <i>J</i> = 8.2 Hz, 2H).</div></div><div id="sec4_65" class="NLM_sec NLM_sec_level_2"><div id="ac_i91" class="anchor-spacer"></div><h3 class="article-section__title" id="_i91"> 1-(4-(Fluoro(3-fluoro-5-(trifluoromethyl)phenyl)methyl)pyrimidin-2-yl)indoline-4-carboxylic Acid (<b>27a</b>)</h3><div class="NLM_p last">To a solution of <b>26a</b> (210 mg, 0.6 mmol) in DCM (5 mL) was added DAST (322 mg, 1.8 mmol) at 0 °C, and the mixture solution was stirred at 0 °C for 10 min. After the reaction was completed (detected by TLC), the reaction mixture was worked up by the addition of water and then extracted with EtOAc (20 mL × 3). The combined EtOAc extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and condensed by rotary evaporation to yield a yellow oil. The residue was dissolved in THF (2 mL) and H<sub>2</sub>O (2 mL), and the mixture solution was stirred at reflux overnight. The reaction was cooled to room temperature, and a yellow solid precipitated from the solution. The yellow solid was filtered and washed with water, and the cake was collected and dried to afford the product as light yellow solid <b>27a</b> (140 mg, 54% for two steps). <sup>1</sup>H NMR (300 MHz, chloroform-<i>d</i>) δ 8.63 (d, <i>J</i> = 5.0 Hz, 1H), 8.49 (d, <i>J</i> = 8.2 Hz, 1H), 7.73–7.64 (m, 2H), 7.46 (d, <i>J</i> = 8.9 Hz, 1H), 7.40–7.29 (m, 2H), 7.04 (dd, <i>J</i> = 5.1, 1.7 Hz, 1H), 6.41 (d, <i>J</i> = 46.4 Hz, 1H), 4.28 (dd, <i>J</i> = 8.3, 3.1 Hz, 2H), 3.61 (t, <i>J</i> = 8.8 Hz, 2H).</div></div><div id="sec4_66" class="NLM_sec NLM_sec_level_2"><div id="ac_i92" class="anchor-spacer"></div><h3 class="article-section__title" id="_i92"> 1-(6-(Fluoro(3-fluoro-5-(trifluoromethyl)phenyl)methyl)pyrimidin-4-yl)indoline-4-carboxylic Acid (<b>27b</b>)</h3><div class="NLM_p last">Compound <b>27b</b> (260 mg, 60%) was synthesized by a procedure similar to that used to prepare compound <b>27a</b> as a yellow solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.01 (s, 1H), 8.71 (d, <i>J</i> = 7.6 Hz, 2H), 7.80–7.71 (m, 3H), 7.56 (ddd, <i>J</i> = 7.8, 3.3, 1.2 Hz, 1H), 7.35 (dd, <i>J</i> = 9.1, 6.9 Hz, 1H), 7.11 (s, 1H), 6.75 (d, <i>J</i> = 45.7 Hz, 1H), 4.26–4.13 (m, 2H), 3.55 (t, <i>J</i> = 8.4 Hz, 2H).</div></div><div id="sec4_67" class="NLM_sec NLM_sec_level_2"><div id="ac_i93" class="anchor-spacer"></div><h3 class="article-section__title" id="_i93"> 1-(6-(Fluoro(3-(trifluoromethyl)phenyl)methyl)pyrimidin-4-yl)indoline-4-carboxylic Acid (<b>27c</b>)</h3><div class="NLM_p last">Compound <b>27c</b> (110 mg, 76%) was synthesized by a procedure similar to that used to prepare compound <b>27a</b> as a yellow solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.71 (s, 1H), 7.90 (s, 1H), 7.83–7.74 (m, 1H), 7.69 (d, <i>J</i> = 7.7 Hz, 1H), 7.56 (dd, <i>J</i> = 7.3, 3.1 Hz, 1H), 7.38 (t, <i>J</i> = 8.0 Hz, 1H), 7.10 (s, 1H), 6.72 (d, <i>J</i> = 45.7 Hz, 1H), 4.20 (dd, <i>J</i> = 9.4, 4.7 Hz, 2H), 3.55 (t, <i>J</i> = 8.6 Hz, 2H).</div></div><div id="sec4_68" class="NLM_sec NLM_sec_level_2"><div id="ac_i94" class="anchor-spacer"></div><h3 class="article-section__title" id="_i94"> 1-(4-(Fluoro(3-fluoro-5-(trifluoromethyl)phenyl)methyl)pyrimidin-2-yl)-<i>N</i>-(2-hydroxyethyl)indoline-4-carboxamide (<b>25g</b>)</h3><div class="NLM_p last">Compound <b>25g</b> (140 mg, 86%) was synthesized by a procedure similar to that used to prepare compound <b>12a</b> as a light yellow solid. <sup>1</sup>H NMR (300 MHz, chloroform-<i>d</i> and MeOD) δ 8.54 (d, <i>J</i> = 5.0 Hz, 1H), 8.27 (d, <i>J</i> = 7.7 Hz, 1H), 7.63 (s, 1H), 7.41 (d, <i>J</i> = 8.9 Hz, 1H), 7.31 (d, <i>J</i> = 8.4 Hz, 1H), 7.21–7.09 (m, 2H), 7.07–6.90 (m, 2H), 6.35 (d, <i>J</i> = 46.3 Hz, 1H), 4.17 (tt, <i>J</i> = 9.1, 3.5 Hz, 2H), 3.75 (t, <i>J</i> = 5.1 Hz, 2H), 3.54 (q, <i>J</i> = 5.3 Hz, 2H), 3.41 (t, <i>J</i> = 8.7 Hz, 2H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub> and MeOD) δ 169.2, 169.1, 166.6 (d, <i>J</i> = 28.5 Hz), 164.0, 160.7, 159.0, 158.4 (d, <i>J</i> = 3.6 Hz), 144.3, 141.5 (dd, <i>J</i> = 21.8, 7.5 Hz), 132.7, 132.5, 131.0, 131.0, 127.5, 119.13–118.56 (m), 116.8 (dd, <i>J</i> = 22.9, 7.7 Hz), 113.2 (d, <i>J</i> = 23.1 Hz), 106.5 (d, <i>J</i> = 6.7 Hz), 91.95 (d, <i>J</i> = 179.2 Hz), 61.5, 49.1, 42.4, 27.2. HRMS (ESI): (M + H)<sup>+</sup> calcd for C<sub>23</sub>H<sub>20</sub>F<sub>5</sub>N<sub>4</sub>O<sub>2</sub>, 479.1501; found, 479.1498.</div></div><div id="sec4_69" class="NLM_sec NLM_sec_level_2"><div id="ac_i95" class="anchor-spacer"></div><h3 class="article-section__title" id="_i95"> 1-(6-(Fluoro(3-fluoro-5-(trifluoromethyl)phenyl)methyl)pyrimidin-4-yl)-<i>N</i>-(2-hydroxyethyl)indoline-4-carboxamide (<b>25h</b>)</h3><div class="NLM_p last">Compound <b>25h</b> (162 mg, 68%) was synthesized by a procedure similar to that used to prepare compound <b>12a</b> as a white solid. <sup>1</sup>H NMR (300 MHz, chloroform-<i>d</i>) δ 8.74 (s, 1H), 8.66 (d, <i>J</i> = 8.1 Hz, 1H), 7.60 (s, 1H), 7.44 (d, <i>J</i> = 8.9 Hz, 1H), 7.37–7.31 (m, 1H), 7.28 (t, <i>J</i> = 4.0 Hz, 1H), 7.19 (d, <i>J</i> = 7.6 Hz, 1H), 6.86 (s, 1H), 6.61 (t, <i>J</i> = 5.8 Hz, 1H), 6.39 (d, <i>J</i> = 46.4 Hz, 1H), 4.11 (t, <i>J</i> = 8.6 Hz, 2H), 3.87 (q, <i>J</i> = 4.8 Hz, 2H), 3.72–3.53 (m, 4H), 2.73 (t, <i>J</i> = 5.0 Hz, 1H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 168.6, 164.9 (d, <i>J</i> = 26.3 Hz), 164.1, 160.7, 159.6, 157.7 (d, <i>J</i> = 3.4 Hz), 144.4, 141.4, 132.8, 130.9, 127.9, 124.8, 121.2, 120.2, 119.1, 117.3 (d, <i>J</i> = 15.5 Hz), 113.4 (d, <i>J</i> = 23.9 Hz), 100.1 (d, <i>J</i> = 8.2 Hz), 92.07 (d, <i>J</i> = 179.4 Hz), 77.4, 62.3, 49.0, 42.6, 27.7. <sup>19</sup>F NMR (282 MHz, chloroform-<i>d</i>) δ −62.8, −109.5 (t, <i>J</i> = 8.7 Hz), −183.9 (d, <i>J</i> = 46.4 Hz). HRMS (ESI): (M + H)<sup>+</sup> calcd for C<sub>23</sub>H<sub>20</sub>F<sub>5</sub>N<sub>4</sub>O<sub>2</sub>, 479.1501; found, 479.1498.</div></div><div id="sec4_70" class="NLM_sec NLM_sec_level_2"><div id="ac_i96" class="anchor-spacer"></div><h3 class="article-section__title" id="_i96"> 1-(6-(Fluoro(3-(trifluoromethyl)phenyl)methyl)pyrimidin-4-yl)-<i>N</i>-(2-hydroxyethyl)indoline-4-carboxamide (<b>25i</b>)</h3><div class="NLM_p last">Compound <b>25i</b> (240 mg, 72%) was synthesized by a procedure similar to that used to prepare compound <b>12a</b> as a white solid. <sup>1</sup>H NMR (300 MHz, chloroform-<i>d</i> and MeOD) δ 8.59 (dd, <i>J</i> = 15.6, 5.0 Hz, 2H), 7.76–7.42 (m, 4H), 7.18 (dt, <i>J</i> = 12.7, 7.0 Hz, 3H), 6.80 (d, <i>J</i> = 4.2 Hz, 1H), 6.35 (dd, <i>J</i> = 46.3, 4.4 Hz, 1H), 4.00 (q, <i>J</i> = 7.3 Hz, 2H), 3.74 (d, <i>J</i> = 5.6 Hz, 2H), 3.49 (dt, <i>J</i> = 20.7, 6.7 Hz, 4H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 168.8, 165.3 (d, <i>J</i> = 26.5 Hz), 159.5, 157.4, 144.1, 138.4 (d, <i>J</i> = 20.5 Hz), 132.5, 131.2, 131.1, 130.8, 130.3 (d, <i>J</i> = 6.5 Hz), 129.2, 127.7, 125.9, 123.5 (dt, <i>J</i> = 6.1, 2.8 Hz) 123.5, 120.5, 118.9, 100.2 (d, <i>J</i> = 8.1 Hz), 92.7 (d, <i>J</i> = 177.7 Hz), 61.3, 48.9, 42.4, 27.5. <sup>19</sup>F NMR (282 MHz, CDCl<sub>3</sub>) δ −62.8, −181.1. HRMS (ESI): (M + H)<sup>+</sup> calcd for C<sub>23</sub>H<sub>21</sub>F<sub>4</sub>N<sub>4</sub>O<sub>2</sub>, 461.1595; found, 461.1590.</div></div><div id="sec4_71" class="NLM_sec NLM_sec_level_2"><div id="ac_i97" class="anchor-spacer"></div><h3 class="article-section__title" id="_i97"> Methyl 1-(6-((3-(Trifluoromethyl)phenyl)amino)pyrimidin-4-yl)indoline-4-carboxylate (<b>29a</b>)</h3><div class="NLM_p last">A mixture of <b>28a</b> (48 mg, 0.3 mmol), Pd(OAc)<sub>2</sub> (3 mg, 0.015 mmol), XantPhos (17 mg, 0.03 mmol), Cs<sub>2</sub>CO<sub>3</sub> (196 mg, 0.6 mmol), and <b>8c</b> (87 mg, 0.3 mmol) in 1,4-dioxane (3 mL) was subjected to three rounds of vacuum evacuation followed by introduction of nitrogen. The reaction mixture was then stirred at 100 °C overnight. The reaction mixture was cooled to room temperature and poured into water and then extracted with EtOAc (10 mL × 3). The organic phase was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and then concentrated under reduced pressure. The residue was purified by silica gel chromatography (gradient: 10 to 20% EtOAc in hexane) to provide product <b>29a</b> (86 mg, 69%) as a yellow solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.72 (s, 1H), 8.65 (dd, <i>J</i> = 8.2, 1.1 Hz, 1H), 8.49 (s, 1H), 8.24 (s, 1H), 7.86 (d, <i>J</i> = 8.0 Hz, 1H), 7.55–7.46 (m, 2H), 7.36–7.27 (m, 2H), 6.11 (s, 1H), 4.03 (t, <i>J</i> = 8.7 Hz, 2H), 3.86 (s, 3H), 3.52 (t, <i>J</i> = 8.7 Hz, 2H).</div></div><div id="sec4_72" class="NLM_sec NLM_sec_level_2"><div id="ac_i98" class="anchor-spacer"></div><h3 class="article-section__title" id="_i98"> Methyl 1-(6-(3-(Trifluoromethyl)phenoxy)pyrimidin-4-yl)indoline-4-carboxylate (<b>29b</b>)</h3><div class="NLM_p last">To a solution of <b>28b</b> (49 mg, 0.3 mmol) in DMF (2 mL) were added cesium carbonate (195 mg, 0.6 mmol) and <b>8c</b> (87 mg, 0.3 mmol), and the reaction was heated to 120 °C overnight. At this point, the reaction mixture was cooled to rt., poured into water (15 mL), and extracted with ethyl acetate (3 × 10 mL). The combined organic extracts were washed with water (10 mL) and brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated <i>in vacuo</i>. The residue was purified by chromatography on silica gel (eluent: 1% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) and yielded product <b>29b</b> (79 mg, 63%) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.69 (t, <i>J</i> = 8.2 Hz, 1H), 8.47 (s, 1H), 7.73–7.50 (m, 5H), 7.36 (t, <i>J</i> = 8.2 Hz, 1H), 6.47 (d, <i>J</i> = 5.4 Hz, 1H), 4.10 (t, <i>J</i> = 8.5 Hz, 2H), 3.86 (s, 3H), 3.54 (t, <i>J</i> = 8.6 Hz, 2H).</div></div><div id="sec4_73" class="NLM_sec NLM_sec_level_2"><div id="ac_i99" class="anchor-spacer"></div><h3 class="article-section__title" id="_i99"> Methyl 1-(6-((3-(Trifluoromethyl)phenyl)thio)pyrimidin-4-yl)indoline-4-carboxylate (<b>29c</b>)</h3><div class="NLM_p last">Compound <b>29c</b> (92 mg, 71%) was synthesized by a procedure similar to that used to prepare compound <b>29b</b> as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.63–8.50 (m, 2H), 8.01–7.85 (m, 3H), 7.75 (t, <i>J</i> = 7.8 Hz, 1H), 7.52 (dd, <i>J</i> = 7.9, 1.1 Hz, 1H), 7.32 (t, <i>J</i> = 8.1 Hz, 1H), 6.52 (d, <i>J</i> = 1.1 Hz, 1H), 3.91 (t, <i>J</i> = 8.6 Hz, 2H), 3.84 (s, 3H), 3.45 (t, <i>J</i> = 8.6 Hz, 2H).</div></div><div id="sec4_74" class="NLM_sec NLM_sec_level_2"><div id="ac_i100" class="anchor-spacer"></div><h3 class="article-section__title" id="_i100"> <i>N</i>-(2-Hydroxyethyl)-1-(6-((3-(trifluoromethyl)phenyl)amino)pyrimidin-4-yl)indoline-4-carboxamide (<b>25j</b>)</h3><div class="NLM_p last">To a solution of <b>29a</b> (41 mg, 0.1 mmol) in con. HCl (4 mL), H<sub>2</sub>O (1 mL) and AcOH (1 mL) were added, and the mixture solution was stirred at reflux overnight. The reaction was cooled to room temperature, and a yellow solid precipitated from the solution. The yellow solid was filtered and washed with water, and the cake was collected and dried to afford the product as a light yellow solid. The yellow solid and 2-aminoethan-1-ol (13 mg, 0.2 mmol) were dissolved in 2 mL of DMF, and the mixture solution was cooled to 0 °C with an ice bath. HOBt (14 mg, 0.1 mmol), EDCI (39 mg, 0.2 mmol), and DMAP (24 mg, 0.2 mmol) were added to the solution at 0 °C. Then, the ice bath was removed, and the mixture solution was stirred at rt. overnight. After the reaction was completed (detected by TLC), the reaction mixture was worked up by the addition of water and then extracted with EtOAc (20 mL × 3). The combined EtOAc extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and condensed by rotary evaporation to yield a yellow oil. This material was further purified by preparative TLC plates using CH<sub>2</sub>Cl<sub>2</sub>/MeOH = 50:1 as the eluent to yield <b>25j</b> as a white solid (43 mg, 73% for two steps). <sup>1</sup>H NMR (300 MHz, chloroform-<i>d</i> and MeOD) δ 8.43–8.25 (m, 2H), 7.66 (s, 1H), 7.55 (d, <i>J</i> = 8.2 Hz, 1H), 7.40 (t, <i>J</i> = 7.9 Hz, 1H), 7.32–7.23 (m, 2H), 7.19–7.03 (m, 2H), 5.89 (s, 1H), 3.80 (t, <i>J</i> = 8.5 Hz, 2H), 3.70 (t, <i>J</i> = 5.2 Hz, 2H), 3.49 (t, <i>J</i> = 5.3 Hz, 2H), 3.34 (t, <i>J</i> = 8.5 Hz, 2H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub> and MeOD) δ 169.2, 166.6, 160.5, 159.7, 157.4, 153.0, 144.8, 139.9, 132.0, 131.6, 131.2, 131.0, 129.7, 127.6, 124.1, 119.6, 117.8, 117.5, 85.9, 61.1, 42.3, 27.4. HRMS (ESI): (M + H)<sup>+</sup> calcd for C<sub>22</sub>H<sub>21</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub>, 444.1642; found, 444.1639.</div></div><div id="sec4_75" class="NLM_sec NLM_sec_level_2"><div id="ac_i101" class="anchor-spacer"></div><h3 class="article-section__title" id="_i101"> <i>N</i>-(2-Hydroxyethyl)-1-(6-(3-(trifluoromethyl)phenoxy)pyrimidin-4-yl)indoline-4-carboxamide (<b>25k</b>)</h3><div class="NLM_p last">Compound <b>25k</b> (48 mg, 43%) was synthesized by a procedure similar to that used to prepare compound <b>25j</b> as a white solid. <sup>1</sup>H NMR (300 MHz, chloroform-<i>d</i> and MeOD) δ 8.50 (d, <i>J</i> = 7.8 Hz, 1H), 8.39 (d, <i>J</i> = 3.5 Hz, 1H), 7.59–7.08 (m, 7H), 6.05 (d, <i>J</i> = 3.5 Hz, 1H), 3.93 (t, <i>J</i> = 8.8 Hz, 2H), 3.69 (q, <i>J</i> = 4.5 Hz, 2H), 3.48 (s, 4H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub> and MeOD) δ 169.3, 169.0, 161.2, 157.4, 152.9, 144.4, 132.3, 131.1, 130.3, 127.7, 124.9, 122.1, 120.3, 118.4, 89.3, 61.1, 42.3, 27.5. HRMS (ESI): (M + H)<sup>+</sup> calcd for C<sub>22</sub>H<sub>20</sub>F<sub>3</sub>N<sub>4</sub>O<sub>3</sub>, 445.1482; found, 445.1480.</div></div><div id="sec4_76" class="NLM_sec NLM_sec_level_2"><div id="ac_i102" class="anchor-spacer"></div><h3 class="article-section__title" id="_i102"> <i>N</i>-(2-Hydroxyethyl)-1-(6-((3-(trifluoromethyl)phenyl)thio)pyrimidin-4-yl)indoline-4-carboxamide (<b>25l</b>)</h3><div class="NLM_p last">Compound <b>25l</b> (64 mg, 56%) was synthesized by a procedure similar to that used to prepare compound <b>25j</b> as a white solid. <sup>1</sup>H NMR (300 MHz, chloroform-<i>d</i> and MeOD) δ 8.47 (d, <i>J</i> = 3.9 Hz, 1H), 8.42–8.28 (m, 1H), 7.92–7.52 (m, 4H), 7.31–7.07 (m, 3H), 6.03 (d, <i>J</i> = 3.8 Hz, 1H), 3.71 (d, <i>J</i> = 5.7 Hz, 4H), 3.49 (t, <i>J</i> = 5.0 Hz, 2H), 3.40 (d, <i>J</i> = 9.4 Hz, 2H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub> and MeOD) δ 169.0, 168.8, 158.5, 157.1, 144.1, 138.6, 132.4, 132.3, 131.9, 131.1, 130.2, 130.2, 127.6, 126.5, 120.4, 118.4, 100.4, 61.2, 48.6, 42.3, 42.2, 27.4. HRMS (ESI): (M + H)<sup>+</sup> calcd for C<sub>22</sub>H<sub>20</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>S, 461.1254; found, 461.1250.</div></div><div id="sec4_77" class="NLM_sec NLM_sec_level_2"><div id="ac_i103" class="anchor-spacer"></div><h3 class="article-section__title" id="_i103"> <i>N</i>-(1,3-Dihydroxypropan-2-yl)-1-(6-(3-fluoro-5-(trifluoromethyl)benzyl)pyrimidin-4-yl)indoline-4-carboxamide (<b>30a</b>)</h3><div class="NLM_p last">Compound <b>30a</b> (28 mg, 57%) was synthesized by a procedure similar to that used to prepare compound <b>12a</b> as a white solid. <sup>1</sup>H NMR (300 MHz, chloroform-<i>d</i> and MeOD) δ 8.68 (s, 1H), 8.55 (d, <i>J</i> = 7.5 Hz, 1H), 7.33 (s, 1H), 7.28–7.11 (m, 4H), 6.40 (s, 1H), 4.10–3.90 (m, 5H), 3.82 (dd, <i>J</i> = 11.3, 4.3 Hz, 2H), 3.70 (dd, <i>J</i> = 11.3, 5.1 Hz, 2H), 3.49 (t, <i>J</i> = 8.5 Hz, 2H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub> and MeOD) δ 168.5, 166.6, 166.0, 159.5, 157.7, 144.3, 141.6, 132.3, 130.9, 127.8, 121.8–121.5 (m), 120.5, 119.7, 119.4, 118.8, 111.5 (d, <i>J</i> = 3.9 Hz), 111.13 (d, <i>J</i> = 3.8 Hz), 104.0, 61.6, 52.6, 48.8, 43.4, 27.5. HRMS (ESI): (M + H)<sup>+</sup> calcd for C<sub>24</sub>H<sub>23</sub>F<sub>4</sub>N<sub>4</sub>O<sub>3</sub>, 491.1701; found, 491.1697.</div></div><div id="sec4_78" class="NLM_sec NLM_sec_level_2"><div id="ac_i104" class="anchor-spacer"></div><h3 class="article-section__title" id="_i104"> 1-(6-(3-Fluoro-5-(trifluoromethyl)benzyl)pyrimidin-4-yl)-<i>N</i>-(2-methoxyethyl)indoline-4-carboxamide (<b>30b</b>)</h3><div class="NLM_p last">Compound <b>30b</b> (30 mg, 65%) was synthesized by a procedure similar to that used to prepare compound <b>12a</b> as a white solid. <sup>1</sup>H NMR (300 MHz, chloroform-<i>d</i>) δ 8.78 (s, 1H), 8.63 (d, <i>J</i> = 8.1 Hz, 1H), 7.38 (s, 1H), 7.31–7.21 (m, 3H), 7.17 (d, <i>J</i> = 7.7 Hz, 1H), 6.47 (d, <i>J</i> = 6.2 Hz, 1H), 6.43 (s, 1H), 4.08 (s, 2H), 4.02 (t, <i>J</i> = 8.6 Hz, 2H), 3.61 (ddd, <i>J</i> = 16.4, 10.7, 6.9 Hz, 6H), 3.42 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 167.6, 166.2, 164.2, 160.9, 159.5, 158.0, 144.5, 141.8 (d, <i>J</i> = 7.6 Hz), 132.9, 132.5, 132.5, 131.2, 127.8, 125.0, 121.7 (t, <i>J</i> = 3.6 Hz), 120.0, 119.6 (d, <i>J</i> = 21.4 Hz), 118.6, 111.3 (dd, <i>J</i> = 24.6, 3.9 Hz), 103.9, 77.4, 77.0, 76.6, 71.2, 48.8, 43.8, 39.5, 27.7. HRMS (ESI): (M + H)<sup>+</sup> calcd for C<sub>24</sub>H<sub>23</sub>F<sub>4</sub>N<sub>4</sub>O<sub>2</sub>, 475.1752; found, 475.1749.</div></div><div id="sec4_79" class="NLM_sec NLM_sec_level_2"><div id="ac_i105" class="anchor-spacer"></div><h3 class="article-section__title" id="_i105"> 1-(6-(3-Fluoro-5-(trifluoromethyl)benzyl)pyrimidin-4-yl)-<i>N</i>-(3-hydroxypropyl)indoline-4-carboxamide (<b>30c</b>)</h3><div class="NLM_p last">Compound <b>30c</b> (26 mg, 56%) was synthesized by a procedure similar to that used to prepare compound <b>12a</b> as a white solid. <sup>1</sup>H NMR (300 MHz, chloroform-<i>d</i>) δ 8.77 (s, 1H), 8.63 (d, <i>J</i> = 8.1 Hz, 1H), 7.38 (s, 1H), 7.29–7.20 (m, 3H), 7.14 (d, <i>J</i> = 7.7 Hz, 1H), 6.64 (t, <i>J</i> = 6.1 Hz, 1H), 6.43 (s, 1H), 4.07 (s, 2H), 4.00 (t, <i>J</i> = 8.6 Hz, 2H), 3.76 (t, <i>J</i> = 5.5 Hz, 2H), 3.69–3.50 (m, 4H), 3.23 (s, 1H), 1.82 (p, <i>J</i> = 5.7 Hz, 2H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 168.7, 166.2, 164.2, 160.9, 159.5, 158.0, 144.6, 141.8 (d, <i>J</i> = 7.5 Hz), 132.6, 131.0, 127.9, 121.8–121.6 (m), 119.8, 119.5, 118.8, 111.7–111.0 (m), 103.9, 59.9, 48.8, 43.8, 37.0, 32.1, 27.7. HRMS (ESI): (M + H)<sup>+</sup> calcd for C<sub>24</sub>H<sub>23</sub>F<sub>4</sub>N<sub>4</sub>O<sub>2</sub>, 475.1752; found, 475.1749.</div></div><div id="sec4_80" class="NLM_sec NLM_sec_level_2"><div id="ac_i106" class="anchor-spacer"></div><h3 class="article-section__title" id="_i106"> 1-(6-(3-Fluoro-5-(trifluoromethyl)benzyl)pyrimidin-4-yl)-<i>N</i>-(4-hydroxybutyl)indoline-4-carboxamide (<b>30d</b>)</h3><div class="NLM_p last">Compound <b>30d</b> (30 mg, 61%) was synthesized by a procedure similar to that used to prepare compound <b>12a</b> as a white solid. <sup>1</sup>H NMR (300 MHz, chloroform-<i>d</i> and MeOD) δ 8.66 (s, 1H), 8.52 (d, <i>J</i> = 8.1 Hz, 1H), 7.33 (s, 1H), 7.27–7.06 (m, 5H), 6.39 (s, 1H), 4.02 (s, 2H), 3.94 (t, <i>J</i> = 8.5 Hz, 2H), 3.61 (t, <i>J</i> = 5.8 Hz, 2H), 3.47 (t, <i>J</i> = 8.5 Hz, 2H), 3.38 (t, <i>J</i> = 6.2 Hz, 2H), 1.63 (dq, <i>J</i> = 12.9, 6.7 Hz, 4H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub> and MeOD) δ 168.5, 165.9, 164.1, 160.8, 159.5, 157.7, 144.2, 141.6 (d, <i>J</i> = 7.7 Hz), 132.3, 131.5, 127.7, 121.6, 120.3, 119.7, 119.4, 118.5, 111.4 (d, <i>J</i> = 3.8 Hz), 111.1 (d, <i>J</i> = 3.7 Hz), 104.0, 61.7, 48.8, 43.3, 39.6, 29.6, 27.4, 25.9. HRMS (ESI): (M + H)<sup>+</sup> calcd for C<sub>25</sub>H<sub>25</sub>F<sub>4</sub>N<sub>4</sub>O<sub>2</sub>, 489.1908; found, 489.1904.</div></div><div id="sec4_81" class="NLM_sec NLM_sec_level_2"><div id="ac_i107" class="anchor-spacer"></div><h3 class="article-section__title" id="_i107"> (1-(6-(3-Fluoro-5-(trifluoromethyl)benzyl)pyrimidin-4-yl)indolin-4-yl)(3-hydroxyazetidin-1-yl)methanone (<b>30e</b>)</h3><div class="NLM_p last">Compound <b>30e</b> (17 mg, 37%) was synthesized by a procedure similar to that used to prepare compound <b>12a</b> as a white solid. <sup>1</sup>H NMR (300 MHz, chloroform-<i>d</i>) δ 8.76 (d, <i>J</i> = 1.0 Hz, 1H), 8.56 (d, <i>J</i> = 8.2 Hz, 1H), 7.38 (s, 1H), 7.24 (d, <i>J</i> = 8.4 Hz, 3H), 7.00 (dd, <i>J</i> = 7.7, 1.0 Hz, 1H), 6.45–6.39 (m, 1H), 4.79–4.66 (m, 1H), 4.41 (s, 2H), 4.11–3.94 (m, 6H), 3.52–3.39 (m, 2H), 3.06 (s, 1H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 169.9, 166.2, 164.2, 160.9, 159.5, 158.0, 144.5, 141.7 (d, <i>J</i> = 7.6 Hz), 132.0, 129.5, 127.5, 121.8–121.6 (m), 120.9, 119.6 (d, <i>J</i> = 21.7 Hz), 118.3, 111.3 (d, <i>J</i> = 28.0 Hz), 103.9, 62.2, 61.7, 58.2, 48.7, 43.7, 27.2. HRMS (ESI): (M + H)<sup>+</sup> calcd for C<sub>24</sub>H<sub>21</sub>F<sub>4</sub>N<sub>4</sub>O<sub>2</sub>, 473.1595; found, 473.1593.</div></div><div id="sec4_82" class="NLM_sec NLM_sec_level_2"><div id="ac_i108" class="anchor-spacer"></div><h3 class="article-section__title" id="_i108"> 1-(6-(3-Fluoro-5-(trifluoromethyl)benzyl)pyrimidin-4-yl)-<i>N</i>-(2-fluoroethyl)indoline-4-carboxamide (<b>30f</b>)</h3><div class="NLM_p last">Compound <b>30f</b> (36 mg, 78%) was synthesized by a procedure similar to that used to prepare compound <b>12a</b> as a white solid. <sup>1</sup>H NMR (300 MHz, chloroform-<i>d</i>) δ 8.83–8.73 (m, 1H), 8.66 (d, <i>J</i> = 8.1 Hz, 1H), 7.39 (s, 1H), 7.33–7.15 (m, 4H), 6.45 (d, <i>J</i> = 9.4 Hz, 2H), 4.71 (t, <i>J</i> = 4.7 Hz, 1H), 4.55 (t, <i>J</i> = 4.7 Hz, 1H), 4.14–3.95 (m, 4H), 3.83 (q, <i>J</i> = 5.1 Hz, 1H), 3.74 (q, <i>J</i> = 5.1 Hz, 1H), 3.58 (t, <i>J</i> = 8.5 Hz, 2H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 167.8, 166.3, 164.2, 160.9, 159.5, 158.0, 144.7, 141.8 (d, <i>J</i> = 7.6 Hz), 132.6, 130.8, 128.0, 121.7 (t, <i>J</i> = 3.5 Hz), 119.9, 119.8, 119.5, 118.9, 111.5 (d, <i>J</i> = 3.7 Hz), 111.2 (d, <i>J</i> = 3.8 Hz), 103.9, 82.8 (d, <i>J</i> = 166.7 Hz), 48.8, 43.8, 40.2 (d, <i>J</i> = 19.5 Hz), 27.7. <sup>19</sup>F NMR (282 MHz, chloroform-<i>d</i>) δ −62.7, −110.6 (t, <i>J</i> = 8.8 Hz), −224.2 (tt, <i>J</i> = 47.4, 28.3 Hz). HRMS (ESI): (M + H)<sup>+</sup> calcd for C<sub>23</sub>H<sub>20</sub>F<sub>5</sub>N<sub>4</sub>O, 473.1595; found, 473.1593.</div></div><div id="sec4_83" class="NLM_sec NLM_sec_level_2"><div id="ac_i109" class="anchor-spacer"></div><h3 class="article-section__title" id="_i109"> 1-(6-(3-Fluoro-5-(trifluoromethyl)benzyl)pyrimidin-4-yl)-<i>N</i>,<i>N</i>-bis(2-hydroxyethyl)indoline-4-carboxamide (<b>30g</b>)</h3><div class="NLM_p last">Compound <b>30g</b> (27 mg, 53%) was synthesized by a procedure similar to that used to prepare compound <b>12a</b> as a white solid. <sup>1</sup>H NMR (300 MHz, chloroform-<i>d</i>) δ 8.71 (s, 1H), 8.45 (d, <i>J</i> = 8.2 Hz, 1H), 7.37 (s, 1H), 7.29–7.17 (m, 3H), 6.97 (d, <i>J</i> = 7.6 Hz, 1H), 6.40 (s, 1H), 4.10–3.57 (m, 12H), 3.44 (t, <i>J</i> = 5.0 Hz, 2H), 3.26 (t, <i>J</i> = 8.5 Hz, 2H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 172.3, 166.2, 164.2, 160.9, 159.5, 158.0, 144.0, 141.7 (d, <i>J</i> = 7.5 Hz), 133.0, 129.7, 127.8, 122.0–121.5 (m), 120.2, 119.8, 119.5, 117.0, 111.3 (d, <i>J</i> = 24.4 Hz), 103.8, 61.1, 60.1, 52.9, 49.1, 48.5, 43.6, 26.1. HRMS (ESI): (M + H)<sup>+</sup> calcd for C<sub>25</sub>H<sub>25</sub>F<sub>4</sub>N<sub>4</sub>O<sub>3</sub>, 505.1857; found, 505.1853.</div></div><div id="sec4_84" class="NLM_sec NLM_sec_level_2"><div id="ac_i110" class="anchor-spacer"></div><h3 class="article-section__title" id="_i110"> Molecular Docking Protocol</h3><div class="NLM_p last">The molecular docking study was performed using Schrödinger Small-Molecule Drug Discovery Suite (Schrödinger, LLC, New York, NY, 2020). The cocrystal structures of GPR52 and compound <b>2</b> (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6LI0">6LI0</a>) were downloaded from the RCS PDB bank. The cocrystal structure was preprocessed and minimized with Schrödinger Protein Preparation Wizard using default settings. The grid center was chosen on the centroid of an existing ligand, and the size of the grid box was set to 30 Å on each side. The 3D structure of ligand <b>12c</b> was created using Schrödinger Maestro, and a low energy conformation was calculated using LigPrep. Docking was employed with Glide using the SP precision. Docked poses were incorporated into Schrödinger Maestro for visualization and analysis of binding site interactions.</div></div><div id="sec4_85" class="NLM_sec NLM_sec_level_2"><div id="ac_i111" class="anchor-spacer"></div><h3 class="article-section__title" id="_i111"> <i>In Vitro</i> Pharmacology</h3><div id="sec4_85_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i112" class="anchor-spacer"></div><h4 class="article-section__title" id="_i112"> Cell Culture and Plasmids</h4><div class="NLM_p last">Wildtype (WT) human embryonic kidney 293 (HEK293) cells were a generous gift from Dr. Asuka Inoue, Tohoku University.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> The wildtype HEK293 cells were cultured in DMEM (Gibco, Carlsbad, CA) with 10% FBS (Omega Scientific, Tarzana, CA) and 10,000 U/mL penicillin–streptomycin (Gibco, Carlsbad, CA) in a humidified incubator at 37 °C in 5% CO<sub>2</sub>. A GPR52 TANGO construct was purchased from Addgene (Watertown, MA). A stop codon was placed in the frame immediately after the receptor coding sequence to generate a human GPR52 WT coding construct. Point mutation of GPR52 WT from GPR52 TANGO was made by polymerase chain reaction (PCR) using the QuikChange II Site-Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, CA) according to the manufacturer’s protocol. Mutagenesis and sequencing primers were obtained from ThermoFisher (Pittsburgh, PA). The primers used to make the GPR52 WT point mutant were 5′–gctaacagctgttccatctaagataccggtggacgcacc–3′ (sense) and 5′–cgattgtcgacaaggtagattctatggccacctgcgtgg–3′ (antisense). Parental DNA in the reaction mixture was digested using restriction endonuclease DpnI (from diplococcus pneumoniae) at 37 °C for one hour. A digestion mixture (2 μL) was transformed into XL1-Blue supercompetent cells by heat shock at 42 °C for 45 s. The reaction was incubated in Super Optimal broth with a catabolite repression medium (Sigma-Aldrich) and then plated onto Luria–Bertani (LB) agar plates containing 100 μg/mL ampicillin. A single colony was selected for sequencing, and the point mutation was verified prior to use (Molecular Genomics Core, University of Texas Medical Branch, Galveston, TX).</div></div><div id="sec4_85_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i113" class="anchor-spacer"></div><h4 class="article-section__title" id="_i113"> Transfections</h4><div class="NLM_p last">For the cAMP Glosensor assays, 6.5 × 10<sup>5</sup> wildtype HEK293 cells were plated in 6-well plates (Corning, Oneonta, NY) 24 h before transfection to achieve 70–80% confluency the following day. Each well of wildtype HEK293 cells was transiently transfected with 0.10 μg of wildtype human GPR52 plasmid cDNA and 1 μg of the 22F Glosensor plasmid (Promega, Madison, WI) using 10 μL of Lipofectamine 2000 (Invitrogen, Waltham, MA) in 1 mL of OptiMEM (Gibco, Carlsbad, CA) and 1 mL of growth media.</div></div><div id="sec4_85_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i114" class="anchor-spacer"></div><h4 class="article-section__title" id="_i114"> cAMP Glosensor Assay</h4><div class="NLM_p last">Eighteen hours after transfection, wildtype HEK293 cells with GPR52 and Glosensor constructs (see <a class="ref internalNav" href="#sec4_85_2" aria-label="Transfections">Transfections</a> above), cells were seeded at 60,000 cells/well in growth media into poly-<span class="smallcaps smallerCapital">l</span>-lysine (Trevigen, Gaithersburg, MD) coated 96-well white clear-bottom cell culture plates (Greiner Bio-One, Monroe, NC). Four hours later, complete media was aspirated and replaced with 90 μL of a 1% Glosensor reagent (Promega, Madison, WI) in 1× Hanks’ balanced salt solution (HBSS) and 20 mM HEPES. Cells were serum-starved for 2 h at room temperature in the dark. Test compounds were weighed and diluted to 2 mM in DMSO. Serial dilutions of each test compound were prepared at 10× final concentration and transferred to a 96-well source plate. Cells were incubated with 10 μL of 10× drug solutions for 15 min. LCPS were recorded on a Microbeta2 Microplate counter (PerkinElmer, Waltham, MA). Data from at least three independent experiments (<i>n</i> = 3 to 21) conducted in technical triplicate are presented as percentage of compound <b>4</b> response. All <i>in vitro</i> pharmacological data were analyzed using GraphPad Prism 7.05 software (La Jolla, CA). Data from cAMP ligand dose response assays are presented as the half maximum (EC<sub>50</sub>, nM) and maximum effect (<i>E</i><sub>max</sub>) (means ± SEM) as computed by GraphPad using a four-parameter nonlinear regression curve-fitting algorithm. All <i>E</i><sub>max</sub> ligand responses were scaled relative to 3 μM compound <b>4</b> in cells treated for each assay (3 μM compound <b>4</b> response set to 100%).</div></div><div id="sec4_85_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i115" class="anchor-spacer"></div><h4 class="article-section__title" id="_i115"> <i>In Vivo</i> PK and Brain Permeability Studies</h4><div class="NLM_p">Male Sprague Dawley rats (<i>n</i> = 3 per treatment group; Beijing Vital River Laboratory, Animal Technology Co., Ltd., Beijing, China) weighing 200–250 g at the beginning of the experiment were housed three per cage in a pathogen-free, temperature-controlled (20–26 °C), and humidity-controlled (40–70%) environment with a 12 h light–dark cycle and <i>ad libitum</i> access to food and filtered water. Rats were randomly assigned to treatment groups. A vehicle [10% dimethyl sulfoxide (DMSO) and 90% 2-hydroxypropyl-β-cyclodextrin (HP-β-CD); Cyclodextrin Technologies Development, Inc., High Springs, FL, USA] or compound <b>12c</b> dissolved in the vehicle was administered to rats IV at 10 mg/kg or PO at 20 mg/kg. The rat was restrained manually at the designated time points (0.08, 0.25, 0.5, 1.0, 2.0, 4.0, 8.0, and 24 h post-dosing for IV; 0.25, 0.5, 1.0, 2.0, 4.0, 8.0, and 24 h post-dosing for PO). Blood (yielding ∼50 μL of plasma) samples (100 μL) are taken from the animal’s jugular vein and placed into micro K<sub>2</sub>EDTA tubes. Blood samples were placed on ice and centrifuged at 8000 rpm for 5 min at 4 °C to generate plasma samples within 0.5 h of collection. Brain samples were collected at 0.25 and 1 h post-dosing. All samples were stored at −20 °C. The concentration of <b>12c</b> in each sample was analyzed by Sundia MediTech Co., Ltd. The study and the related standard operating procedures were reviewed and approved by the Sundia Institutional Animal Care and Use Committee. The Sundia animal facility is approved with yearly inspection by the Shanghai Laboratory Animal Management Committee. All treatment assignments were blinded to investigators who performed PK assays and end point statistical analyses.</div><div class="NLM_p last">The PK parameters of compound <b>12c</b> were calculated according to a non-compartmental model using WinNonlin (Pharsight Corporation, ver 5.3, Mountain View, CA, USA). The peak concentration (<i>C</i><sub>max</sub>) was directly obtained by visual inspection of the plasma concentration–time profile. The elimination rate constant (λ) was obtained by the least-squares fitted terminal log-linear portion of the slope of the plasma concentration–time profile. The elimination half-life (<i>t</i><sub>1/2</sub>) was evaluated according to 0.693/λ. The area under the plasma concentration–time curve from 0 to time <i>t</i> (AUC<sub>0–<i>t</i></sub>) was evaluated using the linear trapezoidal rule and further extrapolated to infinity (AUC<sub>0–∞</sub>) according to the following equation: AUC<sub>0–∞</sub> = AUC<sub>0–<i>t</i></sub> + <i>C</i><sub>last</sub>/λ. The pharmacokinetic parameters were presented as mean ± SEM.</div></div></div><div id="sec4_86" class="NLM_sec NLM_sec_level_2"><div id="ac_i116" class="anchor-spacer"></div><h3 class="article-section__title" id="_i116"> <i>In Vivo</i> Pharmacology of Compound <b>12c</b></h3><div id="sec4_86_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i117" class="anchor-spacer"></div><h4 class="article-section__title" id="_i117"> Animals</h4><div class="NLM_p last">Naïve male C57/BL6 mice (<i>n</i> = 60; Jackson Laboratory, Bar Harbor, ME) weighing between 24 and 31 g (∼60 days of age) at the beginning of the experiment were housed four/cage in a temperature- (21–23 °C) and humidity-controlled (40–50%) environment on a 12 h light/dark cycle (lights on at 0600). Mice were provided <i>ad libitum</i> access to chow and water for 14–20 days prior to experiments, which were carried out in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals (2011) and with the approval of the Institutional Animal Care and Use Committee at the University of Texas Medical Branch.</div></div><div id="sec4_86_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i118" class="anchor-spacer"></div><h4 class="article-section__title" id="_i118"> Drugs</h4><div class="NLM_p last">Compound <b>12c</b> was dissolved in 0.9% saline containing 20% HP-β-CD with a final pH of the solution adjusted to 7.4. Dextroamphetamine (Sigma-Aldrich, St Louis, MO, USA) was prepared in 0.9% saline. Compounds were then administered IP at 2 mL/1 kg body weight.</div></div><div id="sec4_86_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i119" class="anchor-spacer"></div><h4 class="article-section__title" id="_i119"> Locomotor Activity Assessment</h4><div class="NLM_p">A modified open field activity system (San Diego Instruments, San Diego, California, U.S.A.) was employed to quantify activity under low-light conditions.<a onclick="showRef(event, 'ref32 ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref32 ref33 ref34">(32−34)</a> Clear Plexiglas chambers (40 × 40 × 40 cm) were surrounded by a 4 × 4 photobeam matrix positioned ∼1 cm above the chamber floor. Horizontal activity was quantified as the sum of photobeam breaks that occurred within the inner central 16 × 16 cm area and in the surrounding outer 12 × 12 cm perimeter of the activity monitor.</div><div class="NLM_p last">A between-subjects design was employed to study the efficacy of compound <b>12c</b> to impact horizontal activity. Mice were handled three times/week for two weeks prior to the study and were habituated to the motor activity monitors 1 h/day for three days. Mice were transported in their home cages and allowed to acclimate to the testing room for 1 h prior to evaluation. On the day of the test, mice were weighed and randomized into five treatment groups for compound <b>12c</b> administration (<i>n</i> = 12/dose). One animal was excluded as an outlier (i.e., horizontal activity two standard deviations from the mean) with <i>n</i> = 11 for 1 mg/kg compound <b>12c</b>). Following IP administration of the vehicle or compound <b>12c</b> (0.3, 1, 3, and 10 mg/kg), automated activity monitoring began immediately and continued for 30 min. Mice were then injected with AMPH (3 mg/kg IP), and activity was monitored for the next 90 min. All testings occurred between 0800 and 1700 h.</div></div><div id="sec4_86_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i120" class="anchor-spacer"></div><h4 class="article-section__title" id="_i120"> Statistical Analyses</h4><div class="NLM_p last">Locomotor activities are presented as mean horizontal activity (mean ± SEM). A one-way ANOVA for a between-subjects design was employed to analyze horizontal activity. <i>A priori</i> comparisons were defined prior to the start of experimentation and conducted by Dunnett’s procedure,<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> with an experiment-wise error rate set at α = 0.05. Investigators who performed compound administration were blinded to treatment assignments and endpoint statistical analyses.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i121"><a href="/doi/suppl/10.1021/acs.jmedchem.0c01498" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72420" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72420" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c01498?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01498</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Figures S1 and S2, HPLC analysis spectra of representative compounds, and <sup>1</sup>H and <sup>13</sup>C NMR spectra of all new compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01498/suppl_file/jm0c01498_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and data (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01498/suppl_file/jm0c01498_si_002.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Docking compound <b>12c</b> with GPR52 (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01498/suppl_file/jm0c01498_si_003.pdb" class="ext-link">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01498/suppl_file/jm0c01498_si_001.pdf">jm0c01498_si_001.pdf (4.32 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01498/suppl_file/jm0c01498_si_002.csv">jm0c01498_si_002.csv (3.03 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01498/suppl_file/jm0c01498_si_003.pdb">jm0c01498_si_003.pdb (807.35 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c01498" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22317" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22317" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John A. Allen</span> - <span class="hlFld-Affiliation affiliation">Chemical
Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas 77555, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Center
for Addiction Research, University of Texas
Medical Branch, Galveston, Texas 77555, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#bcd6d3ddddd0d0d9d2fcc9c8d1de92d9d8c9"><span class="__cf_email__" data-cfemail="284247494944444d46685d5c454a064d4c5d">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jia Zhou</span> - <span class="hlFld-Affiliation affiliation">Chemical
Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas 77555, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Center
for Addiction Research, University of Texas
Medical Branch, Galveston, Texas 77555, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2811-1090" title="Orcid link">http://orcid.org/0000-0002-2811-1090</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#1f75766577706a5f6a6b727d317a7b6a"><span class="__cf_email__" data-cfemail="452f2c3f2d2a3005303128276b202130">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pingyuan Wang</span> - <span class="hlFld-Affiliation affiliation">Chemical
Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas 77555, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniel E. Felsing</span> - <span class="hlFld-Affiliation affiliation">Center
for Addiction Research, University of Texas
Medical Branch, Galveston, Texas 77555, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Haiying Chen</span> - <span class="hlFld-Affiliation affiliation">Chemical
Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas 77555, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sonja J. Stutz</span> - <span class="hlFld-Affiliation affiliation">Center
for Addiction Research, University of Texas
Medical Branch, Galveston, Texas 77555, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ryan E. Murphy</span> - <span class="hlFld-Affiliation affiliation">Center
for Addiction Research, University of Texas
Medical Branch, Galveston, Texas 77555, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kathryn A. Cunningham</span> - <span class="hlFld-Affiliation affiliation">Chemical
Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas 77555, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Center
for Addiction Research, University of Texas
Medical Branch, Galveston, Texas 77555, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4257-1739" title="Orcid link">http://orcid.org/0000-0002-4257-1739</a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>P.W. and D.E.F contributed equally and should be considered as cofirst authors.</p><span class="author-information-subsection-header">Author Contributions</span><p>J.A.A and J.Z. are equal contributors.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i124">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86146" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86146" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by grants T32 DA 007287 and U18 DA052543 from the National Institutes of Health, the PhRMA foundation, and the Center for Addiction Research at the University of Texas Medical Branch (UTMB). J.Z. is also partially supported by the John D. Stobo, M. D., Distinguished Chair Endowment Fund. The authors would like to acknowledge Robert Fox for <i>in vivo</i> assay assistance and the preparation of amphetamine solutions for <i>in vivo</i> injections. The authors would also like to acknowledge Dr. Asuka Inoue, Tohoku University, for the generous gift of the HEK cell line, Dr. Lawrence C. Sowers at the UTMB Department of Pharmacology and Toxicology as well as Dr. Tianzhi Wang at the NMR core facility of UTMB for the NMR spectroscopy assistance, and Dr. Xuemei Luo at the UTMB Mass Spectrometry Core with the funding support from the University of Texas System Proteomics Network for the HRMS analysis.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">ABBREVIATIONS Used</td></tr><tr><td class="NLM_term">GPCRs</td><td class="NLM_def"><p class="first last">G-protein-coupled receptors</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">U.S. Food and Drug Administration</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">NAc</td><td class="NLM_def"><p class="first last">nucleus accumbens</p></td></tr><tr><td class="NLM_term">MSNs</td><td class="NLM_def"><p class="first last">medium spiny neurons</p></td></tr><tr><td class="NLM_term">cAMP</td><td class="NLM_def"><p class="first last">cyclic adenosine monophosphate</p></td></tr><tr><td class="NLM_term">NMDA</td><td class="NLM_def"><p class="first last"><i>N</i>-methyl-<span class="smallcaps smallerCapital">d</span>-aspartate</p></td></tr><tr><td class="NLM_term">SUD</td><td class="NLM_def"><p class="first last">substance use disorder</p></td></tr><tr><td class="NLM_term">ECL2</td><td class="NLM_def"><p class="first last">extracellular loop 2</p></td></tr><tr><td class="NLM_term">EC<sub>50</sub></td><td class="NLM_def"><p class="first last">half maximal effective concentration</p></td></tr><tr><td class="NLM_term">HTS</td><td class="NLM_def"><p class="first last">high-throughput screening</p></td></tr><tr><td class="NLM_term">TM</td><td class="NLM_def"><p class="first last">transmembrane helix</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylformamide</p></td></tr><tr><td class="NLM_term">EDCI</td><td class="NLM_def"><p class="first last"><i>N</i>-(3-dimethylaminopropyl)-<i>N</i>′-ethylcarbodiimide hydrochloride</p></td></tr><tr><td class="NLM_term">DMAP</td><td class="NLM_def"><p class="first last">4-dimethylaminopyridine</p></td></tr><tr><td class="NLM_term">XantPhos</td><td class="NLM_def"><p class="first last">4,5-bis(diphenylphosphino)-9,9-dimethylxanthene</p></td></tr><tr><td class="NLM_term"><i>m</i>CPBA</td><td class="NLM_def"><p class="first last"><i>meta</i>-chloroperoxybenzoic acid</p></td></tr><tr><td class="NLM_term">DAST</td><td class="NLM_def"><p class="first last">diethylaminosulfur trifluoride</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">NIMH</td><td class="NLM_def"><p class="first last">National Institute of Mental Health</p></td></tr><tr><td class="NLM_term">PDSP</td><td class="NLM_def"><p class="first last">psychoactive drug screening program</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">human ether-a-go-go-related gene</p></td></tr><tr><td class="NLM_term">PO</td><td class="NLM_def"><p class="first last">oral</p></td></tr><tr><td class="NLM_term">IV</td><td class="NLM_def"><p class="first last">intravenous</p></td></tr><tr><td class="NLM_term">AMPH</td><td class="NLM_def"><p class="first last">amphetamine</p></td></tr><tr><td class="NLM_term">WT</td><td class="NLM_def"><p class="first last">wildtype</p></td></tr><tr><td class="NLM_term">HEK293</td><td class="NLM_def"><p class="first last">human embryonic kidney 293</p></td></tr><tr><td class="NLM_term">PCR</td><td class="NLM_def"><p class="first last">polymerase chain reaction</p></td></tr><tr><td class="NLM_term">HBSS</td><td class="NLM_def"><p class="first last">Hanks’ balanced salt solution</p></td></tr><tr><td class="NLM_term">IP</td><td class="NLM_def"><p class="first last">intraperitoneal</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i126">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37351" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37351" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 35 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span> <span> </span><span class="NLM_article-title">Strategies to discover unexpected targets for drugs active at G protein-coupled receptors</span>. <i>Annu. Rev. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">117</span>– <span class="NLM_lpage">144</span>, <span class="refDoi"> DOI: 10.1146/annurev-pharmtox-010510-100553</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=10.1146%2Fannurev-pharmtox-010510-100553" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=20868273" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisFOjurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2011&pages=117-144&author=J.+A.+Allenauthor=B.+L.+Roth&title=Strategies+to+discover+unexpected+targets+for+drugs+active+at+G+protein-coupled+receptors&doi=10.1146%2Fannurev-pharmtox-010510-100553"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies to discover unexpected targets for drugs active at G protein-coupled receptors</span></div><div class="casAuthors">Allen, John A.; Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">117-144</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  G protein-coupled receptors (GPCRs) are an evolutionarily conserved family of signaling mols. comprising approx. 2% of the human genome; this receptor family remains a central focus in basic pharmacol. studies and drug discovery efforts.  Detailed studies of drug action at GPCRs over the past decade have revealed existing and novel ligands that exhibit polypharmacol.-i.e., drugs with activity at more than 1 receptor target for which they were designed.  These "off-target" drug actions can be a liability that causes adverse side effects; however, in several cases, drugs with less selectivity demonstrate better clin. efficacy.  Here we review phys. screening and cheminformatic approaches that define drug activity at the GPCR receptorome.  In many cases, such profiling has revealed unexpected targets that explain therapeutic actions as well as off-targets underlying drug side effects.  Such drug-receptor profiling has also provided new insights into mechanisms of action of existing drugs and has suggested directions for future drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGondPzdCWKsd7Vg90H21EOLACvtfcHk0ljMO927albEnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisFOjurs%253D&md5=0699e67e114115904dff749d1251f91b</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1146%2Fannurev-pharmtox-010510-100553&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-pharmtox-010510-100553%26sid%3Dliteratum%253Aachs%26aulast%3DAllen%26aufirst%3DJ.%2BA.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DStrategies%2520to%2520discover%2520unexpected%2520targets%2520for%2520drugs%2520active%2520at%2520G%2520protein-coupled%2520receptors%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2011%26volume%3D51%26spage%3D117%26epage%3D144%26doi%3D10.1146%2Fannurev-pharmtox-010510-100553" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wold, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span> <span> </span><span class="NLM_article-title">Allosteric modulation of class A GPCRs: targets, agents, and emerging concepts</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">88</span>– <span class="NLM_lpage">127</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00875</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00875" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsV2lsLbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=88-127&author=E.+A.+Woldauthor=J.+Chenauthor=K.+A.+Cunninghamauthor=J.+Zhou&title=Allosteric+modulation+of+class+A+GPCRs%3A+targets%2C+agents%2C+and+emerging+concepts&doi=10.1021%2Facs.jmedchem.8b00875"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric Modulation of Class A GPCRs: Targets, Agents, and Emerging Concepts</span></div><div class="casAuthors">Wold, Eric A.; Chen, Jianping; Cunningham, Kathryn A.; Zhou, Jia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">88-127</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">G-protein-coupled receptors (GPCRs) have been tractable drug targets for decades with over one-third of currently marketed drugs targeting GPCRs.  Of these, the class A GPCR superfamily is highly represented, and continued drug discovery for this family of receptors may provide novel therapeutics for a vast range of diseases.  GPCR allosteric modulation is an innovative targeting approach that broadens the available small mol. toolbox and is proving to be a viable drug discovery strategy, as evidenced by recent FDA approvals and clin. trials.  Numerous class A GPCR allosteric modulators have been discovered recently, and emerging trends such as the availability of GPCR crystal structures, diverse functional assays, and structure-based computational approaches are improving optimization and development.  This Perspective provides an update on allosterically targeted class A GPCRs and their disease indications and the medicinal chem. approaches toward novel allosteric modulators and highlights emerging trends and opportunities in the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7zBEGIhRgD7Vg90H21EOLACvtfcHk0ljMO927albEnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsV2lsLbK&md5=c724b7cb534a9eb52c371961bb9c9b42</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00875&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00875%26sid%3Dliteratum%253Aachs%26aulast%3DWold%26aufirst%3DE.%2BA.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DCunningham%26aufirst%3DK.%2BA.%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DAllosteric%2520modulation%2520of%2520class%2520A%2520GPCRs%253A%2520targets%252C%2520agents%252C%2520and%2520emerging%2520concepts%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D88%26epage%3D127%26doi%3D10.1021%2Facs.jmedchem.8b00875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wild, C.</span></span> <span> </span><span class="NLM_article-title">GPCR drug discovery: emerging targets, novel approaches and future trends</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1363</span>– <span class="NLM_lpage">1364</span>, <span class="refDoi"> DOI: 10.2174/156802661916190828093500</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=10.2174%2F156802661916190828093500" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=31513505" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvV2isLfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=1363-1364&author=J.+Zhouauthor=C.+Wild&title=GPCR+drug+discovery%3A+emerging+targets%2C+novel+approaches+and+future+trends&doi=10.2174%2F156802661916190828093500"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">GPCR Drug Discovery: Emerging Targets, Novel Approaches and Future Trends</span></div><div class="casAuthors">Zhou, Jia; Wild, Christopher</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1363-1364</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon7RPLZ3B3ALVg90H21EOLACvtfcHk0lgb8HrnFgVFrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvV2isLfO&md5=ce49981d9123aae0ef48e1cbc47c704b</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.2174%2F156802661916190828093500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802661916190828093500%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DWild%26aufirst%3DC.%26atitle%3DGPCR%2520drug%2520discovery%253A%2520emerging%2520targets%252C%2520novel%2520approaches%2520and%2520future%2520trends%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2019%26volume%3D19%26spage%3D1363%26epage%3D1364%26doi%3D10.2174%2F156802661916190828093500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Overington, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Lazikani, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span> <span> </span><span class="NLM_article-title">How many drug targets are there?</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">993</span>– <span class="NLM_lpage">996</span>, <span class="refDoi"> DOI: 10.1038/nrd2199</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=10.1038%2Fnrd2199" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=17139284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1Kju7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=993-996&author=J.+P.+Overingtonauthor=B.+Al-Lazikaniauthor=A.+L.+Hopkins&title=How+many+drug+targets+are+there%3F&doi=10.1038%2Fnrd2199"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">How many drug targets are there?</span></div><div class="casAuthors">Overington, John P.; Al-Lazikani, Bissan; Hopkins, Andrew L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">993-996</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  For the past decade, the no. of mol. targets for approved drugs has been debated.  Here, we reconcile apparently contradictory previous reports into a comprehensive survey, and propose a consensus no. of current drug targets for all classes of approved therapeutic drugs.  One striking feature is the relatively const. historical rate of target innovation (the rate at which drugs against new targets are launched); however, the rate of developing drugs against new families is significantly lower.  The recent approval of drugs that target protein kinases highlights two addnl. trends: an emerging realization of the importance of polypharmacol., and also the power of a gene-family-led approach in generating novel and important therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDoZu-pkUsAbVg90H21EOLACvtfcHk0lgb8HrnFgVFrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1Kju7jM&md5=14b5716f4e10b57ae71bf67e52a21929</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrd2199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2199%26sid%3Dliteratum%253Aachs%26aulast%3DOverington%26aufirst%3DJ.%2BP.%26aulast%3DAl-Lazikani%26aufirst%3DB.%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26atitle%3DHow%2520many%2520drug%2520targets%2520are%2520there%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D993%26epage%3D996%26doi%3D10.1038%2Fnrd2199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lagerström, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiöth, H. B.</span></span> <span> </span><span class="NLM_article-title">Structural diversity of G protein-coupled receptors and significance for drug discovery</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">339</span>– <span class="NLM_lpage">357</span>, <span class="refDoi"> DOI: 10.1038/nrd2518</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=10.1038%2Fnrd2518" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=18382464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A280%3ADC%252BD1c3itl2juw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=339-357&author=M.+C.+Lagerstr%C3%B6mauthor=H.+B.+Schi%C3%B6th&title=Structural+diversity+of+G+protein-coupled+receptors+and+significance+for+drug+discovery&doi=10.1038%2Fnrd2518"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Structural diversity of G protein-coupled receptors and significance for drug discovery</span></div><div class="casAuthors">Lagerstrom Malin C; Schioth Helgi B</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Drug discovery</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">339-57</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">G protein-coupled receptors (GPCRs) are the largest family of membrane-bound receptors and also the targets of many drugs.  Understanding of the functional significance of the wide structural diversity of GPCRs has been aided considerably in recent years by the sequencing of the human genome and by structural studies, and has important implications for the future therapeutic potential of targeting this receptor family.  This article aims to provide a comprehensive overview of the five main human GPCR families--Rhodopsin, Secretin, Adhesion, Glutamate and Frizzled/Taste2--with a focus on gene repertoire, general ligand preference, common and unique structural features, and the potential for future drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSr8CC5dLjDFTC850By6mxpfW6udTcc2ebCOwj81G3Tp7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c3itl2juw%253D%253D&md5=3e9de54162c071b7927d975b964abea2</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrd2518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2518%26sid%3Dliteratum%253Aachs%26aulast%3DLagerstr%25C3%25B6m%26aufirst%3DM.%2BC.%26aulast%3DSchi%25C3%25B6th%26aufirst%3DH.%2BB.%26atitle%3DStructural%2520diversity%2520of%2520G%2520protein-coupled%2520receptors%2520and%2520significance%2520for%2520drug%2520discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2008%26volume%3D7%26spage%3D339%26epage%3D357%26doi%3D10.1038%2Fnrd2518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hauser, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attwood, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rask-Andersen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiöth, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gloriam, D. E.</span></span> <span> </span><span class="NLM_article-title">Trends in GPCR drug discovery: new agents, targets and indications</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">829</span>– <span class="NLM_lpage">842</span>, <span class="refDoi"> DOI: 10.1038/nrd.2017.178</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=10.1038%2Fnrd.2017.178" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=29075003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslansbzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=829-842&author=A.+S.+Hauserauthor=M.+M.+Attwoodauthor=M.+Rask-Andersenauthor=H.+B.+Schi%C3%B6thauthor=D.+E.+Gloriam&title=Trends+in+GPCR+drug+discovery%3A+new+agents%2C+targets+and+indications&doi=10.1038%2Fnrd.2017.178"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Trends in GPCR drug discovery: new agents, targets and indications</span></div><div class="casAuthors">Hauser, Alexander S.; Attwood, Misty M.; Rask-Andersen, Mathias; Schioth, Helgi B.; Gloriam, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">829-842</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">G protein-coupled receptors (GPCRs) are the most intensively studied drug targets, mostly due to their substantial involvement in human pathophysiol. and their pharmacol. tractability.  Here, we report an up-to-date anal. of all GPCR drugs and agents in clin. trials, which reveals current trends across mol. types, drug targets and therapeutic indications, including showing that 475 drugs (∼34% of all drugs approved by the US Food and Drug Administration (FDA)) act at 108 unique GPCRs.  Approx. 321 agents are currently in clin. trials, of which ∼20% target 66 potentially novel GPCR targets without an approved drug, and the no. of biol. drugs, allosteric modulators and biased agonists has increased.  The major disease indications for GPCR modulators show a shift towards diabetes, obesity and Alzheimer disease, although several central nervous system disorders are also highly represented.  The 224 (56%) non-olfactory GPCRs that have not yet been explored in clin. trials have broad untapped therapeutic potential, particularly in genetic and immune system disorders.  Finally, we provide an interactive online resource to analyze and infer trends in GPCR drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9iw1QqR9GKrVg90H21EOLACvtfcHk0ljfsJuiheL4SQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslansbzF&md5=560893258493bd96c0af24d3bef08b6f</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2017.178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2017.178%26sid%3Dliteratum%253Aachs%26aulast%3DHauser%26aufirst%3DA.%2BS.%26aulast%3DAttwood%26aufirst%3DM.%2BM.%26aulast%3DRask-Andersen%26aufirst%3DM.%26aulast%3DSchi%25C3%25B6th%26aufirst%3DH.%2BB.%26aulast%3DGloriam%26aufirst%3DD.%2BE.%26atitle%3DTrends%2520in%2520GPCR%2520drug%2520discovery%253A%2520new%2520agents%252C%2520targets%2520and%2520indications%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26spage%3D829%26epage%3D842%26doi%3D10.1038%2Fnrd.2017.178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irwin, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoichet, B. K.</span></span> <span> </span><span class="NLM_article-title">Discovery of new GPCR ligands to illuminate new biology</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1143</span>– <span class="NLM_lpage">1151</span>, <span class="refDoi"> DOI: 10.1038/nchembio.2490</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=10.1038%2Fnchembio.2490" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=29045379" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1OhsrnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=1143-1151&author=B.+L.+Rothauthor=J.+J.+Irwinauthor=B.+K.+Shoichet&title=Discovery+of+new+GPCR+ligands+to+illuminate+new+biology&doi=10.1038%2Fnchembio.2490"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of new GPCR ligands to illuminate new biology</span></div><div class="casAuthors">Roth, Bryan L.; Irwin, John J.; Shoichet, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1143-1151</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Although a plurality of drugs target G-protein-coupled receptors (GPCRs), most have emerged from classical medicinal chem. and pharmacol. programs and resemble one another structurally and functionally.  Though effective, these drugs are often promiscuous.  With the realization that GPCRs signal via multiple pathways, and with the emergence of crystal structures for this family of proteins, there is an opportunity to target GPCRs with new chemotypes and confer new signaling modalities.  The authors consider structure-based and phys. screening methods that have led to the discovery of new reagents, focusing particularly on the former.  The authors illustrate their use against previously untargeted or orphan GPCRs, against allosteric sites, and against classical orthosteric sites that selectively activate one downstream pathway over others.  The ligands that emerge are often chem. novel, which can lead to new biol. effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0g7QvZBYzkLVg90H21EOLACvtfcHk0ljfsJuiheL4SQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1OhsrnK&md5=6b1682d6b1475dc1a0e8834895c4ae6c</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2490&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2490%26sid%3Dliteratum%253Aachs%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DIrwin%26aufirst%3DJ.%2BJ.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26atitle%3DDiscovery%2520of%2520new%2520GPCR%2520ligands%2520to%2520illuminate%2520new%2520biology%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2017%26volume%3D13%26spage%3D1143%26epage%3D1151%26doi%3D10.1038%2Fnchembio.2490" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ye, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wold, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span> <span> </span><span class="NLM_article-title">Orphan receptor GPR88 as an emerging neurotherapeutic target</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">190</span>– <span class="NLM_lpage">200</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.8b00572</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.8b00572" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVyhs7fO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=190-200&author=N.+Yeauthor=B.+Liauthor=Q.+Maoauthor=E.+A.+Woldauthor=S.+Tianauthor=J.+A.+Allenauthor=J.+Zhou&title=Orphan+receptor+GPR88+as+an+emerging+neurotherapeutic+target&doi=10.1021%2Facschemneuro.8b00572"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Orphan Receptor GPR88 as an Emerging Neurotherapeutic Target</span></div><div class="casAuthors">Ye, Na; Li, Bang; Mao, Qi; Wold, Eric A.; Tian, Sheng; Allen, John A.; Zhou, Jia</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">190-200</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Although G protein-coupled receptors (GPCRs) are recognized as pivotal drug targets involved in multiple physiol. and pathol. processes, the majority of GPCRs including orphan GPCRs (oGPCRs) are unexploited.  GPR88, a brain-specific oGPCR with particularly robust expression in the striatum, regulates diverse brain and behavioral functions, including cognition, mood, movement control, and reward-based learning, and is thus emerging as a novel drug target for central nervous system disorders including schizophrenia, Parkinson's disease, anxiety, and addiction.  Nevertheless, no effective GPR88 synthetic ligands have yet entered into clin. trials, and GPR88 endogenous ligands remain unknown.  Despite the recent discovery and early stage study of several GPR88 agonists, such as 2-PCCA, RTI-13951-33, and phenylglycinol derivs., further research into GPR88 pharmacol., medicinal chem., and chem. biol. is urgently needed to yield structurally diversified GPR88-specific ligands.  Drug-like pharmacol. tool function and relevant signaling elucidation will also accelerate the evaluation of this receptor as a viable neurotherapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoP8O0djL7NL7Vg90H21EOLACvtfcHk0lg1YXdc5LgvGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVyhs7fO&md5=0511e92dd00711cb2b4f83a6e5b82818</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.8b00572&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.8b00572%26sid%3Dliteratum%253Aachs%26aulast%3DYe%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DMao%26aufirst%3DQ.%26aulast%3DWold%26aufirst%3DE.%2BA.%26aulast%3DTian%26aufirst%3DS.%26aulast%3DAllen%26aufirst%3DJ.%2BA.%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DOrphan%2520receptor%2520GPR88%2520as%2520an%2520emerging%2520neurotherapeutic%2520target%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2019%26volume%3D10%26spage%3D190%26epage%3D200%26doi%3D10.1021%2Facschemneuro.8b00572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sawzdargo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heng, H. H. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Dowd, B. F.</span></span> <span> </span><span class="NLM_article-title">Identification and cloning of three novel human G protein-coupled receptor genes GPR52, ΨGPR53 and GPR55: GPR55 is extensively expressed in human brain</span>. <i>Mol. Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">193</span>– <span class="NLM_lpage">198</span>, <span class="refDoi"> DOI: 10.1016/S0169-328X(98)00277-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=10.1016%2FS0169-328X%2898%2900277-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=9931487" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A528%3ADyaK1MXmtVGqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=1999&pages=193-198&author=M.+Sawzdargoauthor=T.+Nguyenauthor=D.+K.+Leeauthor=K.+R.+Lynchauthor=R.+Chengauthor=H.+H.+Q.+Hengauthor=S.+R.+Georgeauthor=B.+F.+O%E2%80%99Dowd&title=Identification+and+cloning+of+three+novel+human+G+protein-coupled+receptor+genes+GPR52%2C+%CE%A8GPR53+and+GPR55%3A+GPR55+is+extensively+expressed+in+human+brain&doi=10.1016%2FS0169-328X%2898%2900277-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and cloning of three novel human G protein-coupled receptor genes GPR52, ΨGPR53 and GPR55: GPR55 is extensively expressed in human brain</span></div><div class="casAuthors">Sawzdargo, Marek; Nguyen, Tuan; Lee, Dennis K.; Lynch, Kevin R.; Cheng, Regina; Heng, Henry H. Q.; George, Susan R.; O'Dowd, Brian F.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Brain Research</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">193-198</span>CODEN:
                <span class="NLM_cas:coden">MBREE4</span>;
        ISSN:<span class="NLM_cas:issn">0169-328X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">The G protein-coupled receptor (GPCR) family share a structural motif of seven transmembrane segments with large nos. of conserved residues in those regions.  Here, we report the identification and cloning of two novel human intronless GPCR genes, GPR52, GPR55 and a pseudogene ΨGPR53.  GPR55 was identified from the expressed sequence tags (EST) database whereas GPR52 and pseudogene ΨGPR53 originated from the high throughput genome (HTG) database.  A partial cDNA clone obtained from the IMAGE Consortium of GPR55 was used to screen a human genomic library to acquire the full length gene.  GPR52 and ΨGPR53 were amplified from human genomic DNA using primers based on the HTG sequences.  GPR55 and GPR52 encode receptors of 319 and 361 amino acids, resp.  GPR55 gene was mapped to chromosome 2q37, using fluorescence in situ hybridization (FISH), and its mRNA transcripts have been detected in the caudate nucleus and putamen, but not in five other brain regions.  Human receptors showing the highest amino acid identity to GPR55 include P2Y5 (29%), GPR23 (30%), GPR35 (27%) and CCR4 (23%).  GPR52 gene localized to chromosome 1q24 shares the highest identity with GPR21 (71%), histamine H2 (27%) and 5-HT4 (26%) human receptors.  ΨGPR53 is a pseudogene mapped to chromosome 6p21 that demonstrates the highest similarity to the MRG (35%), MAS (28%) and C5a (24%) human receptor genes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSppMAt-L_hrVg90H21EOLACvtfcHk0lg1YXdc5LgvGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmtVGqtg%253D%253D&md5=31817286bae73c3afef42e7471a3af07</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2FS0169-328X%2898%2900277-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-328X%252898%252900277-0%26sid%3Dliteratum%253Aachs%26aulast%3DSawzdargo%26aufirst%3DM.%26aulast%3DNguyen%26aufirst%3DT.%26aulast%3DLee%26aufirst%3DD.%2BK.%26aulast%3DLynch%26aufirst%3DK.%2BR.%26aulast%3DCheng%26aufirst%3DR.%26aulast%3DHeng%26aufirst%3DH.%2BH.%2BQ.%26aulast%3DGeorge%26aufirst%3DS.%2BR.%26aulast%3DO%25E2%2580%2599Dowd%26aufirst%3DB.%2BF.%26atitle%3DIdentification%2520and%2520cloning%2520of%2520three%2520novel%2520human%2520G%2520protein-coupled%2520receptor%2520genes%2520GPR52%252C%2520%25CE%25A8GPR53%2520and%2520GPR55%253A%2520GPR55%2520is%2520extensively%2520expressed%2520in%2520human%2520brain%26jtitle%3DMol.%2520Brain%2520Res.%26date%3D1999%26volume%3D64%26spage%3D193%26epage%3D198%26doi%3D10.1016%2FS0169-328X%2898%2900277-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Komatsu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maruyama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinohara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakuma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imaichi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chikatsu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuniyeda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu, F. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mun, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyajima, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itoh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, M.</span></span> <span> </span><span class="NLM_article-title">Anatomical transcriptome of G protein-coupled receptors leads to the identification of a novel therapeutic candidate GPR52 for psychiatric disorders</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">e90134</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0090134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=10.1371%2Fjournal.pone.0090134" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=24587241" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVKjsbfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&author=H.+Komatsuauthor=M.+Maruyamaauthor=S.+Yaoauthor=T.+Shinoharaauthor=K.+Sakumaauthor=S.+Imaichiauthor=T.+Chikatsuauthor=K.+Kuniyedaauthor=F.+K.+Siuauthor=L.+S.+Pengauthor=K.+Zhuoauthor=L.+S.+Munauthor=T.+M.+Hanauthor=Y.+Matsumotoauthor=T.+Hashimotoauthor=N.+Miyajimaauthor=Y.+Itohauthor=K.+Ogiauthor=Y.+Habataauthor=M.+Mori&title=Anatomical+transcriptome+of+G+protein-coupled+receptors+leads+to+the+identification+of+a+novel+therapeutic+candidate+GPR52+for+psychiatric+disorders&doi=10.1371%2Fjournal.pone.0090134"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Anatomical transcriptome of G protein-coupled receptors leads to the identification of a novel therapeutic candidate GPR52 for psychiatric disorders</span></div><div class="casAuthors">Komatsu, Hidetoshi; Maruyama, Minoru; Yao, Shuuhei; Shinohara, Tokuyuki; Sakuma, Kensuke; Imaichi, Sachiko; Chikatsu, Tomoko; Kuniyeda, Kanako; Siu, Foo Kok; Peng, Lam Sock; Zhuo, Katherine; Mun, Lay Sock; Han, Tan Min; Matsumoto, Yoshio; Hashimoto, Tadatoshi; Miyajima, Nobuyuki; Itoh, Yasuaki; Ogi, Kazuhiro; Habata, Yugo; Mori, Masaaki</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e90134/1-e90134/16, 16 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Many drugs of abuse and most neuropharmacol. agents regulate G protein-coupled receptors (GPCRs) in the central nervous system (CNS)_ENREF_1.  The striatum, in which dopamine D1 and D2 receptors are enriched, is strongly innervated by the ventral tegmental area (VTA), which is the origin of dopaminergic cell bodies of the mesocorticolimbic dopamine system_ENREF_3 and plays a central role in the development of psychiatric disorders_ENREF_4.  Here we report the comprehensive and anatomical transcript profiling of 322 non-odorant GPCRs in mouse tissue by quant. real-time PCR (qPCR), leading to the identification of neurotherapeutic receptors exclusively expressed in the CNS, esp. in the striatum.  Among them, GPR6, GPR52, and GPR88, known as orphan GPCRs, were shown to co-localize either with a D2 receptor alone or with both D1 and D2 receptors in neurons of the basal ganglia.  Intriguingly, we found that GPR52 was well conserved among vertebrates, is Gs-coupled and responsive to the antipsychotic drug, reserpine.  We used three types of transgenic (Tg) mice employing a Cre-lox system under the control of the GPR52 promoter, namely, GPR52-LacZ Tg, human GPR52 (hGPR52) Tg, and hGPR52-GFP Tg mice.  Detailed histol. investigation suggests that GPR52 may modulate dopaminergic and glutamatergic transmission in neuronal circuits responsible for cognitive function and emotion.  In support of our prediction, GPR52 knockout and transgenic mice exhibited psychosis-related and antipsychotic-like behaviors, resp.  Therefore, we propose that GPR52 has the potential of being a therapeutic psychiatric receptor.  This approach may help identify potential therapeutic targets for CNS diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoceoSKPwv1nrVg90H21EOLACvtfcHk0lgp7HXLnBthrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVKjsbfF&md5=fdaf1c9f4a80ef12adf400eef5eec2f3</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0090134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0090134%26sid%3Dliteratum%253Aachs%26aulast%3DKomatsu%26aufirst%3DH.%26aulast%3DMaruyama%26aufirst%3DM.%26aulast%3DYao%26aufirst%3DS.%26aulast%3DShinohara%26aufirst%3DT.%26aulast%3DSakuma%26aufirst%3DK.%26aulast%3DImaichi%26aufirst%3DS.%26aulast%3DChikatsu%26aufirst%3DT.%26aulast%3DKuniyeda%26aufirst%3DK.%26aulast%3DSiu%26aufirst%3DF.%2BK.%26aulast%3DPeng%26aufirst%3DL.%2BS.%26aulast%3DZhuo%26aufirst%3DK.%26aulast%3DMun%26aufirst%3DL.%2BS.%26aulast%3DHan%26aufirst%3DT.%2BM.%26aulast%3DMatsumoto%26aufirst%3DY.%26aulast%3DHashimoto%26aufirst%3DT.%26aulast%3DMiyajima%26aufirst%3DN.%26aulast%3DItoh%26aufirst%3DY.%26aulast%3DOgi%26aufirst%3DK.%26aulast%3DHabata%26aufirst%3DY.%26aulast%3DMori%26aufirst%3DM.%26atitle%3DAnatomical%2520transcriptome%2520of%2520G%2520protein-coupled%2520receptors%2520leads%2520to%2520the%2520identification%2520of%2520a%2520novel%2520therapeutic%2520candidate%2520GPR52%2520for%2520psychiatric%2520disorders%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26doi%3D10.1371%2Fjournal.pone.0090134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, R. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sodaei, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aguet, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segrè, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanz, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinhart, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ardlie, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guigö, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, H. S.</span></span> <span> </span><span class="NLM_article-title">A systematic survey of human tissue-specific gene expression and splicing reveals new opportunities for therapeutic target identification and evaluation</span>. <i>bioRxiv</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_fpage">311563</span>, <span class="refDoi"> DOI: 10.1101/311563</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=10.1101%2F311563" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&pages=311563&author=R.+Y.+Yangauthor=J.+Quanauthor=R.+Sodaeiauthor=F.+Aguetauthor=A.+V.+Segr%C3%A8author=J.+A.+Allenauthor=T.+A.+Lanzauthor=V.+Reinhartauthor=M.+Crawfordauthor=S.+Hassonauthor=K.+G.+Ardlieauthor=R.+Guig%C3%B6author=H.+S.+Xi&title=A+systematic+survey+of+human+tissue-specific+gene+expression+and+splicing+reveals+new+opportunities+for+therapeutic+target+identification+and+evaluation&doi=10.1101%2F311563"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1101%2F311563&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252F311563%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DR.%2BY.%26aulast%3DQuan%26aufirst%3DJ.%26aulast%3DSodaei%26aufirst%3DR.%26aulast%3DAguet%26aufirst%3DF.%26aulast%3DSegr%25C3%25A8%26aufirst%3DA.%2BV.%26aulast%3DAllen%26aufirst%3DJ.%2BA.%26aulast%3DLanz%26aufirst%3DT.%2BA.%26aulast%3DReinhart%26aufirst%3DV.%26aulast%3DCrawford%26aufirst%3DM.%26aulast%3DHasson%26aufirst%3DS.%26aulast%3DArdlie%26aufirst%3DK.%2BG.%26aulast%3DGuig%25C3%25B6%26aufirst%3DR.%26aulast%3DXi%26aufirst%3DH.%2BS.%26atitle%3DA%2520systematic%2520survey%2520of%2520human%2520tissue-specific%2520gene%2520expression%2520and%2520splicing%2520reveals%2520new%2520opportunities%2520for%2520therapeutic%2520target%2520identification%2520and%2520evaluation%26jtitle%3DbioRxiv%26date%3D2018%26spage%3D311563%26doi%3D10.1101%2F311563" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, F.</span></span> <span> </span><span class="NLM_article-title">Structural basis of ligand recognition and self-activation of orphan GPR52</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>579</i></span>,  <span class="NLM_fpage">152</span>– <span class="NLM_lpage">157</span>, <span class="refDoi"> DOI: 10.1038/s41586-020-2019-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=10.1038%2Fs41586-020-2019-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=32076264" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjsVejsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=579&publication_year=2020&pages=152-157&author=X.+Linauthor=M.+Liauthor=N.+Wangauthor=Y.+Wuauthor=Z.+Luoauthor=S.+Guoauthor=G.+W.+Hanauthor=S.+Liauthor=Y.+Yueauthor=X.+Weiauthor=X.+Xieauthor=Y.+Chenauthor=S.+Zhaoauthor=J.+Wuauthor=M.+Leiauthor=F.+Xu&title=Structural+basis+of+ligand+recognition+and+self-activation+of+orphan+GPR52&doi=10.1038%2Fs41586-020-2019-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis of ligand recognition and self-activation of orphan GPR52</span></div><div class="casAuthors">Lin, Xi; Li, Mingyue; Wang, Niandong; Wu, Yiran; Luo, Zhipu; Guo, Shimeng; Han, Gye-Won; Li, Shaobai; Yue, Yang; Wei, Xiaohu; Xie, Xin; Chen, Yong; Zhao, Suwen; Wu, Jian; Lei, Ming; Xu, Fei</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">579</span>
        (<span class="NLM_cas:issue">7797</span>),
    <span class="NLM_cas:pages">152-157</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">GPR52 is a class-A orphan G-protein-coupled receptor that is highly expressed in the brain and represents a promising therapeutic target for the treatment of Huntington's disease and several psychiatric disorders.  Pathol. malfunction of GPR52 signaling occurs primarily through the heterotrimeric Gs protein, but it is unclear how GPR52 and Gs couple for signal transduction and whether a native ligand or other activating input is required.  Here we present the high-resoln. structures of human GPR52 in three states: a ligand-free state, a Gs-coupled self-activation state and a potential allosteric ligand-bound state.  Together, our structures reveal that extracellular loop 2 occupies the orthosteric binding pocket and operates as a built-in agonist, conferring an intrinsically high level of basal activity to GPR52.  A fully active state is achieved when Gs is coupled to GPR52 in the absence of an external agonist.  The receptor also features a side pocket for ligand binding.  These insights into the structure and function of GPR52 could improve our understanding of other self-activated GPCRs, enable the identification of endogenous and tool ligands, and guide drug discovery efforts that target GPR52.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotl_2-sJeM_bVg90H21EOLACvtfcHk0lgYSggtjgv1Rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjsVejsLg%253D&md5=a0c899853309addd569f16f70c221e7c</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fs41586-020-2019-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-020-2019-0%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DN.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DLuo%26aufirst%3DZ.%26aulast%3DGuo%26aufirst%3DS.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DYue%26aufirst%3DY.%26aulast%3DWei%26aufirst%3DX.%26aulast%3DXie%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DLei%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DF.%26atitle%3DStructural%2520basis%2520of%2520ligand%2520recognition%2520and%2520self-activation%2520of%2520orphan%2520GPR52%26jtitle%3DNature%26date%3D2020%26volume%3D579%26spage%3D152%26epage%3D157%26doi%3D10.1038%2Fs41586-020-2019-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martin, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steurer, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aronstam, R. S.</span></span> <span> </span><span class="NLM_article-title">Constitutive activity among orphan class-A G protein coupled receptors</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>, <span class="NLM_elocation-id">e0138463</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0138463</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=10.1371%2Fjournal.pone.0138463" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=26384023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A528%3ADC%252BC28XkvFCjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&author=A.+L.+Martinauthor=M.+A.+Steurerauthor=R.+S.+Aronstam&title=Constitutive+activity+among+orphan+class-A+G+protein+coupled+receptors&doi=10.1371%2Fjournal.pone.0138463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Constitutive activity among orphan class-A G protein coupled receptors</span></div><div class="casAuthors">Martin, Adam L.; Steurer, Michael A.; Aronstam, Robert S.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e0138463/1-e0138463/12</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The purpose of this study was to evaluate the extent of constitutive activity among orphan class-A G protein coupled receptors within the cAMP signaling pathway.  Constitutive signaling was revealed by changes in gene expression under control of the cAMP response element.  Gene expression was measured in Chinese hamster ovary cells transiently cotransfected with plasmids contg. a luciferase reporter and orphan receptor.  Criteria adopted for defining constitutive activation were: (1) 200% elevation over baseline reporter gene expression; (2) 40% inhibition of baseline expression; and (3) 40% inhibition of expression stimulated by 3 μM forskolin.  Five patterns of activity were noted: (1) inhibition under both baseline and forskolin stimulated expression (GPR15, GPR17, GPR18, GPR20, GPR25, GPR27, GPR31, GPR32, GPR45, GPR57, GPR68, GPR83, GPR84, GPR132, GPR150, GPR176); (2) no effect on baseline expression, but inhibition of forskolin stimulated expression (GPR4, GPR26, GPR61, GPR62, GPR78, GPR101, GPR119); (3) elevation of baseline signaling coupled with inhibition of forskolin stimulated expression (GPR6, GPR12); (4) elevation of baseline signaling without inhibition of forskolin stimulated expression (GPR3, GPR21, GPR52, GPR65); and (5) no effect on expression (GPR1, GPR19, GPR22, GPR34, GPR35, GPR39, GPR63, GPR82, GPR85, GPR87).  Constitutive activity was obsd. in 75% of the orphan class-A receptors examd. (30 of 40).  This constitutive signaling cannot be explained by simple overexpression of the receptor.  Inhibition of cAMP mediated expression was far more common (65%) than stimulation of expression (15%).  Orphan receptors that were closely related based on amino acid homol. tended to have similar effects on gene expression.  These results suggest that identification of inverse agonists may be a fruitful approach for categorizing these orphan receptors and targeting them for pharmacol. intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAzoFrN1fJO7Vg90H21EOLACvtfcHk0lgYSggtjgv1Rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XkvFCjtw%253D%253D&md5=94482d03b35bec1f4c2967b8d88d5ef0</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0138463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0138463%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DA.%2BL.%26aulast%3DSteurer%26aufirst%3DM.%2BA.%26aulast%3DAronstam%26aufirst%3DR.%2BS.%26atitle%3DConstitutive%2520activity%2520among%2520orphan%2520class-A%2520G%2520protein%2520coupled%2520receptors%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26doi%3D10.1371%2Fjournal.pone.0138463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Setoh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kono, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyanohana, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiraishi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harasawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ota, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Odani, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanzaki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoyama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kori, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of the first potent and orally available agonist of the orphan G-protein-coupled receptor 52</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">5226</span>– <span class="NLM_lpage">5237</span>, <span class="refDoi"> DOI: 10.1021/jm5002919</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5002919" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A528%3ADC%252BC2cXptVaitrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5226-5237&author=M.+Setohauthor=N.+Ishiiauthor=M.+Konoauthor=Y.+Miyanohanaauthor=E.+Shiraishiauthor=T.+Harasawaauthor=H.+Otaauthor=T.+Odaniauthor=N.+Kanzakiauthor=K.+Aoyamaauthor=T.+Hamadaauthor=M.+Kori&title=Discovery+of+the+first+potent+and+orally+available+agonist+of+the+orphan+G-protein-coupled+receptor+52&doi=10.1021%2Fjm5002919"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the First Potent and Orally Available Agonist of the Orphan G-Protein-Coupled Receptor 52</span></div><div class="casAuthors">Setoh, Masaki; Ishii, Naoki; Kono, Mitsunori; Miyanohana, Yuhei; Shiraishi, Eri; Harasawa, Toshiya; Ota, Hiroyuki; Odani, Tomoyuki; Kanzaki, Naoyuki; Aoyama, Kazunobu; Hamada, Teruki; Kori, Masakuni</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5226-5237</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">G-protein-coupled receptor 52 (GPR52) is an orphan Gs-coupled G-protein-coupled receptor.  GPR52 inhibits dopamine D2 receptor signaling and activates dopamine D1/N-methyl-D-aspartate receptors via intracellular cAMP accumulation, and therefore, GPR52 agonists may have potential as a novel class of antipsychotics.  A series of GPR52 agonists with a bicyclic core was designed to fix the conformation of the phenethyl ether moiety of compds. I (X = 3-CF3, 3-Cl-5-F).  3-[2-(3-Chloro-5-fluorobenzyl)-1-benzothiophen-7-yl]-N-(2-methoxyethyl)benzamide II showed potent activity (pEC50 = 7.53 ± 0.08) and good pharmacokinetic properties.  II significantly suppressed methamphetamine-induced hyperactivity in mice after oral administration of 3 mg/kg without disturbance of motor function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5q71EZhoMH7Vg90H21EOLACvtfcHk0lgYSggtjgv1Rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXptVaitrg%253D&md5=46531c63142e9d7bdb2f0ff8aa5ee414</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm5002919&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5002919%26sid%3Dliteratum%253Aachs%26aulast%3DSetoh%26aufirst%3DM.%26aulast%3DIshii%26aufirst%3DN.%26aulast%3DKono%26aufirst%3DM.%26aulast%3DMiyanohana%26aufirst%3DY.%26aulast%3DShiraishi%26aufirst%3DE.%26aulast%3DHarasawa%26aufirst%3DT.%26aulast%3DOta%26aufirst%3DH.%26aulast%3DOdani%26aufirst%3DT.%26aulast%3DKanzaki%26aufirst%3DN.%26aulast%3DAoyama%26aufirst%3DK.%26aulast%3DHamada%26aufirst%3DT.%26aulast%3DKori%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520the%2520first%2520potent%2520and%2520orally%2520available%2520agonist%2520of%2520the%2520orphan%2520G-protein-coupled%2520receptor%252052%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5226%26epage%3D5237%26doi%3D10.1021%2Fjm5002919" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nishiyama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harasawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurimoto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maruyama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komatsu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakuma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimojo, M.</span></span> <span> </span><span class="NLM_article-title">FTBMT, a novel and selective GPR52 agonist, demonstrates antipsychotic-like and procognitive effects in rodents, revealing a potential therapeutic agent for schizophrenia</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>363</i></span>,  <span class="NLM_fpage">253</span>– <span class="NLM_lpage">264</span>, <span class="refDoi"> DOI: 10.1124/jpet.117.242925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=10.1124%2Fjpet.117.242925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=28851764" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtleltrnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2017&pages=253-264&author=K.+Nishiyamaauthor=H.+Suzukiauthor=T.+Harasawaauthor=N.+Suzukiauthor=E.+Kurimotoauthor=T.+Kawaiauthor=M.+Maruyamaauthor=H.+Komatsuauthor=K.+Sakumaauthor=Y.+Shimizuauthor=M.+Shimojo&title=FTBMT%2C+a+novel+and+selective+GPR52+agonist%2C+demonstrates+antipsychotic-like+and+procognitive+effects+in+rodents%2C+revealing+a+potential+therapeutic+agent+for+schizophrenia&doi=10.1124%2Fjpet.117.242925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">FTBMT, a novel and selective GPR52 agonist, demonstrates antipsychotic-like and procognitive effects in rodents, revealing a potential therapeutic agent for schizophrenia</span></div><div class="casAuthors">Nishiyama, Keiji; Suzuki, Hirobumi; Harasawa, Toshiya; Suzuki, Noriko; Kurimoto, Emi; Kawai, Takayuki; Maruyama, Minoru; Komatsu, Hidetoshi; Sakuma, Kensuke; Shimizu, Yuji; Shimojo, Masato</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">253-264</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">GPR52 is a Gs-coupled G protein-coupled receptor that is predominantly expressed in the striatum and nucleus accumbens (NAc) and was recently proposed as a potential therapeutic target for schizophrenia.  In the current study, we investigated the in vitro and in vivo pharmacol. activities of a novel GPR52 agonist, 4-(3-(3-fluoro-5-(trifluoromethyl)- benzyl)-5-methyl-1H-1,2,4-triazol-1-yl)-2-methylbenzamide (FTBMT).  FTBMT functioned as a selective GPR52 agonist in vitro and in vivo, as demonstrated by the activation of Camp signaling in striatal neurons.  FTBMT inhibited MK-801-induced hyperactivity, an animal model for acute psychosis, without causing catalepsy in mice.  The c-fos expression also revealed that FTBMT preferentially induced neuronal activation in the shell of the Nac compared with the striatum, thereby supporting its antipsychotic-like activity with less catalepsy.  Furthermore, FTBMT improved recognition memory in a novel object recognition test and attenuated MK-801-induced working memory deficits in a radial arm maze test in rats.  These recognitive effects were supported by the results of FTBMTinduced c-fos expression in the brain regions related to cognition, including the medial prefrontal cortex, entorhinal cortex, and hippocampus.  Taken together, these findings suggest that FTBMT shows antipsychotic and recognitive properties without causing catalepsy in rodents.  Given its unique pharmacol. profile, which differs from that of current antipsychotics, FTBMT may provide a new therapeutic option for the treatment of pos. and cognitive symptoms of schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfDMCk_-onqbVg90H21EOLACvtfcHk0lhvQ49jA6XPIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtleltrnE&md5=bc4e4d18018bb6aab15cda72e8966094</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1124%2Fjpet.117.242925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.117.242925%26sid%3Dliteratum%253Aachs%26aulast%3DNishiyama%26aufirst%3DK.%26aulast%3DSuzuki%26aufirst%3DH.%26aulast%3DHarasawa%26aufirst%3DT.%26aulast%3DSuzuki%26aufirst%3DN.%26aulast%3DKurimoto%26aufirst%3DE.%26aulast%3DKawai%26aufirst%3DT.%26aulast%3DMaruyama%26aufirst%3DM.%26aulast%3DKomatsu%26aufirst%3DH.%26aulast%3DSakuma%26aufirst%3DK.%26aulast%3DShimizu%26aufirst%3DY.%26aulast%3DShimojo%26aufirst%3DM.%26atitle%3DFTBMT%252C%2520a%2520novel%2520and%2520selective%2520GPR52%2520agonist%252C%2520demonstrates%2520antipsychotic-like%2520and%2520procognitive%2520effects%2520in%2520rodents%252C%2520revealing%2520a%2520potential%2520therapeutic%2520agent%2520for%2520schizophrenia%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2017%26volume%3D363%26spage%3D253%26epage%3D264%26doi%3D10.1124%2Fjpet.117.242925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, Y. G. A. J.</span>; <span class="NLM_string-name">Korman, H.</span>; <span class="NLM_string-name">Lehmann, J.</span>; <span class="NLM_string-name">Ren, A. S.</span>; <span class="NLM_string-name">Semple, G.</span></span> <span> </span><span class="NLM_article-title">1-Heteroaryl-indoline-4-carboxamines as modulators of GPR52 usedul for the treatment or prevention of disorders related thereto</span>. <span class="NLM_patent">WO2016176571 A1</span>, Nov 3, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=Y.+G.+A.+J.+Xiong&author=H.+Korman&author=J.+Lehmann&author=A.+S.+Ren&author=G.+Semple&title=1-Heteroaryl-indoline-4-carboxamines+as+modulators+of+GPR52+usedul+for+the+treatment+or+prevention+of+disorders+related+thereto"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DXiong%26aufirst%3DY.%2BG.%2BA.%2BJ.%26atitle%3D1-Heteroaryl-indoline-4-carboxamines%2520as%2520modulators%2520of%2520GPR52%2520usedul%2520for%2520the%2520treatment%2520or%2520prevention%2520of%2520disorders%2520related%2520thereto%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tokumaru, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomura, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakahata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurimoto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoyama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aso, K.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and pharmacological evaluation of 4-azolyl-benzamide derivatives as novel GPR52 agonists</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">3098</span>– <span class="NLM_lpage">3115</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2017.03.064</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=10.1016%2Fj.bmc.2017.03.064" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=28433511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtlWqur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=3098-3115&author=K.+Tokumaruauthor=Y.+Itoauthor=I.+Nomuraauthor=T.+Nakahataauthor=Y.+Shimizuauthor=E.+Kurimotoauthor=K.+Aoyamaauthor=K.+Aso&title=Design%2C+synthesis%2C+and+pharmacological+evaluation+of+4-azolyl-benzamide+derivatives+as+novel+GPR52+agonists&doi=10.1016%2Fj.bmc.2017.03.064"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and pharmacological evaluation of 4-azolyl-benzamide derivatives as novel GPR52 agonists</span></div><div class="casAuthors">Tokumaru, Kazuyuki; Ito, Yoshiteru; Nomura, Izumi; Nakahata, Takashi; Shimizu, Yuji; Kurimoto, Emi; Aoyama, Kazunobu; Aso, Kazuyoshi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3098-3115</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">G protein-coupled receptor 52 (GPR52) agonists are expected to improve the symptoms of psychiatric disorders.  During exploration for a novel class of GPR52 agonists with good pharmacokinetic profiles, the authors synthesized (I; half maximal effective concn. (EC50) = 75 nM, maximal response (Emax) = 122%) starting from a high-throughput screening hit II (EC50 = 470 nM, Emax = 56%).  The structural features of a reported GPR52 agonist were applied to II, led to design 4-azolylbenzamides as novel GPR52 agonists.  A structure-activity relationship study of 4-azolylbenzamide resulted in the design of the 1,2,4-triazole deriv. I, which demonstrated excellent bioavailability in rats (F = 53.8%).  Oral administration of I (10 mg/kg) significantly suppressed methamphetamine-induced hyperlocomotion in mice.  Thus, I is a promising lead compd. for drug discovery research of GPR52 agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH6Ea1gQem0bVg90H21EOLACvtfcHk0lg1DU-GlktzZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtlWqur8%253D&md5=e692d0e006899851b0520591c347d7f4</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2017.03.064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2017.03.064%26sid%3Dliteratum%253Aachs%26aulast%3DTokumaru%26aufirst%3DK.%26aulast%3DIto%26aufirst%3DY.%26aulast%3DNomura%26aufirst%3DI.%26aulast%3DNakahata%26aufirst%3DT.%26aulast%3DShimizu%26aufirst%3DY.%26aulast%3DKurimoto%26aufirst%3DE.%26aulast%3DAoyama%26aufirst%3DK.%26aulast%3DAso%26aufirst%3DK.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520pharmacological%2520evaluation%2520of%25204-azolyl-benzamide%2520derivatives%2520as%2520novel%2520GPR52%2520agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26spage%3D3098%26epage%3D3115%26doi%3D10.1016%2Fj.bmc.2017.03.064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakahata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokumaru, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setoh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harasawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoyama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aso, K.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of 1-(1-benzothiophen-7-yl)-1H-pyrazole, a novel series of G protein-coupled receptor 52 (GPR52) agonists</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1598</span>– <span class="NLM_lpage">1608</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2018.02.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=10.1016%2Fj.bmc.2018.02.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=29478803" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjt1Sgsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=1598-1608&author=T.+Nakahataauthor=K.+Tokumaruauthor=Y.+Itoauthor=N.+Ishiiauthor=M.+Setohauthor=Y.+Shimizuauthor=T.+Harasawaauthor=K.+Aoyamaauthor=T.+Hamadaauthor=M.+Koriauthor=K.+Aso&title=Design+and+synthesis+of+1-%281-benzothiophen-7-yl%29-1H-pyrazole%2C+a+novel+series+of+G+protein-coupled+receptor+52+%28GPR52%29+agonists&doi=10.1016%2Fj.bmc.2018.02.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of 1-(1-benzothiophen-7-yl)-1H-pyrazole, a novel series of G protein-coupled receptor 52 (GPR52) agonists</span></div><div class="casAuthors">Nakahata, Takashi; Tokumaru, Kazuyuki; Ito, Yoshiteru; Ishii, Naoki; Setoh, Masaki; Shimizu, Yuji; Harasawa, Toshiya; Aoyama, Kazunobu; Hamada, Teruki; Kori, Masakuni; Aso, Kazuyoshi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1598-1608</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">G-protein-coupled receptor 52 (GPR52) is classified as an orphan Gs-coupled G-protein-coupled receptor.  GPR52 cancels dopamine D2 receptor signaling and activates dopamine D1/N-methyl-D-aspartate receptors via intracellular cAMP accumulation.  Therefore, GPR52 agonists are expected to alleviate symptoms of psychotic disorders.  A novel series of 1-(benzothiophen-7-yl)-1H-pyrazole as GPR52 agonists was designed and synthesized.  The first orally active GPR52 agonist with high lipophilicity and poor aq. soly. still remained as issues for candidate selection.  To resolve these issues, replacement of the benzene ring at the 7-position of compd. 1b with heterocylic rings, such as pyrazole and pyridine, was greatly expected to reduce lipophilicity to levels for which calcd. logD values were lower than that of compd. 1b.  While evaluating the pyrazole derivs., introduction of a Me substituent at the 3-position of the pyrazole ring led to increased GPR52 agonistic activity.  Moreover, addnl. Me substituent at the 5-position of the pyrazole and further introduction of hydroxy group to lower logD led to significant improvement of soly. while maintaining the activity.  As a result, the authors identified 3-methyl-5-hydroxymethyl-1H-pyrazole deriv. 17 (N-(2-hydroxyethyl)-5-(hydroxymethyl)-3-methyl-1-(2-(3-(trifluoromethyl)benzyl)-1-benzothiophen-7-yl)-1H-pyrazole-4-carboxamide) (GPR52 EC50 = 21 nM, Emax = 103%, logD = 2.21, Soly. at pH 6.8 = 21 μg/mL) with potent GPR52 agonistic activity and good soly. compared to compd. 1b.  Furthermore, this compd. 17 dose-dependently suppressed methamphetamine-induced hyperlocomotion in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVMXRLUNGxrrVg90H21EOLACvtfcHk0lg1DU-GlktzZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjt1Sgsr4%253D&md5=45802ee39f844ddaab20ae4cfd61d26e</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2018.02.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2018.02.005%26sid%3Dliteratum%253Aachs%26aulast%3DNakahata%26aufirst%3DT.%26aulast%3DTokumaru%26aufirst%3DK.%26aulast%3DIto%26aufirst%3DY.%26aulast%3DIshii%26aufirst%3DN.%26aulast%3DSetoh%26aufirst%3DM.%26aulast%3DShimizu%26aufirst%3DY.%26aulast%3DHarasawa%26aufirst%3DT.%26aulast%3DAoyama%26aufirst%3DK.%26aulast%3DHamada%26aufirst%3DT.%26aulast%3DKori%26aufirst%3DM.%26aulast%3DAso%26aufirst%3DK.%26atitle%3DDesign%2520and%2520synthesis%2520of%25201-%25281-benzothiophen-7-yl%2529-1H-pyrazole%252C%2520a%2520novel%2520series%2520of%2520G%2520protein-coupled%2520receptor%252052%2520%2528GPR52%2529%2520agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26spage%3D1598%26epage%3D1608%26doi%3D10.1016%2Fj.bmc.2018.02.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Synopsis of some recent tactical application of bioisosteres in drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">2529</span>– <span class="NLM_lpage">2591</span>, <span class="refDoi"> DOI: 10.1021/jm1013693</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1013693" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsVCnu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2529-2591&author=N.+A.+Meanwell&title=Synopsis+of+some+recent+tactical+application+of+bioisosteres+in+drug+design&doi=10.1021%2Fjm1013693"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design</span></div><div class="casAuthors">Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2529-2591</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The established utility of bioisosteres is broad in nature, extending to improving potency, enhancing selectivity, altering phys. properties, reducing or redirecting metab., eliminating or modifying toxicophores, and acquiring novel intellectual property.  In this Perspective, some contemporary themes exploring the role of isosteres in drug design are sampled, with an emphasis placed on tactical applications designed to solve the kinds of problems that impinge on compd. optimization and the long-term success of drug candidates.  Interesting concepts that may have been poorly effective in the context examd. are captured, since the ideas may have merit in alternative circumstances.  A comprehensive cataloging of bioisosteres is beyond the scope of what will be provided, although a synopsis of relevant isosteres of a particular functionality is summarized in a succinct fashion in several sections.  Isosterism has also found productive application in the design and optimization of organocatalysts, and there are several examples in which functional mimicry established initially in a medicinal chem. setting has been adopted by this community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ9z_aPcU4ubVg90H21EOLACvtfcHk0lg1DU-GlktzZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsVCnu7o%253D&md5=0637ab60c379bef535f3f709b26f3582</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm1013693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1013693%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DSynopsis%2520of%2520some%2520recent%2520tactical%2520application%2520of%2520bioisosteres%2520in%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D2529%26epage%3D2591%26doi%3D10.1021%2Fjm1013693" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">The influence of bioisosteres in drug design: tactical applications to address developability problems</span>. <i>Tactics Contemp. Drug Des.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">283</span>– <span class="NLM_lpage">382</span>, <span class="refDoi"> DOI: 10.1007/7355_2013_29</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=10.1007%2F7355_2013_29" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2015&pages=283-382&author=N.+A.+Meanwell&title=The+influence+of+bioisosteres+in+drug+design%3A+tactical+applications+to+address+developability+problems&doi=10.1007%2F7355_2013_29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1007%2F7355_2013_29&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F7355_2013_29%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DThe%2520influence%2520of%2520bioisosteres%2520in%2520drug%2520design%253A%2520tactical%2520applications%2520to%2520address%2520developability%2520problems%26jtitle%3DTactics%2520Contemp.%2520Drug%2520Des.%26date%3D2015%26volume%3D9%26spage%3D283%26epage%3D382%26doi%3D10.1007%2F7355_2013_29" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pennington, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moustakas, D. T.</span></span> <span> </span><span class="NLM_article-title">The necessary nitrogen atom: a versatile high-impact design element for multiparameter optimization</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">3552</span>– <span class="NLM_lpage">3579</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01807</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01807" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A528%3ADC%252BC2sXit1yit74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=3552-3579&author=L.+D.+Penningtonauthor=D.+T.+Moustakas&title=The+necessary+nitrogen+atom%3A+a+versatile+high-impact+design+element+for+multiparameter+optimization&doi=10.1021%2Facs.jmedchem.6b01807"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The Necessary Nitrogen Atom: A Versatile High-Impact Design Element for Multiparameter Optimization</span></div><div class="casAuthors">Pennington, Lewis D.; Moustakas, Demetri T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3552-3579</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  There is a continued desire in biomedical research to reduce the no. and duration of design cycles required to optimize lead compds. into high-quality chem. probes or safe and efficacious drug candidates.  The insightful application of impactful mol. design elements is one approach toward achieving this goal.  The replacement of a CH group with a N atom in arom. and heteroarom. ring systems can have many important effects on mol. and physicochem. properties and intra- and intermol. interactions that can translate to improved pharmacol. profiles.  In this Perspective, the "necessary nitrogen atom" is shown to be a versatile high-impact design element for multiparameter optimization, wherein ≥10-, 100-, or 1000-fold improvement in a variety of key pharmacol. parameters can be realized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8ZLKZMgt6IbVg90H21EOLACvtfcHk0ljAkNz91KEZMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXit1yit74%253D&md5=002aaee48995e7954647a1f75183db4d</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01807%26sid%3Dliteratum%253Aachs%26aulast%3DPennington%26aufirst%3DL.%2BD.%26aulast%3DMoustakas%26aufirst%3DD.%2BT.%26atitle%3DThe%2520necessary%2520nitrogen%2520atom%253A%2520a%2520versatile%2520high-impact%2520design%2520element%2520for%2520multiparameter%2520optimization%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D3552%26epage%3D3579%26doi%3D10.1021%2Facs.jmedchem.6b01807" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cesta, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somersan Karakaya, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javidnia, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gold, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez Quezada, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abramyan, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kireev, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aubé, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarry, S. M.</span></span> <span> </span><span class="NLM_article-title">Synthesis and antibacterial evaluation of cephalosporin isosteres</span>. <i>Asian J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1053</span>– <span class="NLM_lpage">1057</span>, <span class="refDoi"> DOI: 10.1002/ajoc.201900058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=10.1002%2Fajoc.201900058" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmtVCltbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2019&pages=1053-1057&author=D.+J.+Cestaauthor=S.+S.+Somersan+Karakayaauthor=K.+Saitoauthor=P.+E.+Javidniaauthor=J.+Robertsauthor=Y.+Lingauthor=B.+S.+Goldauthor=L.+Lopez+Quezadaauthor=D.+Zhangauthor=T.+M.+Abramyanauthor=D.+B.+Kireevauthor=J.+Aub%C3%A9author=S.+M.+Scarry&title=Synthesis+and+antibacterial+evaluation+of+cephalosporin+isosteres&doi=10.1002%2Fajoc.201900058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Antibacterial Evaluation of Cephalosporin Isosteres</span></div><div class="casAuthors">Cesta, Drew J.; Somersan Karakaya, Selin; Saito, Kohta; Javidnia, Prisca E.; Roberts, Julia; Ling, Yan; Gold, Ben S.; Lopez Quezada, Landys; Zhang, David; Abramyan, Tigran M.; Kireev, Dmitri B.; Aube, Jeffrey; Scarry, Sarah M.</div><div class="citationInfo"><span class="NLM_cas:title">Asian Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1053-1057</span>CODEN:
                <span class="NLM_cas:coden">AJOCC7</span>;
        ISSN:<span class="NLM_cas:issn">2193-5807</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">As part of a program to explore the chem. of β-lactams and their derivs., a focused set of benzazetidine, indoline, and indole heterocycles, as well as flexible unconstrained variations of the four-membered heterocyclic compds were prepd.  These analogs mimic the three-dimensional shape of cephalosporins but are not prone to covalent binding via ring opening.  Although these analogs were inactive against the ESKAPE pathogens and Mtb, they represent unique and underexplored chemotypes for future biol. screening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovWA0C3JZtBrVg90H21EOLACvtfcHk0ljAkNz91KEZMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmtVCltbg%253D&md5=41d79f79f053fbba7e986e0901f3374f</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1002%2Fajoc.201900058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fajoc.201900058%26sid%3Dliteratum%253Aachs%26aulast%3DCesta%26aufirst%3DD.%2BJ.%26aulast%3DSomersan%2BKarakaya%26aufirst%3DS.%2BS.%26aulast%3DSaito%26aufirst%3DK.%26aulast%3DJavidnia%26aufirst%3DP.%2BE.%26aulast%3DRoberts%26aufirst%3DJ.%26aulast%3DLing%26aufirst%3DY.%26aulast%3DGold%26aufirst%3DB.%2BS.%26aulast%3DLopez%2BQuezada%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DAbramyan%26aufirst%3DT.%2BM.%26aulast%3DKireev%26aufirst%3DD.%2BB.%26aulast%3DAub%25C3%25A9%26aufirst%3DJ.%26aulast%3DScarry%26aufirst%3DS.%2BM.%26atitle%3DSynthesis%2520and%2520antibacterial%2520evaluation%2520of%2520cephalosporin%2520isosteres%26jtitle%3DAsian%2520J.%2520Org.%2520Chem.%26date%3D2019%26volume%3D8%26spage%3D1053%26epage%3D1057%26doi%3D10.1002%2Fajoc.201900058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sengmany, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebre, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Gall, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Léonel, E.</span></span> <span> </span><span class="NLM_article-title">Selective mono-amination of dichlorodiazines</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">4859</span>– <span class="NLM_lpage">4867</span>, <span class="refDoi"> DOI: 10.1016/j.tet.2015.05.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=10.1016%2Fj.tet.2015.05.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A528%3ADC%252BC2MXptFCgsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2015&pages=4859-4867&author=S.+Sengmanyauthor=J.+Lebreauthor=E.+Le+Gallauthor=E.+L%C3%A9onel&title=Selective+mono-amination+of+dichlorodiazines&doi=10.1016%2Fj.tet.2015.05.056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Selective mono-amination of dichlorodiazines</span></div><div class="casAuthors">Sengmany, Stephane; Lebre, Julie; Le Gall, Erwan; Leonel, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">4859-4867</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">3,6-Dichloropyridazine, 4,6-dichloropyrimidine, 2,4-dichloropyrimidine, and 3,5-dichloropyridazine underwent chemoselective monosubstitution reactions with amines using triethylamine as a base in ethanol at either ambient temp. or reflux to give monoamino monochloro pyridazines and pyrimidines.  The methodol. is general and efficient despite noticeable differences in reactivity between diazines; while dichloropyridazine and dichloropyrazine require several hours of heating at reflux for the reaction to proceed, dichloropyrimidines reach completion within minutes at room temp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIme9bD3r9s7Vg90H21EOLACvtfcHk0ljAkNz91KEZMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXptFCgsbk%253D&md5=71f462180114a1f0e4b8672523d60856</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2015.05.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2015.05.056%26sid%3Dliteratum%253Aachs%26aulast%3DSengmany%26aufirst%3DS.%26aulast%3DLebre%26aufirst%3DJ.%26aulast%3DLe%2BGall%26aufirst%3DE.%26aulast%3DL%25C3%25A9onel%26aufirst%3DE.%26atitle%3DSelective%2520mono-amination%2520of%2520dichlorodiazines%26jtitle%3DTetrahedron%26date%3D2015%26volume%3D71%26spage%3D4859%26epage%3D4867%26doi%3D10.1016%2Fj.tet.2015.05.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Loksha, Y. M.</span></span> <span> </span><span class="NLM_article-title">Novel synthetic route for 5-substituted 6-arylmethylluracils from 2,4,6-trichloropyrimidines</span>. <i>J. Heterocycl. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">1296</span>– <span class="NLM_lpage">1301</span>, <span class="refDoi"> DOI: 10.1002/jhet.239</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=10.1002%2Fjhet.239" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFSgtr%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2009&pages=1296-1301&author=Y.+M.+Loksha&title=Novel+synthetic+route+for+5-substituted+6-arylmethylluracils+from+2%2C4%2C6-trichloropyrimidines&doi=10.1002%2Fjhet.239"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Novel synthetic route for 5-substituted 6-arylmethylluracils from 2,4,6-trichloropyrimidines</span></div><div class="casAuthors">Loksha, Yasser M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Heterocyclic Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1296-1301</span>CODEN:
                <span class="NLM_cas:coden">JHTCAD</span>;
        ISSN:<span class="NLM_cas:issn">1943-5193</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Treatment of 2,4,6-trichloropyrimidines with the sodium salt of benzyl cyanide derivs. afforded 5-substituted 4-aryl(cyanomethyl)-2,6-dichloropyrimidines.  They were alkylated with Me iodide to furnish 4-(1-aryl-1-cyanoethyl)-2,6-dichloropyrimidines.  These compds. were hydrolyzed with concd. hydrochloric acid to afford 5-substituted 6-arylalkyluracils.  5-Bromo-6-arymethylluracils were synthesized by bromination of 6-arylmethylluracils with N-bromosuccinimide (NBS).  Refluxing 2-(2,6-dichloro-5-ethylpyrimidin-4-yl)-2-(3,5-dimethylphenyl)acetonitrile with sodium methoxide followed by oxidn. afforded (3,5-dimethylphenyl)(5-ethyl-2,6-dimethoxypyrimidin-4-yl)methanone.  Addn. of methylmagnesium bromide gave the tertiary alc. deriv. which was fluorinated by diethylaminosulfurtrifluoride and deprotected by trimethylsilyl iodide to furnish 6-(1-(3,5-dimethylphenyl)-1-fluoroethyl)-5-ethylpyrimidine-2,4(1H,3H)-dione.  J. Heterocyclic Chem., (2009).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPVplefNz_xbVg90H21EOLACvtfcHk0ljAkNz91KEZMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFSgtr%252FO&md5=4eb3539191bee15ea0c2a4e8086ad2d2</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1002%2Fjhet.239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjhet.239%26sid%3Dliteratum%253Aachs%26aulast%3DLoksha%26aufirst%3DY.%2BM.%26atitle%3DNovel%2520synthetic%2520route%2520for%25205-substituted%25206-arylmethylluracils%2520from%25202%252C4%252C6-trichloropyrimidines%26jtitle%3DJ.%2520Heterocycl.%2520Chem.%26date%3D2009%26volume%3D46%26spage%3D1296%26epage%3D1301%26doi%3D10.1002%2Fjhet.239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gray, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mente, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMarco, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Efremov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tierney, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volfson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davoren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guilmette, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salafia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozak, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehlers, M. D.</span></span> <span> </span><span class="NLM_article-title">Impaired β-arrestin recruitment and reduced desensitization by non-catechol agonists of the D1 dopamine receptor</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">674</span>, <span class="refDoi"> DOI: 10.1038/s41467-017-02776-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=10.1038%2Fs41467-017-02776-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=29445200" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A280%3ADC%252BC1Mrhsl2nsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=674&author=D.+L.+Grayauthor=J.+A.+Allenauthor=S.+Menteauthor=R.+E.+O%E2%80%99Connorauthor=G.+J.+DeMarcoauthor=I.+Efremovauthor=P.+Tierneyauthor=D.+Volfsonauthor=J.+Davorenauthor=E.+Guilmetteauthor=M.+Salafiaauthor=R.+Kozakauthor=M.+D.+Ehlers&title=Impaired+%CE%B2-arrestin+recruitment+and+reduced+desensitization+by+non-catechol+agonists+of+the+D1+dopamine+receptor&doi=10.1038%2Fs41467-017-02776-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Impaired β-arrestin recruitment and reduced desensitization by non-catechol agonists of the D1 dopamine receptor</span></div><div class="casAuthors">Gray David L; Mente Scot; Efremov Ivan; Davoren Jennifer; Gray David L; Allen John A; Tierney Patrick; Volfson Dmitri; Guilmette Edward; Kozak Rouba; Ehlers Michael D; Allen John A; O'Connor Rebecca E; Salafia Michelle; DeMarco George J; Ehlers Michael D</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">674</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Selective activation of dopamine D1 receptors (D1Rs) has been pursued for 40 years as a therapeutic strategy for neurologic and psychiatric diseases due to the fundamental role of D1Rs in motor function, reward processing, and cognition.  All known D1R-selective agonists are catechols, which are rapidly metabolized and desensitize the D1R after prolonged exposure, reducing agonist response.  As such, drug-like selective D1R agonists have remained elusive.  Here we report a novel series of selective, potent non-catechol D1R agonists with promising in vivo pharmacokinetic properties.  These ligands stimulate adenylyl cyclase signaling and are efficacious in a rodent model of Parkinson's disease after oral administration.  They exhibit distinct binding to the D1R orthosteric site and a novel functional profile including minimal receptor desensitization, reduced recruitment of β-arrestin, and sustained in vivo efficacy.  These results reveal a novel class of D1 agonists with favorable drug-like properties, and define the molecular basis for catechol-specific recruitment of β-arrestin to D1Rs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcShdJOozuyZkBe4jJGKT5N0fW6udTcc2eaq9ciGj9ZGqLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mrhsl2nsQ%253D%253D&md5=2ba64bda304b083647eedff999f3fdcd</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fs41467-017-02776-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-017-02776-7%26sid%3Dliteratum%253Aachs%26aulast%3DGray%26aufirst%3DD.%2BL.%26aulast%3DAllen%26aufirst%3DJ.%2BA.%26aulast%3DMente%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DR.%2BE.%26aulast%3DDeMarco%26aufirst%3DG.%2BJ.%26aulast%3DEfremov%26aufirst%3DI.%26aulast%3DTierney%26aufirst%3DP.%26aulast%3DVolfson%26aufirst%3DD.%26aulast%3DDavoren%26aufirst%3DJ.%26aulast%3DGuilmette%26aufirst%3DE.%26aulast%3DSalafia%26aufirst%3DM.%26aulast%3DKozak%26aufirst%3DR.%26aulast%3DEhlers%26aufirst%3DM.%2BD.%26atitle%3DImpaired%2520%25CE%25B2-arrestin%2520recruitment%2520and%2520reduced%2520desensitization%2520by%2520non-catechol%2520agonists%2520of%2520the%2520D1%2520dopamine%2520receptor%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26spage%3D674%26doi%3D10.1038%2Fs41467-017-02776-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Besnard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruda, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setola, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abecassis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguiz, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norval, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sassano, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeons, F. R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stojanovski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seidah, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Constam, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bickerton, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wetsel, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span> <span> </span><span class="NLM_article-title">Automated design of ligands to polypharmacological profiles</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>492</i></span>,  <span class="NLM_fpage">215</span>– <span class="NLM_lpage">220</span>, <span class="refDoi"> DOI: 10.1038/nature11691</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=10.1038%2Fnature11691" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=23235874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVamurfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=492&publication_year=2012&pages=215-220&author=J.+Besnardauthor=G.+F.+Rudaauthor=V.+Setolaauthor=K.+Abecassisauthor=R.+M.+Rodriguizauthor=X.-P.+Huangauthor=S.+Norvalauthor=M.+F.+Sassanoauthor=A.+I.+Shinauthor=L.+A.+Websterauthor=F.+R.+C.+Simeonsauthor=L.+Stojanovskiauthor=A.+Pratauthor=N.+G.+Seidahauthor=D.+B.+Constamauthor=G.+R.+Bickertonauthor=K.+D.+Readauthor=W.+C.+Wetselauthor=I.+H.+Gilbertauthor=B.+L.+Rothauthor=A.+L.+Hopkins&title=Automated+design+of+ligands+to+polypharmacological+profiles&doi=10.1038%2Fnature11691"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Automated design of ligands to polypharmacological profiles</span></div><div class="casAuthors">Besnard, Jeremy; Ruda, Gian Filippo; Setola, Vincent; Abecassis, Keren; Rodriguiz, Ramona M.; Huang, Xi-Ping; Norval, Suzanne; Sassano, Maria F.; Shin, Antony I.; Webster, Lauren A.; Simeons, Frederick R. C.; Stojanovski, Laste; Prat, Annik; Seidah, Nabil G.; Constam, Daniel B.; Bickerton, G. Richard; Read, Kevin D.; Wetsel, William C.; Gilbert, Ian H.; Roth, Bryan L.; Hopkins, Andrew L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">492</span>
        (<span class="NLM_cas:issue">7428</span>),
    <span class="NLM_cas:pages">215-220</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. efficacy and safety of a drug is detd. by its activity profile across many proteins in the proteome.  However, designing drugs with a specific multi-target profile is both complex and difficult.  Therefore methods to design drugs rationally a priori against profiles of several proteins would have immense value in drug discovery.  Here is described a new approach for the automated design of ligands against profiles of multiple drug targets.  The method is demonstrated by the evolution of an approved acetylcholinesterase inhibitor drug donepezil (I) into brain-penetrable ligands with either specific polypharmacol. or exquisite selectivity profiles for G-protein-coupled receptors.  Overall, 800 ligand-target predictions of prospectively designed ligands were tested exptl., of which 75% were confirmed to be correct.  Target engagement in vivo is also demonstrated.  The approach can be a useful source of drug leads when multi-target profiles are required to achieve either selectivity over other drug targets or a desired polypharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNu5bwrBD3tbVg90H21EOLACvtfcHk0lh7LN-y6baRrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVamurfN&md5=ace6cced250cf968d327b482a5bf1798</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnature11691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11691%26sid%3Dliteratum%253Aachs%26aulast%3DBesnard%26aufirst%3DJ.%26aulast%3DRuda%26aufirst%3DG.%2BF.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DAbecassis%26aufirst%3DK.%26aulast%3DRodriguiz%26aufirst%3DR.%2BM.%26aulast%3DHuang%26aufirst%3DX.-P.%26aulast%3DNorval%26aufirst%3DS.%26aulast%3DSassano%26aufirst%3DM.%2BF.%26aulast%3DShin%26aufirst%3DA.%2BI.%26aulast%3DWebster%26aufirst%3DL.%2BA.%26aulast%3DSimeons%26aufirst%3DF.%2BR.%2BC.%26aulast%3DStojanovski%26aufirst%3DL.%26aulast%3DPrat%26aufirst%3DA.%26aulast%3DSeidah%26aufirst%3DN.%2BG.%26aulast%3DConstam%26aufirst%3DD.%2BB.%26aulast%3DBickerton%26aufirst%3DG.%2BR.%26aulast%3DRead%26aufirst%3DK.%2BD.%26aulast%3DWetsel%26aufirst%3DW.%2BC.%26aulast%3DGilbert%26aufirst%3DI.%2BH.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26atitle%3DAutomated%2520design%2520of%2520ligands%2520to%2520polypharmacological%2520profiles%26jtitle%3DNature%26date%3D2012%26volume%3D492%26spage%3D215%26epage%3D220%26doi%3D10.1038%2Fnature11691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalyaanamoorthy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barakat, K. H.</span></span> <span> </span><span class="NLM_article-title">Development of safe drugs: the hERG challenge</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">525</span>– <span class="NLM_lpage">555</span>, <span class="refDoi"> DOI: 10.1002/med.21445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=10.1002%2Fmed.21445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=28467598" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A280%3ADC%252BC1crjs1aiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2018&pages=525-555&author=S.+Kalyaanamoorthyauthor=K.+H.+Barakat&title=Development+of+safe+drugs%3A+the+hERG+challenge&doi=10.1002%2Fmed.21445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Safe Drugs: The hERG Challenge</span></div><div class="casAuthors">Kalyaanamoorthy Subha; Barakat Khaled H; Barakat Khaled H; Barakat Khaled H</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal research reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">525-555</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Drug-induced blockade of human ether-a-go-go-related gene (hERG) remains a major impediment in delivering safe drugs to the market.  Several drugs have been withdrawn from the market due to their severe cardiotoxic side effects triggered by their off-target interactions with hERG.  Thus, identifying the potential hERG blockers at early stages of lead discovery is fast evolving as a standard in drug design and development.  A number of in silico structure-based models of hERG have been developed as a low-cost solution to evaluate drugs for hERG liability, and it is now agreed that the hERG blockers bind at the large central cavity of the channel.  Nevertheless, there is no clear convergence on the appropriate drug binding modes against the channel.  The proposed binding modes differ in their orientations and interpretations on the role of key residues in the channel.  Such ambiguities in the modes of binding remain to be a significant challenge in achieving efficient computational predictive models and in saving many important already Food and Drug Administration approved drugs.  In this review, we discuss the spectrum of reported binding modes for hERG blockers, the various in silico models developed for predicting a drug's affinity to hERG, and the known successful optimization strategies to avoid off-target interactions with hERG.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSVn-pfX7PHl11C8OJBvdfbfW6udTcc2eaq9ciGj9ZGqLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1crjs1aiug%253D%253D&md5=50557713c0d70c32f92c425b38a693b2</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1002%2Fmed.21445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21445%26sid%3Dliteratum%253Aachs%26aulast%3DKalyaanamoorthy%26aufirst%3DS.%26aulast%3DBarakat%26aufirst%3DK.%2BH.%26atitle%3DDevelopment%2520of%2520safe%2520drugs%253A%2520the%2520hERG%2520challenge%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2018%26volume%3D38%26spage%3D525%26epage%3D555%26doi%3D10.1002%2Fmed.21445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, D. J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fone, K. C. F.</span></span> <span> </span><span class="NLM_article-title">Animal models of schizophrenia</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>164</i></span>,  <span class="NLM_fpage">1162</span>– <span class="NLM_lpage">1194</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2011.01386.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=10.1111%2Fj.1476-5381.2011.01386.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=21449915" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlShtrjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=2011&pages=1162-1194&author=C.+A.+Jonesauthor=D.+J.+G.+Watsonauthor=K.+C.+F.+Fone&title=Animal+models+of+schizophrenia&doi=10.1111%2Fj.1476-5381.2011.01386.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Animal models of schizophrenia</span></div><div class="casAuthors">Jones, C. A.; Watson, D. J. G.; Fone, K. C. F.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">164</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1162-1194</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Developing reliable, predictive animal models for complex psychiatric disorders, such as schizophrenia, is essential to increase our understanding of the neurobiol. basis of the disorder and for the development of novel drugs with improved therapeutic efficacy.  All available animal models of schizophrenia fit into four different induction categories: developmental, drug-induced, lesion or genetic manipulation, and the best characterized examples of each type are reviewed herein.  Most rodent models have behavioral phenotype changes that resemble "pos.-like" symptoms of schizophrenia, probably reflecting altered mesolimbic dopamine function, but fewer models also show altered social interaction, and learning and memory impairment, analogous to neg. and cognitive symptoms of schizophrenia resp.  The neg. and cognitive impairments in schizophrenia are resistant to treatment with current antipsychotics, even after remission of the psychosis, which limits their therapeutic efficacy.  The MATRICS initiative developed a consensus on the core cognitive deficits of schizophrenic patients, and recommended a standardized test battery to evaluate them.  More recently, work has begun to identify specific rodent behavioral tasks with translational relevance to specific cognitive domains affected in schizophrenia, and where available this review focuses on reporting the effect of current and potential antipsychotics on these tasks.  The review also highlights the need to develop more comprehensive animal models that more adequately replicate deficits in neg. and cognitive symptoms.  Increasing information on the neurochem. and structural CNS changes accompanying each model will also help assess treatments that prevent the development of schizophrenia rather than treating the symptoms, another pivotal change required to enable new more effective therapeutic strategies to be developed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFknIty9aCwLVg90H21EOLACvtfcHk0lhBopmBwyKqbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlShtrjF&md5=705007a976f8f01dafef40ead145abf2</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01386.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01386.x%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DC.%2BA.%26aulast%3DWatson%26aufirst%3DD.%2BJ.%2BG.%26aulast%3DFone%26aufirst%3DK.%2BC.%2BF.%26atitle%3DAnimal%2520models%2520of%2520schizophrenia%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D164%26spage%3D1162%26epage%3D1194%26doi%3D10.1111%2Fj.1476-5381.2011.01386.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dichter, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damiano, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J. A.</span></span> <span> </span><span class="NLM_article-title">Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings</span>. <i>J. Neurodev. Disord.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">19</span>, <span class="refDoi"> DOI: 10.1186/1866-1955-4-19</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=10.1186%2F1866-1955-4-19" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=22958744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A280%3ADC%252BC38bltFWgtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=19&author=G.+S.+Dichterauthor=C.+A.+Damianoauthor=J.+A.+Allen&title=Reward+circuitry+dysfunction+in+psychiatric+and+neurodevelopmental+disorders+and+genetic+syndromes%3A+animal+models+and+clinical+findings&doi=10.1186%2F1866-1955-4-19"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings</span></div><div class="casAuthors">Dichter Gabriel S; Damiano Cara A; Allen John A</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neurodevelopmental disorders</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">19</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract"> This review summarizes evidence of dysregulated reward circuitry function in a range of neurodevelopmental and psychiatric disorders and genetic syndromes.  First, the contribution of identifying a core mechanistic process across disparate disorders to disease classification is discussed, followed by a review of the neurobiology of reward circuitry.  We next consider preclinical animal models and clinical evidence of reward-pathway dysfunction in a range of disorders, including psychiatric disorders (i.e., substance-use disorders, affective disorders, eating disorders, and obsessive compulsive disorders), neurodevelopmental disorders (i.e., schizophrenia, attention-deficit/hyperactivity disorder, autism spectrum disorders, Tourette's syndrome, conduct disorder/oppositional defiant disorder), and genetic syndromes (i.e., Fragile X syndrome, Prader-Willi syndrome, Williams syndrome, Angelman syndrome, and Rett syndrome).  We also provide brief overviews of effective psychopharmacologic agents that have an effect on the dopamine system in these disorders.  This review concludes with methodological considerations for future research designed to more clearly probe reward-circuitry dysfunction, with the ultimate goal of improved intervention strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR0ZAxAERVU-cve_zCu79I8fW6udTcc2ebwSLT--SkSi7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38bltFWgtw%253D%253D&md5=f0ad1c200b755c84f08bd6b25c149f52</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1186%2F1866-1955-4-19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1866-1955-4-19%26sid%3Dliteratum%253Aachs%26aulast%3DDichter%26aufirst%3DG.%2BS.%26aulast%3DDamiano%26aufirst%3DC.%2BA.%26aulast%3DAllen%26aufirst%3DJ.%2BA.%26atitle%3DReward%2520circuitry%2520dysfunction%2520in%2520psychiatric%2520and%2520neurodevelopmental%2520disorders%2520and%2520genetic%2520syndromes%253A%2520animal%2520models%2520and%2520clinical%2520findings%26jtitle%3DJ.%2520Neurodev.%2520Disord.%26date%3D2012%26volume%3D4%26spage%3D19%26doi%3D10.1186%2F1866-1955-4-19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Komatsu, H.</span></span> <span> </span><span class="NLM_article-title">Novel therapeutic GPCRs for psychiatric disorders</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">14109</span>– <span class="NLM_lpage">14121</span>, <span class="refDoi"> DOI: 10.3390/ijms160614109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=10.3390%2Fijms160614109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=26101869" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvValtLjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=14109-14121&author=H.+Komatsu&title=Novel+therapeutic+GPCRs+for+psychiatric+disorders&doi=10.3390%2Fijms160614109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Novel therapeutic GPCRs for psychiatric disorders</span></div><div class="casAuthors">Komatsu, Hidetoshi</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">14109-14121</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">G protein-coupled receptors (GPCRs) are the most common targets of the neuropharmacol. drugs in the central nervous system (CNS).  GPCRs are activated by manifold neurotransmitters, and their activation in turn evokes slow synaptic transmission.  They are deeply involved in multiple neurol. and psychiatric disorders such as Parkinson's disease and schizophrenia.  In the brain, the striatum is strongly innervated by the ventral tegmental area (VTA) and plays a central role in manifestation of psychiatric disorders.  Recently, anatomical and comprehensive transcriptome anal. of the non-odorant GPCR superfamily revealed that the orphan GPCRs GPR88, GPR6, and GPR52, as well as dopamine D1 and D2 receptors and the adenosine A2a receptor, are the most highly enriched in the rodent striatum.  Genetically engineered animal models and mol. biol. studies have suggested that these striatally enriched GPCRs have a potential to be therapeutic psychiatric receptors.  This review summarizes the current understanding of the therapeutic GPCR candidates for psychiatric disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3ibl5_GgvcrVg90H21EOLACvtfcHk0lhBopmBwyKqbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvValtLjM&md5=1d5f1f6aea76058deabe7a918f995953</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.3390%2Fijms160614109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms160614109%26sid%3Dliteratum%253Aachs%26aulast%3DKomatsu%26aufirst%3DH.%26atitle%3DNovel%2520therapeutic%2520GPCRs%2520for%2520psychiatric%2520disorders%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2015%26volume%3D16%26spage%3D14109%26epage%3D14121%26doi%3D10.3390%2Fijms160614109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grundmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merten, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malfacini, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rüttiger, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziegler, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benkel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishida, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reher, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawakami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rick, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kühl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imhof, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">König, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomeza, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wess, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostenis, E.</span></span> <span> </span><span class="NLM_article-title">Lack of beta-arrestin signaling in the absence of active G proteins</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">341</span>, <span class="refDoi"> DOI: 10.1038/s41467-017-02661-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=10.1038%2Fs41467-017-02661-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=29362459" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A280%3ADC%252BC1MvjsFKiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=341&author=M.+Grundmannauthor=N.+Mertenauthor=D.+Malfaciniauthor=A.+Inoueauthor=P.+Preisauthor=K.+Simonauthor=N.+R%C3%BCttigerauthor=N.+Zieglerauthor=T.+Benkelauthor=N.+K.+Schmittauthor=S.+Ishidaauthor=I.+M%C3%BCllerauthor=R.+Reherauthor=K.+Kawakamiauthor=A.+Inoueauthor=U.+Rickauthor=T.+K%C3%BChlauthor=D.+Imhofauthor=J.+Aokiauthor=G.+M.+K%C3%B6nigauthor=C.+Hoffmannauthor=J.+Gomezaauthor=J.+Wessauthor=E.+Kostenis&title=Lack+of+beta-arrestin+signaling+in+the+absence+of+active+G+proteins&doi=10.1038%2Fs41467-017-02661-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Lack of beta-arrestin signaling in the absence of active G proteins</span></div><div class="casAuthors">Grundmann Manuel; Merten Nicole; Malfacini Davide; Preis Philip; Simon Katharina; Benkel Tobias; Schmitt Nina Katharina; Muller Ines; Rick Ulrike; Gomeza Jesus; Kostenis Evi; Inoue Asuka; Ishida Satoru; Kawakami Kouki; Inoue Ayumi; Aoki Junken; Inoue Asuka; Ruttiger Nelly; Hoffmann Carsten; Ziegler Nicole; Reher Raphael; Konig Gabriele M; Kuhl Toni; Imhof Diana; Aoki Junken; Wess Jurgen</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">341</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">G protein-independent, arrestin-dependent signaling is a paradigm that broadens the signaling scope of G protein-coupled receptors (GPCRs) beyond G proteins for numerous biological processes.  However, arrestin signaling in the collective absence of functional G proteins has never been demonstrated.  Here we achieve a state of "zero functional G" at the cellular level using HEK293 cells depleted by CRISPR/Cas9 technology of the Gs/q/12 families of Gα proteins, along with pertussis toxin-mediated inactivation of Gi/o.  Together with HEK293 cells lacking β-arrestins ("zero arrestin"), we systematically dissect G protein- from arrestin-driven signaling outcomes for a broad set of GPCRs.  We use biochemical, biophysical, label-free whole-cell biosensing and ERK phosphorylation to identify four salient features for all receptors at "zero functional G": arrestin recruitment and internalization, but-unexpectedly-complete failure to activate ERK and whole-cell responses.  These findings change our understanding of how GPCRs function and in particular of how they activate ERK1/2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRVakKpC8MvOyA3UY9EwTNrfW6udTcc2eaDop1qldcO4rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MvjsFKiug%253D%253D&md5=4afaac8e9bb4a87bd9d02ea469024efc</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fs41467-017-02661-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-017-02661-3%26sid%3Dliteratum%253Aachs%26aulast%3DGrundmann%26aufirst%3DM.%26aulast%3DMerten%26aufirst%3DN.%26aulast%3DMalfacini%26aufirst%3DD.%26aulast%3DInoue%26aufirst%3DA.%26aulast%3DPreis%26aufirst%3DP.%26aulast%3DSimon%26aufirst%3DK.%26aulast%3DR%25C3%25BCttiger%26aufirst%3DN.%26aulast%3DZiegler%26aufirst%3DN.%26aulast%3DBenkel%26aufirst%3DT.%26aulast%3DSchmitt%26aufirst%3DN.%2BK.%26aulast%3DIshida%26aufirst%3DS.%26aulast%3DM%25C3%25BCller%26aufirst%3DI.%26aulast%3DReher%26aufirst%3DR.%26aulast%3DKawakami%26aufirst%3DK.%26aulast%3DInoue%26aufirst%3DA.%26aulast%3DRick%26aufirst%3DU.%26aulast%3DK%25C3%25BChl%26aufirst%3DT.%26aulast%3DImhof%26aufirst%3DD.%26aulast%3DAoki%26aufirst%3DJ.%26aulast%3DK%25C3%25B6nig%26aufirst%3DG.%2BM.%26aulast%3DHoffmann%26aufirst%3DC.%26aulast%3DGomeza%26aufirst%3DJ.%26aulast%3DWess%26aufirst%3DJ.%26aulast%3DKostenis%26aufirst%3DE.%26atitle%3DLack%2520of%2520beta-arrestin%2520signaling%2520in%2520the%2520absence%2520of%2520active%2520G%2520proteins%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26spage%3D341%26doi%3D10.1038%2Fs41467-017-02661-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simmler, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anacker, A. M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levin, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaswani, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gresch, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nackenoff, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anastasio, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stutz, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veenstra-VanderWeele, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blakely, R. D.</span></span> <span> </span><span class="NLM_article-title">Blockade of the 5-HT transporter contributes to the behavioural, neuronal and molecular effects of cocaine</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>174</i></span>,  <span class="NLM_fpage">2716</span>– <span class="NLM_lpage">2738</span>, <span class="refDoi"> DOI: 10.1111/bph.13899</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=10.1111%2Fbph.13899" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=28585320" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFCgtLjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2017&pages=2716-2738&author=L.+D.+Simmlerauthor=A.+M.+J.+Anackerauthor=M.+H.+Levinauthor=N.+M.+Vaswaniauthor=P.+J.+Greschauthor=A.+G.+Nackenoffauthor=N.+C.+Anastasioauthor=S.+J.+Stutzauthor=K.+A.+Cunninghamauthor=J.+Wangauthor=B.+Zhangauthor=L.+K.+Henryauthor=A.+Stewartauthor=J.+Veenstra-VanderWeeleauthor=R.+D.+Blakely&title=Blockade+of+the+5-HT+transporter+contributes+to+the+behavioural%2C+neuronal+and+molecular+effects+of+cocaine&doi=10.1111%2Fbph.13899"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Blockade of the 5-HT transporter contributes to the behavioural, neuronal and molecular effects of cocaine</span></div><div class="casAuthors">Simmler, Linda D.; Anacker, Allison M. J.; Levin, Michael H.; Vaswani, Nina M.; Gresch, Paul J.; Nackenoff, Alex G.; Anastasio, Noelle C.; Stutz, Sonja J.; Cunningham, Kathryn A.; Wang, Jing; Zhang, Bing; Henry, L. Keith; Stewart, Adele; Veenstra-VanderWeele, Jeremy; Blakely, Randy D.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2716-2738</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose : The psychostimulant cocaine induces complex mol., cellular and behavioral responses as a consequence of inhibiting presynaptic dopamine, noradrenaline and 5-HT transporters.  To elucidate 5-HT transporter (SERT)-specific contributions to cocaine action, we evaluated cocaine effects in the SERT Met172 knock-in mouse, which expresses a SERT coding substitution that eliminates high-affinity cocaine recognition.  Exptl. Approach : We measured the effects of SERT Met172 on cocaine antagonism of 5-HT re-uptake using ex vivo synaptosome prepns. and in vivo microdialysis.  We assessed SERT dependence of cocaine actions behaviorally through acute and chronic locomotor activation, sensitization, conditioned place preference (CPP) and oral cocaine consumption.  We used c-Fos, quant. RT-PCR and RNA sequencing methods for insights into cellular and mol. networks supporting SERT-dependent cocaine actions.  Key Results : SERT Met172 mice demonstrated functional insensitivity for cocaine at SERT.  Although they displayed wild-type levels of acute cocaine-induced hyperactivity or chronic sensitization, the pattern of acute motor activation was different, with a bias toward thigmotaxis.  CPP was increased, and a time-dependent elevation in oral cocaine consumption was obsd.  SERT Met172 mice displayed relatively higher levels of neuronal activation in the hippocampus, piriform cortex and prelimbic cortex (PrL), accompanied by region-dependent changes in immediate early gene expression.  Distinct SERT-dependent gene expression networks triggered by acute and chronic cocaine administration were identified, including PrL Akt and nucleus accumbens ERK1/2 signalling.  Conclusion and Implications : Our studies reveal distinct SERT contributions to cocaine action, reinforcing the possibility of targeting specific aspects of cocaine addiction by modulation of 5-HT signalling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorlo6wcxCpw7Vg90H21EOLACvtfcHk0ljXm9g9c4gGNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFCgtLjE&md5=87411dc7c77d4a6ef13e3537da978733</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1111%2Fbph.13899&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.13899%26sid%3Dliteratum%253Aachs%26aulast%3DSimmler%26aufirst%3DL.%2BD.%26aulast%3DAnacker%26aufirst%3DA.%2BM.%2BJ.%26aulast%3DLevin%26aufirst%3DM.%2BH.%26aulast%3DVaswani%26aufirst%3DN.%2BM.%26aulast%3DGresch%26aufirst%3DP.%2BJ.%26aulast%3DNackenoff%26aufirst%3DA.%2BG.%26aulast%3DAnastasio%26aufirst%3DN.%2BC.%26aulast%3DStutz%26aufirst%3DS.%2BJ.%26aulast%3DCunningham%26aufirst%3DK.%2BA.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DHenry%26aufirst%3DL.%2BK.%26aulast%3DStewart%26aufirst%3DA.%26aulast%3DVeenstra-VanderWeele%26aufirst%3DJ.%26aulast%3DBlakely%26aufirst%3DR.%2BD.%26atitle%3DBlockade%2520of%2520the%25205-HT%2520transporter%2520contributes%2520to%2520the%2520behavioural%252C%2520neuronal%2520and%2520molecular%2520effects%2520of%2520cocaine%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2017%26volume%3D174%26spage%3D2716%26epage%3D2738%26doi%3D10.1111%2Fbph.13899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cortez, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bulavin, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGrath, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakamiya, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papaconstantinou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dineley, K. T.</span></span> <span> </span><span class="NLM_article-title">Aged dominant negative p38α MAPK mice are resistant to age-dependent decline in adult-neurogenesis and context discrimination fear conditioning</span>. <i>Behav. Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>322</i></span>,  <span class="NLM_fpage">212</span>– <span class="NLM_lpage">222</span>, <span class="refDoi"> DOI: 10.1016/j.bbr.2016.10.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=10.1016%2Fj.bbr.2016.10.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=27765672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslKms7fO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=322&publication_year=2017&pages=212-222&author=I.+Cortezauthor=D.+V.+Bulavinauthor=P.+Wuauthor=E.+L.+McGrathauthor=K.+A.+Cunninghamauthor=M.+Wakamiyaauthor=J.+Papaconstantinouauthor=K.+T.+Dineley&title=Aged+dominant+negative+p38%CE%B1+MAPK+mice+are+resistant+to+age-dependent+decline+in+adult-neurogenesis+and+context+discrimination+fear+conditioning&doi=10.1016%2Fj.bbr.2016.10.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Aged dominant negative p38α MAPK mice are resistant to age-dependent decline in adult-neurogenesis and context discrimination fear conditioning</span></div><div class="casAuthors">Cortez, IbDanelo; Bulavin, Dmitry V.; Wu, Ping; McGrath, Erica L.; Cunningham, Kathryn A.; Wakamiya, Maki; Papaconstantinou, John; Dineley, Kelly T.</div><div class="citationInfo"><span class="NLM_cas:title">Behavioural Brain Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">322</span>
        (<span class="NLM_cas:issue">Part_B</span>),
    <span class="NLM_cas:pages">212-222</span>CODEN:
                <span class="NLM_cas:coden">BBREDI</span>;
        ISSN:<span class="NLM_cas:issn">0166-4328</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A major aspect of mammalian aging is the decline in functional competence of many self-renewing cell types, including adult-born neuronal precursors.  Since age-related senescence of self-renewal occurs simultaneously with chronic up-regulation of the p38MAPKalpha (p38α) signaling pathway, we used the dominant neg. mouse model for attenuated p38α activity (DN-p38αAF/+) in which Thr180 and Tyr182 are mutated (T → A/Y → F) to prevent phosphorylation activation (DN-p38αAF/+) and kinase activity.  As a result, aged DN-p38αAF/+ mice are resistant to age-dependent decline in proliferation and regeneration of several peripheral tissue progenitors when compared to wild-type littermates.  Aging is the major risk factor for non-inherited forms of Alzheimer's disease (AD); environmental and genetic risk factors that accelerate the senescence phenotype are thought to contribute to an individual's relative risk.  In the present study, we evaluated aged DN-p38αAF/+ and wildtype littermates in a series of behavioral paradigms to test if p38α mutant mice exhibit altered baseline abnormalities in neurol. reflexes, locomotion, anxiety-like behavior, and age-dependent cognitive decline.  While aged DN-p38αAF/+ and wildtype littermates appear equal in all tested baseline neurol. and behavioral parameters, DN-p38αAF/+ exhibit superior context discrimination fear conditioning.  Context discrimination is a cognitive task that is supported by proliferation and differentiation of adult-born neurons in the dentate gyrus of the hippocampus.  Consistent with enhanced context discrimination in aged DN-p38αAF/+, we discovered enhanced prodn. of adult-born neurons in the dentate gyrus of DN-p38αAF/+ mice compared to wildtype littermates.  Our findings support the notion that p38α inhibition has therapeutic utility in aging diseases that affect cognition, such as AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFlQci7hho0rVg90H21EOLACvtfcHk0ljXm9g9c4gGNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslKms7fO&md5=a0364b7630f749cb1ab66cdc58727a75</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.bbr.2016.10.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbr.2016.10.023%26sid%3Dliteratum%253Aachs%26aulast%3DCortez%26aufirst%3DI.%26aulast%3DBulavin%26aufirst%3DD.%2BV.%26aulast%3DWu%26aufirst%3DP.%26aulast%3DMcGrath%26aufirst%3DE.%2BL.%26aulast%3DCunningham%26aufirst%3DK.%2BA.%26aulast%3DWakamiya%26aufirst%3DM.%26aulast%3DPapaconstantinou%26aufirst%3DJ.%26aulast%3DDineley%26aufirst%3DK.%2BT.%26atitle%3DAged%2520dominant%2520negative%2520p38%25CE%25B1%2520MAPK%2520mice%2520are%2520resistant%2520to%2520age-dependent%2520decline%2520in%2520adult-neurogenesis%2520and%2520context%2520discrimination%2520fear%2520conditioning%26jtitle%3DBehav.%2520Brain%2520Res.%26date%3D2017%26volume%3D322%26spage%3D212%26epage%3D222%26doi%3D10.1016%2Fj.bbr.2016.10.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anastasio, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stutz, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bubar, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swinford, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbertson, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenzweig-Lipson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moeller, F. G.</span></span> <span> </span><span class="NLM_article-title">Synergism between a serotonin 5-HT<sub>2A</sub> receptor (5-HT<sub>2A</sub>R) antagonist and 5-HT<sub>2C</sub>R agonist suggests new pharmacotherapeutics for cocaine addiction</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">110</span>– <span class="NLM_lpage">121</span>, <span class="refDoi"> DOI: 10.1021/cn300072u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn300072u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFOntb7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=110-121&author=K.+A.+Cunninghamauthor=N.+C.+Anastasioauthor=R.+G.+Foxauthor=S.+J.+Stutzauthor=M.+J.+Bubarauthor=S.+E.+Swinfordauthor=C.+S.+Watsonauthor=S.+R.+Gilbertsonauthor=K.+C.+Riceauthor=S.+Rosenzweig-Lipsonauthor=F.+G.+Moeller&title=Synergism+between+a+serotonin+5-HT2A+receptor+%285-HT2AR%29+antagonist+and+5-HT2CR+agonist+suggests+new+pharmacotherapeutics+for+cocaine+addiction&doi=10.1021%2Fcn300072u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Synergism Between a Serotonin 5-HT2A Receptor (5-HT2AR) Antagonist and 5-HT2CR Agonist Suggests New Pharmacotherapeutics for Cocaine Addiction</span></div><div class="casAuthors">Cunningham, Kathryn A.; Anastasio, Noelle C.; Fox, Robert G.; Stutz, Sonja J.; Bubar, Marcy J.; Swinford, Sarah E.; Watson, Cheryl S.; Gilbertson, Scott R.; Rice, Kenner C.; Rosenzweig-Lipson, Sharon; Moeller, F. Gerard</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">110-121</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Relapse to cocaine dependence, even after extended abstinence, involves a no. of liability factors including impulsivity (predisposition toward rapid, unplanned reactions to stimuli without regard to neg. consequences) and cue reactivity (sensitivity to cues assocd. with cocaine-taking which can promote cocaine-seeking).  These factors have been mechanistically linked to serotonin (5-hydroxytryptamine, 5-HT) signaling through the 5-HT2A receptor (5-HT2AR) and 5-HT2CR; either a selective 5-HT2AR antagonist or a 5-HT2CR agonist suppresses impulsivity and cocaine-seeking in preclin. models.  We conducted proof-of-concept analyses to evaluate whether a combination of 5-HT2AR antagonist plus 5-HT2CR agonist would have synergistic effects over these liability factors for relapse as measured in a 1-choice serial reaction time task and cocaine self-administration/reinstatement assay.  Combined administration of a dose of the selective 5-HT2AR antagonist M100907 plus the 5-HT2CR agonist WAY163909, each ineffective alone, synergistically suppressed cocaine-induced hyperactivity, inherent and cocaine-evoked impulsive action, as well as cue- and cocaine-primed reinstatement of cocaine-seeking behavior.  The identification of synergism between a 5-HT2AR antagonist plus a 5-HT2CR agonist to attenuate these factors important in relapse indicates the promise of a bifunctional ligand as an anti-addiction pharmacotherapeutic, setting the stage to develop new ligands with improved efficacy, potency, selectivity, and in vivo profiles over the individual mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraOi38lqJqXLVg90H21EOLACvtfcHk0lhPeKZrSYw4Uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFOntb7J&md5=5f392443d0452d11cb30fc69c053d12c</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fcn300072u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn300072u%26sid%3Dliteratum%253Aachs%26aulast%3DCunningham%26aufirst%3DK.%2BA.%26aulast%3DAnastasio%26aufirst%3DN.%2BC.%26aulast%3DFox%26aufirst%3DR.%2BG.%26aulast%3DStutz%26aufirst%3DS.%2BJ.%26aulast%3DBubar%26aufirst%3DM.%2BJ.%26aulast%3DSwinford%26aufirst%3DS.%2BE.%26aulast%3DWatson%26aufirst%3DC.%2BS.%26aulast%3DGilbertson%26aufirst%3DS.%2BR.%26aulast%3DRice%26aufirst%3DK.%2BC.%26aulast%3DRosenzweig-Lipson%26aufirst%3DS.%26aulast%3DMoeller%26aufirst%3DF.%2BG.%26atitle%3DSynergism%2520between%2520a%2520serotonin%25205-HT2A%2520receptor%2520%25285-HT2AR%2529%2520antagonist%2520and%25205-HT2CR%2520agonist%2520suggests%2520new%2520pharmacotherapeutics%2520for%2520cocaine%2520addiction%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2013%26volume%3D4%26spage%3D110%26epage%3D121%26doi%3D10.1021%2Fcn300072u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keppel, G.</span>; <span class="NLM_string-name">Wickens, T. D.</span></span> <i>Design and analysis: a researcher’s handbook</i>; <span class="NLM_publisher-name">Pearson Prentice Hall</span>: <span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=G.+Keppel&author=T.+D.+Wickens&title=Design+and+analysis%3A+a+researcher%E2%80%99s+handbook"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DKeppel%26aufirst%3DG.%26btitle%3DDesign%2520and%2520analysis%253A%2520a%2520researcher%25E2%2580%2599s%2520handbook%26pub%3DPearson%2520Prentice%2520Hall%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/medium/jm0c01498_0020.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/large/jm0c01498_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01498&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/medium/jm0c01498_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/large/jm0c01498_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of representative reported GPR52 agonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/large/jm0c01498_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01498&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/medium/jm0c01498_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/large/jm0c01498_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Proposed structural modifications of three substructures (A, B, and C) based on advanced chemical lead <b>4</b> for SAR exploration to understand the key interactions of agonists with the receptor GPR52 and to identify newer ligands.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/large/jm0c01498_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01498&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/medium/jm0c01498_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/large/jm0c01498_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthetic Routes of Compounds <b>12a</b>–<b>c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/large/jm0c01498_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01498&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) CF<sub>3</sub>COOH, Et<sub>3</sub>SiH, CH<sub>2</sub>Cl<sub>2</sub>, overnight, and 89%. (b) Et<sub>3</sub>N, EtOH, rt., overnight, and 63–67%. (c) 2-(3-Fluoro-5-(trifluoromethyl)phenyl)acetonitrile (<b>9a</b>), NaH, DMF, 0 °C to rt., 2 h, and 53–66%. (d) Con. HCl/AcOH/H<sub>2</sub>O, reflux, overnight, and 91–93%. (e) NH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>OH, EDCI, DMAP, DMF, rt., overnight, and 73–83%.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/medium/jm0c01498_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/large/jm0c01498_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthetic Routes of Compound <b>12d</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/large/jm0c01498_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01498&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaH, DMF, 0 °C to rt., 2 h, and 73%. (b) (1) Con. HCl/AcOH/H<sub>2</sub>O, reflux, and overnight; (2) POCl<sub>3</sub>, reflux, 3 h, and 51% for two steps. (c) <b>6</b>, Pd(OAc)<sub>2</sub>, XantPhos, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, 100 °C, overnight, and 56%. (d) (1) 2 N NaOH, MeOH, reflux, and 1 h; (2) 2 N HCl, rt., and 95%. (e) NH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>OH, EDCI, DMAP, DMF, rt., overnight, and 83%.</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/medium/jm0c01498_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/large/jm0c01498_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthetic Routes of Compounds <b>12e</b> and <b>12f</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/large/jm0c01498_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01498&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaH, DMF, 0 °C to rt., 2 h, 36% for <b>17a</b>, and 63% for <b>17b</b>. (b) HCl, AcOH, H<sub>2</sub>O, 120 °C, overnight, 78% for <b>18a</b>, and 83% for <b>18b</b>. (c) POCl<sub>3</sub>, 120 °C, 12 h, 83% for <b>19a</b>, and 80% for <b>19b</b>. (d) <b>6</b>, Pd(OAc)<sub>2</sub>, XantPhos, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxnae, 100 °C, overnight, 64% for <b>20a</b>, and 60% for <b>20b</b>. (e) (i) 2 N NaOH, MeOH, reflux, and 1 h; (ii) 2 N HCl, rt., 92% for <b>21a</b>, and 90% for <b>21b</b>. (f) NH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>OH, EDCI, DMAP, DMF, rt., overnight, 79% for <b>12e</b>, and 59% for <b>12f</b>.</p></p></figure><figure data-id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/medium/jm0c01498_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/large/jm0c01498_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthetic Routes of Compounds <b>23a</b>–<b>k</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/large/jm0c01498_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01498&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (1) NaH, DMF, 0 °C to rt., and 2 h; (2) Con. HCl/AcOH/H<sub>2</sub>O, reflux, overnight, and 54–90% for two steps. (b) NH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>OH, EDCI, DMAP, DMF, rt., overnight, and 29–83%.</p></p></figure><figure data-id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/medium/jm0c01498_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/large/jm0c01498_0011.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthetic Routes of Compounds <b>25a</b>–<b>i</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/large/jm0c01498_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01498&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) For <b>24a</b>, (i) <b>7a</b>, NaH, DMF, 0 °C to rt., and 2 h; (ii) <i>m</i>CPBA, 0 °C to rt., 10 min, and 47% for two steps; (iii) <b>6</b>, XantPhos, Cs<sub>2</sub>CO<sub>3</sub>, Pd(OAc)<sub>2</sub>, 1,4-dioxane, 100 °C, overnight, and 82%; for <b>24b</b> and <b>24c</b>, (i) <b>8c</b>, NaH, DMF, 0 °C to rt., and 2 h; (ii) <i>m</i>CPBA, 0 °C to rt., 10 min, 49% over two steps for <b>24b</b>, and 79% over two steps for <b>24c</b>. (b) (i) Con. HCl/AcOH/H<sub>2</sub>O, reflux, and overnight; (ii) NH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>OH, EDCI, DMAP, DMF, rt., overnight, and 63–77% for two steps. (c) NaBH<sub>4</sub>, DMF/MeOH, 0 °C to rt., 30 min, and 68–90%. (d) (i) NaBH<sub>4</sub>, DMF/MeOH, 0 °C to rt., and 30 min; (ii) con. HCl/AcOH/H<sub>2</sub>O, reflux, overnight, and 78–90%. (e) (i) DAST, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt., and 10 min; (ii) THF/H<sub>2</sub>O, reflux, overnight, and 60–76% for two steps. (f) NH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>OH, EDCI, DMAP, DMF, rt., overnight, and 68–86%.</p></p></figure><figure data-id="sch6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/medium/jm0c01498_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/large/jm0c01498_0012.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthetic Routes of Compounds <b>25j</b>–<b>l</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/large/jm0c01498_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01498&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) For <b>29a</b>, Pd(OAc)<sub>2</sub>, XantPhos, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxnae, 100 °C, overnight, and 69%; for <b>29b</b> and <b>29c</b>, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 120 °C, overnight, 63% for <b>29b</b>, and 71% for <b>29c</b>. (b) (i) Con. HCl/AcOH/H<sub>2</sub>O, reflux, and overnight; (ii) NH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>OH, EDCI, DMAP, DMF, rt., overnight, and 43–73% for two steps.</p></p></figure><figure data-id="sch7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/medium/jm0c01498_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/large/jm0c01498_0013.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthetic Routes of Compounds <b>30a</b>–<b>g</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/large/jm0c01498_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01498&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) EDCI, DMAP, DMF, rt., overnight, and 37–78%.</p></p></figure><figure data-id="fig3" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/medium/jm0c01498_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/large/jm0c01498_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Concentration responses of select GPR52 agonists on cAMP signaling in HEK293 cells. HEK293 cells expressing human GPR52 and the cAMP Glosensor reporter were subjected to twelve-point concentration response (0.3 nM–30 μM) testing. (A) Modifications around ring B (magenta): comparison with compounds <b>4</b>, <b>12a</b>, <b>12b</b>, <b>12c</b>, and <b>12e</b>. (B) Modifications around ring C (cyan): comparison with compounds <b>4</b>, <b>23a</b>, <b>23d</b>, <b>23f</b>, <b>23i</b>, <b>23j</b>. (C) Modifications around carbon linker (cyan): comparison with compounds <b>4</b>, <b>25c</b>, <b>25e</b>, <b>25g</b>, <b>25i</b>, and <b>25l</b>. (D) Modifications around head group A (green): comparison with compounds <b>4</b>, <b>30a</b>, <b>30c</b>, <b>30d</b>, and <b>30g</b>. All results are presented as the mean ± SEM from triplicate testing in a representative experiment, with similar results observed in 3–17 experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/large/jm0c01498_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01498&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/medium/jm0c01498_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/large/jm0c01498_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Putative binding mode and molecular docking of compound <b>12c</b> with GPR52 (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6LI0">6LI0</a>). (A) Docking of compound <b>12c</b> (magenta) into the binding pocket of GPR52. Important residues are drawn as sticks. Hydrogen bonds are shown as dashed red lines. (B) Docking of compound <b>12c</b> into the binding pocket of GPR52 in 2D view. Hydrogen bonds are shown as magenta lines, and π–π interaction is shown as a green line.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/large/jm0c01498_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01498&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/medium/jm0c01498_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/large/jm0c01498_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Compound <b>12c</b> shows antipsychotic-like activity in mice. (A) Time course of horizontal activity (counts/5 min; mean ± SEM) following injection of the vehicle (black circles) or compound <b>12c</b> (0.3 (blue squares), 1 (burgundy triangles), 3 (green inverted triangles), or 10 mg/kg IP (red diamonds) is shown during automated activity monitoring for 30 min (blue dotted box)). Mice were then injected with amphetamine (AMPH; 3 mg/kg IP), and activity was monitored for the next 90 min. Horizontal activity (counts/5 min; mean ± SEM) during the first 30 min following AMPH injection is illustrated (purple dotted box). (B) Bar graph showing horizontal activity/30 min (mean ± SEM) following injection of the vehicle (Veh) or compound <b>12c</b>. (C) Bar graph showing horizontal activity (mean ± SEM) in the first 30 min period after AMPH injection. Filled circles indicate horizontal activity for individual animals. <i>n</i> = 12 mice/dose except for the 1 mg/kg AMPH (<i>n</i> = 11 mice/dose). *<i>P</i> < 0.05 <i>vs</i> Veh.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01498/20201120/images/large/jm0c01498_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01498&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i126">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80372" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80372" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 35 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span> <span> </span><span class="NLM_article-title">Strategies to discover unexpected targets for drugs active at G protein-coupled receptors</span>. <i>Annu. Rev. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">117</span>– <span class="NLM_lpage">144</span>, <span class="refDoi"> DOI: 10.1146/annurev-pharmtox-010510-100553</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=10.1146%2Fannurev-pharmtox-010510-100553" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=20868273" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisFOjurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2011&pages=117-144&author=J.+A.+Allenauthor=B.+L.+Roth&title=Strategies+to+discover+unexpected+targets+for+drugs+active+at+G+protein-coupled+receptors&doi=10.1146%2Fannurev-pharmtox-010510-100553"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies to discover unexpected targets for drugs active at G protein-coupled receptors</span></div><div class="casAuthors">Allen, John A.; Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">117-144</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  G protein-coupled receptors (GPCRs) are an evolutionarily conserved family of signaling mols. comprising approx. 2% of the human genome; this receptor family remains a central focus in basic pharmacol. studies and drug discovery efforts.  Detailed studies of drug action at GPCRs over the past decade have revealed existing and novel ligands that exhibit polypharmacol.-i.e., drugs with activity at more than 1 receptor target for which they were designed.  These "off-target" drug actions can be a liability that causes adverse side effects; however, in several cases, drugs with less selectivity demonstrate better clin. efficacy.  Here we review phys. screening and cheminformatic approaches that define drug activity at the GPCR receptorome.  In many cases, such profiling has revealed unexpected targets that explain therapeutic actions as well as off-targets underlying drug side effects.  Such drug-receptor profiling has also provided new insights into mechanisms of action of existing drugs and has suggested directions for future drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGondPzdCWKsd7Vg90H21EOLACvtfcHk0lgffvVfXt5Xfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisFOjurs%253D&md5=0699e67e114115904dff749d1251f91b</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1146%2Fannurev-pharmtox-010510-100553&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-pharmtox-010510-100553%26sid%3Dliteratum%253Aachs%26aulast%3DAllen%26aufirst%3DJ.%2BA.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DStrategies%2520to%2520discover%2520unexpected%2520targets%2520for%2520drugs%2520active%2520at%2520G%2520protein-coupled%2520receptors%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2011%26volume%3D51%26spage%3D117%26epage%3D144%26doi%3D10.1146%2Fannurev-pharmtox-010510-100553" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wold, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span> <span> </span><span class="NLM_article-title">Allosteric modulation of class A GPCRs: targets, agents, and emerging concepts</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">88</span>– <span class="NLM_lpage">127</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00875</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00875" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsV2lsLbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=88-127&author=E.+A.+Woldauthor=J.+Chenauthor=K.+A.+Cunninghamauthor=J.+Zhou&title=Allosteric+modulation+of+class+A+GPCRs%3A+targets%2C+agents%2C+and+emerging+concepts&doi=10.1021%2Facs.jmedchem.8b00875"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric Modulation of Class A GPCRs: Targets, Agents, and Emerging Concepts</span></div><div class="casAuthors">Wold, Eric A.; Chen, Jianping; Cunningham, Kathryn A.; Zhou, Jia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">88-127</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">G-protein-coupled receptors (GPCRs) have been tractable drug targets for decades with over one-third of currently marketed drugs targeting GPCRs.  Of these, the class A GPCR superfamily is highly represented, and continued drug discovery for this family of receptors may provide novel therapeutics for a vast range of diseases.  GPCR allosteric modulation is an innovative targeting approach that broadens the available small mol. toolbox and is proving to be a viable drug discovery strategy, as evidenced by recent FDA approvals and clin. trials.  Numerous class A GPCR allosteric modulators have been discovered recently, and emerging trends such as the availability of GPCR crystal structures, diverse functional assays, and structure-based computational approaches are improving optimization and development.  This Perspective provides an update on allosterically targeted class A GPCRs and their disease indications and the medicinal chem. approaches toward novel allosteric modulators and highlights emerging trends and opportunities in the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7zBEGIhRgD7Vg90H21EOLACvtfcHk0liMy9gy_8KHpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsV2lsLbK&md5=c724b7cb534a9eb52c371961bb9c9b42</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00875&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00875%26sid%3Dliteratum%253Aachs%26aulast%3DWold%26aufirst%3DE.%2BA.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DCunningham%26aufirst%3DK.%2BA.%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DAllosteric%2520modulation%2520of%2520class%2520A%2520GPCRs%253A%2520targets%252C%2520agents%252C%2520and%2520emerging%2520concepts%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D88%26epage%3D127%26doi%3D10.1021%2Facs.jmedchem.8b00875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wild, C.</span></span> <span> </span><span class="NLM_article-title">GPCR drug discovery: emerging targets, novel approaches and future trends</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1363</span>– <span class="NLM_lpage">1364</span>, <span class="refDoi"> DOI: 10.2174/156802661916190828093500</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=10.2174%2F156802661916190828093500" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=31513505" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvV2isLfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=1363-1364&author=J.+Zhouauthor=C.+Wild&title=GPCR+drug+discovery%3A+emerging+targets%2C+novel+approaches+and+future+trends&doi=10.2174%2F156802661916190828093500"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">GPCR Drug Discovery: Emerging Targets, Novel Approaches and Future Trends</span></div><div class="casAuthors">Zhou, Jia; Wild, Christopher</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1363-1364</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon7RPLZ3B3ALVg90H21EOLACvtfcHk0liMy9gy_8KHpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvV2isLfO&md5=ce49981d9123aae0ef48e1cbc47c704b</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.2174%2F156802661916190828093500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802661916190828093500%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DWild%26aufirst%3DC.%26atitle%3DGPCR%2520drug%2520discovery%253A%2520emerging%2520targets%252C%2520novel%2520approaches%2520and%2520future%2520trends%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2019%26volume%3D19%26spage%3D1363%26epage%3D1364%26doi%3D10.2174%2F156802661916190828093500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Overington, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Lazikani, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span> <span> </span><span class="NLM_article-title">How many drug targets are there?</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">993</span>– <span class="NLM_lpage">996</span>, <span class="refDoi"> DOI: 10.1038/nrd2199</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=10.1038%2Fnrd2199" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=17139284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1Kju7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=993-996&author=J.+P.+Overingtonauthor=B.+Al-Lazikaniauthor=A.+L.+Hopkins&title=How+many+drug+targets+are+there%3F&doi=10.1038%2Fnrd2199"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">How many drug targets are there?</span></div><div class="casAuthors">Overington, John P.; Al-Lazikani, Bissan; Hopkins, Andrew L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">993-996</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  For the past decade, the no. of mol. targets for approved drugs has been debated.  Here, we reconcile apparently contradictory previous reports into a comprehensive survey, and propose a consensus no. of current drug targets for all classes of approved therapeutic drugs.  One striking feature is the relatively const. historical rate of target innovation (the rate at which drugs against new targets are launched); however, the rate of developing drugs against new families is significantly lower.  The recent approval of drugs that target protein kinases highlights two addnl. trends: an emerging realization of the importance of polypharmacol., and also the power of a gene-family-led approach in generating novel and important therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDoZu-pkUsAbVg90H21EOLACvtfcHk0liMy9gy_8KHpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1Kju7jM&md5=14b5716f4e10b57ae71bf67e52a21929</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrd2199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2199%26sid%3Dliteratum%253Aachs%26aulast%3DOverington%26aufirst%3DJ.%2BP.%26aulast%3DAl-Lazikani%26aufirst%3DB.%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26atitle%3DHow%2520many%2520drug%2520targets%2520are%2520there%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D993%26epage%3D996%26doi%3D10.1038%2Fnrd2199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lagerström, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiöth, H. B.</span></span> <span> </span><span class="NLM_article-title">Structural diversity of G protein-coupled receptors and significance for drug discovery</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">339</span>– <span class="NLM_lpage">357</span>, <span class="refDoi"> DOI: 10.1038/nrd2518</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=10.1038%2Fnrd2518" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=18382464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A280%3ADC%252BD1c3itl2juw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=339-357&author=M.+C.+Lagerstr%C3%B6mauthor=H.+B.+Schi%C3%B6th&title=Structural+diversity+of+G+protein-coupled+receptors+and+significance+for+drug+discovery&doi=10.1038%2Fnrd2518"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Structural diversity of G protein-coupled receptors and significance for drug discovery</span></div><div class="casAuthors">Lagerstrom Malin C; Schioth Helgi B</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Drug discovery</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">339-57</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">G protein-coupled receptors (GPCRs) are the largest family of membrane-bound receptors and also the targets of many drugs.  Understanding of the functional significance of the wide structural diversity of GPCRs has been aided considerably in recent years by the sequencing of the human genome and by structural studies, and has important implications for the future therapeutic potential of targeting this receptor family.  This article aims to provide a comprehensive overview of the five main human GPCR families--Rhodopsin, Secretin, Adhesion, Glutamate and Frizzled/Taste2--with a focus on gene repertoire, general ligand preference, common and unique structural features, and the potential for future drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSr8CC5dLjDFTC850By6mxpfW6udTcc2eb37RH6DFbhB7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c3itl2juw%253D%253D&md5=3e9de54162c071b7927d975b964abea2</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrd2518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2518%26sid%3Dliteratum%253Aachs%26aulast%3DLagerstr%25C3%25B6m%26aufirst%3DM.%2BC.%26aulast%3DSchi%25C3%25B6th%26aufirst%3DH.%2BB.%26atitle%3DStructural%2520diversity%2520of%2520G%2520protein-coupled%2520receptors%2520and%2520significance%2520for%2520drug%2520discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2008%26volume%3D7%26spage%3D339%26epage%3D357%26doi%3D10.1038%2Fnrd2518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hauser, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attwood, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rask-Andersen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiöth, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gloriam, D. E.</span></span> <span> </span><span class="NLM_article-title">Trends in GPCR drug discovery: new agents, targets and indications</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">829</span>– <span class="NLM_lpage">842</span>, <span class="refDoi"> DOI: 10.1038/nrd.2017.178</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=10.1038%2Fnrd.2017.178" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=29075003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslansbzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=829-842&author=A.+S.+Hauserauthor=M.+M.+Attwoodauthor=M.+Rask-Andersenauthor=H.+B.+Schi%C3%B6thauthor=D.+E.+Gloriam&title=Trends+in+GPCR+drug+discovery%3A+new+agents%2C+targets+and+indications&doi=10.1038%2Fnrd.2017.178"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Trends in GPCR drug discovery: new agents, targets and indications</span></div><div class="casAuthors">Hauser, Alexander S.; Attwood, Misty M.; Rask-Andersen, Mathias; Schioth, Helgi B.; Gloriam, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">829-842</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">G protein-coupled receptors (GPCRs) are the most intensively studied drug targets, mostly due to their substantial involvement in human pathophysiol. and their pharmacol. tractability.  Here, we report an up-to-date anal. of all GPCR drugs and agents in clin. trials, which reveals current trends across mol. types, drug targets and therapeutic indications, including showing that 475 drugs (∼34% of all drugs approved by the US Food and Drug Administration (FDA)) act at 108 unique GPCRs.  Approx. 321 agents are currently in clin. trials, of which ∼20% target 66 potentially novel GPCR targets without an approved drug, and the no. of biol. drugs, allosteric modulators and biased agonists has increased.  The major disease indications for GPCR modulators show a shift towards diabetes, obesity and Alzheimer disease, although several central nervous system disorders are also highly represented.  The 224 (56%) non-olfactory GPCRs that have not yet been explored in clin. trials have broad untapped therapeutic potential, particularly in genetic and immune system disorders.  Finally, we provide an interactive online resource to analyze and infer trends in GPCR drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9iw1QqR9GKrVg90H21EOLACvtfcHk0lhlZRELCSnIZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslansbzF&md5=560893258493bd96c0af24d3bef08b6f</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2017.178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2017.178%26sid%3Dliteratum%253Aachs%26aulast%3DHauser%26aufirst%3DA.%2BS.%26aulast%3DAttwood%26aufirst%3DM.%2BM.%26aulast%3DRask-Andersen%26aufirst%3DM.%26aulast%3DSchi%25C3%25B6th%26aufirst%3DH.%2BB.%26aulast%3DGloriam%26aufirst%3DD.%2BE.%26atitle%3DTrends%2520in%2520GPCR%2520drug%2520discovery%253A%2520new%2520agents%252C%2520targets%2520and%2520indications%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26spage%3D829%26epage%3D842%26doi%3D10.1038%2Fnrd.2017.178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irwin, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoichet, B. K.</span></span> <span> </span><span class="NLM_article-title">Discovery of new GPCR ligands to illuminate new biology</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1143</span>– <span class="NLM_lpage">1151</span>, <span class="refDoi"> DOI: 10.1038/nchembio.2490</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=10.1038%2Fnchembio.2490" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=29045379" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1OhsrnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=1143-1151&author=B.+L.+Rothauthor=J.+J.+Irwinauthor=B.+K.+Shoichet&title=Discovery+of+new+GPCR+ligands+to+illuminate+new+biology&doi=10.1038%2Fnchembio.2490"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of new GPCR ligands to illuminate new biology</span></div><div class="casAuthors">Roth, Bryan L.; Irwin, John J.; Shoichet, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1143-1151</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Although a plurality of drugs target G-protein-coupled receptors (GPCRs), most have emerged from classical medicinal chem. and pharmacol. programs and resemble one another structurally and functionally.  Though effective, these drugs are often promiscuous.  With the realization that GPCRs signal via multiple pathways, and with the emergence of crystal structures for this family of proteins, there is an opportunity to target GPCRs with new chemotypes and confer new signaling modalities.  The authors consider structure-based and phys. screening methods that have led to the discovery of new reagents, focusing particularly on the former.  The authors illustrate their use against previously untargeted or orphan GPCRs, against allosteric sites, and against classical orthosteric sites that selectively activate one downstream pathway over others.  The ligands that emerge are often chem. novel, which can lead to new biol. effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0g7QvZBYzkLVg90H21EOLACvtfcHk0lhlZRELCSnIZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1OhsrnK&md5=6b1682d6b1475dc1a0e8834895c4ae6c</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2490&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2490%26sid%3Dliteratum%253Aachs%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DIrwin%26aufirst%3DJ.%2BJ.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26atitle%3DDiscovery%2520of%2520new%2520GPCR%2520ligands%2520to%2520illuminate%2520new%2520biology%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2017%26volume%3D13%26spage%3D1143%26epage%3D1151%26doi%3D10.1038%2Fnchembio.2490" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ye, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wold, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span> <span> </span><span class="NLM_article-title">Orphan receptor GPR88 as an emerging neurotherapeutic target</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">190</span>– <span class="NLM_lpage">200</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.8b00572</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.8b00572" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVyhs7fO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=190-200&author=N.+Yeauthor=B.+Liauthor=Q.+Maoauthor=E.+A.+Woldauthor=S.+Tianauthor=J.+A.+Allenauthor=J.+Zhou&title=Orphan+receptor+GPR88+as+an+emerging+neurotherapeutic+target&doi=10.1021%2Facschemneuro.8b00572"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Orphan Receptor GPR88 as an Emerging Neurotherapeutic Target</span></div><div class="casAuthors">Ye, Na; Li, Bang; Mao, Qi; Wold, Eric A.; Tian, Sheng; Allen, John A.; Zhou, Jia</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">190-200</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Although G protein-coupled receptors (GPCRs) are recognized as pivotal drug targets involved in multiple physiol. and pathol. processes, the majority of GPCRs including orphan GPCRs (oGPCRs) are unexploited.  GPR88, a brain-specific oGPCR with particularly robust expression in the striatum, regulates diverse brain and behavioral functions, including cognition, mood, movement control, and reward-based learning, and is thus emerging as a novel drug target for central nervous system disorders including schizophrenia, Parkinson's disease, anxiety, and addiction.  Nevertheless, no effective GPR88 synthetic ligands have yet entered into clin. trials, and GPR88 endogenous ligands remain unknown.  Despite the recent discovery and early stage study of several GPR88 agonists, such as 2-PCCA, RTI-13951-33, and phenylglycinol derivs., further research into GPR88 pharmacol., medicinal chem., and chem. biol. is urgently needed to yield structurally diversified GPR88-specific ligands.  Drug-like pharmacol. tool function and relevant signaling elucidation will also accelerate the evaluation of this receptor as a viable neurotherapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoP8O0djL7NL7Vg90H21EOLACvtfcHk0lipFDhorSx1vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVyhs7fO&md5=0511e92dd00711cb2b4f83a6e5b82818</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.8b00572&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.8b00572%26sid%3Dliteratum%253Aachs%26aulast%3DYe%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DMao%26aufirst%3DQ.%26aulast%3DWold%26aufirst%3DE.%2BA.%26aulast%3DTian%26aufirst%3DS.%26aulast%3DAllen%26aufirst%3DJ.%2BA.%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DOrphan%2520receptor%2520GPR88%2520as%2520an%2520emerging%2520neurotherapeutic%2520target%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2019%26volume%3D10%26spage%3D190%26epage%3D200%26doi%3D10.1021%2Facschemneuro.8b00572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sawzdargo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heng, H. H. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Dowd, B. F.</span></span> <span> </span><span class="NLM_article-title">Identification and cloning of three novel human G protein-coupled receptor genes GPR52, ΨGPR53 and GPR55: GPR55 is extensively expressed in human brain</span>. <i>Mol. Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">193</span>– <span class="NLM_lpage">198</span>, <span class="refDoi"> DOI: 10.1016/S0169-328X(98)00277-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=10.1016%2FS0169-328X%2898%2900277-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=9931487" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A528%3ADyaK1MXmtVGqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=1999&pages=193-198&author=M.+Sawzdargoauthor=T.+Nguyenauthor=D.+K.+Leeauthor=K.+R.+Lynchauthor=R.+Chengauthor=H.+H.+Q.+Hengauthor=S.+R.+Georgeauthor=B.+F.+O%E2%80%99Dowd&title=Identification+and+cloning+of+three+novel+human+G+protein-coupled+receptor+genes+GPR52%2C+%CE%A8GPR53+and+GPR55%3A+GPR55+is+extensively+expressed+in+human+brain&doi=10.1016%2FS0169-328X%2898%2900277-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and cloning of three novel human G protein-coupled receptor genes GPR52, ΨGPR53 and GPR55: GPR55 is extensively expressed in human brain</span></div><div class="casAuthors">Sawzdargo, Marek; Nguyen, Tuan; Lee, Dennis K.; Lynch, Kevin R.; Cheng, Regina; Heng, Henry H. Q.; George, Susan R.; O'Dowd, Brian F.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Brain Research</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">193-198</span>CODEN:
                <span class="NLM_cas:coden">MBREE4</span>;
        ISSN:<span class="NLM_cas:issn">0169-328X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">The G protein-coupled receptor (GPCR) family share a structural motif of seven transmembrane segments with large nos. of conserved residues in those regions.  Here, we report the identification and cloning of two novel human intronless GPCR genes, GPR52, GPR55 and a pseudogene ΨGPR53.  GPR55 was identified from the expressed sequence tags (EST) database whereas GPR52 and pseudogene ΨGPR53 originated from the high throughput genome (HTG) database.  A partial cDNA clone obtained from the IMAGE Consortium of GPR55 was used to screen a human genomic library to acquire the full length gene.  GPR52 and ΨGPR53 were amplified from human genomic DNA using primers based on the HTG sequences.  GPR55 and GPR52 encode receptors of 319 and 361 amino acids, resp.  GPR55 gene was mapped to chromosome 2q37, using fluorescence in situ hybridization (FISH), and its mRNA transcripts have been detected in the caudate nucleus and putamen, but not in five other brain regions.  Human receptors showing the highest amino acid identity to GPR55 include P2Y5 (29%), GPR23 (30%), GPR35 (27%) and CCR4 (23%).  GPR52 gene localized to chromosome 1q24 shares the highest identity with GPR21 (71%), histamine H2 (27%) and 5-HT4 (26%) human receptors.  ΨGPR53 is a pseudogene mapped to chromosome 6p21 that demonstrates the highest similarity to the MRG (35%), MAS (28%) and C5a (24%) human receptor genes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSppMAt-L_hrVg90H21EOLACvtfcHk0lipFDhorSx1vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmtVGqtg%253D%253D&md5=31817286bae73c3afef42e7471a3af07</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2FS0169-328X%2898%2900277-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-328X%252898%252900277-0%26sid%3Dliteratum%253Aachs%26aulast%3DSawzdargo%26aufirst%3DM.%26aulast%3DNguyen%26aufirst%3DT.%26aulast%3DLee%26aufirst%3DD.%2BK.%26aulast%3DLynch%26aufirst%3DK.%2BR.%26aulast%3DCheng%26aufirst%3DR.%26aulast%3DHeng%26aufirst%3DH.%2BH.%2BQ.%26aulast%3DGeorge%26aufirst%3DS.%2BR.%26aulast%3DO%25E2%2580%2599Dowd%26aufirst%3DB.%2BF.%26atitle%3DIdentification%2520and%2520cloning%2520of%2520three%2520novel%2520human%2520G%2520protein-coupled%2520receptor%2520genes%2520GPR52%252C%2520%25CE%25A8GPR53%2520and%2520GPR55%253A%2520GPR55%2520is%2520extensively%2520expressed%2520in%2520human%2520brain%26jtitle%3DMol.%2520Brain%2520Res.%26date%3D1999%26volume%3D64%26spage%3D193%26epage%3D198%26doi%3D10.1016%2FS0169-328X%2898%2900277-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Komatsu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maruyama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinohara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakuma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imaichi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chikatsu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuniyeda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu, F. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mun, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyajima, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itoh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, M.</span></span> <span> </span><span class="NLM_article-title">Anatomical transcriptome of G protein-coupled receptors leads to the identification of a novel therapeutic candidate GPR52 for psychiatric disorders</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">e90134</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0090134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=10.1371%2Fjournal.pone.0090134" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=24587241" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVKjsbfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&author=H.+Komatsuauthor=M.+Maruyamaauthor=S.+Yaoauthor=T.+Shinoharaauthor=K.+Sakumaauthor=S.+Imaichiauthor=T.+Chikatsuauthor=K.+Kuniyedaauthor=F.+K.+Siuauthor=L.+S.+Pengauthor=K.+Zhuoauthor=L.+S.+Munauthor=T.+M.+Hanauthor=Y.+Matsumotoauthor=T.+Hashimotoauthor=N.+Miyajimaauthor=Y.+Itohauthor=K.+Ogiauthor=Y.+Habataauthor=M.+Mori&title=Anatomical+transcriptome+of+G+protein-coupled+receptors+leads+to+the+identification+of+a+novel+therapeutic+candidate+GPR52+for+psychiatric+disorders&doi=10.1371%2Fjournal.pone.0090134"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Anatomical transcriptome of G protein-coupled receptors leads to the identification of a novel therapeutic candidate GPR52 for psychiatric disorders</span></div><div class="casAuthors">Komatsu, Hidetoshi; Maruyama, Minoru; Yao, Shuuhei; Shinohara, Tokuyuki; Sakuma, Kensuke; Imaichi, Sachiko; Chikatsu, Tomoko; Kuniyeda, Kanako; Siu, Foo Kok; Peng, Lam Sock; Zhuo, Katherine; Mun, Lay Sock; Han, Tan Min; Matsumoto, Yoshio; Hashimoto, Tadatoshi; Miyajima, Nobuyuki; Itoh, Yasuaki; Ogi, Kazuhiro; Habata, Yugo; Mori, Masaaki</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e90134/1-e90134/16, 16 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Many drugs of abuse and most neuropharmacol. agents regulate G protein-coupled receptors (GPCRs) in the central nervous system (CNS)_ENREF_1.  The striatum, in which dopamine D1 and D2 receptors are enriched, is strongly innervated by the ventral tegmental area (VTA), which is the origin of dopaminergic cell bodies of the mesocorticolimbic dopamine system_ENREF_3 and plays a central role in the development of psychiatric disorders_ENREF_4.  Here we report the comprehensive and anatomical transcript profiling of 322 non-odorant GPCRs in mouse tissue by quant. real-time PCR (qPCR), leading to the identification of neurotherapeutic receptors exclusively expressed in the CNS, esp. in the striatum.  Among them, GPR6, GPR52, and GPR88, known as orphan GPCRs, were shown to co-localize either with a D2 receptor alone or with both D1 and D2 receptors in neurons of the basal ganglia.  Intriguingly, we found that GPR52 was well conserved among vertebrates, is Gs-coupled and responsive to the antipsychotic drug, reserpine.  We used three types of transgenic (Tg) mice employing a Cre-lox system under the control of the GPR52 promoter, namely, GPR52-LacZ Tg, human GPR52 (hGPR52) Tg, and hGPR52-GFP Tg mice.  Detailed histol. investigation suggests that GPR52 may modulate dopaminergic and glutamatergic transmission in neuronal circuits responsible for cognitive function and emotion.  In support of our prediction, GPR52 knockout and transgenic mice exhibited psychosis-related and antipsychotic-like behaviors, resp.  Therefore, we propose that GPR52 has the potential of being a therapeutic psychiatric receptor.  This approach may help identify potential therapeutic targets for CNS diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoceoSKPwv1nrVg90H21EOLACvtfcHk0lgFJF_Ve2z-IA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVKjsbfF&md5=fdaf1c9f4a80ef12adf400eef5eec2f3</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0090134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0090134%26sid%3Dliteratum%253Aachs%26aulast%3DKomatsu%26aufirst%3DH.%26aulast%3DMaruyama%26aufirst%3DM.%26aulast%3DYao%26aufirst%3DS.%26aulast%3DShinohara%26aufirst%3DT.%26aulast%3DSakuma%26aufirst%3DK.%26aulast%3DImaichi%26aufirst%3DS.%26aulast%3DChikatsu%26aufirst%3DT.%26aulast%3DKuniyeda%26aufirst%3DK.%26aulast%3DSiu%26aufirst%3DF.%2BK.%26aulast%3DPeng%26aufirst%3DL.%2BS.%26aulast%3DZhuo%26aufirst%3DK.%26aulast%3DMun%26aufirst%3DL.%2BS.%26aulast%3DHan%26aufirst%3DT.%2BM.%26aulast%3DMatsumoto%26aufirst%3DY.%26aulast%3DHashimoto%26aufirst%3DT.%26aulast%3DMiyajima%26aufirst%3DN.%26aulast%3DItoh%26aufirst%3DY.%26aulast%3DOgi%26aufirst%3DK.%26aulast%3DHabata%26aufirst%3DY.%26aulast%3DMori%26aufirst%3DM.%26atitle%3DAnatomical%2520transcriptome%2520of%2520G%2520protein-coupled%2520receptors%2520leads%2520to%2520the%2520identification%2520of%2520a%2520novel%2520therapeutic%2520candidate%2520GPR52%2520for%2520psychiatric%2520disorders%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26doi%3D10.1371%2Fjournal.pone.0090134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, R. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sodaei, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aguet, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segrè, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanz, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinhart, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ardlie, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guigö, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, H. S.</span></span> <span> </span><span class="NLM_article-title">A systematic survey of human tissue-specific gene expression and splicing reveals new opportunities for therapeutic target identification and evaluation</span>. <i>bioRxiv</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_fpage">311563</span>, <span class="refDoi"> DOI: 10.1101/311563</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=10.1101%2F311563" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&pages=311563&author=R.+Y.+Yangauthor=J.+Quanauthor=R.+Sodaeiauthor=F.+Aguetauthor=A.+V.+Segr%C3%A8author=J.+A.+Allenauthor=T.+A.+Lanzauthor=V.+Reinhartauthor=M.+Crawfordauthor=S.+Hassonauthor=K.+G.+Ardlieauthor=R.+Guig%C3%B6author=H.+S.+Xi&title=A+systematic+survey+of+human+tissue-specific+gene+expression+and+splicing+reveals+new+opportunities+for+therapeutic+target+identification+and+evaluation&doi=10.1101%2F311563"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1101%2F311563&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252F311563%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DR.%2BY.%26aulast%3DQuan%26aufirst%3DJ.%26aulast%3DSodaei%26aufirst%3DR.%26aulast%3DAguet%26aufirst%3DF.%26aulast%3DSegr%25C3%25A8%26aufirst%3DA.%2BV.%26aulast%3DAllen%26aufirst%3DJ.%2BA.%26aulast%3DLanz%26aufirst%3DT.%2BA.%26aulast%3DReinhart%26aufirst%3DV.%26aulast%3DCrawford%26aufirst%3DM.%26aulast%3DHasson%26aufirst%3DS.%26aulast%3DArdlie%26aufirst%3DK.%2BG.%26aulast%3DGuig%25C3%25B6%26aufirst%3DR.%26aulast%3DXi%26aufirst%3DH.%2BS.%26atitle%3DA%2520systematic%2520survey%2520of%2520human%2520tissue-specific%2520gene%2520expression%2520and%2520splicing%2520reveals%2520new%2520opportunities%2520for%2520therapeutic%2520target%2520identification%2520and%2520evaluation%26jtitle%3DbioRxiv%26date%3D2018%26spage%3D311563%26doi%3D10.1101%2F311563" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, F.</span></span> <span> </span><span class="NLM_article-title">Structural basis of ligand recognition and self-activation of orphan GPR52</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>579</i></span>,  <span class="NLM_fpage">152</span>– <span class="NLM_lpage">157</span>, <span class="refDoi"> DOI: 10.1038/s41586-020-2019-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=10.1038%2Fs41586-020-2019-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=32076264" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjsVejsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=579&publication_year=2020&pages=152-157&author=X.+Linauthor=M.+Liauthor=N.+Wangauthor=Y.+Wuauthor=Z.+Luoauthor=S.+Guoauthor=G.+W.+Hanauthor=S.+Liauthor=Y.+Yueauthor=X.+Weiauthor=X.+Xieauthor=Y.+Chenauthor=S.+Zhaoauthor=J.+Wuauthor=M.+Leiauthor=F.+Xu&title=Structural+basis+of+ligand+recognition+and+self-activation+of+orphan+GPR52&doi=10.1038%2Fs41586-020-2019-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis of ligand recognition and self-activation of orphan GPR52</span></div><div class="casAuthors">Lin, Xi; Li, Mingyue; Wang, Niandong; Wu, Yiran; Luo, Zhipu; Guo, Shimeng; Han, Gye-Won; Li, Shaobai; Yue, Yang; Wei, Xiaohu; Xie, Xin; Chen, Yong; Zhao, Suwen; Wu, Jian; Lei, Ming; Xu, Fei</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">579</span>
        (<span class="NLM_cas:issue">7797</span>),
    <span class="NLM_cas:pages">152-157</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">GPR52 is a class-A orphan G-protein-coupled receptor that is highly expressed in the brain and represents a promising therapeutic target for the treatment of Huntington's disease and several psychiatric disorders.  Pathol. malfunction of GPR52 signaling occurs primarily through the heterotrimeric Gs protein, but it is unclear how GPR52 and Gs couple for signal transduction and whether a native ligand or other activating input is required.  Here we present the high-resoln. structures of human GPR52 in three states: a ligand-free state, a Gs-coupled self-activation state and a potential allosteric ligand-bound state.  Together, our structures reveal that extracellular loop 2 occupies the orthosteric binding pocket and operates as a built-in agonist, conferring an intrinsically high level of basal activity to GPR52.  A fully active state is achieved when Gs is coupled to GPR52 in the absence of an external agonist.  The receptor also features a side pocket for ligand binding.  These insights into the structure and function of GPR52 could improve our understanding of other self-activated GPCRs, enable the identification of endogenous and tool ligands, and guide drug discovery efforts that target GPR52.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotl_2-sJeM_bVg90H21EOLACvtfcHk0lgFJF_Ve2z-IA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjsVejsLg%253D&md5=a0c899853309addd569f16f70c221e7c</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fs41586-020-2019-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-020-2019-0%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DN.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DLuo%26aufirst%3DZ.%26aulast%3DGuo%26aufirst%3DS.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DYue%26aufirst%3DY.%26aulast%3DWei%26aufirst%3DX.%26aulast%3DXie%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DLei%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DF.%26atitle%3DStructural%2520basis%2520of%2520ligand%2520recognition%2520and%2520self-activation%2520of%2520orphan%2520GPR52%26jtitle%3DNature%26date%3D2020%26volume%3D579%26spage%3D152%26epage%3D157%26doi%3D10.1038%2Fs41586-020-2019-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martin, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steurer, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aronstam, R. S.</span></span> <span> </span><span class="NLM_article-title">Constitutive activity among orphan class-A G protein coupled receptors</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>, <span class="NLM_elocation-id">e0138463</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0138463</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=10.1371%2Fjournal.pone.0138463" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=26384023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A528%3ADC%252BC28XkvFCjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&author=A.+L.+Martinauthor=M.+A.+Steurerauthor=R.+S.+Aronstam&title=Constitutive+activity+among+orphan+class-A+G+protein+coupled+receptors&doi=10.1371%2Fjournal.pone.0138463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Constitutive activity among orphan class-A G protein coupled receptors</span></div><div class="casAuthors">Martin, Adam L.; Steurer, Michael A.; Aronstam, Robert S.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e0138463/1-e0138463/12</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The purpose of this study was to evaluate the extent of constitutive activity among orphan class-A G protein coupled receptors within the cAMP signaling pathway.  Constitutive signaling was revealed by changes in gene expression under control of the cAMP response element.  Gene expression was measured in Chinese hamster ovary cells transiently cotransfected with plasmids contg. a luciferase reporter and orphan receptor.  Criteria adopted for defining constitutive activation were: (1) 200% elevation over baseline reporter gene expression; (2) 40% inhibition of baseline expression; and (3) 40% inhibition of expression stimulated by 3 μM forskolin.  Five patterns of activity were noted: (1) inhibition under both baseline and forskolin stimulated expression (GPR15, GPR17, GPR18, GPR20, GPR25, GPR27, GPR31, GPR32, GPR45, GPR57, GPR68, GPR83, GPR84, GPR132, GPR150, GPR176); (2) no effect on baseline expression, but inhibition of forskolin stimulated expression (GPR4, GPR26, GPR61, GPR62, GPR78, GPR101, GPR119); (3) elevation of baseline signaling coupled with inhibition of forskolin stimulated expression (GPR6, GPR12); (4) elevation of baseline signaling without inhibition of forskolin stimulated expression (GPR3, GPR21, GPR52, GPR65); and (5) no effect on expression (GPR1, GPR19, GPR22, GPR34, GPR35, GPR39, GPR63, GPR82, GPR85, GPR87).  Constitutive activity was obsd. in 75% of the orphan class-A receptors examd. (30 of 40).  This constitutive signaling cannot be explained by simple overexpression of the receptor.  Inhibition of cAMP mediated expression was far more common (65%) than stimulation of expression (15%).  Orphan receptors that were closely related based on amino acid homol. tended to have similar effects on gene expression.  These results suggest that identification of inverse agonists may be a fruitful approach for categorizing these orphan receptors and targeting them for pharmacol. intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAzoFrN1fJO7Vg90H21EOLACvtfcHk0lgKzrRmRh1rmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XkvFCjtw%253D%253D&md5=94482d03b35bec1f4c2967b8d88d5ef0</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0138463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0138463%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DA.%2BL.%26aulast%3DSteurer%26aufirst%3DM.%2BA.%26aulast%3DAronstam%26aufirst%3DR.%2BS.%26atitle%3DConstitutive%2520activity%2520among%2520orphan%2520class-A%2520G%2520protein%2520coupled%2520receptors%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26doi%3D10.1371%2Fjournal.pone.0138463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Setoh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kono, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyanohana, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiraishi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harasawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ota, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Odani, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanzaki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoyama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kori, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of the first potent and orally available agonist of the orphan G-protein-coupled receptor 52</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">5226</span>– <span class="NLM_lpage">5237</span>, <span class="refDoi"> DOI: 10.1021/jm5002919</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5002919" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A528%3ADC%252BC2cXptVaitrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5226-5237&author=M.+Setohauthor=N.+Ishiiauthor=M.+Konoauthor=Y.+Miyanohanaauthor=E.+Shiraishiauthor=T.+Harasawaauthor=H.+Otaauthor=T.+Odaniauthor=N.+Kanzakiauthor=K.+Aoyamaauthor=T.+Hamadaauthor=M.+Kori&title=Discovery+of+the+first+potent+and+orally+available+agonist+of+the+orphan+G-protein-coupled+receptor+52&doi=10.1021%2Fjm5002919"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the First Potent and Orally Available Agonist of the Orphan G-Protein-Coupled Receptor 52</span></div><div class="casAuthors">Setoh, Masaki; Ishii, Naoki; Kono, Mitsunori; Miyanohana, Yuhei; Shiraishi, Eri; Harasawa, Toshiya; Ota, Hiroyuki; Odani, Tomoyuki; Kanzaki, Naoyuki; Aoyama, Kazunobu; Hamada, Teruki; Kori, Masakuni</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5226-5237</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">G-protein-coupled receptor 52 (GPR52) is an orphan Gs-coupled G-protein-coupled receptor.  GPR52 inhibits dopamine D2 receptor signaling and activates dopamine D1/N-methyl-D-aspartate receptors via intracellular cAMP accumulation, and therefore, GPR52 agonists may have potential as a novel class of antipsychotics.  A series of GPR52 agonists with a bicyclic core was designed to fix the conformation of the phenethyl ether moiety of compds. I (X = 3-CF3, 3-Cl-5-F).  3-[2-(3-Chloro-5-fluorobenzyl)-1-benzothiophen-7-yl]-N-(2-methoxyethyl)benzamide II showed potent activity (pEC50 = 7.53 ± 0.08) and good pharmacokinetic properties.  II significantly suppressed methamphetamine-induced hyperactivity in mice after oral administration of 3 mg/kg without disturbance of motor function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5q71EZhoMH7Vg90H21EOLACvtfcHk0lgKzrRmRh1rmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXptVaitrg%253D&md5=46531c63142e9d7bdb2f0ff8aa5ee414</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm5002919&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5002919%26sid%3Dliteratum%253Aachs%26aulast%3DSetoh%26aufirst%3DM.%26aulast%3DIshii%26aufirst%3DN.%26aulast%3DKono%26aufirst%3DM.%26aulast%3DMiyanohana%26aufirst%3DY.%26aulast%3DShiraishi%26aufirst%3DE.%26aulast%3DHarasawa%26aufirst%3DT.%26aulast%3DOta%26aufirst%3DH.%26aulast%3DOdani%26aufirst%3DT.%26aulast%3DKanzaki%26aufirst%3DN.%26aulast%3DAoyama%26aufirst%3DK.%26aulast%3DHamada%26aufirst%3DT.%26aulast%3DKori%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520the%2520first%2520potent%2520and%2520orally%2520available%2520agonist%2520of%2520the%2520orphan%2520G-protein-coupled%2520receptor%252052%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5226%26epage%3D5237%26doi%3D10.1021%2Fjm5002919" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nishiyama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harasawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurimoto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maruyama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komatsu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakuma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimojo, M.</span></span> <span> </span><span class="NLM_article-title">FTBMT, a novel and selective GPR52 agonist, demonstrates antipsychotic-like and procognitive effects in rodents, revealing a potential therapeutic agent for schizophrenia</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>363</i></span>,  <span class="NLM_fpage">253</span>– <span class="NLM_lpage">264</span>, <span class="refDoi"> DOI: 10.1124/jpet.117.242925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=10.1124%2Fjpet.117.242925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=28851764" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtleltrnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2017&pages=253-264&author=K.+Nishiyamaauthor=H.+Suzukiauthor=T.+Harasawaauthor=N.+Suzukiauthor=E.+Kurimotoauthor=T.+Kawaiauthor=M.+Maruyamaauthor=H.+Komatsuauthor=K.+Sakumaauthor=Y.+Shimizuauthor=M.+Shimojo&title=FTBMT%2C+a+novel+and+selective+GPR52+agonist%2C+demonstrates+antipsychotic-like+and+procognitive+effects+in+rodents%2C+revealing+a+potential+therapeutic+agent+for+schizophrenia&doi=10.1124%2Fjpet.117.242925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">FTBMT, a novel and selective GPR52 agonist, demonstrates antipsychotic-like and procognitive effects in rodents, revealing a potential therapeutic agent for schizophrenia</span></div><div class="casAuthors">Nishiyama, Keiji; Suzuki, Hirobumi; Harasawa, Toshiya; Suzuki, Noriko; Kurimoto, Emi; Kawai, Takayuki; Maruyama, Minoru; Komatsu, Hidetoshi; Sakuma, Kensuke; Shimizu, Yuji; Shimojo, Masato</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">253-264</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">GPR52 is a Gs-coupled G protein-coupled receptor that is predominantly expressed in the striatum and nucleus accumbens (NAc) and was recently proposed as a potential therapeutic target for schizophrenia.  In the current study, we investigated the in vitro and in vivo pharmacol. activities of a novel GPR52 agonist, 4-(3-(3-fluoro-5-(trifluoromethyl)- benzyl)-5-methyl-1H-1,2,4-triazol-1-yl)-2-methylbenzamide (FTBMT).  FTBMT functioned as a selective GPR52 agonist in vitro and in vivo, as demonstrated by the activation of Camp signaling in striatal neurons.  FTBMT inhibited MK-801-induced hyperactivity, an animal model for acute psychosis, without causing catalepsy in mice.  The c-fos expression also revealed that FTBMT preferentially induced neuronal activation in the shell of the Nac compared with the striatum, thereby supporting its antipsychotic-like activity with less catalepsy.  Furthermore, FTBMT improved recognition memory in a novel object recognition test and attenuated MK-801-induced working memory deficits in a radial arm maze test in rats.  These recognitive effects were supported by the results of FTBMTinduced c-fos expression in the brain regions related to cognition, including the medial prefrontal cortex, entorhinal cortex, and hippocampus.  Taken together, these findings suggest that FTBMT shows antipsychotic and recognitive properties without causing catalepsy in rodents.  Given its unique pharmacol. profile, which differs from that of current antipsychotics, FTBMT may provide a new therapeutic option for the treatment of pos. and cognitive symptoms of schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfDMCk_-onqbVg90H21EOLACvtfcHk0lhjzUtS_rsRVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtleltrnE&md5=bc4e4d18018bb6aab15cda72e8966094</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1124%2Fjpet.117.242925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.117.242925%26sid%3Dliteratum%253Aachs%26aulast%3DNishiyama%26aufirst%3DK.%26aulast%3DSuzuki%26aufirst%3DH.%26aulast%3DHarasawa%26aufirst%3DT.%26aulast%3DSuzuki%26aufirst%3DN.%26aulast%3DKurimoto%26aufirst%3DE.%26aulast%3DKawai%26aufirst%3DT.%26aulast%3DMaruyama%26aufirst%3DM.%26aulast%3DKomatsu%26aufirst%3DH.%26aulast%3DSakuma%26aufirst%3DK.%26aulast%3DShimizu%26aufirst%3DY.%26aulast%3DShimojo%26aufirst%3DM.%26atitle%3DFTBMT%252C%2520a%2520novel%2520and%2520selective%2520GPR52%2520agonist%252C%2520demonstrates%2520antipsychotic-like%2520and%2520procognitive%2520effects%2520in%2520rodents%252C%2520revealing%2520a%2520potential%2520therapeutic%2520agent%2520for%2520schizophrenia%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2017%26volume%3D363%26spage%3D253%26epage%3D264%26doi%3D10.1124%2Fjpet.117.242925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, Y. G. A. J.</span>; <span class="NLM_string-name">Korman, H.</span>; <span class="NLM_string-name">Lehmann, J.</span>; <span class="NLM_string-name">Ren, A. S.</span>; <span class="NLM_string-name">Semple, G.</span></span> <span> </span><span class="NLM_article-title">1-Heteroaryl-indoline-4-carboxamines as modulators of GPR52 usedul for the treatment or prevention of disorders related thereto</span>. <span class="NLM_patent">WO2016176571 A1</span>, Nov 3, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=Y.+G.+A.+J.+Xiong&author=H.+Korman&author=J.+Lehmann&author=A.+S.+Ren&author=G.+Semple&title=1-Heteroaryl-indoline-4-carboxamines+as+modulators+of+GPR52+usedul+for+the+treatment+or+prevention+of+disorders+related+thereto"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DXiong%26aufirst%3DY.%2BG.%2BA.%2BJ.%26atitle%3D1-Heteroaryl-indoline-4-carboxamines%2520as%2520modulators%2520of%2520GPR52%2520usedul%2520for%2520the%2520treatment%2520or%2520prevention%2520of%2520disorders%2520related%2520thereto%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tokumaru, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomura, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakahata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurimoto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoyama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aso, K.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and pharmacological evaluation of 4-azolyl-benzamide derivatives as novel GPR52 agonists</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">3098</span>– <span class="NLM_lpage">3115</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2017.03.064</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=10.1016%2Fj.bmc.2017.03.064" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=28433511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtlWqur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=3098-3115&author=K.+Tokumaruauthor=Y.+Itoauthor=I.+Nomuraauthor=T.+Nakahataauthor=Y.+Shimizuauthor=E.+Kurimotoauthor=K.+Aoyamaauthor=K.+Aso&title=Design%2C+synthesis%2C+and+pharmacological+evaluation+of+4-azolyl-benzamide+derivatives+as+novel+GPR52+agonists&doi=10.1016%2Fj.bmc.2017.03.064"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and pharmacological evaluation of 4-azolyl-benzamide derivatives as novel GPR52 agonists</span></div><div class="casAuthors">Tokumaru, Kazuyuki; Ito, Yoshiteru; Nomura, Izumi; Nakahata, Takashi; Shimizu, Yuji; Kurimoto, Emi; Aoyama, Kazunobu; Aso, Kazuyoshi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3098-3115</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">G protein-coupled receptor 52 (GPR52) agonists are expected to improve the symptoms of psychiatric disorders.  During exploration for a novel class of GPR52 agonists with good pharmacokinetic profiles, the authors synthesized (I; half maximal effective concn. (EC50) = 75 nM, maximal response (Emax) = 122%) starting from a high-throughput screening hit II (EC50 = 470 nM, Emax = 56%).  The structural features of a reported GPR52 agonist were applied to II, led to design 4-azolylbenzamides as novel GPR52 agonists.  A structure-activity relationship study of 4-azolylbenzamide resulted in the design of the 1,2,4-triazole deriv. I, which demonstrated excellent bioavailability in rats (F = 53.8%).  Oral administration of I (10 mg/kg) significantly suppressed methamphetamine-induced hyperlocomotion in mice.  Thus, I is a promising lead compd. for drug discovery research of GPR52 agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH6Ea1gQem0bVg90H21EOLACvtfcHk0lhjzUtS_rsRVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtlWqur8%253D&md5=e692d0e006899851b0520591c347d7f4</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2017.03.064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2017.03.064%26sid%3Dliteratum%253Aachs%26aulast%3DTokumaru%26aufirst%3DK.%26aulast%3DIto%26aufirst%3DY.%26aulast%3DNomura%26aufirst%3DI.%26aulast%3DNakahata%26aufirst%3DT.%26aulast%3DShimizu%26aufirst%3DY.%26aulast%3DKurimoto%26aufirst%3DE.%26aulast%3DAoyama%26aufirst%3DK.%26aulast%3DAso%26aufirst%3DK.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520pharmacological%2520evaluation%2520of%25204-azolyl-benzamide%2520derivatives%2520as%2520novel%2520GPR52%2520agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26spage%3D3098%26epage%3D3115%26doi%3D10.1016%2Fj.bmc.2017.03.064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakahata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokumaru, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setoh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harasawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoyama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aso, K.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of 1-(1-benzothiophen-7-yl)-1H-pyrazole, a novel series of G protein-coupled receptor 52 (GPR52) agonists</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1598</span>– <span class="NLM_lpage">1608</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2018.02.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=10.1016%2Fj.bmc.2018.02.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=29478803" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjt1Sgsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=1598-1608&author=T.+Nakahataauthor=K.+Tokumaruauthor=Y.+Itoauthor=N.+Ishiiauthor=M.+Setohauthor=Y.+Shimizuauthor=T.+Harasawaauthor=K.+Aoyamaauthor=T.+Hamadaauthor=M.+Koriauthor=K.+Aso&title=Design+and+synthesis+of+1-%281-benzothiophen-7-yl%29-1H-pyrazole%2C+a+novel+series+of+G+protein-coupled+receptor+52+%28GPR52%29+agonists&doi=10.1016%2Fj.bmc.2018.02.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of 1-(1-benzothiophen-7-yl)-1H-pyrazole, a novel series of G protein-coupled receptor 52 (GPR52) agonists</span></div><div class="casAuthors">Nakahata, Takashi; Tokumaru, Kazuyuki; Ito, Yoshiteru; Ishii, Naoki; Setoh, Masaki; Shimizu, Yuji; Harasawa, Toshiya; Aoyama, Kazunobu; Hamada, Teruki; Kori, Masakuni; Aso, Kazuyoshi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1598-1608</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">G-protein-coupled receptor 52 (GPR52) is classified as an orphan Gs-coupled G-protein-coupled receptor.  GPR52 cancels dopamine D2 receptor signaling and activates dopamine D1/N-methyl-D-aspartate receptors via intracellular cAMP accumulation.  Therefore, GPR52 agonists are expected to alleviate symptoms of psychotic disorders.  A novel series of 1-(benzothiophen-7-yl)-1H-pyrazole as GPR52 agonists was designed and synthesized.  The first orally active GPR52 agonist with high lipophilicity and poor aq. soly. still remained as issues for candidate selection.  To resolve these issues, replacement of the benzene ring at the 7-position of compd. 1b with heterocylic rings, such as pyrazole and pyridine, was greatly expected to reduce lipophilicity to levels for which calcd. logD values were lower than that of compd. 1b.  While evaluating the pyrazole derivs., introduction of a Me substituent at the 3-position of the pyrazole ring led to increased GPR52 agonistic activity.  Moreover, addnl. Me substituent at the 5-position of the pyrazole and further introduction of hydroxy group to lower logD led to significant improvement of soly. while maintaining the activity.  As a result, the authors identified 3-methyl-5-hydroxymethyl-1H-pyrazole deriv. 17 (N-(2-hydroxyethyl)-5-(hydroxymethyl)-3-methyl-1-(2-(3-(trifluoromethyl)benzyl)-1-benzothiophen-7-yl)-1H-pyrazole-4-carboxamide) (GPR52 EC50 = 21 nM, Emax = 103%, logD = 2.21, Soly. at pH 6.8 = 21 μg/mL) with potent GPR52 agonistic activity and good soly. compared to compd. 1b.  Furthermore, this compd. 17 dose-dependently suppressed methamphetamine-induced hyperlocomotion in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVMXRLUNGxrrVg90H21EOLACvtfcHk0lgkIgZndBPETQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjt1Sgsr4%253D&md5=45802ee39f844ddaab20ae4cfd61d26e</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2018.02.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2018.02.005%26sid%3Dliteratum%253Aachs%26aulast%3DNakahata%26aufirst%3DT.%26aulast%3DTokumaru%26aufirst%3DK.%26aulast%3DIto%26aufirst%3DY.%26aulast%3DIshii%26aufirst%3DN.%26aulast%3DSetoh%26aufirst%3DM.%26aulast%3DShimizu%26aufirst%3DY.%26aulast%3DHarasawa%26aufirst%3DT.%26aulast%3DAoyama%26aufirst%3DK.%26aulast%3DHamada%26aufirst%3DT.%26aulast%3DKori%26aufirst%3DM.%26aulast%3DAso%26aufirst%3DK.%26atitle%3DDesign%2520and%2520synthesis%2520of%25201-%25281-benzothiophen-7-yl%2529-1H-pyrazole%252C%2520a%2520novel%2520series%2520of%2520G%2520protein-coupled%2520receptor%252052%2520%2528GPR52%2529%2520agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26spage%3D1598%26epage%3D1608%26doi%3D10.1016%2Fj.bmc.2018.02.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Synopsis of some recent tactical application of bioisosteres in drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">2529</span>– <span class="NLM_lpage">2591</span>, <span class="refDoi"> DOI: 10.1021/jm1013693</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1013693" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsVCnu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2529-2591&author=N.+A.+Meanwell&title=Synopsis+of+some+recent+tactical+application+of+bioisosteres+in+drug+design&doi=10.1021%2Fjm1013693"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design</span></div><div class="casAuthors">Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2529-2591</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The established utility of bioisosteres is broad in nature, extending to improving potency, enhancing selectivity, altering phys. properties, reducing or redirecting metab., eliminating or modifying toxicophores, and acquiring novel intellectual property.  In this Perspective, some contemporary themes exploring the role of isosteres in drug design are sampled, with an emphasis placed on tactical applications designed to solve the kinds of problems that impinge on compd. optimization and the long-term success of drug candidates.  Interesting concepts that may have been poorly effective in the context examd. are captured, since the ideas may have merit in alternative circumstances.  A comprehensive cataloging of bioisosteres is beyond the scope of what will be provided, although a synopsis of relevant isosteres of a particular functionality is summarized in a succinct fashion in several sections.  Isosterism has also found productive application in the design and optimization of organocatalysts, and there are several examples in which functional mimicry established initially in a medicinal chem. setting has been adopted by this community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ9z_aPcU4ubVg90H21EOLACvtfcHk0lgkIgZndBPETQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsVCnu7o%253D&md5=0637ab60c379bef535f3f709b26f3582</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm1013693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1013693%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DSynopsis%2520of%2520some%2520recent%2520tactical%2520application%2520of%2520bioisosteres%2520in%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D2529%26epage%3D2591%26doi%3D10.1021%2Fjm1013693" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">The influence of bioisosteres in drug design: tactical applications to address developability problems</span>. <i>Tactics Contemp. Drug Des.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">283</span>– <span class="NLM_lpage">382</span>, <span class="refDoi"> DOI: 10.1007/7355_2013_29</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=10.1007%2F7355_2013_29" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2015&pages=283-382&author=N.+A.+Meanwell&title=The+influence+of+bioisosteres+in+drug+design%3A+tactical+applications+to+address+developability+problems&doi=10.1007%2F7355_2013_29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1007%2F7355_2013_29&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F7355_2013_29%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DThe%2520influence%2520of%2520bioisosteres%2520in%2520drug%2520design%253A%2520tactical%2520applications%2520to%2520address%2520developability%2520problems%26jtitle%3DTactics%2520Contemp.%2520Drug%2520Des.%26date%3D2015%26volume%3D9%26spage%3D283%26epage%3D382%26doi%3D10.1007%2F7355_2013_29" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pennington, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moustakas, D. T.</span></span> <span> </span><span class="NLM_article-title">The necessary nitrogen atom: a versatile high-impact design element for multiparameter optimization</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">3552</span>– <span class="NLM_lpage">3579</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01807</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01807" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A528%3ADC%252BC2sXit1yit74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=3552-3579&author=L.+D.+Penningtonauthor=D.+T.+Moustakas&title=The+necessary+nitrogen+atom%3A+a+versatile+high-impact+design+element+for+multiparameter+optimization&doi=10.1021%2Facs.jmedchem.6b01807"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The Necessary Nitrogen Atom: A Versatile High-Impact Design Element for Multiparameter Optimization</span></div><div class="casAuthors">Pennington, Lewis D.; Moustakas, Demetri T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3552-3579</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  There is a continued desire in biomedical research to reduce the no. and duration of design cycles required to optimize lead compds. into high-quality chem. probes or safe and efficacious drug candidates.  The insightful application of impactful mol. design elements is one approach toward achieving this goal.  The replacement of a CH group with a N atom in arom. and heteroarom. ring systems can have many important effects on mol. and physicochem. properties and intra- and intermol. interactions that can translate to improved pharmacol. profiles.  In this Perspective, the "necessary nitrogen atom" is shown to be a versatile high-impact design element for multiparameter optimization, wherein ≥10-, 100-, or 1000-fold improvement in a variety of key pharmacol. parameters can be realized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8ZLKZMgt6IbVg90H21EOLACvtfcHk0ljpztiYgTQryQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXit1yit74%253D&md5=002aaee48995e7954647a1f75183db4d</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01807%26sid%3Dliteratum%253Aachs%26aulast%3DPennington%26aufirst%3DL.%2BD.%26aulast%3DMoustakas%26aufirst%3DD.%2BT.%26atitle%3DThe%2520necessary%2520nitrogen%2520atom%253A%2520a%2520versatile%2520high-impact%2520design%2520element%2520for%2520multiparameter%2520optimization%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D3552%26epage%3D3579%26doi%3D10.1021%2Facs.jmedchem.6b01807" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cesta, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somersan Karakaya, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javidnia, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gold, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez Quezada, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abramyan, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kireev, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aubé, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarry, S. M.</span></span> <span> </span><span class="NLM_article-title">Synthesis and antibacterial evaluation of cephalosporin isosteres</span>. <i>Asian J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1053</span>– <span class="NLM_lpage">1057</span>, <span class="refDoi"> DOI: 10.1002/ajoc.201900058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=10.1002%2Fajoc.201900058" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmtVCltbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2019&pages=1053-1057&author=D.+J.+Cestaauthor=S.+S.+Somersan+Karakayaauthor=K.+Saitoauthor=P.+E.+Javidniaauthor=J.+Robertsauthor=Y.+Lingauthor=B.+S.+Goldauthor=L.+Lopez+Quezadaauthor=D.+Zhangauthor=T.+M.+Abramyanauthor=D.+B.+Kireevauthor=J.+Aub%C3%A9author=S.+M.+Scarry&title=Synthesis+and+antibacterial+evaluation+of+cephalosporin+isosteres&doi=10.1002%2Fajoc.201900058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Antibacterial Evaluation of Cephalosporin Isosteres</span></div><div class="casAuthors">Cesta, Drew J.; Somersan Karakaya, Selin; Saito, Kohta; Javidnia, Prisca E.; Roberts, Julia; Ling, Yan; Gold, Ben S.; Lopez Quezada, Landys; Zhang, David; Abramyan, Tigran M.; Kireev, Dmitri B.; Aube, Jeffrey; Scarry, Sarah M.</div><div class="citationInfo"><span class="NLM_cas:title">Asian Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1053-1057</span>CODEN:
                <span class="NLM_cas:coden">AJOCC7</span>;
        ISSN:<span class="NLM_cas:issn">2193-5807</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">As part of a program to explore the chem. of β-lactams and their derivs., a focused set of benzazetidine, indoline, and indole heterocycles, as well as flexible unconstrained variations of the four-membered heterocyclic compds were prepd.  These analogs mimic the three-dimensional shape of cephalosporins but are not prone to covalent binding via ring opening.  Although these analogs were inactive against the ESKAPE pathogens and Mtb, they represent unique and underexplored chemotypes for future biol. screening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovWA0C3JZtBrVg90H21EOLACvtfcHk0lgEjazuIBUWwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmtVCltbg%253D&md5=41d79f79f053fbba7e986e0901f3374f</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1002%2Fajoc.201900058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fajoc.201900058%26sid%3Dliteratum%253Aachs%26aulast%3DCesta%26aufirst%3DD.%2BJ.%26aulast%3DSomersan%2BKarakaya%26aufirst%3DS.%2BS.%26aulast%3DSaito%26aufirst%3DK.%26aulast%3DJavidnia%26aufirst%3DP.%2BE.%26aulast%3DRoberts%26aufirst%3DJ.%26aulast%3DLing%26aufirst%3DY.%26aulast%3DGold%26aufirst%3DB.%2BS.%26aulast%3DLopez%2BQuezada%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DAbramyan%26aufirst%3DT.%2BM.%26aulast%3DKireev%26aufirst%3DD.%2BB.%26aulast%3DAub%25C3%25A9%26aufirst%3DJ.%26aulast%3DScarry%26aufirst%3DS.%2BM.%26atitle%3DSynthesis%2520and%2520antibacterial%2520evaluation%2520of%2520cephalosporin%2520isosteres%26jtitle%3DAsian%2520J.%2520Org.%2520Chem.%26date%3D2019%26volume%3D8%26spage%3D1053%26epage%3D1057%26doi%3D10.1002%2Fajoc.201900058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sengmany, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebre, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Gall, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Léonel, E.</span></span> <span> </span><span class="NLM_article-title">Selective mono-amination of dichlorodiazines</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">4859</span>– <span class="NLM_lpage">4867</span>, <span class="refDoi"> DOI: 10.1016/j.tet.2015.05.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=10.1016%2Fj.tet.2015.05.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A528%3ADC%252BC2MXptFCgsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2015&pages=4859-4867&author=S.+Sengmanyauthor=J.+Lebreauthor=E.+Le+Gallauthor=E.+L%C3%A9onel&title=Selective+mono-amination+of+dichlorodiazines&doi=10.1016%2Fj.tet.2015.05.056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Selective mono-amination of dichlorodiazines</span></div><div class="casAuthors">Sengmany, Stephane; Lebre, Julie; Le Gall, Erwan; Leonel, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">4859-4867</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">3,6-Dichloropyridazine, 4,6-dichloropyrimidine, 2,4-dichloropyrimidine, and 3,5-dichloropyridazine underwent chemoselective monosubstitution reactions with amines using triethylamine as a base in ethanol at either ambient temp. or reflux to give monoamino monochloro pyridazines and pyrimidines.  The methodol. is general and efficient despite noticeable differences in reactivity between diazines; while dichloropyridazine and dichloropyrazine require several hours of heating at reflux for the reaction to proceed, dichloropyrimidines reach completion within minutes at room temp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIme9bD3r9s7Vg90H21EOLACvtfcHk0lgEjazuIBUWwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXptFCgsbk%253D&md5=71f462180114a1f0e4b8672523d60856</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2015.05.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2015.05.056%26sid%3Dliteratum%253Aachs%26aulast%3DSengmany%26aufirst%3DS.%26aulast%3DLebre%26aufirst%3DJ.%26aulast%3DLe%2BGall%26aufirst%3DE.%26aulast%3DL%25C3%25A9onel%26aufirst%3DE.%26atitle%3DSelective%2520mono-amination%2520of%2520dichlorodiazines%26jtitle%3DTetrahedron%26date%3D2015%26volume%3D71%26spage%3D4859%26epage%3D4867%26doi%3D10.1016%2Fj.tet.2015.05.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Loksha, Y. M.</span></span> <span> </span><span class="NLM_article-title">Novel synthetic route for 5-substituted 6-arylmethylluracils from 2,4,6-trichloropyrimidines</span>. <i>J. Heterocycl. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">1296</span>– <span class="NLM_lpage">1301</span>, <span class="refDoi"> DOI: 10.1002/jhet.239</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=10.1002%2Fjhet.239" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFSgtr%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2009&pages=1296-1301&author=Y.+M.+Loksha&title=Novel+synthetic+route+for+5-substituted+6-arylmethylluracils+from+2%2C4%2C6-trichloropyrimidines&doi=10.1002%2Fjhet.239"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Novel synthetic route for 5-substituted 6-arylmethylluracils from 2,4,6-trichloropyrimidines</span></div><div class="casAuthors">Loksha, Yasser M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Heterocyclic Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1296-1301</span>CODEN:
                <span class="NLM_cas:coden">JHTCAD</span>;
        ISSN:<span class="NLM_cas:issn">1943-5193</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Treatment of 2,4,6-trichloropyrimidines with the sodium salt of benzyl cyanide derivs. afforded 5-substituted 4-aryl(cyanomethyl)-2,6-dichloropyrimidines.  They were alkylated with Me iodide to furnish 4-(1-aryl-1-cyanoethyl)-2,6-dichloropyrimidines.  These compds. were hydrolyzed with concd. hydrochloric acid to afford 5-substituted 6-arylalkyluracils.  5-Bromo-6-arymethylluracils were synthesized by bromination of 6-arylmethylluracils with N-bromosuccinimide (NBS).  Refluxing 2-(2,6-dichloro-5-ethylpyrimidin-4-yl)-2-(3,5-dimethylphenyl)acetonitrile with sodium methoxide followed by oxidn. afforded (3,5-dimethylphenyl)(5-ethyl-2,6-dimethoxypyrimidin-4-yl)methanone.  Addn. of methylmagnesium bromide gave the tertiary alc. deriv. which was fluorinated by diethylaminosulfurtrifluoride and deprotected by trimethylsilyl iodide to furnish 6-(1-(3,5-dimethylphenyl)-1-fluoroethyl)-5-ethylpyrimidine-2,4(1H,3H)-dione.  J. Heterocyclic Chem., (2009).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPVplefNz_xbVg90H21EOLACvtfcHk0lgEjazuIBUWwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFSgtr%252FO&md5=4eb3539191bee15ea0c2a4e8086ad2d2</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1002%2Fjhet.239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjhet.239%26sid%3Dliteratum%253Aachs%26aulast%3DLoksha%26aufirst%3DY.%2BM.%26atitle%3DNovel%2520synthetic%2520route%2520for%25205-substituted%25206-arylmethylluracils%2520from%25202%252C4%252C6-trichloropyrimidines%26jtitle%3DJ.%2520Heterocycl.%2520Chem.%26date%3D2009%26volume%3D46%26spage%3D1296%26epage%3D1301%26doi%3D10.1002%2Fjhet.239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gray, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mente, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMarco, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Efremov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tierney, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volfson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davoren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guilmette, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salafia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozak, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehlers, M. D.</span></span> <span> </span><span class="NLM_article-title">Impaired β-arrestin recruitment and reduced desensitization by non-catechol agonists of the D1 dopamine receptor</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">674</span>, <span class="refDoi"> DOI: 10.1038/s41467-017-02776-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=10.1038%2Fs41467-017-02776-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=29445200" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A280%3ADC%252BC1Mrhsl2nsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=674&author=D.+L.+Grayauthor=J.+A.+Allenauthor=S.+Menteauthor=R.+E.+O%E2%80%99Connorauthor=G.+J.+DeMarcoauthor=I.+Efremovauthor=P.+Tierneyauthor=D.+Volfsonauthor=J.+Davorenauthor=E.+Guilmetteauthor=M.+Salafiaauthor=R.+Kozakauthor=M.+D.+Ehlers&title=Impaired+%CE%B2-arrestin+recruitment+and+reduced+desensitization+by+non-catechol+agonists+of+the+D1+dopamine+receptor&doi=10.1038%2Fs41467-017-02776-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Impaired β-arrestin recruitment and reduced desensitization by non-catechol agonists of the D1 dopamine receptor</span></div><div class="casAuthors">Gray David L; Mente Scot; Efremov Ivan; Davoren Jennifer; Gray David L; Allen John A; Tierney Patrick; Volfson Dmitri; Guilmette Edward; Kozak Rouba; Ehlers Michael D; Allen John A; O'Connor Rebecca E; Salafia Michelle; DeMarco George J; Ehlers Michael D</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">674</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Selective activation of dopamine D1 receptors (D1Rs) has been pursued for 40 years as a therapeutic strategy for neurologic and psychiatric diseases due to the fundamental role of D1Rs in motor function, reward processing, and cognition.  All known D1R-selective agonists are catechols, which are rapidly metabolized and desensitize the D1R after prolonged exposure, reducing agonist response.  As such, drug-like selective D1R agonists have remained elusive.  Here we report a novel series of selective, potent non-catechol D1R agonists with promising in vivo pharmacokinetic properties.  These ligands stimulate adenylyl cyclase signaling and are efficacious in a rodent model of Parkinson's disease after oral administration.  They exhibit distinct binding to the D1R orthosteric site and a novel functional profile including minimal receptor desensitization, reduced recruitment of β-arrestin, and sustained in vivo efficacy.  These results reveal a novel class of D1 agonists with favorable drug-like properties, and define the molecular basis for catechol-specific recruitment of β-arrestin to D1Rs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcShdJOozuyZkBe4jJGKT5N0fW6udTcc2eZIZA0ZJUHxwLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mrhsl2nsQ%253D%253D&md5=2ba64bda304b083647eedff999f3fdcd</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fs41467-017-02776-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-017-02776-7%26sid%3Dliteratum%253Aachs%26aulast%3DGray%26aufirst%3DD.%2BL.%26aulast%3DAllen%26aufirst%3DJ.%2BA.%26aulast%3DMente%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DR.%2BE.%26aulast%3DDeMarco%26aufirst%3DG.%2BJ.%26aulast%3DEfremov%26aufirst%3DI.%26aulast%3DTierney%26aufirst%3DP.%26aulast%3DVolfson%26aufirst%3DD.%26aulast%3DDavoren%26aufirst%3DJ.%26aulast%3DGuilmette%26aufirst%3DE.%26aulast%3DSalafia%26aufirst%3DM.%26aulast%3DKozak%26aufirst%3DR.%26aulast%3DEhlers%26aufirst%3DM.%2BD.%26atitle%3DImpaired%2520%25CE%25B2-arrestin%2520recruitment%2520and%2520reduced%2520desensitization%2520by%2520non-catechol%2520agonists%2520of%2520the%2520D1%2520dopamine%2520receptor%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26spage%3D674%26doi%3D10.1038%2Fs41467-017-02776-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Besnard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruda, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setola, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abecassis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguiz, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norval, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sassano, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeons, F. R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stojanovski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seidah, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Constam, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bickerton, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wetsel, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span> <span> </span><span class="NLM_article-title">Automated design of ligands to polypharmacological profiles</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>492</i></span>,  <span class="NLM_fpage">215</span>– <span class="NLM_lpage">220</span>, <span class="refDoi"> DOI: 10.1038/nature11691</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=10.1038%2Fnature11691" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=23235874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVamurfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=492&publication_year=2012&pages=215-220&author=J.+Besnardauthor=G.+F.+Rudaauthor=V.+Setolaauthor=K.+Abecassisauthor=R.+M.+Rodriguizauthor=X.-P.+Huangauthor=S.+Norvalauthor=M.+F.+Sassanoauthor=A.+I.+Shinauthor=L.+A.+Websterauthor=F.+R.+C.+Simeonsauthor=L.+Stojanovskiauthor=A.+Pratauthor=N.+G.+Seidahauthor=D.+B.+Constamauthor=G.+R.+Bickertonauthor=K.+D.+Readauthor=W.+C.+Wetselauthor=I.+H.+Gilbertauthor=B.+L.+Rothauthor=A.+L.+Hopkins&title=Automated+design+of+ligands+to+polypharmacological+profiles&doi=10.1038%2Fnature11691"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Automated design of ligands to polypharmacological profiles</span></div><div class="casAuthors">Besnard, Jeremy; Ruda, Gian Filippo; Setola, Vincent; Abecassis, Keren; Rodriguiz, Ramona M.; Huang, Xi-Ping; Norval, Suzanne; Sassano, Maria F.; Shin, Antony I.; Webster, Lauren A.; Simeons, Frederick R. C.; Stojanovski, Laste; Prat, Annik; Seidah, Nabil G.; Constam, Daniel B.; Bickerton, G. Richard; Read, Kevin D.; Wetsel, William C.; Gilbert, Ian H.; Roth, Bryan L.; Hopkins, Andrew L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">492</span>
        (<span class="NLM_cas:issue">7428</span>),
    <span class="NLM_cas:pages">215-220</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. efficacy and safety of a drug is detd. by its activity profile across many proteins in the proteome.  However, designing drugs with a specific multi-target profile is both complex and difficult.  Therefore methods to design drugs rationally a priori against profiles of several proteins would have immense value in drug discovery.  Here is described a new approach for the automated design of ligands against profiles of multiple drug targets.  The method is demonstrated by the evolution of an approved acetylcholinesterase inhibitor drug donepezil (I) into brain-penetrable ligands with either specific polypharmacol. or exquisite selectivity profiles for G-protein-coupled receptors.  Overall, 800 ligand-target predictions of prospectively designed ligands were tested exptl., of which 75% were confirmed to be correct.  Target engagement in vivo is also demonstrated.  The approach can be a useful source of drug leads when multi-target profiles are required to achieve either selectivity over other drug targets or a desired polypharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNu5bwrBD3tbVg90H21EOLACvtfcHk0liL0Sl-J-0Ghg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVamurfN&md5=ace6cced250cf968d327b482a5bf1798</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnature11691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11691%26sid%3Dliteratum%253Aachs%26aulast%3DBesnard%26aufirst%3DJ.%26aulast%3DRuda%26aufirst%3DG.%2BF.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DAbecassis%26aufirst%3DK.%26aulast%3DRodriguiz%26aufirst%3DR.%2BM.%26aulast%3DHuang%26aufirst%3DX.-P.%26aulast%3DNorval%26aufirst%3DS.%26aulast%3DSassano%26aufirst%3DM.%2BF.%26aulast%3DShin%26aufirst%3DA.%2BI.%26aulast%3DWebster%26aufirst%3DL.%2BA.%26aulast%3DSimeons%26aufirst%3DF.%2BR.%2BC.%26aulast%3DStojanovski%26aufirst%3DL.%26aulast%3DPrat%26aufirst%3DA.%26aulast%3DSeidah%26aufirst%3DN.%2BG.%26aulast%3DConstam%26aufirst%3DD.%2BB.%26aulast%3DBickerton%26aufirst%3DG.%2BR.%26aulast%3DRead%26aufirst%3DK.%2BD.%26aulast%3DWetsel%26aufirst%3DW.%2BC.%26aulast%3DGilbert%26aufirst%3DI.%2BH.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26atitle%3DAutomated%2520design%2520of%2520ligands%2520to%2520polypharmacological%2520profiles%26jtitle%3DNature%26date%3D2012%26volume%3D492%26spage%3D215%26epage%3D220%26doi%3D10.1038%2Fnature11691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalyaanamoorthy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barakat, K. H.</span></span> <span> </span><span class="NLM_article-title">Development of safe drugs: the hERG challenge</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">525</span>– <span class="NLM_lpage">555</span>, <span class="refDoi"> DOI: 10.1002/med.21445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=10.1002%2Fmed.21445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=28467598" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A280%3ADC%252BC1crjs1aiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2018&pages=525-555&author=S.+Kalyaanamoorthyauthor=K.+H.+Barakat&title=Development+of+safe+drugs%3A+the+hERG+challenge&doi=10.1002%2Fmed.21445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Safe Drugs: The hERG Challenge</span></div><div class="casAuthors">Kalyaanamoorthy Subha; Barakat Khaled H; Barakat Khaled H; Barakat Khaled H</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal research reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">525-555</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Drug-induced blockade of human ether-a-go-go-related gene (hERG) remains a major impediment in delivering safe drugs to the market.  Several drugs have been withdrawn from the market due to their severe cardiotoxic side effects triggered by their off-target interactions with hERG.  Thus, identifying the potential hERG blockers at early stages of lead discovery is fast evolving as a standard in drug design and development.  A number of in silico structure-based models of hERG have been developed as a low-cost solution to evaluate drugs for hERG liability, and it is now agreed that the hERG blockers bind at the large central cavity of the channel.  Nevertheless, there is no clear convergence on the appropriate drug binding modes against the channel.  The proposed binding modes differ in their orientations and interpretations on the role of key residues in the channel.  Such ambiguities in the modes of binding remain to be a significant challenge in achieving efficient computational predictive models and in saving many important already Food and Drug Administration approved drugs.  In this review, we discuss the spectrum of reported binding modes for hERG blockers, the various in silico models developed for predicting a drug's affinity to hERG, and the known successful optimization strategies to avoid off-target interactions with hERG.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSVn-pfX7PHl11C8OJBvdfbfW6udTcc2eZ-PldIvgUFirntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1crjs1aiug%253D%253D&md5=50557713c0d70c32f92c425b38a693b2</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1002%2Fmed.21445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21445%26sid%3Dliteratum%253Aachs%26aulast%3DKalyaanamoorthy%26aufirst%3DS.%26aulast%3DBarakat%26aufirst%3DK.%2BH.%26atitle%3DDevelopment%2520of%2520safe%2520drugs%253A%2520the%2520hERG%2520challenge%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2018%26volume%3D38%26spage%3D525%26epage%3D555%26doi%3D10.1002%2Fmed.21445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, D. J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fone, K. C. F.</span></span> <span> </span><span class="NLM_article-title">Animal models of schizophrenia</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>164</i></span>,  <span class="NLM_fpage">1162</span>– <span class="NLM_lpage">1194</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2011.01386.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=10.1111%2Fj.1476-5381.2011.01386.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=21449915" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlShtrjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=2011&pages=1162-1194&author=C.+A.+Jonesauthor=D.+J.+G.+Watsonauthor=K.+C.+F.+Fone&title=Animal+models+of+schizophrenia&doi=10.1111%2Fj.1476-5381.2011.01386.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Animal models of schizophrenia</span></div><div class="casAuthors">Jones, C. A.; Watson, D. J. G.; Fone, K. C. F.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">164</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1162-1194</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Developing reliable, predictive animal models for complex psychiatric disorders, such as schizophrenia, is essential to increase our understanding of the neurobiol. basis of the disorder and for the development of novel drugs with improved therapeutic efficacy.  All available animal models of schizophrenia fit into four different induction categories: developmental, drug-induced, lesion or genetic manipulation, and the best characterized examples of each type are reviewed herein.  Most rodent models have behavioral phenotype changes that resemble "pos.-like" symptoms of schizophrenia, probably reflecting altered mesolimbic dopamine function, but fewer models also show altered social interaction, and learning and memory impairment, analogous to neg. and cognitive symptoms of schizophrenia resp.  The neg. and cognitive impairments in schizophrenia are resistant to treatment with current antipsychotics, even after remission of the psychosis, which limits their therapeutic efficacy.  The MATRICS initiative developed a consensus on the core cognitive deficits of schizophrenic patients, and recommended a standardized test battery to evaluate them.  More recently, work has begun to identify specific rodent behavioral tasks with translational relevance to specific cognitive domains affected in schizophrenia, and where available this review focuses on reporting the effect of current and potential antipsychotics on these tasks.  The review also highlights the need to develop more comprehensive animal models that more adequately replicate deficits in neg. and cognitive symptoms.  Increasing information on the neurochem. and structural CNS changes accompanying each model will also help assess treatments that prevent the development of schizophrenia rather than treating the symptoms, another pivotal change required to enable new more effective therapeutic strategies to be developed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFknIty9aCwLVg90H21EOLACvtfcHk0lim3EeTGFgAFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlShtrjF&md5=705007a976f8f01dafef40ead145abf2</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01386.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01386.x%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DC.%2BA.%26aulast%3DWatson%26aufirst%3DD.%2BJ.%2BG.%26aulast%3DFone%26aufirst%3DK.%2BC.%2BF.%26atitle%3DAnimal%2520models%2520of%2520schizophrenia%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D164%26spage%3D1162%26epage%3D1194%26doi%3D10.1111%2Fj.1476-5381.2011.01386.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dichter, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damiano, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J. A.</span></span> <span> </span><span class="NLM_article-title">Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings</span>. <i>J. Neurodev. Disord.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">19</span>, <span class="refDoi"> DOI: 10.1186/1866-1955-4-19</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=10.1186%2F1866-1955-4-19" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=22958744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A280%3ADC%252BC38bltFWgtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=19&author=G.+S.+Dichterauthor=C.+A.+Damianoauthor=J.+A.+Allen&title=Reward+circuitry+dysfunction+in+psychiatric+and+neurodevelopmental+disorders+and+genetic+syndromes%3A+animal+models+and+clinical+findings&doi=10.1186%2F1866-1955-4-19"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings</span></div><div class="casAuthors">Dichter Gabriel S; Damiano Cara A; Allen John A</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neurodevelopmental disorders</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">19</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract"> This review summarizes evidence of dysregulated reward circuitry function in a range of neurodevelopmental and psychiatric disorders and genetic syndromes.  First, the contribution of identifying a core mechanistic process across disparate disorders to disease classification is discussed, followed by a review of the neurobiology of reward circuitry.  We next consider preclinical animal models and clinical evidence of reward-pathway dysfunction in a range of disorders, including psychiatric disorders (i.e., substance-use disorders, affective disorders, eating disorders, and obsessive compulsive disorders), neurodevelopmental disorders (i.e., schizophrenia, attention-deficit/hyperactivity disorder, autism spectrum disorders, Tourette's syndrome, conduct disorder/oppositional defiant disorder), and genetic syndromes (i.e., Fragile X syndrome, Prader-Willi syndrome, Williams syndrome, Angelman syndrome, and Rett syndrome).  We also provide brief overviews of effective psychopharmacologic agents that have an effect on the dopamine system in these disorders.  This review concludes with methodological considerations for future research designed to more clearly probe reward-circuitry dysfunction, with the ultimate goal of improved intervention strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR0ZAxAERVU-cve_zCu79I8fW6udTcc2eaN1Dm-64HF37ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38bltFWgtw%253D%253D&md5=f0ad1c200b755c84f08bd6b25c149f52</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1186%2F1866-1955-4-19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1866-1955-4-19%26sid%3Dliteratum%253Aachs%26aulast%3DDichter%26aufirst%3DG.%2BS.%26aulast%3DDamiano%26aufirst%3DC.%2BA.%26aulast%3DAllen%26aufirst%3DJ.%2BA.%26atitle%3DReward%2520circuitry%2520dysfunction%2520in%2520psychiatric%2520and%2520neurodevelopmental%2520disorders%2520and%2520genetic%2520syndromes%253A%2520animal%2520models%2520and%2520clinical%2520findings%26jtitle%3DJ.%2520Neurodev.%2520Disord.%26date%3D2012%26volume%3D4%26spage%3D19%26doi%3D10.1186%2F1866-1955-4-19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Komatsu, H.</span></span> <span> </span><span class="NLM_article-title">Novel therapeutic GPCRs for psychiatric disorders</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">14109</span>– <span class="NLM_lpage">14121</span>, <span class="refDoi"> DOI: 10.3390/ijms160614109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=10.3390%2Fijms160614109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=26101869" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvValtLjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=14109-14121&author=H.+Komatsu&title=Novel+therapeutic+GPCRs+for+psychiatric+disorders&doi=10.3390%2Fijms160614109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Novel therapeutic GPCRs for psychiatric disorders</span></div><div class="casAuthors">Komatsu, Hidetoshi</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">14109-14121</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">G protein-coupled receptors (GPCRs) are the most common targets of the neuropharmacol. drugs in the central nervous system (CNS).  GPCRs are activated by manifold neurotransmitters, and their activation in turn evokes slow synaptic transmission.  They are deeply involved in multiple neurol. and psychiatric disorders such as Parkinson's disease and schizophrenia.  In the brain, the striatum is strongly innervated by the ventral tegmental area (VTA) and plays a central role in manifestation of psychiatric disorders.  Recently, anatomical and comprehensive transcriptome anal. of the non-odorant GPCR superfamily revealed that the orphan GPCRs GPR88, GPR6, and GPR52, as well as dopamine D1 and D2 receptors and the adenosine A2a receptor, are the most highly enriched in the rodent striatum.  Genetically engineered animal models and mol. biol. studies have suggested that these striatally enriched GPCRs have a potential to be therapeutic psychiatric receptors.  This review summarizes the current understanding of the therapeutic GPCR candidates for psychiatric disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3ibl5_GgvcrVg90H21EOLACvtfcHk0liYFHH3v4FmMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvValtLjM&md5=1d5f1f6aea76058deabe7a918f995953</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.3390%2Fijms160614109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms160614109%26sid%3Dliteratum%253Aachs%26aulast%3DKomatsu%26aufirst%3DH.%26atitle%3DNovel%2520therapeutic%2520GPCRs%2520for%2520psychiatric%2520disorders%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2015%26volume%3D16%26spage%3D14109%26epage%3D14121%26doi%3D10.3390%2Fijms160614109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grundmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merten, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malfacini, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rüttiger, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziegler, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benkel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishida, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reher, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawakami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rick, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kühl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imhof, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">König, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomeza, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wess, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostenis, E.</span></span> <span> </span><span class="NLM_article-title">Lack of beta-arrestin signaling in the absence of active G proteins</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">341</span>, <span class="refDoi"> DOI: 10.1038/s41467-017-02661-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=10.1038%2Fs41467-017-02661-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=29362459" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A280%3ADC%252BC1MvjsFKiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=341&author=M.+Grundmannauthor=N.+Mertenauthor=D.+Malfaciniauthor=A.+Inoueauthor=P.+Preisauthor=K.+Simonauthor=N.+R%C3%BCttigerauthor=N.+Zieglerauthor=T.+Benkelauthor=N.+K.+Schmittauthor=S.+Ishidaauthor=I.+M%C3%BCllerauthor=R.+Reherauthor=K.+Kawakamiauthor=A.+Inoueauthor=U.+Rickauthor=T.+K%C3%BChlauthor=D.+Imhofauthor=J.+Aokiauthor=G.+M.+K%C3%B6nigauthor=C.+Hoffmannauthor=J.+Gomezaauthor=J.+Wessauthor=E.+Kostenis&title=Lack+of+beta-arrestin+signaling+in+the+absence+of+active+G+proteins&doi=10.1038%2Fs41467-017-02661-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Lack of beta-arrestin signaling in the absence of active G proteins</span></div><div class="casAuthors">Grundmann Manuel; Merten Nicole; Malfacini Davide; Preis Philip; Simon Katharina; Benkel Tobias; Schmitt Nina Katharina; Muller Ines; Rick Ulrike; Gomeza Jesus; Kostenis Evi; Inoue Asuka; Ishida Satoru; Kawakami Kouki; Inoue Ayumi; Aoki Junken; Inoue Asuka; Ruttiger Nelly; Hoffmann Carsten; Ziegler Nicole; Reher Raphael; Konig Gabriele M; Kuhl Toni; Imhof Diana; Aoki Junken; Wess Jurgen</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">341</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">G protein-independent, arrestin-dependent signaling is a paradigm that broadens the signaling scope of G protein-coupled receptors (GPCRs) beyond G proteins for numerous biological processes.  However, arrestin signaling in the collective absence of functional G proteins has never been demonstrated.  Here we achieve a state of "zero functional G" at the cellular level using HEK293 cells depleted by CRISPR/Cas9 technology of the Gs/q/12 families of Gα proteins, along with pertussis toxin-mediated inactivation of Gi/o.  Together with HEK293 cells lacking β-arrestins ("zero arrestin"), we systematically dissect G protein- from arrestin-driven signaling outcomes for a broad set of GPCRs.  We use biochemical, biophysical, label-free whole-cell biosensing and ERK phosphorylation to identify four salient features for all receptors at "zero functional G": arrestin recruitment and internalization, but-unexpectedly-complete failure to activate ERK and whole-cell responses.  These findings change our understanding of how GPCRs function and in particular of how they activate ERK1/2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRVakKpC8MvOyA3UY9EwTNrfW6udTcc2eaN1Dm-64HF37ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MvjsFKiug%253D%253D&md5=4afaac8e9bb4a87bd9d02ea469024efc</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fs41467-017-02661-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-017-02661-3%26sid%3Dliteratum%253Aachs%26aulast%3DGrundmann%26aufirst%3DM.%26aulast%3DMerten%26aufirst%3DN.%26aulast%3DMalfacini%26aufirst%3DD.%26aulast%3DInoue%26aufirst%3DA.%26aulast%3DPreis%26aufirst%3DP.%26aulast%3DSimon%26aufirst%3DK.%26aulast%3DR%25C3%25BCttiger%26aufirst%3DN.%26aulast%3DZiegler%26aufirst%3DN.%26aulast%3DBenkel%26aufirst%3DT.%26aulast%3DSchmitt%26aufirst%3DN.%2BK.%26aulast%3DIshida%26aufirst%3DS.%26aulast%3DM%25C3%25BCller%26aufirst%3DI.%26aulast%3DReher%26aufirst%3DR.%26aulast%3DKawakami%26aufirst%3DK.%26aulast%3DInoue%26aufirst%3DA.%26aulast%3DRick%26aufirst%3DU.%26aulast%3DK%25C3%25BChl%26aufirst%3DT.%26aulast%3DImhof%26aufirst%3DD.%26aulast%3DAoki%26aufirst%3DJ.%26aulast%3DK%25C3%25B6nig%26aufirst%3DG.%2BM.%26aulast%3DHoffmann%26aufirst%3DC.%26aulast%3DGomeza%26aufirst%3DJ.%26aulast%3DWess%26aufirst%3DJ.%26aulast%3DKostenis%26aufirst%3DE.%26atitle%3DLack%2520of%2520beta-arrestin%2520signaling%2520in%2520the%2520absence%2520of%2520active%2520G%2520proteins%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26spage%3D341%26doi%3D10.1038%2Fs41467-017-02661-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simmler, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anacker, A. M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levin, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaswani, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gresch, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nackenoff, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anastasio, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stutz, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veenstra-VanderWeele, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blakely, R. D.</span></span> <span> </span><span class="NLM_article-title">Blockade of the 5-HT transporter contributes to the behavioural, neuronal and molecular effects of cocaine</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>174</i></span>,  <span class="NLM_fpage">2716</span>– <span class="NLM_lpage">2738</span>, <span class="refDoi"> DOI: 10.1111/bph.13899</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=10.1111%2Fbph.13899" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=28585320" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFCgtLjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2017&pages=2716-2738&author=L.+D.+Simmlerauthor=A.+M.+J.+Anackerauthor=M.+H.+Levinauthor=N.+M.+Vaswaniauthor=P.+J.+Greschauthor=A.+G.+Nackenoffauthor=N.+C.+Anastasioauthor=S.+J.+Stutzauthor=K.+A.+Cunninghamauthor=J.+Wangauthor=B.+Zhangauthor=L.+K.+Henryauthor=A.+Stewartauthor=J.+Veenstra-VanderWeeleauthor=R.+D.+Blakely&title=Blockade+of+the+5-HT+transporter+contributes+to+the+behavioural%2C+neuronal+and+molecular+effects+of+cocaine&doi=10.1111%2Fbph.13899"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Blockade of the 5-HT transporter contributes to the behavioural, neuronal and molecular effects of cocaine</span></div><div class="casAuthors">Simmler, Linda D.; Anacker, Allison M. J.; Levin, Michael H.; Vaswani, Nina M.; Gresch, Paul J.; Nackenoff, Alex G.; Anastasio, Noelle C.; Stutz, Sonja J.; Cunningham, Kathryn A.; Wang, Jing; Zhang, Bing; Henry, L. Keith; Stewart, Adele; Veenstra-VanderWeele, Jeremy; Blakely, Randy D.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2716-2738</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose : The psychostimulant cocaine induces complex mol., cellular and behavioral responses as a consequence of inhibiting presynaptic dopamine, noradrenaline and 5-HT transporters.  To elucidate 5-HT transporter (SERT)-specific contributions to cocaine action, we evaluated cocaine effects in the SERT Met172 knock-in mouse, which expresses a SERT coding substitution that eliminates high-affinity cocaine recognition.  Exptl. Approach : We measured the effects of SERT Met172 on cocaine antagonism of 5-HT re-uptake using ex vivo synaptosome prepns. and in vivo microdialysis.  We assessed SERT dependence of cocaine actions behaviorally through acute and chronic locomotor activation, sensitization, conditioned place preference (CPP) and oral cocaine consumption.  We used c-Fos, quant. RT-PCR and RNA sequencing methods for insights into cellular and mol. networks supporting SERT-dependent cocaine actions.  Key Results : SERT Met172 mice demonstrated functional insensitivity for cocaine at SERT.  Although they displayed wild-type levels of acute cocaine-induced hyperactivity or chronic sensitization, the pattern of acute motor activation was different, with a bias toward thigmotaxis.  CPP was increased, and a time-dependent elevation in oral cocaine consumption was obsd.  SERT Met172 mice displayed relatively higher levels of neuronal activation in the hippocampus, piriform cortex and prelimbic cortex (PrL), accompanied by region-dependent changes in immediate early gene expression.  Distinct SERT-dependent gene expression networks triggered by acute and chronic cocaine administration were identified, including PrL Akt and nucleus accumbens ERK1/2 signalling.  Conclusion and Implications : Our studies reveal distinct SERT contributions to cocaine action, reinforcing the possibility of targeting specific aspects of cocaine addiction by modulation of 5-HT signalling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorlo6wcxCpw7Vg90H21EOLACvtfcHk0lhp4d-dub5Etw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFCgtLjE&md5=87411dc7c77d4a6ef13e3537da978733</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1111%2Fbph.13899&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.13899%26sid%3Dliteratum%253Aachs%26aulast%3DSimmler%26aufirst%3DL.%2BD.%26aulast%3DAnacker%26aufirst%3DA.%2BM.%2BJ.%26aulast%3DLevin%26aufirst%3DM.%2BH.%26aulast%3DVaswani%26aufirst%3DN.%2BM.%26aulast%3DGresch%26aufirst%3DP.%2BJ.%26aulast%3DNackenoff%26aufirst%3DA.%2BG.%26aulast%3DAnastasio%26aufirst%3DN.%2BC.%26aulast%3DStutz%26aufirst%3DS.%2BJ.%26aulast%3DCunningham%26aufirst%3DK.%2BA.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DHenry%26aufirst%3DL.%2BK.%26aulast%3DStewart%26aufirst%3DA.%26aulast%3DVeenstra-VanderWeele%26aufirst%3DJ.%26aulast%3DBlakely%26aufirst%3DR.%2BD.%26atitle%3DBlockade%2520of%2520the%25205-HT%2520transporter%2520contributes%2520to%2520the%2520behavioural%252C%2520neuronal%2520and%2520molecular%2520effects%2520of%2520cocaine%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2017%26volume%3D174%26spage%3D2716%26epage%3D2738%26doi%3D10.1111%2Fbph.13899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cortez, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bulavin, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGrath, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakamiya, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papaconstantinou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dineley, K. T.</span></span> <span> </span><span class="NLM_article-title">Aged dominant negative p38α MAPK mice are resistant to age-dependent decline in adult-neurogenesis and context discrimination fear conditioning</span>. <i>Behav. Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>322</i></span>,  <span class="NLM_fpage">212</span>– <span class="NLM_lpage">222</span>, <span class="refDoi"> DOI: 10.1016/j.bbr.2016.10.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=10.1016%2Fj.bbr.2016.10.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=27765672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslKms7fO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=322&publication_year=2017&pages=212-222&author=I.+Cortezauthor=D.+V.+Bulavinauthor=P.+Wuauthor=E.+L.+McGrathauthor=K.+A.+Cunninghamauthor=M.+Wakamiyaauthor=J.+Papaconstantinouauthor=K.+T.+Dineley&title=Aged+dominant+negative+p38%CE%B1+MAPK+mice+are+resistant+to+age-dependent+decline+in+adult-neurogenesis+and+context+discrimination+fear+conditioning&doi=10.1016%2Fj.bbr.2016.10.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Aged dominant negative p38α MAPK mice are resistant to age-dependent decline in adult-neurogenesis and context discrimination fear conditioning</span></div><div class="casAuthors">Cortez, IbDanelo; Bulavin, Dmitry V.; Wu, Ping; McGrath, Erica L.; Cunningham, Kathryn A.; Wakamiya, Maki; Papaconstantinou, John; Dineley, Kelly T.</div><div class="citationInfo"><span class="NLM_cas:title">Behavioural Brain Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">322</span>
        (<span class="NLM_cas:issue">Part_B</span>),
    <span class="NLM_cas:pages">212-222</span>CODEN:
                <span class="NLM_cas:coden">BBREDI</span>;
        ISSN:<span class="NLM_cas:issn">0166-4328</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A major aspect of mammalian aging is the decline in functional competence of many self-renewing cell types, including adult-born neuronal precursors.  Since age-related senescence of self-renewal occurs simultaneously with chronic up-regulation of the p38MAPKalpha (p38α) signaling pathway, we used the dominant neg. mouse model for attenuated p38α activity (DN-p38αAF/+) in which Thr180 and Tyr182 are mutated (T → A/Y → F) to prevent phosphorylation activation (DN-p38αAF/+) and kinase activity.  As a result, aged DN-p38αAF/+ mice are resistant to age-dependent decline in proliferation and regeneration of several peripheral tissue progenitors when compared to wild-type littermates.  Aging is the major risk factor for non-inherited forms of Alzheimer's disease (AD); environmental and genetic risk factors that accelerate the senescence phenotype are thought to contribute to an individual's relative risk.  In the present study, we evaluated aged DN-p38αAF/+ and wildtype littermates in a series of behavioral paradigms to test if p38α mutant mice exhibit altered baseline abnormalities in neurol. reflexes, locomotion, anxiety-like behavior, and age-dependent cognitive decline.  While aged DN-p38αAF/+ and wildtype littermates appear equal in all tested baseline neurol. and behavioral parameters, DN-p38αAF/+ exhibit superior context discrimination fear conditioning.  Context discrimination is a cognitive task that is supported by proliferation and differentiation of adult-born neurons in the dentate gyrus of the hippocampus.  Consistent with enhanced context discrimination in aged DN-p38αAF/+, we discovered enhanced prodn. of adult-born neurons in the dentate gyrus of DN-p38αAF/+ mice compared to wildtype littermates.  Our findings support the notion that p38α inhibition has therapeutic utility in aging diseases that affect cognition, such as AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFlQci7hho0rVg90H21EOLACvtfcHk0lhp4d-dub5Etw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslKms7fO&md5=a0364b7630f749cb1ab66cdc58727a75</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.bbr.2016.10.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbr.2016.10.023%26sid%3Dliteratum%253Aachs%26aulast%3DCortez%26aufirst%3DI.%26aulast%3DBulavin%26aufirst%3DD.%2BV.%26aulast%3DWu%26aufirst%3DP.%26aulast%3DMcGrath%26aufirst%3DE.%2BL.%26aulast%3DCunningham%26aufirst%3DK.%2BA.%26aulast%3DWakamiya%26aufirst%3DM.%26aulast%3DPapaconstantinou%26aufirst%3DJ.%26aulast%3DDineley%26aufirst%3DK.%2BT.%26atitle%3DAged%2520dominant%2520negative%2520p38%25CE%25B1%2520MAPK%2520mice%2520are%2520resistant%2520to%2520age-dependent%2520decline%2520in%2520adult-neurogenesis%2520and%2520context%2520discrimination%2520fear%2520conditioning%26jtitle%3DBehav.%2520Brain%2520Res.%26date%3D2017%26volume%3D322%26spage%3D212%26epage%3D222%26doi%3D10.1016%2Fj.bbr.2016.10.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anastasio, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stutz, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bubar, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swinford, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbertson, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenzweig-Lipson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moeller, F. G.</span></span> <span> </span><span class="NLM_article-title">Synergism between a serotonin 5-HT<sub>2A</sub> receptor (5-HT<sub>2A</sub>R) antagonist and 5-HT<sub>2C</sub>R agonist suggests new pharmacotherapeutics for cocaine addiction</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">110</span>– <span class="NLM_lpage">121</span>, <span class="refDoi"> DOI: 10.1021/cn300072u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn300072u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFOntb7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=110-121&author=K.+A.+Cunninghamauthor=N.+C.+Anastasioauthor=R.+G.+Foxauthor=S.+J.+Stutzauthor=M.+J.+Bubarauthor=S.+E.+Swinfordauthor=C.+S.+Watsonauthor=S.+R.+Gilbertsonauthor=K.+C.+Riceauthor=S.+Rosenzweig-Lipsonauthor=F.+G.+Moeller&title=Synergism+between+a+serotonin+5-HT2A+receptor+%285-HT2AR%29+antagonist+and+5-HT2CR+agonist+suggests+new+pharmacotherapeutics+for+cocaine+addiction&doi=10.1021%2Fcn300072u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Synergism Between a Serotonin 5-HT2A Receptor (5-HT2AR) Antagonist and 5-HT2CR Agonist Suggests New Pharmacotherapeutics for Cocaine Addiction</span></div><div class="casAuthors">Cunningham, Kathryn A.; Anastasio, Noelle C.; Fox, Robert G.; Stutz, Sonja J.; Bubar, Marcy J.; Swinford, Sarah E.; Watson, Cheryl S.; Gilbertson, Scott R.; Rice, Kenner C.; Rosenzweig-Lipson, Sharon; Moeller, F. Gerard</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">110-121</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Relapse to cocaine dependence, even after extended abstinence, involves a no. of liability factors including impulsivity (predisposition toward rapid, unplanned reactions to stimuli without regard to neg. consequences) and cue reactivity (sensitivity to cues assocd. with cocaine-taking which can promote cocaine-seeking).  These factors have been mechanistically linked to serotonin (5-hydroxytryptamine, 5-HT) signaling through the 5-HT2A receptor (5-HT2AR) and 5-HT2CR; either a selective 5-HT2AR antagonist or a 5-HT2CR agonist suppresses impulsivity and cocaine-seeking in preclin. models.  We conducted proof-of-concept analyses to evaluate whether a combination of 5-HT2AR antagonist plus 5-HT2CR agonist would have synergistic effects over these liability factors for relapse as measured in a 1-choice serial reaction time task and cocaine self-administration/reinstatement assay.  Combined administration of a dose of the selective 5-HT2AR antagonist M100907 plus the 5-HT2CR agonist WAY163909, each ineffective alone, synergistically suppressed cocaine-induced hyperactivity, inherent and cocaine-evoked impulsive action, as well as cue- and cocaine-primed reinstatement of cocaine-seeking behavior.  The identification of synergism between a 5-HT2AR antagonist plus a 5-HT2CR agonist to attenuate these factors important in relapse indicates the promise of a bifunctional ligand as an anti-addiction pharmacotherapeutic, setting the stage to develop new ligands with improved efficacy, potency, selectivity, and in vivo profiles over the individual mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraOi38lqJqXLVg90H21EOLACvtfcHk0lhp4d-dub5Etw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFOntb7J&md5=5f392443d0452d11cb30fc69c053d12c</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fcn300072u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn300072u%26sid%3Dliteratum%253Aachs%26aulast%3DCunningham%26aufirst%3DK.%2BA.%26aulast%3DAnastasio%26aufirst%3DN.%2BC.%26aulast%3DFox%26aufirst%3DR.%2BG.%26aulast%3DStutz%26aufirst%3DS.%2BJ.%26aulast%3DBubar%26aufirst%3DM.%2BJ.%26aulast%3DSwinford%26aufirst%3DS.%2BE.%26aulast%3DWatson%26aufirst%3DC.%2BS.%26aulast%3DGilbertson%26aufirst%3DS.%2BR.%26aulast%3DRice%26aufirst%3DK.%2BC.%26aulast%3DRosenzweig-Lipson%26aufirst%3DS.%26aulast%3DMoeller%26aufirst%3DF.%2BG.%26atitle%3DSynergism%2520between%2520a%2520serotonin%25205-HT2A%2520receptor%2520%25285-HT2AR%2529%2520antagonist%2520and%25205-HT2CR%2520agonist%2520suggests%2520new%2520pharmacotherapeutics%2520for%2520cocaine%2520addiction%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2013%26volume%3D4%26spage%3D110%26epage%3D121%26doi%3D10.1021%2Fcn300072u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keppel, G.</span>; <span class="NLM_string-name">Wickens, T. D.</span></span> <i>Design and analysis: a researcher’s handbook</i>; <span class="NLM_publisher-name">Pearson Prentice Hall</span>: <span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=G.+Keppel&author=T.+D.+Wickens&title=Design+and+analysis%3A+a+researcher%E2%80%99s+handbook"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DKeppel%26aufirst%3DG.%26btitle%3DDesign%2520and%2520analysis%253A%2520a%2520researcher%25E2%2580%2599s%2520handbook%26pub%3DPearson%2520Prentice%2520Hall%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6LI1" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6LI1','PDB','6LI1'); return false;">PDB: 6LI1</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6LI2" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6LI2','PDB','6LI2'); return false;">PDB: 6LI2</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6LI0" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6LI0','PDB','6LI0'); return false;">PDB: 6LI0</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i121"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01498">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_01423"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01498?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01498</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Figures S1 and S2, HPLC analysis spectra of representative compounds, and <sup>1</sup>H and <sup>13</sup>C NMR spectra of all new compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01498/suppl_file/jm0c01498_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01498/suppl_file/jm0c01498_si_002.csv">CSV</a>)</p></li><li><p class="inline">Docking compound <b>12c</b> with GPR52 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01498/suppl_file/jm0c01498_si_003.pdb">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01498/suppl_file/jm0c01498_si_001.pdf">jm0c01498_si_001.pdf (4.32 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01498/suppl_file/jm0c01498_si_002.csv">jm0c01498_si_002.csv (3.03 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01498/suppl_file/jm0c01498_si_003.pdb">jm0c01498_si_003.pdb (807.35 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01498&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01498%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-22" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01498" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679abb251c2a3cd0","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
